Alerta Tecnológico nº 10

INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL



Pedidos de Patentes

sobre Células-tronco

Pedidos Publicados no 2º Semestre de 2008

Diretoria de Articulação e Informação Tecnológica – Dart

Centro de Divulgação, Documentação e Informação Tecnológica - Cedin

Divisão de Estudos e Programas – Diespro

Julho de 2009

INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

Presidente: Jorge de Paula Costa Ávila

Vice-Presidente: Ademir Tardelli

DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA - DART

Diretor: Sérgio Medeiros Paulino de Carvalho

CENTRO DE DIVULGAÇÃO, DOCUMENTAÇÃO E INFORMAÇÃO TECNOLÓGICA - CEDIN

Chefe: Raul Suster

DIVISÃO DE ESTUDOS E PROGRAMAS - DIESPRO

Chefe: Luci Mary Gonzalez Gullo

Equipe da DIESPRO:

Cristina d'Urso de Souza Mendes – Pesquisadora
Jeziel da Silva Nunes – Pesquisador
Luciana Goulart de Oliveira - Pesquisadora
Marcos Tiago Duarte – Analista de Propriedade Industrial
Priscila Rohem dos Santos - Pesquisadora
Rafaela Di Sabato Guerrante – Pesquisadora
Sabrina da Silva Santos – Pesquisadora
Sérgio Barcelos Theotonio - Pesquisador
Suzanne de Oliveira Rodrigues - Técnica

ALERTA TECNOLÓGICO

O Instituto Nacional da Propriedade Industrial (INPI) é uma Autarquia Federal, vinculada ao Ministério do Desenvolvimento, Indústria e Comércio Exterior (MDIC), responsável pela concessão de patentes, registros de desenhos industriais, registro de marcas, averbação de contratos de transferência de tecnologia, registro de programas de computador, indicações geográficas e topografias de circuito integrado.

O Centro de Divulgação, Documentação e Informação Tecnológica (CEDIN), subordinado à Diretoria de Articulação e Informação Tecnológica (DART), mantém um acervo com a descrição dos pedidos de patente e de registros de desenho industrial. Uma de suas atribuições é divulgar e disseminar a utilização destas informações bibliográficas e técnicas. Para tanto, o CEDIN dispõe da Divisão de Estudos e Programas – DIESPRO, cuja incumbência é elaborar publicações fundamentadas, essencialmente, em informações extraídas de documentos de patente.

A patente é uma importante fonte formal de informação, por meio da qual pode-se ter acesso a detalhes técnicos de invenções que, em alguns casos, não estão descritos em outros meios de divulgação (livros, artigos técnicos etc.).

O objetivo desta publicação, de periodicidade semestral, é o de alertar sobre os principais depositantes de patente em determinado setor e período de tempo, os países onde o primeiro depósito foi solicitado (país de prioridade), as áreas tecnológicas mais solicitadas e de divulgar os títulos dos pedidos de patente publicados mundialmente em determinado período. Desta forma, busca-se contribuir para a atualização periódica do público alvo deste Alerta Tecnológico.

Esta publicação consiste de:

[1]Uma família de patentes é a coleção de documentos de patente relacionados à mesma invenção ou a invenções correlacionadas, publicados em diferentes países. Cada documento de patente da família baseia-se, normalmente, nos dados do primeiro pedido depositado no país da prioridade. Existem diferentes estruturas de famílias de patente. Para este Alerta, o termo família de patente refere-se ao conceito de "família simples", na qual todos os documentos de patente têm em comum o número e a data da prioridade unionista (WIPO, 2008).

[2] Conforme estabelecido pela Convenção de Paris (CUP) em seu Art. 4º, o primeiro pedido de patente depositado em um dos países membros da Convenção serve de base para depósitos subseqüentes relacionados à mesma matéria, efetuados pelo mesmo depositante ou por seus sucessores legais. Tem-se assim, o **Direito de Prioridade**. O prazo para exercer tal direito é de 12 meses, para invenção e modelo de utilidade. Ver art. 16, da Lei da Propriedade Industrial (LPI), nº 9.279/96 – disponível em www.inpi.gov.br.

Mais detalhes sobre cada pedido de patente (resumo da invenção, nome(s) do(s) inventor(es), cópia do documento completo etc.) podem ser obtidos nas seguintes bases de patente disponíveis gratuitamente na internet:

1. Base Brasileira de Pedidos de Patente[3]: http://www.inpi.gov.br
2. Base do Escritório Europeu de Patentes[4]: http://ep.espacenet.com
3. Base do Escritório Americano de Patentes[5]: http://www.uspto.gov

Caso haja interesse em se conhecer o(s) depósito(s) de patente no Brasil, correspondente(s) (família do pedido de patente[1]) aos pedidos de patente estrangeiros listados no Anexo I, sugere-se uma busca de família dos pedidos de interesse. Neste caso, o Centro de Documentação do INPI – CEDIN informará os procedimentos a serem seguidos. Abaixo, seguem endereço e formas de contatar o CEDIN.

INPI/DART/CEDIN:

Instituto Nacional da Propriedade Industrial – INPI
Diretoria de Articulação e Informação Tecnológica - DART
Centro de Divulgação, Documentação e Informação Tecnológica – CEDIN

Praça Mauá, 7, sala 714, Centro, Rio de Janeiro, RJ , CEP 20083-900
Tel. (21) 2139 3101 , Fax. (21) 2139 3354
e-mail: cedin@inpi.gov.br

As cópias integrais dos pedidos de patente de interesse podem ser solicitadas por meio do endereço copdocpat@inpi.gov.br ou por correio postal ao endereço acima.

[3] Esta base contém somente pedidos de patente depositados e publicados no Brasil a partir de 1982.
[4] Contém pedidos de patente depositados e publicados em mais de 70 países.
[5] Contém somente pedidos depositados e publicados nos Estados Unidos.

PEDIDOS DE PATENTES SOBRE CÉLULAS-TRONCO

As células-tronco são células capazes de se diferenciar nos tecidos que compõem o corpo humano. Estas células são, hoje, objeto de intensas pesquisas, dada a vasta gama de aplicações terapêuticas que podem advir de seu uso. O tratamento de doenças cardiovasculares, neurodegenerativas – como Alzheimer e Parkinson -, nefropatias, diabetes tipo I, doenças hematológicas, imunodeficências e traumas da medula espinhal são alguns dos exemplos dessas aplicações.

As células-tronco podem ser classificadas em **células embrionárias** ou **células adultas**, as primeiras apresentando grandes vantagens em função de sua capacidade de diferenciação em maior número de tecidos.

As fontes de células-tronco mais utilizadas hoje no mundo são os embriões recém-fecundados (blastocistos), criados por fertilização *in vitro* e que não serão empregados no tratamento de infertilidade; os embriões criados por clonagem; as células germinativas ou órgãos de fetos abortados; o sangue retirado do cordão umbilical no momento do nascimento; alguns tecidos adultos, como a medula óssea; e algumas células maduras de tecido adulto, reprogramadas para se comportarem como células-tronco. Há que se destacar a discussão ética, e bastante polêmica, com relação à destruição de embriões recém-fecundados e, principalmente daqueles produzidos por clonagem, para a obtenção de células-tronco.

Em muitos países, as descobertas relacionadas às possíveis aplicações terapêuticas destas células foram divulgadas pela mídia de forma sensacionalista e recebidas com festa pela sociedade. Entretanto, a realidade parece não ser bem esta. Em primeiro lugar, o estágio de desenvolvimento em que se encontram determinadas linhas de pesquisa com esta tecnologia dificilmente permitirão que os cientistas respondam à sociedade no tempo esperado e com a qualidade dos resultados que se prevê; e, um segundo aspecto já abordados se refere às grandes questões éticas envolvidas na destruição de embriões para a obtenção das células-tronco.

Diante do cenário apresentado e da escassez de levantamentos relacionados aos depósitos de patente sobre células-tronco no mundo, o INPI vem, por meio do CEDIN, facilitar ao público interessado o acesso a estas informações.

Dessa forma, este Alerta Tecnológico tem como objetivo divulgar, a cada semestre, os novos pedidos de patente sobre células-tronco (suas aplicações terapêuticas, técnicas relacionadas a seu isolamento, purificação, cultivo e diferenciação etc) publicados no mundo.

Para o levantamento em questão, foram selecionados os documentos de patente contendo, em seu título ou resumo, uma (ou mais) das seguintes palavras-chave: **célula(s)-tronco**, **célula(s) tronco**, **célula(s) embrionária(s)**, **célula(s) embriônica(s)**. Não foi possível empregar a classificação internacional de patente[6] (CIP) na busca efetuada, visto que não há nenhuma CIP específica para as referidas células, sendo esta tecnologia classificada em várias CIPs diferentes, que de alguma forma estão relacionadas ao tema[7]:

[6] O sistema da Classificação Internacional de Patentes resultou dos esforços conjuntos de órgãos de propriedade industrial de vários países, com o objetivo de dispor, de forma organizada e padronizada, os documentos de patente, a fim de facilitar o acesso (busca) às informações tecnológicas e legais contidas nesses documentos. O Acordo de Estrasburgo relativo à Classificação Internacional de Patentes, concluído em 1971, entrou em vigor em 1975 e é administrado pela Organização Mundial da Propriedade Intelectual (OMPI). Qualquer país membro da Convenção da União de Paris pode se tornar membro do Acordo de Estrasburgo. Em julho de 2008, além dos 58 Estados que fazem parte deste Acordo, mais de 100 escritórios nacionais, 4 escritórios regionais e a Secretaria da OMPI, atuando como escritório receptor do Tratado de Cooperação em Matéria de Patentes (PCT), também utilizavam a Classificação Internacional de Patentes.
A edição atual da CIP (8ª edição) entrou em vigor em 01/01/2006 e está disponível no *site* da OMPI (http://www.wipo.int/classifications/ipc/) e no *site* do INPI (http://pesquisa.inpi.gov.br/ipc/index.php).

[7] Um documento de patente pode conter uma ou mais classificações.

Resultados

O gráfico nº 1 permite a identificação dos países[8] de prioridade dos documentos recuperados no período e a ocorrência de documentos em cada país.

Gráfico 1: Número de Pedidos de Patente Publicados no Mundo sobre Células-tronco (2º semestre 2008) x Países de Prioridade



Fonte: Elaboração própria a partir da banco de dados EPOQUE[9]

De acordo com o gráfico nº 1 os cinco principais países de prioridade são:

- US – Estados Unidos da América,
- JP – Japão,
- KR – Coréia
- CN – China e
- EP - Europa.

[8] A lista com os códigos dos países está disponível no Anexo I.
[9] O banco de dados EPOQUE é disponibilizado ao INPI, via acesso remoto, pelo Escritório Europeu de Patentes.

Na tabela nº 1, a seguir, são identificados os depositantes com maior número de pedidos de patente publicados no período e o(s) país(es) de prioridade de cada um dos pedidos[10].

Tabela nº 1: Relação dos principais depositantes, dos países de prioridade de seus pedidos e do nº de pedidos de patentes publicados no 2º semestre de 2008

Nome do Depositante	*Prioridade*	*Total de Documentos*
DANCU MICHAEL	TW US	14
ANTHROGENESIS CORP	AU US	14
UNIV ZHEJIANG	CN	8
SEOUL NAT UNIV IND FOUNDATION	KR US	8
TRUSTEES OF THE UNIVERSITY OF	US	7
RNL BIO CO LTD	KR	7
CEDARS SINAI MEDICAL CENTER	EP US	6
AGENCY SCIENCE TECH & RES	AU US IB SG	6
GERON CORP	AU US	6
UNIV MICHIGAN	US	6
UNIV KYOTO	JP	6
PROSTEMICS	KR	6
WANG JIA-LUN	US	5
HARIRI ROBERT J	US	5
YE QIAN	US	5
GLYKOS FINLAND LTD	FI	5
SATOMAA TERO	FI	5
NATUNEN JARI	FI	5
SUOMEN PUNAINEN RISTI VERIPALV	FI	5
LAINE JARMO	FI	5
HEISKANEN ANNAMARI	FI	5
MASSACHUSETTS INST TECHNOLOGY	US	5
OLYMPUS CORP	JP	5
NUVELO INC	US	5
WISCONSIN ALUMNI RES FOUND	US	5
OSIRIS THERAPEUTICS INC	US	5
PROCURE THERAPEUTICS LTD	EP GB	5
EDINGER JAMES W	US	4
UNIV NEW YORK	US	4
THOMSON JAMES A	US	4
UNIV MONASH	AU US	4
UNIV HIROSHIMA	JP	4
IMGEN CO LTD	KR	4
UNIV CALIFORNIA	US	4

[10] Um pedido de patente pode ter mais de um país de prioridade.

Tabela nº 1: Relação dos principais depositantes, dos países de prioridade de seus pedidos e do nº de pedidos de patentes publicados no 2º semestre de 2008 (cont.)

Nome do Depositante	*Prioridade*	*Total de Documentos*
SHROFF GEETA	IN US IB	4
SCRIPPS RESEARCH INST	US	4
INTERNAT STEM CELL CORP	US	4
VIVALIS	EP FR US	4
UNIV VIRGINIA	US	4
GEN HOSPITAL CORP	US	4
GAMIDA CELL LTD	AU IL US	4
CHABIOTECH CO LTD	KR	4
UNIV COLUMBIA	US	4
COLLEGE OF MEDICINE POCHON CHA	KR	4
UNIV DUKE	EP US	4
NEVADA CANCER INST	US	4
UNIV SHANGHAI	CN	4
UNIV TEXAS	US	4
IMPOLA ULLA	FI	4
TIITINEN SARI	FI	4
SAARINEN JUHANI	FI	4
VALMU LEENA	FI	4
OLONEN ANNE	FI	4
HADASIT MED RES SERVICE	US	4
BLOMQVIST MARIA	FI	4

Fonte: Elaboração própria a partir da banco de dados EPOQUE.

O gráfico nº 2 permite o monitoramento das principais tecnologias relacionadas ao tema, descritas nos pedidos de patente publicados no período.

Gráfico 2: Número de Documentos de Patente x Classificação Internacional de Patentes (CIP)



Fonte: Elaboração própria a partir da banco de dados EPOQUE

C12N 5/ – Células não diferenciadas de animais ou plantas, por ex., linhagem de células**;** Tecidos**;** Sua cultura ou manutenção**;** Seus meios de cultura**.**

A61K 35/ – Preparações medicinais contendo materiais de constituição indeterminada ou seus produtos de reação.

C12N 15/ – Mutação ou engenharia genética**;** DNA ou RNA concernentes à engenharia genética, vetores, por ex., plasmídeos ou seu isolamento, preparação ou purificação; Uso de seus hospedeiros.

C12Q 1/ – Processos de medição ou ensaio envolvendo enzimas ou microorganismos; Composições para esse fim**;** Processos de preparação de tais composições.

G01N 33/ – Investigação ou análise de materiais por métodos específicos não abrangidos pelos grupos G01N 1/00 até G01N 31/00.

A61K 38/ – Preparações medicinais contendo peptídeos.

A61P 25/ – Drogas para o tratamento de doenças do sistema nervoso.

A61K 48/ – Preparações medicinais contendo material genético o qual é inserido nas células dos corpos vivos para tratar doenças genéticas**;** Geneterapia.

A61P 43/ – Drogas para fins específicos, não previstos nos grupos A61P 1/00 até A61P 41/00.

A61L 27/ – Materiais para próteses ou para revestimento de próteses.

A61K 31/ – Preparações medicinais contendo ingredientes ativos orgânicos.

A61P 9/ – Drogas para o tratamento de distúrbios do sistema cardiovascular.

C07K 14/ – Peptídeos tendo mais de 20 aminoácidos**;** Gastrinas**;** Somatoestatinas**;** Melanotropinas**;** Derivados dos mesmos.

A61P 35/ – Agentes antineoplásticos.

A61P 37/ – Drogas para o tratamento de distúrbios imunológicos ou alérgicos.

A61F 2/ – Filtros implantáveis nos vasos sanguíneos; Próteses, i.e., substitutos artificiais ou substituições de partes do corpo; Mecanismos para conectá-los ao corpo; Dispositivos que promovem desobstrução ou previnem colapso de estruturas tubulares do corpo, por ex.,stents.

A61K 39/ –Preparações medicinais contendo antígenos ou anticorpos.

A01K 67/ –Criação ou reprodução de animais, não incluídas em outro local; Novas criações de animais.

C07K 16/ – Imunoglobulinas, por ex., anticorpos mono- ou policlonais.

A61P 1/ – Drogas para o tratamento de distúrbios do trato alimentar ou do sistema digestivo.

Tabela nº 2: Dados bibliográficos dos pedidos de patente publicados no 2º semestre de 2008

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AR060996	EP - 20060009703 - 11/05/2006	HOFFMANN LA ROCHE		Raton Inmunorreconstituido
AR062271	US - 20060836409P - 07/08/2006	GENZYME CORP		Uso De Una Cantidad Efectiva De Al Menos Un Inhibidor De Cxcr4, Al Menos Un Agonista De Cxcr2 Y G-Csf Para Movilizar Las Celulas Progenitoras Y/O Celulas Madre
AU2002349641B	JP - 20010350541 - 15/11/2001 ; WO - 2002JP11914 - 15/11/2002	BIOS RES INST INC ; ENDO FUMIO	A61K 35/12 ; A61P 1/16 ; A61P 1/18 ; A61P 43/00 ; C12N 5/06 ; C12N 5/08	Stem Cells Originating In Salivary Duct Epithelial Cells And Use Thereof

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AU2002355970B	AU - 2001PR07036 - 15/08/2001 ; AU - 20020355970 - 15/08/2002 ; WO - 2002AU01101 - 15/08/2002	PETER MACCALLUM CANCER INST	A61K 35/14 ; A61K 35/23 ; A61K 35/28 ; A61K 35/30 ; A61K 35/32 ; A61K 35/36 ; A61K 35/39 ; A61K 35/407 ; A61K 35/48 ; A61P 1/16 ; A61P 1/18 ; A61P 13/12 ; A61P 15/00 ; A61P 17/00 ; A61P 17/02 ; A61P 19/00 ; A61P 19/04 ; A61P 19/08 ; A61P 25/00 ; A61P 37/00 ; A61P 37/04 ; A61P 43/00 ; A61P 7/00 ; A61P 7/06 ; C07K 16/40 ; C12N 5/06 ; C12N 9/48 ; C12Q 1/02 ; G01N 33/50 ; G01N 33/53; G01N 33/569; G01N 33/573	Identification And Isolation Of Somatic Stem Cells And Uses Thereof+I1

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AU2002363659B	US - 20010335878P - 15/11/2001 ; US - 20020356295P - 13/02/2002 ; WO - 2002US36966 - 15/11/2002	CHILDRENS MEDICAL CENTER	A61K 35/12 ; A61K 35/14 ; A61K 35/30 ; A61K 35/32 ; A61K 35/34 ; A61K 35/407 ; A61P 1/16 ; A61P 19/08 ; A61P 21/00 ; A61P 25/00 ; A61P 25/16 ; A61P 43/00 ; A61P 7/00 ; C12N 1/04 ; C12N 15/09 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08 ; G01N 33/53 ; G01N 33/567	Methods Of Isolation, Expansion And Differentiation Of Fetal Stem Cells From Chorionic Villus, Amniotic Fluid, And Placenta And Therapeutic Uses Thereof
AU2003208577B	IL - 20020152904 - 17/11/2002 ; US - 20020350360P - 24/01/2002 ; US - 20020376183P - 30/04/2002 ; US - 20020404137P - 19/08/2002 ; WO - 2003IL00064 - 26/01/2003	GAMIDA CELL LTD	A61K 35/14 ; A61K 35/28 ; A61K 35/44 ; A61K 47/22 ; A61P 43/00 ; C07C 51/09 ; C12N 15/09 ; C12N 5/06 ; C12N 5/10 ; C12Q 1/02 ; G01N 33/50	Expansion Of Renewable Stem Cell Populations
AU2003238620B	JP - 20020024382 - 31/01/2002 ; WO - 2003JP00999 - 31/01/2003	ASAHI TECHNO GLASS CORP	A01N 1/02 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Liquid For Frozen Storage Of Primate Embryo Stem Cells And Frozen Storage Method

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AU2008202656	US - 20020365361P - 15/03/2002 ; AU - 20030233399 - 14/03/2003 ; WO - 2003US07852 - 14/03/2003 ; AU - 20080202656 - 16/06/2008	UNIV NORTH CAROLINA ; VESTA THERAPEUTICS INC	A61K 35/12 ; A61K 35/407 ; A61P 1/16 ; C12N 5/06 ; C12N 5/08 ; C12N 5/10	Primitive And Proximal Hepatic Stem Cells
AU2008202757	US - 20010952522 - 10/09/2001	UNIV CALIFORNIA	A61L 27/00 ; C12M 3/08 ; C12N 15/09 ; C12N 5/06 ; C12N 5/10	Adipose-Derived Stem Cells And Lattices
AU2008203103	AU - 20000076115 - 25/09/2000 ; AU - 20060201625 - 19/04/2006 ; AU - 20080203103 - 14/07/2008	CYBIOS LLC	A61K 35/12 ; A61K 48/00 ; C12N 5/06 ; G01N 33/50	Pluripotent Embyonic-Like Stem Cells, Compositions, Methods And Uses Thereof
AU2002335921B	AU - 2001PR08565 - 30/10/2001 ; AU - 20020335921 - 24/10/2002 ; WO - 2002AU01443 - 24/10/2002	PETER MACCALLUM CANCER INST	A61K 35/12 ; A61P 35/02 ; A61P 7/00 ; A61P 7/06 ; A61P 9/00 ; C12N 15/09 ; C12N 5/06 ; C12Q 1/04 ; G01N 33/53 ; G01N 33/566 ; G01N 33/569	Detection Of Haematopoietic Stem Cells And Progeny And Uses Thereof

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AU2008203234	US - 20020399192P - 30/07/2002 ; AU - 20030250697 - 30/07/2003 ; WO - 2003CA01151 - 30/07/2003 ; AU - 20080203234 - 21/07/2008	STEM CELL THERAPEUTICS INC	A61K 31/198 ; A61K 31/565 ; A61K 35/12 ; A61K 38/00 ; A61K 38/19 ; A61K 38/20 ; A61K 38/22 ; A61K 38/24 ; A61K 38/27 ; A61P 25/00 ; A61P 43/00 ; C12N 5/06 ; C12N 5/08	Oligodendrocyte Production From Multipotent Neural Stem Cells
AU2008249204	US - 20020076180 - 13/02/2002 ; US - 20020437292P - 31/12/2002 ; AU - 20030216286 - 13/02/2003 ; AU - 20080249204 - 25/11/2008	ANTHROGENESIS CORP	A61K 35/28 ; A61K 35/48 ; A61P 17/02 ; A61P 19/00 ; A61P 21/00 ; A61P 25/00 ; A61P 25/02 ; A61P 25/28 ; A61P 29/00 ; A61P 3/10 ; A61P 37/06 ; A61P 9/00 ; A61P 9/10 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Embryonic-Like Stem Cells Derived From Post-Partum Mammalian Placenta, And Uses And Methods Of Treatment Using Said Cells
AU2008203432	JP - 20010350541 - 15/11/2001 ; AU - 20020349641 - 15/11/2002	BIOS RES INST INC ; FUMIO ENDO	A61K 35/12 ; A61P 1/16 ; A61P 1/18 ; A61P 43/00 ; C12N 5/06 ; C12N 5/08	Stem Cells Originating In Salivary Duct Epithelial Cells And Use Thereof

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AU2008229689	IL - 20020152904 - 17/11/2002 ; US - 20020350360P - 24/01/2002 ; US - 20020376183P - 30/04/2002 ; US - 20020404137P - 19/08/2002 ; AU - 20030208577 - 26/01/2003 ; WO - 2003IL00064 - 26/01/2003 ; AU - 20080229689 - 29/09/2008	GAMIDA CELL LTD	A61K 35/14 ; A61K 35/28 ; A61K 35/44 ; A61K 47/22 ; A61P 43/00 ; C07C 51/09 ; C12N 15/09 ; C12N 5/06 ; C12N 5/10 ; C12Q 1/02 ; G01N 33/50	Expansion Of Renewable Stem Cell Populations
AU2008243182	US - 20010338979P - 07/12/2001 ; AU - 20020366603 - 06/12/2002 ; WO - 2002US39091 - 06/12/2002 ; AU - 20080243182 - 10/11/2008	GERON CORP ; ROBARTS RES INST	A61K 35/12 ; A61K 48/00 ; A61P 29/00 ; A61P 35/00 ; A61P 35/02 ; A61P 37/02 ; A61P 43/00 ; A61P 7/00 ; C12N 5/06 ; C12N 5/08 ; C12N 5/10	Hematopoietic Cells From Human Embryonic Stem Cells
AU2008243183	US - 20010332510P - 26/11/2001 ; AU - 20020360424 - 26/11/2002 ; WO - 2002US37899 - 26/11/2002 ; AU - 20080243183 - 07/11/2008	ADVANCED CELL TECH INC	A61K 35/28 ; A61K 35/48 ; A61P 13/12 ; A61P 25/00 ; A61P 43/00 ; A61P 5/50 ; A61P 9/00 ; C12N 15/09 ; C12N 15/87 ; C12N 5/10	Methods For Making And Using Reprogrammed Human Somatic Cell Nuclei And Autologous And Isogenic Human Stem Cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
AU2008243281	US - 20050651633P - 11/02/2005 ; AU - 20060213572 - 13/02/2006 ; WO - 2006IB00278 - 13/02/2006 ; AU - 20080243281 - 14/11/2008	AGENCY SCIENCE TECH & RES	C12N 5/02 ; C12N 5/06 ; C12N 5/08	Methods Of Proliferating Stem Cells
BRPI0516969	US - 20040622318P - 25/10/2004 ; WO - 2005US38500 - 25/10/2005	CELLERANT THERAPEUTICS INC	C12N 5/00 ; C12N 5/08	Método DE PREPARAR UMA Composição Terapêutica, Composição Terapêutica, E, METODO DE TRATAR UM PACIENTE HUMANO SOFRENDO DE HEMATOPOJESE DEFICIENTE. A Presente Descrição Se Refere A Um Método De Expandir Células Progenitoras Mielóides Através Do Cultivo De Uma População Inicial De Células Em Um Meio Compreendendo Uma Mistura De Citocinas E Fatores De Crescimento Que Promove Crescimento E Expansão Das Células Progenitoras Mielóides. A População De Células Expandida Fornece Uma Fonte De Células Como Tratamentos Terapêuticos Para Neutropenia E/Ou Trombocitopenia Surgindo Em Pacientes Sujeitos À Terapia Mieloablativa E Transplante De Célula Tronco Hematopoiética.
CA2582551	CA - 20072582551 - 22/03/2007	MUSCULOSKELETAL TRANSPLANT	A61L 27/10 ; A61L 27/38 ; A61L 27/54	The Invention Is Directed Toward A Sterile Formable Implant Composition For Application To A Bone Defect Site Comprising Bioactive Glass Particles In An Aqueous Carrie R Solution, The Bioactive Glass Particles Being Added To A Viscous Carrier At A Concentration Ranging From About 68% To About 76% (W/W), The Carrier Comprising A Mixture Of Glycerol And Polyethylene Glycol Ranging From 24% To 32% (W/W) With The Ratio Of Glycerol To Polyethylene Glycol Ranging From About 45:55 To About 65:35.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CA2584494	CA - 20072584494 - 27/03/2007	MEDIN JEFFREY A	A61K 48/00 ; A61P 3/00	A Composition Comprising: A Stably Integrating Delivery Vector; An Modified Mammalian Thymidylate Kinase (Tmpk) Activator Polynucleotide Wherein The Modified Mammalian Tmpk Polynucleotide Encodinges A Modified Mammalian Tmpk Polypeptide That Increases Phosphorylation Of Converts A Prodrug Relative To Phosophorylation Of The Prodrug By Wild-Type Mammalian Tmpk Polypeptideto A Drug; And/Or A Targeting Polynucleotide Encoding A Cell Surface Polypeptide That Selectively Binds A Toxic Binding Agent. The Invention Also Relates To Use Of These Compositions In Methods Of Treatment Of Diseases Such As Fabry Disease.
CA2637157	US - 20070726676 - 22/03/2007 ; WO - 2008US57828 - 21/03/2008	OSIRIS THERAPEUTICS INC	A61K 35/14 ; A61K 35/28 ; A61P 11/00 ; A61P 17/02 ; A61P 19/02 ; A61P 29/00 ; A61P 35/00 ; A61P 37/00 ; A61P 9/00 ; C12N 5/00 ; C12N 5/06 ; H04Q 7/20	Methods Of Treating Autoimmune Diseases, Allergic Responses, Cancer, Inflammatory Diseases, Or Fibrosis In An Animal, Promoting Would Healing, Repairing Epithelial Damage And Promoting Angiogenesis In An Organ Or Tissue Of An Animal By Administering To The Anim Al Mesenchymal Stem Cells In An Effective Amount.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CA2584758	CA - 20072584758 - 02/04/2007	VOON GERARD G V	A01K 67/027 ; C12N 15/00 ; C12N 15/09 ; C12N 15/63 ; C12N 15/85 ; C12N 15/87 ; C12N 15/88 ; C12N 5/00	Three Parts Of Animal Cloning Techniques Not Well Known Just Below Are To Be Incorporated To All The Techniques Below (Source Of Cells): 1. Leaving The Host's Cytoplasm - And Proteins All Is Left In The Oocyte (Which We Will Try Fertilized Or Unfertilized) Except The Nucleus Is Removed. 2. The Second Is To Starve The Tissue Cultured Cells (Which Has The DNA You Want To Clone) Before Micro Injection Into The Host Oocyte And Electrical Or Heat Shock To Fuse The Injected DNA With The Host Oocyte Cytoplasm. This Seems To Be The Trick To Cause The Cells To Multiply Into A Blastocyst. 3. We Also Plan To Add Ligase And Polymerase, Polyethylene Glycol And Other Such DNA Helping Binding Enzymes (Ase...) To The DNA Donor To Be Cloned Animal/Person/Plants. Sources Of Cells Include (The Following Techniques Are More Cloning Then In Vitro Since The Resulting Tissue Are The Same DNA As The Adult, Making The Artificially Grow N Organs, Neurons And Muscles Blood, Bone Marrow Cells Compatible, And Solving The Tissue Rejection Problem.
CA2592198	CA - 20072592198 - 18/06/2007	ETHICON INC	A61L 31/06 ; A61L 31/14 ; A61L 31/16 ; B32B 27/08 ; B32B 33/00 ; B32B 5/08 ; D04H 1/40	The Present Invention Is Directed To A Multilayered Fabric Comprising A Firs T Absorbable Nonwoven Fabric And A Second Absorbable Woven Or Knitted Fabric, And Its Method Of Manufacture.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101215545	CN - 20071308075 - 31/12/2007	UNIV ZHEJIANG	C12N 5/06 ; C12N 5/08	The Invention Provides A Method For Inducing Mesenchymal Stem Cell In The Bone Marrow To Obtain The Nerve Prosoma Cell, Which Comprises The Following Steps: Doing Generation Culture For The Separated And Purified Mesenchymal Stem Cell In The Bone Marrow, Switching Stable Generation Mesenchymal Stem Cell Into Induction Culture Medium, Inducing And Culturing For 7-20 D, Obtaining Nerve Prosoma Cell. The Induction Culture Medium Is Basic Culture Medium Which Is Charged With Growth Factor, Wherein The Growth Factor Mainly Comprises An Epiderm Growth Factor (EGF), A Base Fibroblast Growth Factor (Bfgf), An Insulin Growth Factor-1 (IGF-1) And A Nerve Nourishment Factor 3 (NT-3). The Invention Provides A Method For Inducing Mesenchymal Stem Cell In The Bone Marrow To Obtain The Nerve Prosoma Cell Which Can Be Differentiated Into Nerve Cell And The Nerve Prosoma Cell Can Be Switched Into Inner Ear Hair Cell And Inner Ear Supporting Cells, Which Provides Experiment Evidence For Cochlear Cell Transplantation Therapeutic Sound Perception Nerve Deafness And Solves The Problem Of The Transplantation Cell Resource.
CN101215546	CN - 20071308076 - 31/12/2007	UNIV ZHEJIANG	C12N 5/06 ; C12N 5/08	The Invention Provides A Method For Inducing Mesenchymal Stem Cell In The Bone Marrow To Obtain The Inner Ear Hair Cell Prosoma, Which Comprises The Following Steps: Doing Generation Culture For The Separated And Purified Mesenchymal Stem Cell In The Bone Marrow, Switching Stable Generation Mesenchymal Stem Cell Into Induction Culture Medium, Inducing And Culturing For 7-20 D, Obtaining The Inner Ear Hair Cell Prosoma. The Induction Culture Medium Is Basic Culture Medium Which Is Charged With Growth Factor, Wherein The Growth Factor Mainly Comprises An Epiderm Growth Factor (EGF) And An Insulin Growth Factor-1 (IGF-1), The Charging Quantity Is EGF 10-30ng/Ml Basic Culture Medium And IGF-1 40-60ng/Ml Basic Culture Medium. The Beneficial Effect Of The Invention Is That The Invention Provides A Method For Inducing Mesenchymal Stem Cell In The Bone Marrow To Obtain The Inner Ear Hair Cell Prosoma And Supplies A Firm Base For Cochlear Cell Transplantation Therapeutic Sound Perception Nerve Deafness, Which Is Provided With Significant Clinical Meaning.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101215547	CN - 20081001107 - 15/01/2008	DAILIANG LIU	C12N 5/06 ; C12N 5/08	The Invention Relates To The Biological Cell Extract And Application Field And Provides A Method For Separating, Purifying And Extracting Mesenchymal Stem Cell In The Fat, Which Comprises The Following Steps: First, Extracting Fat Source Under Sterile Condition, Soaking By Buffer, Rinsing, Adopting Nutrient Solution To Do Water-Bath Oscillation And Digestion, Fetching The Sieved Digestion Material To Do Centrifugal Disposal, Obtaining Base Microtubule Layer, Sedimenting And Removing Erythrocyte, Using Nutrient Solution To Centrifugal And Rinse After Sieving The Digestion Material, Using Physiological Saline To Dilute The Digested And Separated Cell, Separating Electrophoresis Tank Into Three Parts Transversely By Nylon Screen Cloth Evenly, Placing Potassium Chloride And Calcium Gluconate Solution According To Certain Bulk Rate, Inputting AC Power For 2-5 Min, Placing The Obtained Cell In The Middle Electrophoresis Tank To Stir Evenly, Electrophorezing For 15-30 Min Under DC Power, Extracting Cell Liquid In The Electrophoresis Tank At The Positive Electrode Side, Obtaining The Mesenchymal Stem Cell In The Fat. The Method Is Short In Period Without Causing Gene Sorting Disorder Or Mutation On The DNA Vortex Chain.
CN101218342	GB - 20050007755 - 16/04/2005	AXORDIA LTD	C12N 5/06 ; G01N 33/50	Cytotrophoblast Stem Cell
CN101225374	CN - 20081059516 - 25/01/2008	UNIV ZHEJIANG	A61K 36/41 ; A61P 1/16 ; C12N 5/06	The Invention Relates To A Rhodiola Rosea And A Rhodioside Application For Inducing Stem Cells To Directionally Differentiate Into Hepatocytes, In Particular To A Compound Inducer Of The Rhodioside And Cell Growth Factor FGF-4 Used For Inducing Mesenchymal Stem Cells To Directionally Differentiate Into Hepatocytes. The Rhodiola Rosea Develops The New Application Of Rhodiola, Which Induces Mesenchymal Stem Cells And Other Stem Cells To Directionally Differentiate Into Hepatocytes In Vitro, And Provides The Effect Of The Rhodiola Rosea And The Rhodioside On Inducing The Adult Stem Cells To Directionally Differentiate Into Hepatocytes, Which Is Beneficial To Further Research Of The In Vivo Stem Cells Transplantation For Treating Acute Or Chronic Hepatic Injury And Middle-Advanced Liver Disease Field, And Provides The Basic For New Drug Development.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101228264	US - 20050693141P - 22/06/2005	GERON CORP	C12N 5/00 ; C12N 5/08	Differentiation Of Primate Pluripotent Stem Cells To Cardiomyocyte-Lineage Cells.
CN101229241	CN - 20071002670 - 26/01/2007	HEBEI YILING PHARMACEUTICAL IN	A61K 31/045 ; A61K 35/62 ; A61K 35/64 ; A61K 36/71 ; A61P 43/00 ; A61P 9/10	The Invention Discloses The Application Of A Traditional Chinese Medicine Combination In The Preparation Of Medicine Which Enhances The In-Vivo Survival And Cardio Blast Differentiation Of Mesenchymal Stem Cells. The Invention Also Relates To The Application Of The Traditional Chinese Medicine Compound To The Preparation Of Medicine Which Cures The Cardiovascular Disease With Autologous Mesenchymal Stem Cells.
CN101230331	CN - 20081059560 - 31/01/2008	UNIV ZHEJIANG	A01N 1/02 ; A61K 31/7048 ; A61K 35/28 ; A61K 49/00 ; A61L 27/38 ; A61P 1/16 ; C12N 5/06	The Invention Provides A Purpose Of Baicalin On Promoting The Directional Division In Vitro Of Mesenchymal Stem Cells In Bone Marrow. The Invention Also Provides A Method Of Promoting That The Mesenchymal Stem Cells In Bone Marrow Differentiate Into Liver Cells In Vitro. The Invention Adopts Baicalin As Cell Differentiation Accelerant; Under The Condition That Fibroblast Growth Factor-4(FGF-4) Exists, The Invention Induces The Mesenchymal Stem Cells In Bone Marrow To Directionally Differentiate Into Liver Cells. The Invention Also Provides A Purpose That Mesenchymal Stem Cells In Bone Marrow In Vitro Uses The Liver Cells, Which Is Induced And Directionally Divided Into By Baicalin, As The Seed Cells Of Liver Tissue Engineering And Cell Transplantation, Or As The Bio-Artificial Liver. The Invention Also Provides The Purpose Of Baicalin Or The Baicalin Combined With The Transplantation Of Mesenchymal Stem Cells In Bone Marrow In Preparing Liver Diseases Treating Medicine As The Cell Differentiation Accelerant; The Baicalin Is Prepared Into The Medicine Treating Liver Diseases, The Transplantation Of Mesenchymal Stem Cells In Bone Marrow Is Combined To Treat Heavy Liver Disease. The Invention Also Provides The Purpose Of Baicalin Containing Cell Preserving Liquid In Seed Cells Storage.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101230379	JP - 20030083106 - 25/03/2003	JAPAN SCIENCE & TECH AGENCY	A61L 27/00 ; C07K 14/495 ; C07K 14/51 ; C07K 14/52 ; C12N 15/09 ; C12N 5/06 ; C12N 5/10 ; C12Q 1/02 ; G01N 33/15 ; G01N 33/50	Induction Of Differentiation Of Stem Cells, And Control Of Differentiation Potency Of Stem Cells
CN101233226	US - 20050693266P - 22/06/2005	GERON CORP	C12N 5/02	Suspension Culture Of Human Embryonic Stem Cells
CN101233227	JP - 20050028200 - 03/02/2005	UNIV OKAYAMA NAT UNIV CORP	A61L 27/00 ; C12N 15/09 ; C12N 5/06	Method Of Inducing Differentiation Of Embryo-Stem Cell Into Hepatocyte And Hepatocyte Induced By The Method
CN101238129	US - 20050689359P - 10/06/2005	IRM LLC	C07D 487/04 ; C12N 5/06	Compounds That Maintain Pluripotency Of Embryonic Stem Cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101240261	CN - 20071026761 - 06/02/2007	UNIV SUN YAT SEN	C12N 5/08	Human Breast Carcinoma SK-BR-3 Cell Strain As Source Cell For Building Train Adapted By The Invention Is Continuously Inoculated On Female NOD/SCID Mouse Mammary Gland Fat Pad And Filtered In Pressure Of Low Dose Chemotherapy Drug Tail Intravenous Injection To Build Human Breast Carcinoma Cell Line SK-3rd Rich In Tumour Breast Carcinoma Stem Cell. The Proper Of Knub Stem Cell In The Cell Is Increased Greatly Comparing With Non NOD/SCID Vivo Passage Source Cell. The Formation Rate Of Saccule And The Number Of Cell In The Saccule Are Increased Greatly In Case Of Cell Suspension Culture. The Ratio Of Undifferentiation Cancer Cell Is Reduced But Is Higher Evidently Than Source Cell In Process Of SK-3rd Saccule Cell Inducing Differentiation. The Saccule Cell Formed From SK-3rd Cell Has Carcinoma Stem Cell Phenotype Which Gradually Dies Out In Process Of Differentiation. NOD/SCID Mouse Orthotopic Transplantation Has High Tumour-Forming Rate, High Long-Distance Transferring Rate, Short Tumour-Forming Periodic Time And Less Number Of Cells Needed By Tumour-Forming. The Invention Is An Ideal Mould For Studying Breast Carcinoma Stem Cell And Has Wide Applications Foreground For Disclosing Generation Mechanism Of Breast Carcinoma And Neoplastic Treat.
CN101240262	US - 20010338885P - 07/12/2001	GERON CORP	A01N 63/00 ; A61K 48/00 ; A61P 3/10 ; A61P 5/50 ; C12M 3/00 ; C12N 15/17 ; C12N 15/18 ; C12N 15/85 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Islet Cells From Human Embryonic Stem Cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101240263	CN - 20071034396 - 07/02/2007	UNIV CENTRAL SOUTH	A61K 35/28 ; A61P 7/00 ; C12N 15/861 ; C12N 5/10	The Invention Discloses Human Marrow-Interstitial Stem Cell Modified By TPO Gene, Its Preparing Process And Use. The Human Marrow-Interstitial Stem Cell Is Obtained By Recombination Gland Relevant Virus Meso-Guide TPO Gene Decoration. The Preparation Method Comprises The Following Steps Consequently Cloning Human Tyre Liver TPO Gene, Constructing Carrier Plasmid Paav-Tpo-Ires-Hrgfp, Preparing Raav-TPO Viral Vectors, Culturing Human Marrow-Interstitial Stem Cell, Transfecting Raav-TPO On Human Marrow-Interstitial Stem Cell. The Human Marrow-Interstitial Stem Cell Modified By TPO Gene Or Human Marrow-Interstitial Stem Cell Exudate Modified By TPO Gene Can Be Used For Preparing Medicine Of Urging Blood Platelet-Generating. The Mscs Modified By TPO Gene Generates Internal Source TPO Through Cell Secreting For Treating Blood Platelet Reduction So The Side-Effect Generated From Injection Human Recombination TPO Is Not Generated.
CN101245336	CN - 20081020094 - 20/03/2008	MEIRONG WAN	C12N 5/08	The Invention Relates To A Method Of The Induction And Differentiation Of The Neural Stem Cells And The Neural Cells From Bone Marrow Stromal Cells Which Are Cultured By Autologous Bone Marrow, Autologous Serum And Autologous Cerebrospinal Fluid. The Method Pertains To The Methods For Differentiating The Bone Marrow Stem Cells Into The Neural Stem Cells. A Conventional Low-Sugar DMEM/F 12 Culture Medium Is Adopted, The Autologous Serum Replaces The Original Fetal Bovine Serum, The Autologous Cerebrospinal Fluid Replaces The Original Additive And A Stimulating Factor, A Small Amount Of Autologous Bone Marrow Is Used For Culturing More Cells With The Number That Can Meet The Clinical Needs. The Method Has The Advantages Of Low Cost And Easy Material Selection, Avoiding Zoonosis And Foreign Protein Exclusive Reaction, And So On. The Method Of Inducing The Bone Marrow Stromal Cells Into The Neural Stem Cells By Using Cerebrospinal Fluid Can Effectively Solve The Shortcomings Of The Traditional Methods.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101250499	CN - 20081027352 - 11/04/2008	UNIV ZHONGSHAN	C12N 5/06 ; C12N 5/08	The Invention Discloses A Stem Cell Non-Toxic Frozen Stock Solution, The Solution Of The Frozen Stock Solution Each 100 Milliliters Contains Polyvinyl Alcohol 0.1-5g And 1, 2-Dihydroxypropane 1-30g, And Rest Is Water. The Frozen Stock Solution Of The Invention Contains Both Permeable And Impermeable Cryoprotective Agent Simultaneously, In Particular, The Polyvinyl Alcohol Is Adopted As An Impermeable Antifreeze Component, The Frozen Stock Solution Has Prominent Effects Of Preventing Ice Crystals From Growing And Inhibiting Recrystallization, And The Frozen Stock Solution Can Effectively Form The Low Temperature Vitrification Frozen Stock Effect. A Vitrification Frozen Stock Solution System Of The Invention Takes Factors Such As The Toxicity, The Permeability, The Vitrification Ability, The Vitrification Stability, The Heating And Cooling Speed And The Like Into Account, And Thereby Not Only The Vitrification Condition Can Be Entered Easily In The Cooling Process, But Also The Stability Of Vitrification Solution In The Heating Process Can Be Guaranteed. The Multi-Component Frozen Stock Solution Of The Invention Has Simple And General Effects And Is Suitable For Cryopreserving Various Cells, Groups And Organs By Vitrification.
CN101250502	CN - 20081035462 - 01/04/2008	SHANGHAI INST BIOL SCIENCES	A61K 35/12 ; A61P 37/00 ; C12N 15/11 ; C12N 15/63 ; C12N 5/10	The Invention Provides A Method For Preparing Induced Embryonic Stem Cells, Which Comprises Following Steps: Firstly, Introducing Six Transcription Factors Into Adult Cells, Secondly, Culturing The Adult Cells Under The Condition For Culturing The Embryonic Stem Cells, And Enabling The Adult Cells To Form Cells With The Form Of Embryonic Stem Cells. The Method Of The Invention Also Comprises: Cloning The Six Transcription Factors Into A Carrier And Then Transforming The Six Transcription Factors Into The Adult Cells. When The Method Of The Invention Is Adopted To Prepare The Embryonic Stem Cells, The Efficiency Is High, The Acute Rejection Can Be Avoided, The Embryonic Stem Cells Can Be Differentiated Into Different Tissue Cells Under Special Conditions, And The Method Of The Invention Has Wide Applying Prospect.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101252834	US - 20050687127P - 02/06/2005	STEMCYTE INC	A01N 1/02	The Umbilical Cord Blood (UCB) Compositions Of The Present Invention Possess The Unique Features Of Having Plasma That Is Substantially Depleted From The UCB Unit And Red Blood Cells (RBC) That Are Not Depleted From The UCB Unit. Such UCB Units Can Be Prepared By A Process That Combines Plasma Depletion With Cryopreservation, Selection, Thawing, And/Or Transplantation Of Hematopoietic Stem Cells To Provide Superior Clinical Outcome By Maximizing Post-Processing Cell Recovery And Post-Thaw Infusion Cell Dose. Methods For Treating A Wide Variety Of Malignant Diseases And Benign Diseases Associated With The Hematopoietic System By Administering The UCB Compositions Of The Present Invention Are Also Provided.
CN101253274	GB - 20050015305 - 26/07/2005	PROCURE THERAPEUTICS LTD	A61K 39/00 ; A61P 35/00 ; C12Q 1/68	The Present Invention Discloses Gene Markers Of Stem Cells, Typically Prostate Stem Cells, And In Particular Cancer Stem Cells, For Example Prostate Cancer Stem Cells; Therapeutic Agents And Diagnostic Assays Based On Said Stem Cell Genes; And Including Screening Assays To Identify Therapeutic Agents.
CN101254310	CN - 20061123075 - 27/10/2006	UNIV ZHONGSHAN	A61K 45/00 ; A61K 48/00 ; A61P 25/00	The Invention Relates To A Biological Activity Of An Adenovirus Expression Vector Which Is Recombined By Using A Human Neurotrophin-3 Receptor Gene (Human Trkc Gene) And An Application In The Nerve Injury Repair Thereof. The Human Ad-Trkc Can Be Used For Promoting The Survival Of The Injured Central Neurons And The Axonal Regeneration, So As To Promote The Neural Stem Cells To Be More Divided Into The Neurons With The Potential Of Synaptic Formation, Further To Replace The Injured Neurons Or The Dead Neurons. The Biological Activity Strengthens The Protection Mechanism Of The Central Nervous System After The Injury On The Gene Treatment Level, Replaces The Injured Neurons, Participates In The Reconstruction Of The Neural Network And Repairs The Functions Of The Central Nervous. Thus, The Application Has Important Significances For Prolonging The Human Life, Improving The Quality Of Lives Of The Wounds And The Patients, Reducing The Social And The Family Burdens And Promoting The Development Of Chinese Socioeconomic Development.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101258160	KR - 20050084896 - 12/09/2005	GOOD CELL LIFE INC	C07K 2/00	The Present Invention Relates To A Ligand Of Axi Receptor Tyrosine Kinase Used To Induce The Differentiation From Precursor Natural Killer Cell To Mature Natural Killer-Cell. In Addition, It Relates To A Process For Producing Mature Natural Killer Cell Comprising Treating Hematopoietic Stem Cell With Interleukin-7, Stem Cell Factor And Flt3L To Differentiate Into Precursor Natural Killer Cell, And Treating The Resulting Precursor Natural Killer Cell With Ligand Of Axi Receptor Tyrosine Kinase To Produce Mature Natural Killer Cell.
CN101260382	CN - 20081036377 - 21/04/2008	UNIV SHANGHAI	C12N 5/06	The Invention Relates To Application Of A Nano Tio2 Particle In Promotion Of Nerve Stem Cell Proliferation. The Nano Tio2 Particle Is Added And The Function Of Cell Proliferation Is Realized Through Cx43 Dephosphorylation, And The Gross Amount Of Proteins Is Not Changed. The Promotion Function Is Different According To The Difference Of The Concentration Of Added Tio2 Solution; When The Tio2 Concentration Is 150 Micrograms Per Milliliter, The Promotion Function Is The Most Obvious. Simultaneously, The Promotion Function Reaches The Maximum On The Third Day For Cell Growth After Entry Into Logarithmic Phase, Thereby The Normal Life Cycle Of Cells Is Not Affected.
CN101210232	CN - 20061130638 - 28/12/2006	TIANJIN AMCELLGENE ENGINEERING	C12N 5/08	The Invention Discloses A Preservation Solution For Mesenchymal Stem Cells And Application Thereof. The Cell Preservation Solution Contains Human Albumin And Heparin As The Main Components, And Other Auxiliary Reagents Such As Human Cytokine, Phosphate Ion, Metal Ions Or Monosaccharide Are Contained In A Buffer Solution For Preserving Human Mesenchymal Stem Cells. The Preservation Solution Can Keep High Survival Rate Of Human Mesenchymal Stem Cells In Transportation Process, Reduce Adhesion Between Cells And Between The Cell And The Inner Wall Of A Container, And Reduce The Possible Occurrence Of Cell Mass Embolism In Blood Vessel While Clinically Infusing Human Mesenchymal Stem Cells. The Mesenchymal Stem Cells Can Be Maintained In A State Of Single-Cell Suspension At An Environment Temperature Of 4 To 15 DEG C For 24 H, Thus Greatly Enlarging The Clinic Application Range Of The Human Mesenchymal Stem Cells. The Components Used In The Solution Accord With The Clinic Application, And Can Meet The Requirement For Clinic Use Of The Human Mesenchymal Stem Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101260385	CN - 20081047297 - 11/04/2008	INST OF ANIMAL & VETERINARY ME	C12N 7/00	The Invention Relates To A Culture Method For Flue Viruses, Wherein, A Goat Fetal Kidney Cell Is Cultured As A Cell Source For Culture Of The Flue Viruses. Pretreatment Is Performed On Flue Viruses Cultured By Utilization Of A Chick Embryo By Adoption Of Cell Unfreezing Extracts Which Are Unfreezing Extracts Of Animal Fibroblasts And Epithelioid Noble Cells Of Mouse Embryonic Stem Cells. The Virulent Valence Of The Flue Viruses Cultured Is Obviously Higher Than That Of Flue Viruses Cultured By Utilization Of The Prior Art. Moreover, The Cells Used Are Primary Cells, Thereby No Carcinogenesis Material Danger Exists When The Cells Are Used For Production Of Vaccines; The Source Of The Cells Used Is Wide And The Acquisition Cost Is Low; No Trypsin Is Used For Pretreatment Of The Flue Viruses, Thereby The Influence Of The Trypsin On The Virus Producing Cells For Is Avoided.
CN101336298	AU - 20050907287 - 23/12/2005	SIENNA CANCER DIAGNOSTICS LTD	C12Q 1/68	The Present Invention Relates Generally To The Field Of Diagnostic And Prognostic Assays Such As Diagnostic Assays For Conditions Associated With Telomerase Activity. More Particularly, The Present Invention Provides An Assay For Measuring Telomerase Activity As An Indicator Of Cancer, An Inflammatory Disorder And/Or A Condition Involving Embryogenesis And/Or Requiring Stem Cell Proliferation And Agents And Kits Useful For Same. Automated And Partially Automated Assays Permitting High Throughput Screening Also Form Part Of The Present Invention. The Subject Invention Further Contemplates Methods Of Treatment Using Agents Identified By The Subject Assay Or Where Treatment Protocols Are Monitored By The Assay.
CN101260398	CN - 20071086017 - 07/03/2007	STAIDSON BEIJING PHARMACEUTICA	A01K 67/027 ; A61K 38/17 ; A61K 9/08 ; A61P 27/02 ; C12N 15/09 ; C12N 15/12 ; C12N 15/85	The Invention Relates To An Animal Obtained Through A Transgenic Method And A Preparation Method And Application Of The Animal. Particularly, The Invention Relates To Acquisition Of A Transgenic Animal With Stable Expression Of Target Genes Through Mapping And Integration Of The Target Genes Into A Rat Genome By Utilization Of The Embryonic Stem Cell Culture Technology And The Homologous Recombination Technology. The Animal Obtained Through The Method Can Be Applied To Basic Research And Acquisition Of Target Albumen. More Particularly, The Invention Relates To A Method And Application For Gene Mapping And Modification Of A Rat By Utilization Of A Nerve Growth Factor And For Preparation Of A Human-Derived Nerve Growth Factor And Mutant Proteins Of The Human-Derived Nerve Growth Factor.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101263224	US - 20050167061 - 24/06/2005	CELLERIX S L	A61K 35/36 ; A61L 27/38 ; A61P 17/02 ; C12N 5/08	Provided Herein Are Novel Methods And Compositions Utilizing Adipose Tissue-Derived Stromal Stem Cells For Treating Fistulae.
CN101263389	US - 20050697905P - 08/07/2005	BRAINCELLS INC	G01N 33/50 ; G01N 33/94	Methods And Tools For Identifying Agents And Conditions That Modulate Neurogenesis Are Disclosed. The Disclosure Also Relates To Methods And Tools For Identifying Populations Of Neural Stem Cells Suitable For Transplantation.
CN101265503	JP - 20030063077 - 10/03/2003	JAPAN SCIENCE & TECH CORP	C07K 14/47 ; C07K 16/18 ; C12N 15/00 ; C12N 15/09 ; C12N 15/11 ; C12N 5/10 ; C12Q 1/68 ; G01N 33/53	The Invention Provides A Mark That Detects, Separating And Identifying Mesenchymalstemcell And A Method That Adopts The Mark To Detect, Separate And Identify The Mesenchymalstemcell. The Genes Showed In A Sequence List Are Specifically Expressed In The Mesenchymalstemcell. The Genes Compose The Mark That Detects The Mesenchymalstemcell. In Particular, The Invention Contains A Probe That Detects The Mesenchymalstemcell Marked Genes And A Primer For The PCR That Amplifies The Genes Of Detected Cells When Detecting The Mesenchymalstemcell Marked Genes, Further Contains A Polypeptide Mark That Detects The Mesenchymalstemcell Marked Genes Composed Of The Polypeptide Expressed By The Mesenchymalstemcell Marked Genes And An Antibody That Detects The Polypeptide Mark And Is Combined Specifically With The Polypeptide Mark, In Particular Contains A Method That Identifies And Separates The Mesenchymalstemcell By The Probe That Detects The Mesenchymalstemcell Marked Genes And The Antibody That Is Combined Specifically With The Polypeptide Mark.
CN101267779	US - 20050703068P - 27/07/2005	UNIV FLORIDA	A61F 2/00	The Invention Generally Provides Methods For Recruiting Stem Cells To An Ocular Tissue. The Methods Involve Inducing Heat Shock In The Ocular Tissue Using A Subthreshold Laser And/Or An Agent. In Some Embodiments, The Heat Shock Is Induced Following The Administration Of An Agent That Mobilizes Hscs.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101269088	CN - 20071027278 - 23/03/2007	UNIV SUN YAT SEN	A61K 35/28 ; A61P 37/06	The Invention Belongs To The Field Of Stem Cells And Immunology And Relates To A Stem Cell Preparation Used For Preventing And Treating Chronic Graft Versus Host Diseases. The Stem Cell Preparation Used For Preventing And Treating Chronic Graft Versus Host Diseases In The Invention Is A Jointly-Transplanted Stem Cell Preparation Of Mesenchymal Stem Cells And Hemopoietic Stem Cells. The Stem Cell Preparation Is Input Into The Human Receptor Through The Vein, The Input Dose Of Mesenchymal Stem Cells Is Adjustable Based On The Receptor And The Input Dose Of Hemopoietic Stem Cells Is Identical To A Conventional Bone Marrow Transplant Program. Applied To A Patient After A Bone Marrow Transplant, The Stem Cell Preparation In The Invention Can Prevent The Emergence Of Chronic Graft Versus Host Diseases (Cgvhd) After A Bone Marrow Transplant (BMT), The Incidence Rate Of GVHD Is Obviously Reduced And The Severity Is Evidently Lowered Once A GVHD Emerges, Thereby Providing A New Way Of Solving The Problems After A Hemopoietic Stem Cell Transplant Comprehensively.
CN101269089	CN - 20081056753 - 24/01/2008	FIELD OPERATION BLOOD TRANSFUS	A61K 35/28 ; A61K 9/08 ; A61P 37/02 ; C12N 5/10	The Invention Discloses A New Use Of Mesenchymal Stem Cells Modified By CTLA4Ig Gene And Aims To Provide The Application Of Mesenchymal Stem Cells Modified By CTLA4Ig Gene To The Preparation Of Drugs Of Induced Liver Transplantation Immune Tolerance. The Recombined Mesenchymal Stem Cells Modified By CTLA4Ig Gene Are Obtained By Infecting Mesenchymal Stem Cells Outside The Recombined Adenovirus Expressing CTLA4Ig Secretorily. The Mesenchymal Stem Cells Modified By CTLA4Ig Gene Can Be Used As Active Ingredients To Prepare Drugs Of Induced Liver Transplantation Immune Tolerance. The New Use Of Mesenchymal Stem Cells Modified By CTLA4Ig Gene Has Important Guiding Significance In The Clinical Application Of Liver Transplantation, Lays A Foundation For The Specific Immune Tolerance Of Induced Liver Transplantation Donors And Has A Wide Prospect Of Application.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101269237	CN - 20071027279 - 23/03/2007	UNIV SUN YAT SEN	A61L 27/38	The Invention Belongs To The Stem Cells And Immunology Field, And Relates To A Stem Cell Preparation For Preventing Acute Graft-Versus-Host Disease. The Stem Cell Preparation For Preventing Acute Graft-Versus-Host Disease Of The Invention Is A Stem Cell Preparation Jointly Grafted From Mesenchymal Stem Cells And Hematopoietic Stem Cells. The Stem Cell Preparation Is Infused Into The Receptors In The Human Body Through Vein, The Infusion Dosage Of The Mesenchymal Stem Cells Is Adjusted According To The Receptors, And The Infusion Dosage Of The Hematopoietic Stem Cells Refers To The Conventional Bone Marrow Transplantation Program. The Stem Cell Preparation Of The Invention Is Applicable To The Patient The Bone Marrow Of Which Is Transplanted, Can Reduce The Outbreak Rate Of The Acute Graft-Versus-Host Disease (GVHD), Can Lower The Severity Degree Obviously, And Can Provide A New Way For Comprehensively Solving The Problems Raised After Hematopoietic Stem Cells Transplantation.
CN101270349	CN - 20081061267 - 20/03/2008	UNIV ZHEJIANG	C12N 5/08 ; G01N 33/53	The Invention Provides A Method For Separation Of Placenta-Derived Mesenchymal Stem Cells, And For Amplification And Culture In Vitro. After Decidual Tissue Cells On The Side Of A Placenta Matrix Are Adopted And Collected, Primary Culture Cells Are Amplified By Adhering To Wall; The Placenta-Derived Mesenchymal Stem Cells Are Purified By Adopting Positive And Negative Immunological Sorting And Combination Method To Get CD34<->CD105<+> Cells Which Are Secondarily Amplified And Cultured In A Serum-Free Culture System In Vitro. By Adopting The Method Provided By The Invention, Just Few Primary Culture Cells (1X10<5> Cells) Are Needed Every Time To Produce A Good Sorting Result; And The Purification Rate Of The Placenta-Derived Mesenchymal Stem Cells Is Further Improved. Not Only The Culture System Used Has Significant Advantage Of Amplification Over Placenta-Derived Mesenchymal Stem Cells, But Also The Amplified Cells Have Multiplex Differentiation Potential. The Method Can Be Applied For Purification Of Placenta-Derived Mesenchymal Stem Cells And Amplification And Culture In Vitro.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101272798	KR - 20050091155 - 29/09/2005	AJOU UNIVERSITY INDUSTRY ACADE	A61K 35/12	Mesenchymal Stem Cells Expressing A Suicide Gene Show Excellent And Highly Selective Anticancer Effects Against Cancer Tissues Through The Selective Conversion Of A Prodrug Of An Anticancer Agent To The Anticancer Agent At Around The Cancer. Also Disclosed Herein Are A Pharmaceutical Composition For Treating A Cancer Comprising The Mesenchymal Stem Cell; A Kit For Treating A Cancer Comprising An Expression Vector Comprising The Suicide Gene, The Mesenchymal Stem Cell And The Prodrug; And A Method For Treating A Cancer Patient, Which Comprises Successively Administering The Mesenchymal Stem Cell And The Prodrug To The Patient.
CN101273124	US - 20050711249P - 25/08/2005	UNIV ARIZONA	C12N 5/08	Methods For Modeling Cancer Cell Migration, Screening Drugs For Effects On Tumor Cell Migration, And Detecting The Potential For Tumor Cell Migration Relating To The Fusion Of A Bone Marrow Derived Stem Cell With A Genetically Altered Cell (Figure 1). Antibodies Against Ubiquitin Are Shown To Inhibit Tumor Cell Migration.
CN101273983	CN - 20081061401 - 25/04/2008	UNIV ZHEJIANG	A61K 31/352 ; A61L 27/38 ; A61P 25/28 ; C12N 5/06	The Invention Provides A Single Type Nerve Cell Which Is Formed By In Vitro Directed Differentiation Of Sobavachin-Induced Stem Cells (Comprising Embryonic Stem Cells, Neural Stem Cells And Bone Marrow Mesenchymal Stem Cells). The Single Type Nerve Cell Is Applied In The Preparation Of Drugs Used For Stem Cell Transplantation Therapy Of Neurodegenerative Diseases, In The Preparation Of Cell Differentiation Agents Used For Repairing And Reconstructing Of Damaged Nerve Cells And Is Also Applied In The Construction Of A Efficacy Screening And Evaluation Model. The Invention Develops A New Usage Of The Isobavachin, Provides A Physical Basis For The Prevention And Treatment Functions Of The Isobavachin Traditional Chinese Medicine And Also Provides A Basis For The Drug Regulation And Control Regenerative Medicine Or The Tissue Engineering.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101278045	JP - 20050288436 - 30/09/2005	TOBISHI PHARMACEUTICAL CO	C12N 5/06 ; C12N 9/64	The Present Invention Provides An Activating Agent Of Stem Cells And/Or Progenitor Cells Comprising A Thrombin-Like Enzyme Which Can Be Used In Regenerative Medicine, And Particularly In Regenerative Medicine Utilizing Self-Regeneration, Acting Promptly And Moderately Depending On The State Of Advancement And The Degree Of Injured Organs And/Or Tissues To Which Regenerative Medicine Is Applied, With Few Or No Side Effects. The Present Invention Also Provides A Method For Activating Stem Cells And/Or Progenitor Cells In An Animal Comprising The Step Of Administering To The Animal An Effective Amount Of A Thrombin-Like Enzyme And Use Of The Thrombin-Like Enzyme For Activating Stem Cells And/Or Progenitor Cells.
CN101278942	CN - 20081037722 - 20/05/2008	UNIV SHANGHAI	A61K 35/30 ; A61P 25/00 ; A61P 25/16	The Invention Studies Prosthodontic Treatment For PD By Transplanting Nscs-NT3 To A Parkinson Model Rat Brain. APO Rotational Behavior Experiment Finds Out That Nscs-NT3 Has Positive Significance In Functional Recovery Of A Parkinson Rat.
CN101280291	CN - 20081069728 - 23/05/2008	UNIV PLA 3RD MILITARY MEDICAL	C12N 5/06	The Invention Discloses New Application Of Ecdysterone As Inducer For Inducing The Neural Stem Cell Of The Mammal To Differentiate Towards The Neuron, Discloses Cell Culture Medium Used For Inducing The Neural Stem Cell Of The Mammal To Differentiate Towards The Neuron And Provided With Inducer, Namely, Ecdysterone, And Provides The Preparation Method Of The Cell Culture Medium; Experiments Show That The Inducer, Namely, Ecdysterone Is Added In The Differentiation Medium Of The Neural Stem Cell Of The Mammal, The Proportion Of Differentiation Of The Neural Stem Cell Towards The Neuron Is Obviously Improved, Especially The Effect Is Optimum When The Concentration Of The Ecdysterone Is 200 Mg/L, And The Cell Culture Medium With The Ecdysterone Can Induce The Neural Stem Cell Of The Mammal To Differentiate Towards The Neuron, And Has Good Application Value.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101280303	CN - 20081037733 - 20/05/2008	UNIV SHANGHAI	C12N 15/11 ; C12N 5/06	The Invention Relates To A Transcriptional Factor Snare Sequence And The Application Thereof. When The Snare Sequence In The Invention Is Transferred Through The Neural Stem Cell C17.2, The Target Gene Rho-GDI(Gamma) Has An Obvious Inhibiting Effect. The MTT Method Is Used For Detecting The Effect To The Multiplication Of The Cell, But The Cellular Morphology Generates Remarkable Change, After The Confirmation Of The Immunity Group Double Dyeing, The Neural Stem Cell C17.2 Has A Dissimilating Tendency To The Neuron Direction, The Vitro Transferring Experiment Proves That The Snare Sequence In The Invention Can Cause The Transferring Of The Cell, And The Invention Establishes A Certain Foundation For Treating The Nervous System Diseases And The Widespread Application Of The Transplant.
CN101280306	CN - 20081037698 - 20/05/2008	UNIV SHANGHAI	C12N 15/12 ; C12Q 1/68 ; G01N 21/64 ; G01N 33/53	The Invention Relates To A New Usage Of A Neural Stem Cell Differentiating Related Gene DCF1. The Invention Sieves Protein ATP1B1 Interacted With DCF1 Through Utilizing A Yeast-Two Hybrid Technology And Is Positioned Altogether By Using Cell Fluorescence, And The Interaction Is Confirmed Through Immunity And Precipitation. According To A Literature Report, The Interaction Between ATP1B1 And BACE1 Exists, But BACE1 Is An Essential Gene Of The Development Of AD (Alzheimer Disease). After DCF1 Is Muted Through A Rnai Method, The Expression Of ATP1B1 And BACE1 Also Changes Remarkably The Results Prove That The Expression Of BACE1 Can Be Adjusted And Controlled Through Certain Signal Passages Of DCF1, Certain Relation Exists In The Occurrence And The Development Of DCF1 And AD, Which Is Possible To Be A New Drug Effect Target Spot Of AD Treatment, The Interaction Of DCF1 And ATP1B1 Is Found, And The Invention Has A Vital Significance To A Signal Conducting Mechanism During The Understanding Process Of The Development And The Progression Of AD.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101285051	CN - 20081060772 - 18/04/2008	UNIV ZHEJIANG	C12N 5/06 ; C12Q 1/02	The Invention Provides An Application Of Mouse Embryonic Stem Cell-Derived In Vitro Hepatic Cell Model, Which Is Mainly In Screening Cell Differential Agent With Peroxisome Proliferator-Activated Receptor As The Target. The Stem Cell-Derived In Vitro Hepatic Cell Model Can Also Be Used To Explain An Expression Profile And Functions Of Ppars Family Related To The Energy Metabolism During Liver Development And To Reveal The Nature Of A Life Phenomenon Of Embryonic Liver Development, Even To Construct A Highly-Efficient Screening Model With Ppars Family As The Target To Regulate The Primary Screening And Evaluation Of The Potency Of Energy Supply To Livers And Develop A New Energy Metabolism Inducer For Improving The Differentiation Of Stem Cell To Hepatic Cells. The Invention Provides A New Application Of The Embryonic Stem Cell-Derived In Vitro Hepatic Cell Model Which Can Be Used As A Surrogate Model For Use In Research Of Energy Metabolism During The Liver Development To Explain The Expression Traits Of PPAR Related To The Energy System Development Of Liver Mitochondrion, And Can Also Be Used To Screening Cell Differential Agents For Stimulating The Energy Metabolism Of Liver Cells.
CN101285053	CN - 20081011637 - 28/05/2008	UNIV DALIAN TECH	C12M 3/02 ; C12N 5/08	The Invention Discloses A Method For Co-Culturing Cord Blood Stem Cells And Mesenchymal Stem Cells, Belonging To The Biotechnology And Tissue Engineering Technical Field. The Method Is Characterized By Adding No Blood Serum But Only Cytokine And Trophocyte; Wrapping The Trophocyte Calcium Alginate-Chitosan Gel Beads; Using Microcarrier And Rotating Wall Vessel To Implement The Co-Culture Of Cord Blood Stem Cells And Mesenchymal Stem Cells; And Separating And Obtaining The Cord Blood-Derived Stem Cells Respectively. The Invention Has The Advantages That: The Microcarrier Provides A Surface For The Cord Blood Mesenchymal Stem Cells To Adhere To, So The Adherent, Dynamic, Suspension Culture Of The Cord Blood Mesenchymal Stem Cells Can Be Implemented. The Rotating Wall Vessel Provides An Environment For Hemopoietic Stem Cell To Suspend And Growth In, And Also Reduces The Damages Caused By Fluid Shear Stress To The Hemopoietic Stem Cells. The Throphocyte Can Nourish The Cord Blood Stem Cells Outside The Gel Beads, Replace Partially Blood Serum And Contribute To The Separation And Harvest Of Different Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101288768	CN - 20071097869 - 20/04/2007	ACADEMIA SINICA	A61K 38/17 ; A61P 25/28	The Invention Provides A Drug Combination For Treating Progressive Nerve Degradation Or Inhabiting The Happening Of The Progressive Nerve Degradation Of A High Risk Curer. The Drug Combination At Least Comprises The Agent Of A Granulocyte Colony Stimulating Factor Receptor In Effective Quantity, Thereby Moving Hematopoietic Stem Cells To Peripheral Blood From Bone Marrow. The Combination Can Also Be Used For Inhibiting The Happening Of The Progressive Nerve Degradation On The High Risk Curer. In Addition, A Choice Of The Methods Is Provided For Treating The Agent Of The Granulocyte Colony Stimulating Factor Receptor Of The Progressive Nerve Degradation.
CN101288779	CN - 20071098480 - 18/04/2007	INST BASIC MED SCIENCES PLA	A61L 27/38	The Invention Discloses An Injective Myocardial Tissue Engineering Product Basing On Temperature Responsive Chitosan Hydrogel And More Particularly Relates To Liquid Temperature Responsive Chitosan Hydrogel Which Is Used As Stent Material That Is Combined With Seed Cells From Different Sources, Such As Embryonic Stem Cells, Mesenchymal Stem Cells, Human Fetal Cadiacmyocytes, Etc., And Is Injected And Transplanted Into The Specific Region Of An Animal Myocardial Infarction Model For Observing The Condition Of Repairing The Myocardial Infarction Region. Constructed By The Stent Material, The Injective Myocardial Tissue Engineering Product Can Improve The Retention Rate And The Survival Rate Of The Seed Cells, Can Promote The Regeneration Of Myocardial Tissues, Can Increase The Wall Thickness Of The Infarction Region And Can Remold The Shape Of An Original Ventricular And Improve The Heart Function. The Product Is Provided With The Injective Character And Is Convenient For The Treatment Operation, Thereby Avoiding Risks Brought By The Operations Of Cardioplegia Arrest, Extracorporeal Circulation, Etc. The Injective Myocardial Tissue Engineering Product Basing On The Temperature Responsive Chitosan Hydrogel Has The Advantages Of Simple Operation Process And Mild Implementation Condition, Provides A New Product For The Myocardial Tissue Engineering And Has Great Significance For The Clinical Development Of The Tissue Engineering Myocardial Treatment On Heart Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101294146	CN - 20071040179 - 28/04/2007	SHANGHAI INST BIOL SCIENCES	C12N 5/06	The Invention Discloses A Method For Preparing Neural Stem Cells, Which Comprises A Step Of Inductively Culturing P19 Cells In N2B27 Culture Medium To Obtain A Cell Group Containing Neural Stem Cells Above 94%. The Method Can Culture The P19 Cells In An Environment Without Blood Serum And Retinoic Acid, Thus Suppressing The Interference Of The Blood Serum With Complex Components And Preventing The Obtained Neural Stem Cells From Being Transformed Posteriorly By Retinoic Acid. Moreover, The Method Can Directly Transform Pluripotent Stem Cells To Neutral Stem Cells Without Resulting In Selective Cell Apoptosis. The Neutral Stem Cells Obtained By The Invention Have Anterior Neutral Plate Characteristics And Totipotency, And Can Well Simulate The Neurogenesis Process In Body. Accordingly, The Neural Stem Cells Can Be Used As The Research Model For Analyzing Neural Induction And Neural Differentiation Process From Epiblast To Neuroderm, Thus Providing An Ideal Path For Researching Development Of Embryo After Nidation.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101298606	CN - 20081052286 - 14/02/2008	TIANJIN HUANYU SHANGQIAO BUSIN	C12N 5/08 ; G06F 7/00	The Invention Discloses The Preparation, The Storage And An Application Of A Stem Cell Used For The Clinical Care. The Establishment Of The Invention Comprises The Following Steps That: 1) The Decontamination Treatment Of A Placenta And A Umbilical Cord Is Performed; A) Medical Iodine And Alcohol Or Other Disinfector Are Adopted To Process The Surfaces Of The Placenta And The Umbilical Cord; B) The Outer Surfaces Of The Placenta And The Umbilical Cord Are Removed By An Instrument Or Manually; C) The Loss Of The Bacterium And The Stem Cell Of The Placenta And The Umbilical Cord Tissue; 2) The Preparation And Culture Without Bacteria Of The Mesenchyma Stem Cell; A) The Tissue Is Processed Manually Or Automatically Without Bacteria; B) The Tissue Is Grinded Into The Smallest Particles Without Bacteria; C) The Tissue In The 2b Item Of The Enzyme Treatment Is Prepared; D) The Mixture Is Washed And Separated Centrifugally To Collect The Cell; E) The Cell Is Cultured; 3) The Umbilical Cord Mesenchyma Stem Cell Is Stored Safely; A) The Cell Is Collected Into A Storage Pipe Or A Bag In A Sterile Way; B) A Sealing Cover Is Added On The Storage Pipe; C) The Double Layer Of The High Quality Plastic Film Is Covered And Each Pipe Is Sealed By A Pumping Method; D) The Cell Is Stored Inside A Fluid Phase Of A Steam Type Liquid Nitrogen Storage Tank, Or The Safe Injection Fluid Is Prepared.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101300343	KR - 20050109502 - 16/11/2005	RNL BIO CO LTD	A61K 35/12 ; C12N 5/08	This Invention Relates To Human Adipose Tissue-Derived Multipotent Adult Stem Cells. More Particularly, The Invention Relates To Human Adipose Tissue-Derived Multipotent Stem Cells, Which Can Be Maintained In An Undifferentiated State For A Long Period Of Time By Forming Spheres And Have High Proliferation Rates, As Well As Methods For Isolating And Maintaining The Adult Stem Cells, And Methods For Differentiating The Multipotent Adult Stem Cells Into Nerve Cells, Fat Cells, Cartilage Cells, Osteogenic Cells And Insulin-Releasing Pancreatic Beta-Cells. Also, The Invention Relates To Cellular Therapeutic Agents For Treating Osteoarthritis, Osteoporosis And Diabetes And For Forming Breast Tissue, Which Contain The Differentiated Cells Or The Adult Stem Cells. Although The Multipotent Stem Cells Are Adult Stem Cells, They Have The Ability To Differentiate Into Osteogenic Cells, Nerve Cells, Astrocytes, Fat Cells, Chrondrogenic Cells Or Insulin-Releasing Pancreatic Beta-Cells, And So Are Effective In Treating Osteoporosis, Osteoarthritis, Nerve Disease, Diabetes, Etc. Also, The Stem Cells Form Spheres In A Serum-Free Medium Containing CORM-2, And Thus Can Be Maintained In An Undifferentiated State For A Long Period Of Time. Also, The Stem Cells Have Very High Proliferation Rates. Accordingly, The Stem Cells Are Useful As Cellular Therapeutic Agents.
CN101302242	CN - 20071304634 - 28/12/2007 ; CN - 20081097392 - 14/05/2008	SHENZHEN GRADUATE STUDENT ACAD	A61K 31/575 ; A61P 19/10 ; C07J 9/00	The Invention Discloses An Application Of B-Ecdysterone In Making Medicine For Curing And/Or Preventing Osteoporosis. The Invention Respectively Studies The Protective Action Of B-Ecdysterone On Bone Metabolism At Both General Level And Cellular Level. When Cultured Together With Osteoblast Strain MC3T3-E1 And Primary Mice Marrow Stromal Stem Cell, B-Ecdysterone Can Obviously Promote The Osteogenic Differentiation Of Both Cells. A Mice Osteoporosis Model Is Established Through Tretinoin Lavage, And The In Vivo Activity Experiment Of B-Ecdysterone Is Carried Out Through Adopting An Intraperitoneal Injection Method And A Lavage Method; The Results Show That B-Ecdysterone Has The Functions Of Increasing Bone Density, The Content Of Mineral Matters In Bone Tissues And Thighbone Diameter And Improving Hydroxyproline Enzymatic Activity. Therefore, B-Ecdysterone Can Be Used To Make Medicine For Curing And/Or Preventing Osteoporosis As Well As Medicine For Promoting Osteogenic Differentiation And Bone Healing.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101302529	CN - 20071027835 - 08/05/2007	SHANGWU WANG	A61K 35/30 ; A61P 25/00 ; A61P 25/28 ; C12N 15/12 ; C12N 15/63 ; C12N 15/85 ; C12N 5/10	The Invention Relates To A Method For Constructing A Gene-Transfected Neural Stem Cell Coexpressing GDNF And BDNF And Use And Significance Thereof. The Method Is Characterized In That: 1) Expressed GDNF And BDNF Parent Strains Are Human And Are Ribonucleotide Sequences Of GDNF And BDNF Proteins With Mature Coding; 2) N-Ends Of The GDNF And The BDNF Are Connected With A Human I L-2 Secretory Leader Sequence, Expressed Recombinant GDNF And BDNF Are Secreted Proteins; 3) A Constructed Expression Plasmid Contains An Expression Box Which Is Driven By A CMV Promoter And Is Connected With The GDNF And The BDNF Through An Internal Ribosome Binding Site (IRES); 4) The Neural Stem Cell Is Human And Applies An Electric Shock Transduction Method To Become The Gene-Transfected Neural Stem Cell Coexpressing The GDNF And The BDNF. The Gene-Transfected Neural Stem Cell Remedies The Defects Of The GDNF And/Or The BDNF Of The Neural Stem Cell, And Provides A Novel Gene-Transfected Neural Stem Cell Therapy Approach For Clinically Treating Neurodegenerative Diseases Such As Parkinson Disease And/Or Other Central Nervous System Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101306194	CN - 20081058569 - 20/06/2008	BENCHI BIOLOG TECHNOLOGY YUNNA	A61K 31/43 ; A61K 31/7036 ; A61K 38/18 ; A61P 25/00	The Invention Provides A Medicine Used For Curing Nerve Damage And A Method Used For Preparing The Medicine. The Invention Belongs To The Technical Field Of A Biologic Medicine. The Medicine Is Prepared With Snake Venom Nerve Growth Factors NGF, Neurotrophy Factors NTF, Nerve Stem Cells And Schwann Cells According To The Following Method: The Entire Spinal Cord Of A Newborn Animal Or A Fetus Which Can Not Be Conceived Because Of Natural And Man-Made Calamities Is Implanted In Aseptic PBS Liquid Or Culture Fluid; Required Ganglia Are Cleaned And Shorn Again And Again. After The Required Ganglia Are Cultured In A Thermostat Of 37 DEG C For 48 Hours, Little Culture Fluid Is Added; The Required Ganglia Are Cultured For Eight Days Before The Required Ganglia Are Frozen And Deposited For Passage. Before Operation, The Frozen And Deposited Cells Are Revived, And Are Implanted In The Pia Mater Spinalis Of The Damaged Spinal Cord. The Medicine Can Provide The Cultured Cells And The Damaged Neurocyte With New Nutriment And NGF Required For Promoting The Growth. The Implanted Cells Can Be Separated And Added To The Damaged Neural Parts To Repair The Damaged, Dead Or Feeble Cells With Safe And Remarkable Cure Effect.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101306208	CN - 20071099416 - 18/05/2007	ZIDIAN ZHAO	A61L 27/38 ; A61L 27/60	The Invention Relates To A Human Body Liquid State Corium Layer Preparation For Injection And A Preparation Method Thereof, And Belongs To The Field Of Medical Bio Engineering. The Preparation Method Of The Human Body Liquid State Corium Layer Preparation For Injection Comprises The Following Steps: Digesting And Separating The Skin From A Curer Himself; Obtaining Corium Fibroblast Stem Cell, A Fibroblast Fore Body Cell And A Fibroblast Cell; Performing The Extraneous Omnirange Blood Serum-Free Cultivation And Expansion Of The Cells; Preparing Effective Component And Normal Saline Injection Or Other Injection Collected As Well As Other Suitable Components Selected Arbitrarily. The Effective Component Is Composed Of At Least One Of The Corium F Fibroblast Stem Cell, The Fibroblast Fore Body Cell And The Fibroblast Cell Collected After Being Cultivated And Collagen. In Each-Liter Filling Agent For Injection, The Total Quantity Of The Effective Cell Component Is 10,000,000 To 80,000,000, And The Collagen Contain 10-100 Mg/Ml Filling Agent For Injection. The Human Body Liquid State Corium Layer Preparation Has The Advantages That The Used Material Is Derived From The Curer Himself, No Rejection Reaction And Side Effect Occur, The Effect Is Quick After Remedy, The Effect Is Obvious, The Expression Is Natural, The Effect Action Is Durable And Can Be Kept For A Plurality Of Years.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101310010	US - 20010258881P - 02/01/2001	STEMRON INC	A61K 35/12 ; A61K 35/48 ; A61K 48/00 ; A61L 27/00 ; C12N 15/09 ; C12N 5/06 ; C12N 5/08 ; C12N 5/10	A Method Of Producing A Homogenous Population Of Homozygous Stem (HS) Cells Pre-Selected For Immunotype And/Or Genotype From Donor Cells Is Described Herein. The Invention Relates To Methods Of Using Immunohistocompatible HS Cells For Diagnosis, Therapeutic And Cosmetic Transplantation, And The Treatment Of Various Genetic Diseases, Neurodegenerative Diseases, Traumatic Injuries And Cancer. The Invention Further Relates To Methods For Using Histocompatible HS Stem Cells Pre-Selected For A Non-Disease Genotype For Prophylactic And Therapeutic Intervention Including, But Not Limited To, Therapeutic And Cosmetic Transplantation, And The Treatment Of Various Genetic Diseases, Neurodegenerative Diseases, And Cancer. Furthermore, The Invention Relates To A Catalogued Transplant Depository Of HS Cells Derived From Multiple Donors, Each Of The HS Cells Being Homozygous For A Unique HLA Haplotype, For The Purpose Of Having A Constant, Reliable, Comprehensive Supply Of Immunohistocompatible Cells For Diagnosis, Treatment And/Or Transplantation.
CN101310012	US - 20050726750P - 14/10/2005	UNIV MINNESOTA	C12N 5/06	The Invention Provides Methods For Differentiating Non-Embryonic Multipotent Stem Cells Along The Pancreatic Lineage. The Present Invention Further Provides Non- Embryonic Multipotent Stem Cells And Progeny Derived Therefrom To Provide Pancreatic Cells To A Subject.
CN101311263	CN - 20071015617 - 21/05/2007	YUNHAI FANG	C12N 5/06 ; C12N 5/08	The Invention Belongs To The Technical Field Of Biological Cells And Particularly Relates To A Method For Induced Commitment And Differentiation Of Mesenchymal Stem Cells In Vitro Into Lymphatic Endothelial Cells. The Mesenchymal Stem Cells With Certain Purity Are Separated, Cultured And Identified In Vitro, And Then VEGF-C156s With Concentration Of 50ng/Ml Is Used For Induced Commitment And Differentiation To Obtain And Identify The Lymphatic Endothelial Cells So That The Cells Obtained Are Confirmed To Be The Lymphatic Endothelial Cells. The Induced Commitment And Differentiation Of Mesenchymal Stem Cells Into Lymphatic Endothelial Cells Provides Important Basic Data For Experiments In The Treatment Of The Stem Cells In Lymphedema And Research In The Treatment Of Related Diseases In Lymphatic System.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101313065	US - 20050704465P - 01/08/2005	NUPOTENTIAL INC	C12N 15/09	A Method For Treating Cells And/Or Nuclear Transfer Units And/Or Stem Cells In Culture With Such Compounds, Individually Or In Combinations, Is Described. The Method Results In A Globally Hypomethylated Genome And A Restoration Of Cell Differentiation And/Or Developmental Potential, Or Potentiality. In Addition, A Method For The In Vitro Production Of Reprogrammed Cells Which Have Had Differentiation Potential (Totipotential, Pluripotential, Or Multipotential) Restored By Demethylating The Genome Is Described.
CN101314766	CN - 20071099888 - 31/05/2007	INST BASIC MED SCIENCES PLA	C12N 5/08	The Invention Discloses A Method For Separately Culturing A Human Adipose Mesenchymal Stem Cell And A Dedicated Culture Medium Thereof. The Culture Medium Used For Separately Culturing The Human Adipose Mesenchymal Stem Cell Comprises An Animal Cell Basic Culture Medium, Fetal Calf Serum, An Epidermal Growth Factor And A Platelet-Derived Growth Factor. The Final Concentration Of The Fetal Calf Serum Is 1-200 Ml/L, The Final Concentration Of The Epidermal Growth Factor Is 1-100 Ng/Ml, And The Final Concentration Of The Platelet-Derived Growth Factor Is 1-100 Ng/Ml. The Adipose Mesenchymal Stem Cell Of The Invention Has CD31-, CD34-, CD45- And HLA-DR-, As Well As The Phenotype Of CD29+, CD44+, CD105+ And Flk-1+. The Specificity Cell Surface Marker And The Relevant Antihelion Molecule Of A Skeletal Muscle Cell And A Vascular Endothelia Cell Can Be Expressed After Inducement Is Performed In Vitro. Muscle Fiber, Vascular Endothelin And Functional Muscle Satellite Cells Can Be Differentiated In A Muscle Injury Model Mouse Body Caused By Medicine And The Expression Of Dystrophin Protein On The Ducheme Muscular Dystrophy (DMD) Model Mouse (Mdx) Myolemma Can Be Partially Recovered, So As To Release The Pathological Symptom Of The Model Mouse.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101314767	CN - 20081040136 - 03/07/2008	SHANGHAI TIANSHENG BIOTECHOLOG	C12N 5/08 ; C12P 21/04	The Invention Relates To A Culture Solution Of Strengthening Fetal Liver Hematopoietic Stem Cell CD34 Expression And A Preparation Method Thereof And Belongs To The Biological Engineering Technology Field. The Components And The Weight Percentage Of The Culture Solution Are As Follows: 56.5-64.7 Percent Of MEM; 29.4-30.4 Percent Of RPMI-1640; And 5.88-13.0 Percent Of Hanks Etc. The Preparation Method Comprises The Following Steps: (1)Preparing The Basic Culture Solution;(2) Selecting Again Relative Components According To The Weight Percentage, Adding The Same To The Basic Culture Solution In Sequence; Agitating And Dissolving; (3) Purifying A Mesenchymal Cell, Putting In A Culture Bottle, Culturing, Washing, Mixing, Continuously Culturing, Collecting Supernatant Fluid, Filtering, Centrifuging, Removing All Cell Fragments And Non-Soluble Matters, And Obtaining A Conditioned Culture Solution; (4) Mixing The Conditioned Culture Solution With MEM, Utilizing Sodium Bicarbonate To Adjust The Mixed Culture Solution To Ph Of 7.40 To 7.45, Filtering And Obtaining The Culture Solution. The Culture Solution Strengthens Expression Of The CD34 Expression Characteristics Of The Stem Cell. The Stem Cell Reaches An Identifiable And Purified Range, The Identified Quantity Of The Stem Cell Is Improved, The Culture Solution Is Safe And Reliable, And The Clinical Application Is Satisfied.
CN101316926	US - 20050722321P - 30/09/2005	COPYGENE AS	A61K 6/00 ; C12N 5/06	The Present Invention Relates To A Method For Propagating And/Or Differentiating Mammalian Cells, The Method Comprising Exposing Or Co-Culturing Mammalian Cells With One Or More Of Periodontal Ligament Tissue, Periodontal Ligament Proteins Or Factors Derived From Periodontal Ligament Tissue, To Obtain Cells Having PDL Characteristics And Fulfilling At Least One Of The Following: I) Show Periodontal Characteristics As Evidenced With Von Kossa Method In Which Calcium Phosphate Deposits Are Stained Brown To Black, Ii) Show Increased Osteopontin And Osteocalcin And At The Same Time Decreased Bone Sialoprotein (Bone Sialoprotein Il Or BSP), Iii) Are Capable Of Being Implanted To Repair And/Or Regenerate Periodontal Tissue, Iv) Are Capable Of Repairing Disorders Such As Paradentitis Also Called Paradentosis, Or Periodontitis By Healing Of The Gum Line Towards The Teeth, And V) Are Accepted By The Host Without Significant Immune Reaction Or Cell Rejection.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101318031	CN - 20081040559 - 15/07/2008	UNIV PLA 2ND MILITARY MEDICAL	A61L 27/38	The Invention Relates To The Technical Field Of Bioengineered Tissue, The Nerve Bridging Distance Of The Nerve Around The Tissue Engineering Constructed Presently Is Not More Than 30mm Generally, The Demand For Repairing The Deficiency Of Long-Section Nerve In Clinic Can Not Be Satisfied, And The Function Of Restoration After Regeneration Is Not Good. In The Preparation Method Of The Nerves Around The Neuron Tissue Engineering Of The Invention, Hair Follicle Neural Crest Stem Cells Are Selected For Inducing The Mixed Cells Of Differential Nerve-Like Cells And The Schwann Cells To Be Seeded Cells In Specific Condition, Which Is Constructed In The Bracket Of Heterogeneity Cell-Removing Nerve Basilemma Tube According To The Proportion Of 1:1. The Nerves Around The Tissue Engineering Prepared By The Invention Can Avoid Regenerated Axon Exogenesis And Error Entering In Growing Process, Thus Shortening The Time That The Regenerated Nerve Fiber Arrives At The Effector, Avoiding Shrinking Of The Effector. Not Only The Demand For Repairing The Deficiency Of Long-Section Nerve In Clinic Is Satisfied, But Also The Nerve Function Is Restored Well After The Regeneration Of Nerves.
CN101318032	CN - 20072148176U - 06/06/2007 ; CN - 20081111540 - 05/06/2008	JINGXING LI	A61F 2/06 ; A61L 27/36 ; A61L 27/38 ; A61L 27/50	The Invention Discloses A Minorcaliber Tissue Engineering Artificial Vessel. The Excised Extract Cell Umbilical Vessel Is Taken As A Bracket, The Gap Part Of The Bracket Is Filled With Smooth Muscle Cells And Mechanocyte; The Endothelial Progenitor Cells Or Mesenchymal Stem Cells Are Planted In The Surface Of The Inner Wall Of The Excised Extract Cell Umbilical Vessel. The Minorcaliber Tissue Engineering Artificial Vessel Has Good Biocompatibility And Has The Abilities Of Inducing, Supporting And Maintaining Cell Functions, Thus Reducing The Reciprocal Infection Of Virus Among Seeds. The Artificial Vessel Produced By The Invention Overcomes The Problem That The Supply Of Autologous Vessel Plantation Is Limited And The Failure Problem Of The Synthesized Implants For Formation Of Thrombosis And/Or Endometrial Hyperplasia, Thus Improving The Long Transplantation Patency That The Minorcaliber Tissue Engineering Artificial Vessel Is Planted Into Human Body, Leading The Sufferers To Avoid A Secondary Operation. The Raw Materials Of The Artificial Vessel Are Obtained Easily, The Preparation Method Is Simple, And Cost Is Low, Thus Being Accepted By The Sufferers And Having Vast Social Benefit And Economic Benefit.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101326280	US - 20050727004P - 13/10/2005	ANTHROGENESIS CORP	A61K 35/50 ; A61P 37/06 ; C12N 5/06	The Present Invention Provides Methods Of Immunomodulation Using Placental Stem Cells And Placental Stem Cell Populations. The Invention Also Provides Methods Of Producing And Selecting Placental Cells And Cell Populations On The Basis Of Immunomodulation, And Compositions Comprising Such Cells And Cell Populations.
CN101326281	US - 20050727601P - 13/10/2005	ANTHROGENESIS CORP	C12N 5/06	The Present Invention Provides Methods And Compositions For The Production Of Glial Cells And Oligodendrocytes From Placenta Stem Cells. The Invention Further Provides For The Use Of These Glia And Oligodendrocytes In The Treatment Of, And Intervention In, For Example, Trauma, Ischemia And Degenerative Disorders Of The Central Nervous System (CNS), Particularly In The Treatment Of Demyelinating Diseases Such As Multiple Sclerosis.
CN101327318	CN - 20081040558 - 15/07/2008	UNIV PLA 2ND MILITARY MEDICAL	A61K 38/18 ; A61K 9/10 ; A61P 17/02	The Invention Relates To The Medical Technical Field Of Repairing Wounds, Which Can Be Used For Repairing Wounds, Particularly For Healing Deep Burn Wounds. The Invention Provides Mesenchymal Stem Cell Suspension Which Contains Human Epidermal Growth Factor And Bovine Basophilic Fibroblast Growth Factor. The Mesenchymal Stem Cell Provides The Sources For Human Marrows Or Embryo. When In Use, The Stem Cell Suspension Is Directly Injected Or Smeared On Wounds Which Have Been Removed Necrotic Tissues. Animal Experiments Show That The Stem Cell Suspension Can Obviously Repair Deep Burn Wounds; Besides, The New Skin Does Not Tend To Generate Blister Or Ulceration. The Stem Cell Suspension Of The Invention Is Simple In Preparation And Conveniently For Use, Obviously Repairing The Deep Burn Wounds, Thus Effectively Controlling The Hyperplasia Of Anaphase Keloid.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101329300	CN - 20081120086 - 18/07/2008	UNIV ZHEJIANG	G01N 27/447 ; G01N 27/64	The Invention Provides A Buildup Method Of A Protein Difference Expression Atlas When The Committed Differentiation Of Stem Cells Is Induced By Drugs, Which Detailedly Establishes The Protein Difference Expression Atlas Formed By That The Stem Cell Is Induced By The ICA And Directionally Differentiated To Be A Cardiac Muscle Cell; A Model That The Drug Induces The Stem Cell To Be Directionally Differentiated To Be The Cardiac Muscle Cell Is Established So As To Prepare A Two-Dimensional Electrophoresis Protein Sample; Electrophoresis Is Gelled Bidirectionally, Images Are Collected And Analyzed So As To Confirm The Difference Protein. A Comparison Protein Atlas Is Used For Screening And Identifying The Difference Expression Protein When The ES Cell Is Directionally Differentiated To Be The Cardiac Muscle Cell By The Inducing Of The ICA; The Difference Expression Protein Is Used As A Drug Effect Target And Applied To The Preparation Of A Novel Inducer Which Has High-Efficiency And Low-Toxicity And Is Used For Prompting The Stem Cell To Be Differentiated.
CN101330830	US - 20050728131P - 18/10/2005	NAT JEWISH MED RES CT	A01K 67/00 ; A01K 67/033 ; A01N 63/00 ; A01N 65/00 ; C07H 21/02 ; C07H 21/04 ; C12N 5/00 ; C12N 5/02 ; G01N 33/00	Disclosed Are Methods For Conditionally Immortalizing Stem Cells, Including Adult And Embryonic Stem Cells, The Cells Produced By Such Methods, Therapeutic And Laboratory Or Research Methods Of Using Such Cells, And Methods To Identify Compounds Related To Cell Differentiation And Development Or To Treat Diseases, Using Such Cells. A Mouse Model Of Acute Myeloid Leukemia (AML) And Cells And Methods Related To Such Mouse Model Are Also Described.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101330935	US - 20050729172P - 21/10/2005	CELLRES CORP PTE LTD	A61K 31/775 ; A61K 9/70 ; A61L 27/60 ; A61P 17/02 ; C12M 3/04 ; C12N 5/08	The Present Invention Relates To A Skin Equivalent And A Method For Producing The Same, Wherein The Skin Equivalent Comprises A Scaffold And Stem/Progenitor Cells Isolated From The Amniotic Membrane Of Umbilical Cord. These Stem/Progenitor Cells May Be Mesenchymal (UCMC) And/Or Epithelial (UCEC) Stem Cells, Which May Then Be Further Differentiated To Fibroblast And Keratinocytes. Further Described Is A Method For Isolating Stem/Progenitor Cells From The Amniotic Membrane Of Umbilical Cord, Wherein The Method Comprises Separating The Amniotic Membrane From The Other Components Of The Umbilical Cord In Vitro, Culturing The Amniotic Membrane Tissue Under Conditions Allowing Cell Proliferation, And Isolating The Stem/Progenitor Cells From The Tissue Cultures. The Invention Also Refers To Therapeutic Uses Of These Skin Equivalents. Another Aspect Of The Invention Relates To The Generation Of A Mucin-Producing Cell Using Stem/Progenitor Cells Obtained From The Amniotic Membrane Of Umbilical Cord And Therapeutic Uses Thereof. The Invention Further Refers To A Method Of Treating A Bone Or Cartilage Disorder Using UCMC. Furthermore, The Invention Refers To A Method Of Generating A Dopamin And Tyrosin Hydroxylase As Well As A HLA-G And Hepatocytes Using UCMC And/Or UCEC. The Present Invention Also Refers To A Method Of Inducing Proliferation Of Aged Keratinocytes Using UCMC.
CN101331225	KR - 20050117015 - 02/12/2005	SEOUL NAT UNIV IND FOUNDATION	A61K 35/30 ; A61K 35/32 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	The Present Invention Relates To Multipotent Adult Stem Cells Expressing Oct4, Derived From Umbilical Cord Blood (UCB) And Also These Cell Are Expressing CD29, CD31, CD44, Simultaneously, A Method For Preparing The Same, And More Specifically To Multipotent Adult Stem Cells Which Are Obtained By Culturing Umbilical Cord Blood-Derived Monocytes In A Medium Containing Bfgf (Basic Fibroblast Growth Factor) And Human Serum Or Plasma. In Addition, Multipotent Adult Stem Cells Expressing Oct-4 From UCB Are Morphologically Spindle Or Round Shaped Cells Although The Stem Cells According To The Present Invention Are Adult Stem Cells, They Are Multipotent And Capable Of Differentiating Into Ectodermal-, Messodermal-, Emdodermal-Originated Tissue Or Cells Including Osteogenic Cells Or Nerve Cells Etc, Thus They Can Be Effectively Used In The Treatment Of Intractable Diseases And Incurable Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101332135	US - 20070823407 - 27/06/2007	DEPUY PRODUCTS INC	A61F 2/28 ; A61F 2/46 ; A61L 17/00 ; A61L 27/42	The Present Invention Relates To An Osteogenic Prosthesis, Associated Instrument, And Associated Method. A Prosthetic Implant For Securing To Bone To Form An Articulating Joint Is Provided. The Implant Is Prepared By A Process Which Includes The Steps Of Preparing A Porous Surface On A Component To Form A Prosthetic Implant, Placing The Prosthetic Implant Including The Porous Surface In A Fixture Closely Conforming To The Porous Surface Of The Implant And Having An Inlet And An Opposed Outlet, And Directing A Biological Compound Including Stem Cells Into The Inlet, Through The Porous Surface Of The Implant And Out Of The Outlet To Form A Prosthetic Implant Having A Porous Surface Coated With A Portion Of The Biological Compound.
CN101333542	CN - 20071011839 - 25/06/2007	XINGRU HE	C12N 15/85 ; C12N 5/10	The Invention Relates To A Method For Transplanting Gene-Modified Mesenchymal Stem Cells In Eyes To Heal Retinal Injury. The Technical Proposal Is That The Mesenchymal Stem Cells Are Mobilized Into Peripheral Blood By A Stem Cell Mobilizing Agent, And The Stem Cell Mobilizing Agent Separates, Amplifies And Purifies The Mesenchymal Stem Cells By Biological Features Of The Stem Cell Mobilizing Agent; A Sequence Of Human Brain-Derived Neurotrophic Factor Is Cloned From A Genome Of Human Blood Leukocyte To Construct And Recombine An Expression Vector Pcdna Of The Human Brain-Derived Neurotrophic Factor, And The Gene Of The Human Brain-Derived Neurotrophic Factor Is Introduced Into The Mesenchymal Stem Cells; A Retinal Laser Injury Model Is Made; And After A Vitreous Body And A Caudal Limiting Membrane Are Resected, The Mesenchymal Stem Cells, Which Are Modified By The Gene Of The Human Brain-Derived Neurotrophic Factor, Are Transplanted Into Fundus. Therefore, The Healing Effect Is Remarkably Improved Under The Differentiation Effect Of The Mesenchymal Stem Cells And The Specific Expression Effect Of The Human Brain-Derived Neurotrophic Factor. The Method Can Obviously Heal Retinal Injury, And Can Improve The Application Value Of The Stem Cell Transplantation, Thereby Providing A Novel Technology For The Genes And The Stem Cells To Treat Retinal Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
CN101336112	US - 20050269736 - 09/11/2005	ATHERSYS INC	A61K 35/28 ; A61K 39/00 ; A61P 37/06	Isolated Cells Are Described That Are Not Embryonic Stem Cells, Not Embryonic Germ Cells, And Not Germ Cells. The Cells Can Differentiate Into At Least One Cell Type Of Each Of At Least Two Of The Endodermal, Ectodermal, And Mesodermal Lineages. The Cells Do Not Provoke A Harmful Immune Response. The Cells Can Modulate Immune Responses. As An Example, The Cells Can Suppress An Immune Response In A Host Engendered By Allogeneic Cells, Tissues, And Organs. Methods Are Described For Using The Cells, By Themselves Or Adjunctively, To Treat Subjects. For Instance, The Cells Can Be Used Adjunctively For Immunosuppression In Transplant Therapy. Methods For Obtaining The Cells And Compositions For Using Them Also Are Described.
ECSP088799	US - 20060844350P - 14/09/2006 ; IN - 2006DE00582 - 07/03/2006 ; IN - 2006DE01500 - 26/06/2006	SHROFF GEETA	A61K 35/12 ; A61K 35/48 ; C12N 5/06	Composiciones Que Comprenden Células Madre Embrionarias Humanas Y Sus Derivados, Métodos De Uso Y Métodos De Preparación
EP1938845	US - 20020357839P - 21/02/2002 ; EP - 20030251057 - 21/02/2003	GEISTLICH SOEHNE AG	A61L 27/00 ; A61L 27/12 ; A61L 27/24 ; A61L 27/36 ; A61L 27/38 ; A61L 27/40 ; C12N 5/06	A Bone Healing Combination Material Includes A Matrix Carrying Cultivated Bone-Forming Cells Which May Be Osteocytes, Osteoblasts, Stromal Stem Cells Or Stem Cells Committed To Differentiation Into Bone-Forming Osteoblasts. The Matrix Is A Porous Bone Mineral Derived From Natural Bone, The Mineral Having A Crystal Structure Substantially That Of Natural Bone And Being Substantially Free From Endogenous Organic Substances. The Matrix Is Either Collagen-Free Or Is Combined With Purified Collagen Material Derived From Natural Collagen-Containing Animal Tissue And Consisting Of Collagen I, Collagen III Or A Mixture Thereof.
EP1940445	US - 20050710028P - 19/08/2005 ; US - 20050711287P - 25/08/2005 ; WO - 2006US32656 - 21/08/2006	UNIV DUKE	A61K 38/17 ; A61P 9/00	Ti Agents Stem Cell Derived Factors For Treating Pathologic Conditions

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1941027	EP - 20050077221 - 28/09/2005 ; EP - 20060799473 - 28/09/2006 ; WO - 2006NL00484 - 28/09/2006	GLYCOSTEM B V	C12N 5/02 ; C12N 5/08	Methods And Means For Stem Cell Proliferation And Subsequent Generation And Expansion Of Progenitor Cells, As Well As Production Of Effector Cells As Clinical Therapeutics.
EP1941031	US - 20050724328P - 05/10/2005 ; WO - 2006US38524 - 03/10/2006	MAZZONE THEODORE ; TRUSTEES OF THE UNIVERSITY OF ; ZHAO YONG	C12N 5/06 ; C12N 5/08	Isolated Embryonic-Like Stem Cells Derived From Human Umbilical Cord Blood
EP1941032	US - 20050726750P - 14/10/2005 ; WO - 2006US40212 - 16/10/2006	UNIV MINNESOTA	C12N 5/06	Differentiation Of Non-Embryonic Stem Cells To Cells Having A Pancreatic Phenotype
EP1941890	JP - 20050271103 - 16/09/2005 ; WO - 2006JP318901 - 19/09/2006	YOSHIDA KENJI	A61K 35/50 ; A61P 25/16 ; A61P 25/28 ; A61P 35/00 ; A61P 35/02 ; A61P 43/00 ; A61P 7/06 ; A61P 9/04 ; A61P 9/10	Disclosed Is A Hematopoietic Stem Cell Proliferation Inducing Agent Which Comprises A Pulverized Product Of Placenta-Constituting Cells As An Active Ingredient And Can Induce/Proliferate A Hematopoietic Stem Cell In The Peripheral Blood. Since The Proliferation Inducing Agent Can Induce/Proliferate A Hematopoietic Stem Cell To Increase The Amount Of Hematopoietic Stem Cells In The Peripheral Blood, It Becomes Possible To Ensure The Increase In The Amount Of Hematopoietic Stem Cells In The Peripheral Blood. The Proliferation Inducing Agent Can Be Used For The Prevention And Treatment Of Various Diseases Which Are Caused Or Believed To Be Caused By The Decrease In The Amount Of Hematopoietic Stem Cells (E.G., Leukemia, Malignant Lymphoma, Aplastic Anemia, Alzheimer's Disease, Parkinson's Disease, Dilated Cardiomyopathy, Myocardial Infarction) And Produces Extremely Small Adverse Side Effects.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1942739	US - 20050728131P - 18/10/2005 ; US - 20060765993P - 06/02/2006 ; WO - 2006US40379 - 18/10/2006	NAT JEWISH MED & RES CENTER ; UNIV COLORADO	A01K 67/00 ; A01K 67/033 ; A01N 63/00 ; A01N 65/00 ; C07H 21/02 ; C07H 21/04 ; C12N 5/00 ; C12N 5/02 ; G01N 33/00	Conditionally Immortalized Long-Term Stem Cells And Methods Of Making And Using Such Cells
EP1942926	US - 20050724908P - 07/10/2005 ; WO - 2006US39266 - 06/10/2006	NUVELO INC	A61K 39/00 ; A61K 49/00 ; C07H 21/04 ; C07K 14/00 ; C12N 15/74 ; C12P 21/06	Stem Cell Factor-Like Protein Scfa1 And Uses Thereof
EP1947170	JP - 20050307741 - 21/10/2005 ; JP - 20050307742 - 21/10/2005 ; JP - 20050362413 - 15/12/2005 ; WO - 2006JP320956 - 20/10/2006	KANEGAFUCHI CHEMICAL IND	B01D 39/04 ; B01D 39/16 ; C12M 1/26	The Present Invention Has Its Object To Provide A Material For Separating Stem Cell And A Filter For Separating Stem Cell, Each Is Capable Of Selectively Separating And Recovering, In A Simple And Easy Manner, Stem Cells From Body Fluids Or Biological Tissue-Derived Treated Fluids, A Method For Separating And Recovering Stem Cells, And Stem Cells Obtained By Such Method. The Present Invention Is A Material For Separating Stem Cell Which Has A Density K Of 1.0 X 10 4 K 1.0 X 10 6 And A Fiber Diameter Of 3 To 40 [Mu]M; A Filter For Separating Stem Cell Which Comprises The Material For Separating Stem Cell As Packed In A Container Having A Fluid Inlet Port And A Fluid Outlet Port; A Method Of Separating And Recovering Stem Cells Which Comprises Using The Material For Separating Stem Cell Or The Filter For Separating Stem Cell; And A Method Of Producing A Multipotent Cell Fraction.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1947173	EP - 20030818826 - 02/09/2003 ; WO - 2003US27398 - 02/09/2003	REGENETECH INC	C12N 5/00 ; C12N 5/06	A Method Of Preparing Expanded Primate Mammalian Blood Adult Stem Cells Is Provided, Which Method Comprises The Steps Of: A.) Placing Primate Mammalian Blood Adult Stem Cells In A Rotatable Bioreactor; And B.) Controllably Expanding The Blood Adult Stem Cells By A Factor Of At Least Seven Times The Number Per Unit Volume That Were Placed In The Rotatable Bioreactor In Less Than Seven Days While Maintaining Their Three-Dimensional Geometry And Their Cell-To-Cell Support And Cell-To-Cell Geometry By Rotating The Rotatable Bioreactor At A Speed That Suspends The Cells To Prepare Expanded Primate Mammalian Blood Cells.
EP1948246	US - 20050737058P - 14/11/2005 ; WO - 2006US43937 - 13/11/2006	ENTPR PARTNERS VENTURE CAPITAL	A61K 38/18 ; A61K 38/19 ; A61P 9/10	Stem Cell Factor Therapy For Tissue Injury
EP1948786	KR - 20050109502 - 16/11/2005 ; WO - 2005KR04383 - 20/12/2005	RNL BIO CO LTD	A61K 35/12 ; C12N 5/08	Ti Agents Multipotent Stem Cells Derived From Human Adipose Tissue And Cellular Therapeutic Agents Comprising The Same
EP1948787	WO - 2005KR03925 - 18/11/2005	IMGEN CO LTD	C12N 5/06 ; C12N 5/08	Ti Agents Composition Comprising Okadaic Acid For Undifferentiated Proliferation Of Embryonic Stem Cells
EP1948790	IT - 2005TO00819 - 18/11/2005 ; WO - 2006IB54288 - 16/11/2006	UNI DEGLI STUDI DI TORINO	C12N 5/08	Immortal Pluripotent Stem Cell Line, Cell Lines Derived Therefrom, Methods Of Preparing Thereof And Their Uses

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1948791	US - 20050729177P - 21/10/2005 ; US - 20050733309P - 02/11/2005 ; US - 20060758443P - 11/01/2006 ; US - 20060813799P - 14/06/2006 ; WO - 2006US41133 - 19/10/2006	INTERNAT STEM CELL CORP	C12N 5/00	Parthenogenic Activation Of Human Oocytes For The Production Of Human Embryonic Stem Cells
EP1949904	US - 19990131230P - 27/04/1999 ; US - 19990144785P - 20/07/1999 ; EP - 20000918005 - 16/03/2000	LAYTON BIOSCIENCE INC	A61K 35/12 ; A61K 35/30 ; A61P 21/00 ; A61P 25/00 ; A61P 25/28 ; A61P 9/00 ; C12N 5/06 ; C12N 5/08	A Method Of Treating Stroke In A Patient Who Has Undergone A Stroke Comprising Administering At Least 2 Million Suitable Neuronal Cells To At Least One Brain Area Involved In The Stroke. The Method Comprises The Step Of Using A Twist Drill Or A Burr To Form A Hole In The Skull Through Which The Cells Could Be Administered. Exemplary Cells Are Hnt Neuronal Cells, HCN-1 Cells, Fetal Pig Cells, Neural Crest Cells, Neural Stem Cells, Or A Combination Thereof. Also Disclosed Herein Is A Pharmaceutical Composition Of 95% Pure Hnt Neuronal Cells, Which Composition Further Includes A Vial Containing PBS And Human Neuronal Cells. This Vial Is Provided In A Container With Liquid Nitrogen, Whereby The Composition Is Frozen And Maintained At -170 DEG C Before Use. Also Disclosed Are Methods Of Improving Speech, Cognitive, Sensory, And Motor Function In A Person Who Has Experienced Brain Damage Which Interferes With Function By Administering A Sterile Composition Of A Sufficient Number Of Neuronal Cells Or Neural Stem Cells To The Damaged Area. Also Disclosed Is A Method Of Replacing Central Nervous Cells Lost To Neurodegenerative Disease, Trauma Ischemia Or Poisoning.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1950307	JP - 20050313971 - 28/10/2005 ; WO - 2006JP321517 - 27/10/2006	DNAVEC RESEARCH INC	A61K 35/76 ; A61K 38/00 ; A61K 48/00 ; A61P 11/00 ; C12N 15/867 ; C12N 5/10	The Present Inventors Successfully Introduced Genes Into Stem Cells Of Airway Epithelial Tissues Using Simian Immunodeficiency Virus Vectors Pseudotyped With F And HN, Which Are Envelope Glycoproteins Of Sendai Virus. Gene Transfer Into Airway Epithelial Tissue Stem Cells Using A Vector Of The Present Invention Is Useful For Gene Therapy Of Genetic Respiratory Diseases Such As Cystic Fibrosis. Furthermore, It Is Possible To Select Respiratory Organs Such As The Lungs As Production Tissues For Providing Proteins That Are Deficient Due To Genetic Diseases.
EP1951035	US - 20050734754P - 09/11/2005 ; US - 20060771875P - 10/02/2006 ; WO - 2006US43722 - 08/11/2006	UNIV TEXAS	A01K 67/00 ; C12N 15/85	Transgenic Rats And Spermatogonial Stem Cells
EP1951037	US - 20050735715P - 09/11/2005 ; WO - 2006US43794 - 09/11/2006	SCRIPPS RESEARCH INST	A01N 1/02 ; C12N 5/00 ; C12N 5/02 ; G01N 33/567	Selection, Propagation And Use Of Mosaic Aneuploid Stem Cells
EP1951268	KR - 20050091155 - 29/09/2005 ; WO - 2006KR03928 - 29/09/2006	AJOU UNIVERSITY INDUSTRY ACADE	A61K 35/12	Use Of Mesenchymal Stem Cells Genetically Modified To Express A Suicide Gene For Treating A Cancer
EP1951881	US - 20050734336P - 07/11/2005 ; WO - 2006US43430 - 07/11/2006	GEN HOSPITAL CORP ; UNIV NORTH CAROLINA	C07H 21/04 ; C12N 15/85	Methods And Compositions For Modulation Of Stem Cell Aging
EP1954803	KR - 20050117015 - 02/12/2005 ; WO - 2006KR04649 - 07/11/2006	SEOUL NAT UNIV IND FOUNDATION	A61K 35/30 ; A61K 35/32 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Multipotent Adult Stem Cells Having An Ability Of Oct4 Expression Derived From Umbilical Cord Blood And Method For Preparing The Same

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1956079	US - 20010334957P - 25/10/2001 ; US - 20020253759 - 24/09/2002 ; EP - 20020784173 - 18/10/2002	CEDARS SINAI MEDICAL CENTER	A61K 35/30 ; A61P 25/00 ; A61P 25/28 ; A61P 35/00 ; A61P 9/00 ; A61P 9/10 ; C12N 5/06 ; C12N 5/08	The Present Invention Relates To A Method For Generating A Clinically Significant Volume Of Neural Progenitor Cells. The Method Comprises Providing A Mass Of Cells Obtained From A Mammal Including At Least One Stem Cell; And Culturing The Mass Of Cells In A Medium Comprising Fibroblast Growth Factor-2 (FGF-2) And Epidermal Growth Factor (EGF) To Produce A Clinically Significant Volume Of Neural Progenitor Cells. The Invention Also Concerns Neural Progenitor Cells Per Se And Their Use In The Treatment Of Neuropathologic Conditions.
EP1957516	US - 20050734655P - 08/11/2005 ; WO - 2006US43859 - 08/11/2006	CHOONGWAE PHARMA CORP	A61K 31/4985 ; A61P 11/00 ; C07K 5/06	Alfa-Helix Mimetics And Method Relating To The Treatment Of Cancer Stem Cells
EP1957633	US - 20050727004P - 13/10/2005 ; US - 20060835628P - 04/08/2006 ; WO - 2006US40148 - 13/10/2006	ANTHROGENESIS CORP	C12N 5/06	Immunomodulation Using Placental Stem Cells
EP1958648	JP - 20050315447 - 28/10/2005 ; WO - 2006JP321507 - 27/10/2006	DNAVEC CORP	A61K 35/12 ; A61K 35/14 ; A61K 35/76 ; A61K 38/43 ; A61K 48/00 ; A61P 7/04 ; C12N 15/00 ; C12N 5/00	The Present Invention Provides Agents For Treating Blood Coagulation Abnormalities, Which Contain As An Active Ingredient A Lentiviral Vector Carrying A Blood Coagulation Factor Gene Operably Linked To A Promoter Which Induces Platelet-Specific Expression. Agents For Treating Hemophilia A Or Hemophilia B Are Provided By Application Of The Gene Encoding Factor VIII Or Factor IX. Blood Coagulation Abnormalities Can Be Treated By Gene Therapy By Infecting Hematopoietic Stem Cells Or Such With The Therapeutic Agents Of The Present Invention.
EP1960553	US - 20050252458 - 17/10/2005 ; US - 20060824265P - 31/08/2006 ; WO - 2006US40373 - 16/10/2006	ACADEMIA SINICA	C12N 15/86 ; C12N 5/08 ; C12N 7/00 ; C12Q 1/70	Pulmonary Stem Cells, Related Methods And Kits

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1962719	US - 20050711668P - 29/08/2005 ; US - 20060834795P - 02/08/2006 ; WO - 2006IL00998 - 29/08/2006	TECHNION RES AND DEV OF FOUNDA	A61F 2/06	Media For Culturing Stem Cells
EP1963490	US - 20050748951P - 09/12/2005 ; WO - 2006US47136 - 08/12/2006	MASSACHUSETTS INST TECHNOLOGY	C12N 5/06	Methods For Identifying And Targeting Tumor Stem Cells Based On Nuclear Morphology
EP1965812	US - 20050734584P - 08/11/2005 ; WO - 2006US43711 - 08/11/2006	GEORGIA TECH RES INST	A61K 35/12	Acellularized Biomaterial From Embryonic Stem Cells
EP1965826	US - 20050735702P - 10/11/2005 ; US - 20060841766P - 01/09/2006 ; US - 20060858022P - 10/11/2006 ; WO - 2006US43874 - 10/11/2006	GENERVON BIOPHARMACEUTICALS LL	A61K 38/00	Mntf Differentiation And Growth Of Stem Cells
EP1969118	EP - 20050447286 - 21/12/2005 ; EP - 20060819033 - 14/12/2006 ; WO - 2006EP10014 - 17/10/2006 ; WO - 2006EP12046 - 14/12/2006	UNIV LOUVAIN	C12N 5/08	Isolated Liver Stem Cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1969119	US - 20050738119P - 17/11/2005 ; WO - 2006US44593 - 17/11/2006	CLEVELAND CLINIC FOUNDATION	C12N 5/08	Multipotent Neural Stem Cells
EP1970446	JP - 20050359537 - 13/12/2005 ; WO - 2006JP324881 - 06/12/2006	UNIV KYOTO	C07K 14/47 ; C12N 15/09 ; C12N 5/06	There Is Provided A Nuclear Reprogramming Factor For A Somatic Cell, Which Comprises A Gene Product Of Each Of The Following Three Kinds Of Genes: An Oct Family Gene, A Klf Family Gene, And A Myc Family Gene, As A Means For Inducing Reprogramming Of A Differentiated Cell To Conveniently And Highly Reproducibly Establish An Induced Pluripotent Stem Cell Having Pluripotency And Growth Ability Similar To Those Of ES Cells Without Using Embryo Or ES Cell.
EP1971679	US - 20060759157P - 13/01/2006 ; WO - 2007US00274 - 05/01/2007	OSIRIS THERAPEUTICS INC	C12N 5/00	Mesenchymal Stem Cells Expressing Tnf- Receptor
EP1972684	ES - 20020001540 - 02/07/2002 ; WO - 2003ES00285 - 11/06/2003	CHACQUES JUAN CARLOS ; INST CIENTIFICO TECNOL NAVARRA	A61K 31/198 ; A61K 31/727 ; A61K 35/16 ; A61K 35/34 ; A61K 38/00 ; A61K 38/16 ; A61P 21/00 ; A61P 9/10 ; C12N 1/02 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	The Invention Relates To A Medium For The Autologous Culture Of Autologous Human Progenitor Stem Cells, Which Comprises: Between 0.1 And 90 Wt.- % Autologous Human Serum; Between 0.1 And 10,000 UI/Ml Heparin; Between 0.1 And 10,000 UI/Ml Protamine; And A Culture Medium Consisting Of Basic Nutrients With Or Without Glutamine, In A Sufficient Quantity To Make Up 100 Wt.- %, Which Can Be Used To Culture And Expand Autologous Human Progenitor Stem Cells. Compositions Containing Said Cells Can Be Implanted In The Patient Using An Autologous Cellular Cardiomyoplasty Method In Order To Create, Regenerate And Repair Dysfunctional Myocardial Tissue.
EP1973553	US - 20060758387P - 12/01/2006 ; WO - 2007US00794 - 11/01/2007	OSIRIS THERAPEUTICS INC	A61K 35/12	Use Of Mesenchymal Stem Cells For Treating Genetic Diseases And Disorders

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1973938	EP - 20060000452 - 11/01/2006 ; EP - 20060022458 - 27/10/2006 ; EP - 20070713411 - 10/01/2007 ; WO - 2007IT00021 - 10/01/2007	AXXAM S P A	C07K 14/435	Luminescent Stem Cells And Uses Thereof
EP1974012	US - 20050289004 - 29/11/2005 ; WO - 2006IL01381 - 29/11/2006	GAMIDA CELL LTD	A61K 48/00 ; C12N 5/00 ; C12N 5/02	Methods Of Improving Stem Cell Homing And Engraftment
EP1974013	US - 20050754969P - 29/12/2005 ; WO - 2006US49493 - 28/12/2006	ANTHROGENESIS CORP	C12N 5/00	Improved Composition For Collecting And Preserving Placental Stem Cells And Methods Of Using The Composition
EP1974016	US - 20040555118P - 22/03/2004 ; US - 20060541853 - 02/10/2006 ; WO - 2007US20724 - 26/09/2007	OSIRIS THERAPEUTICS INC	A61K 35/14 ; A61K 35/28 ; A61P 1/00 ; A61P 37/06 ; C12N 5/00 ; C12N 5/06 ; C12N 5/08 ; H04Q 7/20	Mesenchymal Stem Cells And Uses Therefor
EP1974018	US - 20050748685P - 08/12/2005 ; WO - 2006US42780 - 02/11/2006	UNIV LOUISVILLE RES FOUND	C12N 5/00	Very Small Embryonic-Like (Vsel) Stem Cells And Methods Of Isolating And Using The Same
EP1974019	EP - 20050380266 - 07/12/2005 ; EP - 20060830436 - 07/12/2006 ; WO - 2006EP69426 - 07/12/2006	CELLERIX S L ; CT INVESTIG ENERGETICAS CIEMAT	A61P 37/06 ; C12N 5/06	Use Of Adipose Tissue Derived Mesenchymal Stem Cells For The Treatment Of Graft Versus Host Disease

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1974022	KR - 20060008874 - 27/01/2006 ; WO - 2006KR04111 - 12/10/2006	PARK BYUNGSOON ; PROSTEMICS CO LTD	A61K 38/00 ; C07K 4/12 ; C12N 5/02 ; C12N 5/08	Mass Producing Method Of Growth Factor Using Adipose Derived Adult Stem Cells
EP1975243	US - 19980111195P - 07/12/1998 ; EP - 19990965994 - 07/12/1999	UNIV DUKE	C07D 207/00 ; C07D 209/00 ; C07D 295/00 ; C12N 5/00 ; C12N 5/06 ; C12Q 1/02 ; C12Q 1/04 ; C12Q 1/32 ; G01N 21/78 ; G01N 33/48	The Present Invention Relates, In General, To Stem Cells, And In Particular, To A Method Of Isolating Stem Cells And To Reagents Suitable For Use In Such A Method. The Invention Further Relates To Stem Cell Populations Isolatable In Accordance With The Present Method.
EP1976977	US - 20050754968P - 29/12/2005 ; US - 20060846641P - 22/09/2006 ; WO - 2006US49491 - 28/12/2006	ANTHROGENESIS CORP	C12N 5/06	Placental Stem Cell Populations
EP1976978	US - 20050754692P - 29/12/2005 ; WO - 2006US49492 - 28/12/2006	ANTHROGENESIS CORP	C12N 5/06	Co-Culture Of Placental Stem Cells And Stem Cells From A Second Source
EP1976979	DE - 200610003996 - 27/01/2006 ; WO - 2007EP00694 - 26/01/2007	FRAUNHOFER GES FORSCHUNG	A61L 27/38 ; C12N 5/06 ; C12N 5/08	Method For Producing Autonomously Contracting Cardiac Muscle Cells From Adult Stem Cells, In Particular Human Adult Stem Cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1977758	US - 20050710028P - 19/08/2005 ; US - 20050711287P - 25/08/2005 ; EP - 20060802032 - 21/08/2006	UNIV DUKE	A61K 38/17 ; A61P 9/00	A Purified Paracrine Factor Of A Mesenchymal Stem Cell, Such As A Secreted Frizzled Related Protein (Sfrp) Is Useful To Reduce Cell Deal And/Or Tissue Injury Associated With Ischemic Conditions.
EP1978977	US - 20060761441P - 24/01/2006 ; WO - 2007US60889 - 23/01/2007	CENTENO CHRISTOPHER J	A61K 35/28 ; G01N 33/53	Mesenchymal Stem Cell Isolation And Transplantation Method And System To Be Used In A Clinical Setting
EP1981970	US - 20060757864P - 11/01/2006 ; US - 20060861080P - 27/11/2006 ; US - 20060861081P - 27/11/2006 ; WO - 2007IL00046 - 11/01/2007	TECHNION RES AND DEV OF FOUNDA	C12N 5/00	Human Embryonic Stem Cell-Derived Connective Tissue Progenitors For Tissue Engineering
EP1981971	US - 20060757864P - 11/01/2006 ; US - 20060861080P - 27/11/2006 ; US - 20060861081P - 27/11/2006 ; WO - 2007IL00047 - 11/01/2007	TECHNION RES AND DEV OF FOUNDA	C12N 5/06	Adult Stem Cell-Derived Connective Tissue Progenitors For Tissue Engineering

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1937801	US - 20050713992P - 02/09/2005 ; WO - 2006SG00232 - 15/08/2006	AGENCY SCIENCE TECH & RES	C12N 5/06 ; C12N 5/08	Abstract of corresponding document: WO 2007027156 (A1) We describe a method of obtaining a cell culture, the method comprising providing a cell obtained by dispersing a human embryonic stem cell (hESC) colony, or a descendent thereof, and propagating the cell in the absence of a feeder cell layer in a serum free medium comprising FGF2 and optionally PDGF AB. Preferably, the human embryonic stem cell (hESC) colony is dispersed with a dispersing agent which is trypsin.
EP1983042	JP - 20060023770 - 31/01/2006 ; WO - 2007JP51563 - 31/01/2007	ASUBIO PHARMA CO LTD ; UNIV KEIO	C12N 5/00 ; C12N 5/06	An Object Of The Present Invention Is To Develop A Method For Purify Cardiomyocytes At A High Degree Of Purification And At A High Yield From A Cell Mixture Comprising Cardiomyocytes Derived From Fetuses And Stem Cells Using Various Features Which Have Not Been Previously Expected To Be Used For Purification Of Cardiomyocytes Or Which Are Newly Found, Wherein Said Method Is Carried Out Without Undergoing Any Genetic Modification Or Without Adding Any Special Proteins Or Biologically Active Agents. The Inventors Of The Present Invention Found That Cardiomyocytes Were Effectively And Highly Selected And Purified By Culturing Cardiomyocytes Derived From Embryonic Stem Cells In The Culture Medium Under A Condition Selected From A Low-Serum-Supplemented Condition, A Low-Glucose-Supplemented Condition, A Low-Nutritional Condition, A Low Calcium Condition, A Mildly-Acidic Ph Condition, A Lactic Acid-Supplemented Condition, An Aspartic Acid/Glutamic Acid-Supplemented Condition, And/Or A Pyruvic Acid-Supplemented Condition. The Inventors Of The Present Invention Further Found That The Above Method Invented In Relation To Embryonic Stem Cells Was Applicable To Select And Purify Cardiomyocytes Derived From Fetuses Or Adult Stem Cells.
EP2009097	GB - 20040006215 - 19/03/2004 ; EP - 20050732870 - 18/03/2005	PROCURE THERAPEUTICS LTD	A61K 39/395 ; C07K 16/30 ; C12N 5/06 ; G01N 33/50 ; G01N 33/574	We Describe A Method For The Isolation Of Normal Prostate Stem Cells Which Express CD133 Antigen; Stem Cells Isolated By The Method And Their Use.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1984020	EP - 20060075119 - 19/01/2006 ; EP - 20070709171 - 19/01/2007 ; WO - 2007NL50023 - 19/01/2007	ACADEMISCH ZIEKENHUIS LEIDEN	A61K 38/55 ; C07K 16/40 ; G01N 33/53	Means And Methods For Modulating Stem Cell Mobilization
EP1984488	US - 20060763333P - 30/01/2006 ; WO - 2007US02572 - 30/01/2007	UNIV VIRGINIA	C12N 5/02	Methods Of Preparing And Characterizing Mesenchymal Stem Cell Aggregates And Uses Thereof
EP1984491	US - 20060773405P - 14/02/2006 ; WO - 2007US62163 - 14/02/2007	CELLERANT THERAPEUTICS INC ; CHRISTENSEN JULLIE LYNN ; KARSUNKY HOLGER	C12N 5/08	Methods And Compositions For Enhancing Engraftment Of Hematopoietic Stem Cells
EP1985280	CH - 20070000701 - 27/04/2007	MIBELLE AG	A61K 8/14 ; A61K 8/97 ; A61K 9/127 ; A61Q 17/00 ; A61Q 19/00 ; A61Q 19/08 ; A61Q 5/02	Cosmetic Product (I) Comprises At Least An Active Agent Derived From Dedifferentiated Plant Cell Suspension, Where The Agent Protects Stem Cells Against Intrinsic And Extrinsic Stress Factors. An Independent Claim Is Included For The Preparation Of An Extract From The Suspension, Comprising Digestion Of Plant Cells Obtained By High Pressure Homogenization And Extraction And Stabilization Of Ingredients With Liposomes, Where Both These Two Steps Are Carried Out Simultaneously In A Single Step.
EP1985305	EP - 20070300979 - 24/04/2007	VIVALIS	A61K 39/145	The Present Invention Relates To The Development And Manufacturing Of Viral Vaccines. In Particular, The Invention Relates To The Field Of Industrial Production Of Viral Vectors And Vaccines, More In Particular To The Use Of Avian Embryonic Stem Cells, Preferably The Ebx TM Cell Line Derived From Duck Embryonic Stem Cells, For The Production Of Viral Vectors And Viruses. The Invention Is Particularly Useful For The Industrial Production Of Viral Vaccines To Prevent Viral Infection Of Humans And Animals.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1985696	GB - 20020022846 - 03/10/2002 ; EP - 20030753734 - 03/10/2003	PLASTICELL LTD	C12N 5/00 ; C12N 5/02 ; C12N 5/06	A Method For Obtaining Differentiated Cells From Stem Cells In Vitro, Comprising The Steps Of: (A) Growing Stem Cells In A Culture Medium Adhered To A Microcarrier Or A Bead, Confined Within A Medium Permeable Barrier Or Entrapped; (B) Transferring The Cells In Step (A) From One Culture Medium To Another; (C) Optionally Repeating Step (B) As Required; And (D) Obtaining The Differentiated Cells.
EP1987135	US - 20060762814P - 27/01/2006 ; WO - 2007US02244 - 26/01/2007	AUXOCELL LAB INC	A61K 35/14 ; C12N 5/06	Methods And Compositions Relating To Stem Cell Transplantation
EP1987136	US - 20060774765P - 16/02/2006 ; WO - 2007US04012 - 15/02/2007	BURNHAM INST FOR MEDICAL RES	C12N 5/08	Media Conditioned By Human Embryonic Stem Cells Or Other Progenitor Cells And Uses Therefor
EP1987143	KR - 20060019012 - 27/02/2006 ; WO - 2006KR01348 - 12/04/2006	IMGEN CO LTD	A61K 48/00 ; C12N 15/10 ; C12N 15/63	De-Differentiation Of Astrocytes Into Neural Stem Cell Using Nanog
EP1987144	KR - 20060019014 - 27/02/2006 ; WO - 2006KR01349 - 12/04/2006	IMGEN CO LTD	A61K 38/00 ; C07K 14/00 ; C12N 15/10	De-Differentiation Of Astrocytes Into Neural Stem Cell Using Shh
EP1987148	KR - 20060019018 - 27/02/2006 ; WO - 2006KR01350 - 12/04/2006	IMGEN CO LTD	A61K 48/00 ; C12N 15/00 ; C12N 15/64 ; C12N 15/867	De-Differentiation Of Astrocytes Into Neural Stem Cell Using Bmi-1

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1988160	JP - 20030166646 - 11/06/2003 ; EP - 20040745816 - 11/06/2004	JAPAN SCIENCE & TECH AGENCY	C12N 5/06 ; C12N 5/08	A Method For Producing Retinal Nerve Cells By Inducing Differentiation Of Iris Pigmented Epithelial Cells Into The Retinal Nerve Cells. In A First Method, Iris Pigmented Epithelial Cells Derived From A Mammal And Embryo Retinal Stem Cells Derived From A Bird Are Co-Cultured. In A Second Method, Iris Pigmented Epithelial Cells Of A Bird Or A Mammal Is Isolated, And The Iris Pigmented Epithelial- Cells Is Subjected To Adherent Culturing. According To These Methods, The Retinal Nerve Cells Can Be Produced By Using Iris Pigmented Epithelial Cells Collected From A Patient Per Se. Therefore, There Is A Possibility That Highly Effective Regenerative Medical Treatment Can Be Realized.
EP1989295	WO - 2006EP01427 - 16/02/2006 ; EP - 20070711561 - 16/02/2007 ; WO - 2007EP01360 - 16/02/2007	UNIV BRUXELLES	A61K 35/28 ; A61P 19/08 ; C12N 5/08	A Method For Osteogenic Differentiation Of Bone Marrow Stem Cells (Bmsc) And Uses Thereof
EP1989296	US - 20060743264P - 09/02/2006 ; WO - 2007US03417 - 08/02/2007	GUMENYUK MARYNA E ; THOMAS JAMES A ; WISCONSIN ALUMNI RES FOUND	C12N 5/06 ; C12N 5/08	Erythroid Cells Producing Adult-Type -Hemoglobin Generated From Human Embryonic Stem Cells
EP1990350	SE - 20020001831 - 14/06/2002 ; US - 20020388298P - 14/06/2002 ; EP - 20030733733 - 12/06/2003	CARTELA R & D AB	C07K 14/705 ; C12N 5/06 ; G01N 33/569	A Marker For Mesenchymal Stem Cells (MSC) Is Provided, Comprising An Integrin Alpha 10 Chain And/Or An Integrin Alpha 11 Chain Expressed On The Cell Surface Of Or Intracellular In A MSC. The Marker Is Used In Methods For Identification Of Mammalian MSC And In Methods For Isolation Of MSC. Also Included Are Isolated Cellular Populations Of Mammalian MSC And A Cellular Composition Comprising The Latter. Moreover, Uses Of Said Marker For Isolation, Modulation And Identification Mammalian MSC Are Provided.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1990407	JP - 20060030997 - 08/02/2006 ; WO - 2007JP50615 - 17/01/2007	UNIV KEIO	A61F 2/14 ; A61L 27/00 ; C12N 5/06	It Is An Object Of The Present Invention To Provide A Feeder Cell With Less Variation In Quality. The Present Invention Relates To A Feeder Cell Derived From A Tissue Stem And/Or Progenitor Cell. A Method Of Preparation Of The Feeder Cell, A Method Of Preparation Of A Cultured Cell Using The Feeder Cell, And A Cell Culturing Kit Are Also Provided.
EP1991665	IT - 2006NA00017 - 20/02/2006 ; WO - 2007EP01416 - 19/02/2007	TESLAB S R L	C12N 5/08	Collection And Selection Methods Of An Embryonic- Like Stem Cell Population From Human Adult Periodontal Follicular Tissues
EP1991666	US - 20060777572P - 27/02/2006 ; US - 20060779841P - 06/03/2006 ; US - 20060779842P - 06/03/2006 ; US - 20060779992P - 06/03/2006 ; US - 20060779997P - 06/03/2006 ; WO - 2007US05142 - 27/02/2007	MORAGA BIOTECH CORP	C12N 5/00	Non-Embryonic Totipotent Blastomere-Like Stem Cells And Methods Therefor
EP1993553	US - 20060778532P - 02/03/2006 ; WO - 2006SG00350 - 15/11/2006	AGENCY SCIENCE TECH & RES	A61K 31/519 ; A61K 31/52 ; A61P 35/00	Methods For Cancer Therapy And Stem Cell Modulation
EP1993575	US - 20060844350P - 14/09/2006 ; IN - 2006DE00582 - 07/03/2006 ; IN - 2006DE01500 - 26/06/2006 ; WO - 2007IB02292 - 06/03/2007	SHROFF GEETA	A61K 35/12 ; A61K 35/48 ; A61P 25/00 ; C12N 5/06	Compositions Comprising Human Embryonic Stem Cells And Their Derivatives, Methods Of Use, And Methods Of Preparation

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1994143	US - 20060765218P - 06/02/2006 ; WO - 2007IL00157 - 06/02/2007	PLURISTEM LIFE SYSTEMS INC	C12N 5/06	Method And Apparatus For Maintenance And Expansion Of Hematopoietic Stem Cells From Mononuclear Cells
EP1994144	US - 20060778913P - 06/03/2006 ; WO - 2007SG00064 - 06/03/2007	AGENCY SCIENCE TECH & RES	A61K 35/12 ; C07K 16/28 ; C12N 5/08 ; C12Q 1/02 ; G01N 33/53	Human Embryonic Stem Cell Methods And Podxl Expression
EP1994163	US - 20060783091P - 16/03/2006 ; WO - 2007US06736 - 16/03/2007	HEALTH RESEARCH INC ; UNIV DUKE	A61K 51/10 ; C07K 16/30 ; C12P 19/00 ; G01N 33/574	Inhibition Of Breast Carcinoma Stem Cell Growth And Metastasis
EP1996698	US - 20060777530P - 01/03/2006 ; WO - 2007GB00731 - 01/03/2007	CARTELA R & D AB	C12N 5/06 ; C12N 5/08	Expansion And Differentiation Of Mesenchymal Stem Cells
EP1999250	CZ - 20060000049 - 25/01/2006 ; WO - 2007CZ00005 - 23/01/2007	UNIV KARLOVA ; USTAV HEMATOLOGIE A KREVNI TRA ; USTAV MAKROMOLEKULARNI CHEMIE	C12M 3/00 ; C12N 5/06	Method Of Cultivation Of Human Mesenchymal Stem Cells, Particularly For The Treatment Of Non-Healing Fractures, And Bioreactor For Carrying Out This Cultivation Method

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP1999252	DK - 20060000381 - 17/03/2006 ; DK - 20060001344 - 17/10/2006 ; US - 20060783054P - 17/03/2006 ; US - 20060851743P - 16/10/2006 ; WO - 2007EP02346 - 16/03/2007	CELLARTIS AB	C12N 5/08	Culture System And Method For Propagation Of Human Blastocyst-Derived Stem Cells
EP1999255	US - 20060785968P - 24/03/2006 ; WO - 2007US07419 - 26/03/2007	CHILDRENS MEDICAL CENTER	A61K 35/14 ; C12N 5/22	Method To Modulate Hematopoietic Stem Cell Growth
EP2000531	EP - 20070450104 - 06/06/2007	BIOMAY AG	C12N 15/86 ; C12N 5/06	The Present Invention Relates To A Method For Inducing Specific Long-Lasting Robust Immunological Tolerance Towards At Least One Polypeptide Derived From At Least One Allergen By Transplanting A Hematopoietic (Stem) Cell Which Is Produced To Display The Said At Least One Polypeptide Derived From At Least One Allergen.
EP2004212	US - 20060783500P - 17/03/2006 ; US - 20060789132P - 05/04/2006 ; US - 20060862669P - 24/10/2006 ; WO - 2007CA00427 - 16/03/2007	STEM CELL THERAPEUTICS CORP	A61K 38/18 ; A61K 38/22 ; A61K 38/24 ; A61P 25/28	Continuous Dosing Regimens For Neural Stem Cell Proliferating Agents And Neural Stem Cell Differentiating Agents
EP2006374	IT - 2004RM00438 - 15/09/2004 ; EP - 20050794564 - 14/09/2005	APOGENIX GMBH	C12N 5/06	The Invention Concerns A Method For The Purification And Amplification In The Undifferentiated State Of Tumoral Stem Cells From Solid Tumours Which Are Most Resistant To Conventional Therapies, Aiming At Devising New Tumour Markers And Therapeutic Targets Both For Early Diagnosis And For Targeted Therapeutic Strategies.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
EP2009096	RU - 20060110590 - 04/04/2006 ; RU - 20060117602 - 23/05/2006 ; RU - 20060117609 - 23/05/2006 ; WO - 2007RU00178 - 04/04/2007	TRANS TECHNOLOGIES LTD	C12N 5/06	Biotransplant For Cellular Therapy Based On Mesenchymal Bone Marrow Stem Cells
ES2306876T	SE - 20020001831 - 14/06/2002 ; US - 20020388298P - 14/06/2002	CARTELA AB	C07K 14/705 ; C12N 5/06 ; G01N 33/569	Marcador Para Celulas Madre Y Su Uso.
ES2304541T	GB - 20020020841 - 07/09/2002 ; GB - 20020026275 - 12/11/2002 ; WO - 2003GB03894 - 08/09/2003	MEDCELL BIOSCIENCE LTD	A61K 35/14 ; A61K 35/28 ; A61P 19/04	Medicamento Que Comprende Celulas Madre Mesenquimales.
ES2307570T	IT - 2001RM00476 - 03/08/2001	HOLOSTEM TERAPIE AVANZATE SRL	A61K 35/44 ; C12N 5/00 ; C12N 5/06 ; C12N 5/08	Laminas De Epitelio Corneal Humano Reconstituidas In Vitro Y Procedimiento Para Su Produccion.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
ES2309012T	US - 19990162558P - 29/10/1999 ; US - 20000182872P - 16/02/2000	GENENTECH INC	A61K 31/337 ; A61K 31/537 ; A61K 39/395 ; A61K 45/00 ; A61K 47/48 ; A61K 51/10 ; A61P 35/00 ; C07K 14/47 ; C07K 14/705 ; C07K 16/18 ; C07K 16/30 ; C07K 16/46 ; C12N 1/21 ; C12N 15/02 ; C12N 15/09 ; C12N 15/13 ; C12N 15/67 ; C12N 5/10 ; C12N 5/16 ; C12P 21/02 ; C12P 21/08	Composiciones Del Anticuerpo Anti-Psca Y A Sus Procedimientos Contra Celulas Cancerigenas Que Expresen Psca.
ES2307969T	GB - 20020022846 - 03/10/2002	PLASTICELL LTD	C12N 5/00 ; C12N 5/02 ; C12N 5/06	Cultivo Celular
GB2446525	JP - 20060257780 - 22/09/2006 ; GB - 20070010095 - 25/05/2007 ; JP - 20070118183 - 27/04/2007 ; WO - 2007GB03636 - 24/09/2007	RIKEN	C12N 5/06	Stem Cells Such As Embryonic Stem Cells (ES Cells), Including Human ES Cells, Are Cultured In A Medium Comprising A ROCK Inhibitor, And A Stem Cell Culture Medium, Optionally Serum Free, Comprises A ROCK Inhibitor.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
GB2446310	US - 20050703073P - 28/07/2005 ; WO - 2006US29483 - 27/07/2006	EDEN BIOTECH LTD	A61K 35/26 ; A61K 35/48 ; C12N 5/08	An Isolated And Purified Cell Line Of Hematopoeitic Stem Cells (HSC) That Are Incapable Of Expressing The CCR5 Receptor On The Cell Surface ("The CCR5 W 32 Cells" Are Used To Regenerate The Immune System In A Subject In Need Thereof And Especially To Treat A Subject Infected With Human Immunodeficiency Virus (HIV). The Method Is Carried Out By Transplanting CCR5 W 32 Into The Recipient Subject. Because Mature Immune Cells Derived From CCR5 W 32 Cells Cannot Express Functional CCR5 Receptors, They Will Be Resistant To Infection By HIV And Other Pathogens That Use The CCR5 Receptor To Infect Cells. An Embodiment Of The Invention Includes Administration Of A Nutritional Regimen To The Patient That Optimizes Conditions For CCR5 W 32 Cell Transplantation. Another Embodiment Of The Invention Includes Co-Transplanting Mesenchymal Cells Along With The HSC In Order To Enhance The Growth And Development Of The Transplanted HSC.
GB2447191	US - 20050753434P - 22/12/2005 ; WO - 2006AU01969 - 22/12/2006	ES CELL INT PTE LTD	C12N 5/08 ; G01N 33/50	The Present Invention Relates To The Induction Of Differentiation In Stem Cells To Cardiomyocytes And Factors Such As Prostaglandin Alone Or In Combination With Other Factors Including Essential Minerals Selected From The Group Including Transferrin And Selenium, Small Molecules Selected From The Group Including A P38 MAPK Inhibitor Such As SB203580 And Protein Growth Factors Of The FGF, IGF And BMP Families Such As But Not Limited To IGF1, FGF2, BMP2, BMP4 And BMP6, And Insulin That Influence The Process Of Differentiation To Cardiomyocytes. Media That Is Appropriate For The Induction Of Differentiation Of Cardiomyocytes From Stem Cells Is Also Provided Wherein The Media Contains These Factors. The Use Of Cardiomyocytes And Cardiac Progenitors Produced By The Directed Differentiation In Transplantation And Screening For Cardiac Compounds Is Also Provided.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
GB2450603	JP - 20070159382 - 15/06/2007	BAYER SCHERING PHARMA AG	C12N 5/06	Human Pluripotent Stem Cells Are Disclosed Which Are Established Form Human Postnatal Tissue Through The Introduction Of Oct3/4, Sox2, And Klf4 Genes, Or Oct3/4, Sox2, And Klf4 Genes In Combination With Either A C-Myc Gene Or A Histone Deacetylase Inhibitor. Methods Of Inducing Human Pluripotent Stem Cells Of The Invention From An Undifferentiated Stem Cell In Human Postnatal Tissue Are Also Claimed, As Are Stem Cells Of The Invention For Use In Cell Replacement Therapy. Undifferentiated Stem Cells In Which Each Of The Genes Tert. Nanog, Oct3/4, And Sox2 Has Not Undergone Epigenetic Inactivation, And Which Can Be Induced Into The Pluripotent Stem Cells Of The Invention, Are Also Claimed.
GB2449001	GB - 20070000478 - 10/01/2007 ; WO - 2008GB00048 - 08/01/2008	STEM CELL SCIENCES	C12Q 1/02 ; G01N 33/50	Assays Are Provided For Assessing The Suitability Of Cell Culture Media And Medium Supplements For The Culture Of Particular Cell Types, Particularly Stem Cells, Including Embryonic Stem Cells.
GB2449042	US - 20060743264P - 09/02/2006 ; WO - 2007US03417 - 08/02/2007	GUMENYUK MARYNA E ; THOMAS JAMES A ; WISCONSIN ALUMNI RES FOUND	C12N 5/06 ; C12N 5/08	Methods And Compositions Of Erythroid Cells That Produce Adult B - Hemoglobin, Generated By Culturing CD31+, CD31+/CD34+ Or CD34+ Cells From Embryonic Stem Cells Under Serum-Free Culture Conditions.
GB2449772	GB - 20070003188 - 19/02/2007 ; GB - 20070006917 - 10/04/2007 ; WO - 2008GB00558 - 19/02/2008	STEM CELL SCIENCES	C12N 5/06 ; C12N 5/08	Methods For Large-Scale Production Of Stem Cells, Including Embryonic Stem Cells, Are Provided. Also Provided Are Methods For Large-Scale Production Of Differentiated Cells Derived From Stem Cells And Use Of Stem Cells Or The Differentiated Progeny Thereof In Assays.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
GB2450059	DK - 20060000381 - 17/03/2006 ; DK - 20060001344 - 17/10/2006 ; US - 20060783054P - 17/03/2006 ; US - 20060851743P - 16/10/2006 ; WO - 2007EP02346 - 16/03/2007	CELLARTIS AB	C12N 5/08	The Present Invention Relates To A Culture System For And A Method For Propagation Of Human Blastocyst-Derived Stem Cells (Hbs Cells) Upon Enzymatic Dissociation Into A Single Cell Suspension. The Culture System For Propagation Of Human Blastocyst-Derived Stem (Hbs) Cells Comprises I) Human Feeder Cells At A Density Of At Least 50,000 Cells/Cm<2>, Ii) One Or More Dissociation Agents For Dissociation Of Hbs Cell Colonies Into A Single Cell Suspension, And Iii) A Supportive Culture Medium, Which Culture System Makes It Possible To Propagate Hbs Cells By Dissociation Of Hbs Cell Colonies Into A Single Cell Suspension At Each Consecutive Passage For An Extended Time Period, While Maintaining The Significant Characteristics Of Hbs Cells.
GB2450599	GB - 20070004406 - 07/03/2007 ; GB - 20070009552 - 18/05/2007 ; WO - 2008GB00813 - 07/03/2008	STEM CELL SCIENCES	C12M 3/00 ; C12N 5/06	Methods Are Provided For Large-Scale Automated Production Of Stem Cells, Including Embryonic Stem Cells, And Differentiated Cells Derived From Stem Cells In Culture. Also Provided Are Populations Of Stem Cells Or Differentiated Cells And Apparatus Adapted For The Large-Scale Production Of Stem Cells Or The Differentiated Progeny Thereof.
HK1053616	US - 20000522030 - 09/03/2000 ; WO - 2001US06912 - 02/03/2001	WISCONSIN ALUMNI RES FOUND	A61K 31/495 ; A61K 9/22 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Serum Free Cultivation Of Primate Embryonic Stem Cells
JP2008148643	JP - 20060341396 - 19/12/2006	OLYMPUS CORP	C12N 5/06	PROBLEM TO BE SOLVED: To Enable The Primary Culture And Subculture Of A Stem Cell To Be Carried Out In A Serum-Free Medium. - SOLUTION: The Serum-Free Medium Is Obtained By Mixing Pannexin In 5-10% Concentration, Bfgf Of 1-100 Ng/Ml, PDGF Of 1-100 Ng/Ml, EGF Of 1-100 Ng/Ml And Vitamin C Of 1-1,000 [Mu]G/Ml With A Basal Medium. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008148693	JP - 20060128106 - 02/05/2006 ; JP - 20070304238 - 26/11/2007	STELIC INST OF REGENERATIV E ME	A61K 35/37 ; A61K 39/00 ; A61K 39/395 ; A61K 45/00 ; A61K 48/00 ; A61L 27/00 ; A61P 31/12 ; A61P 35/00 ; C07K 16/18 ; C12N 15/02 ; C12N 5/06 ; C12P 21/08 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/15 ; G01N 33/48 ; G01N 33/50 ; G01N 33/574	PROBLEM TO BE SOLVED: To Provide A Method For Isolating A Stem Cell In Which A Cell Having A Labeled Cell Nucleus Is Selected As A Stem Cell. - SOLUTION: Disclosed Is A Method For Isolating A Stem Cell By Labeling A Cell Nucleus (E.G., A Nuclear Envelope) Of The Stem Cell. It Is Possible That A Stem Cell Can Be Isolated With Good Efficiency By Labeling Cell Nuclei Of Individual Cells In A Heterologous Cell Population And Selecting A Cell Which Is Still In A Labeled State After Cell Division. It Is Possible To Visualize An Animal Tissue Stem Cell In A Living State By Labeling The Stem Cell With Utilizing The Functions Inherent To A Stem Cell. Further The Animal Tissue Stem Cell Can Be Readily Isolated In A Fresh State Without The Need Of Using Any Genetic Manipulation Or Any Artificial Marker. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008148702	US - 20010343498P - 21/12/2001	IMMUNEX CORP	A61K 35/12 ; A61K 35/14 ; A61K 35/28 ; A61K 35/407 ; A61L 27/00 ; A61P 7/00 ; A61P 9/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/02	PROBLEM TO BE SOLVED: To Provide A Stem Cell Characterized By The Ability To Renew And The Ability To Form Endothelial And/Or Endothelial-Like Cells, A Method For Isolating The Stem Cell And The Use Of The Cell. - SOLUTION: The Method For Culturing A P1H12+ Endothelial Stem Cell Comprises (A) Contact Of A Population Of Human Peripheral Blood Mononuclear Cell (PBMC) Containing The P1H12+ Endothelial Stem Cell With A Molecule Specifically Binding To P1H12+ Under A Condition To Bind The Molecule To The P1H12+ Endothelial Stem Cell, (B) Separation Of The P1H12+ Endothelial Cells Bound To The Molecule From PBMC Cells Which Are Not Bound To The Molecule, (C) Incubation Of The Separated P1H12+ Endothelial Stem Cell In A Medium In Contact With A Surface Covered With Collagen, And (D) The Removal Of The Separated P1H12+ Endothelial Stem Cells Which Are Not Bound To The Collagen-Covered Surface From The Medium. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008163042	JP - 20080058653 - 08/02/2008	KAJISA ISAO	A61K 48/00 ; A61P 43/00	PROBLEM TO BE SOLVED: To Produce An Elixir Of Life And Perfectly Bring About Perennial Long Life By Applying The Newest Science. - SOLUTION: The Oral Elixir Of Life Is Produced By Using Human Ips (Induced Pluripotent Stem) Cell Reprogramming 3 Genes By Taking Out The Human Ips Cell Reprogramming 3 Genes, Oct3/4, Sox2 And Klf4 To Proliferate To Prevail In The Whole Body Of An Aged Adult And Bring Reprogramming Of Aged Cells Back To Young Cells And Bring The Person To Have The Perennial Long Life. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008169118	JP - 20070000728 - 05/01/2007	MARUZEN PHARMA	A61K 36/28 ; A61K 8/97 ; A61P 17/16 ; A61P 43/00 ; A61Q 19/02 ; A61Q 19/08	PROBLEM TO BE SOLVED: To Obtain An Agent For Inhibiting Increase In Expression Of A Stem Cell Factor (SCF) And An Agent For Inhibiting Increase In Expression Of A Basic Fibroblast Growth Factor (Bfgf) Comprising A Substance As An Active Ingredient Having An Inhibitory Action On Increase In Expression Of A Stem Cell Factor (SCF) And An Inhibitory Action On Increase In Expression Of A Basic Fibroblast Growth Factor (Bfgf) By Finding The Substance From Natural Products Having High Safety. - SOLUTION: The Agent For Inhibiting Increase In Expression Of A Stem Cell Factor (SCF) And The Agent For Inhibiting Increase In Expression Of A Basic Fibroblast Growth Factor (Bfgf) Each Comprise An Extract From Arnica Montana As An Active Ingredient. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008173034	JP - 20070008086 - 17/01/2007	NAT INST RADIOLOG	C12N 15/09 ; C12Q 1/68 ; G01N 33/53	PROBLEM TO BE SOLVED: To Provide A Method For Deducing Or Detecting Influence On Stem Cells By Radiation At Low Doses Of About Several Mgy Levels, To Provide A Method For Predicting The Induction Of The Stem Cells To Apoptosis That Stems From Such A Low-Dose Exposure, And To Provide A Method For Screening A Substance Inhibiting A Low-Dose Radiation Inductive Cell Apoptosis And Predicting Induction To Apoptosis. - SOLUTION: The Method For Determining Or Detecting The Low-Dose Exposure To A Stem Cells Comprises Determining The Increase Of The Expression Level Of PPP1CA, BAD And/Or BCL-XL Gene In The Stem Cells. The Method For Predicting The Induction Of The Stem Cells To Apoptosis Stemming From Such A Low-Dose Exposure Is Also Provided. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008178367	JP - 20070015793 - 26/01/2007	SUMITOMO BAKELITE CO	C08J 7/04 ; C12M 3/00 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Culturing Container For Developing An Embryoid (EB), Developing The EB Having A High Quality From An Embryonic Stem Cell (ES Cell) Easily In A Good Efficiency, And To Provide A Method For Producing The Same And A Method For Developing The EB. - SOLUTION: This Method For Producing The Culturing Container For Developing The EB Comprises The Water-Soluble Resin-Covering Layer-Forming Process Of Forming A Water-Soluble Covering Layer By Covering The Inner Surface Of The Culturing Container With The Water-Soluble Resin And After That Process, The Water-Insoluble Cured Film-Modifying Process Of Curing The Water-Soluble Covering Layer To Modify To The Water-Insoluble Cured Film Layer, And The Produced Culturing Container For Developing The EB Is Also Provided. Further, The Method For Developing The EB Is Provided By Seeding And Culturing Non-Differentiated Embryonic Stem Cells In The Container For Developing The EB. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008178403	JP - 20060353710 - 28/12/2006 ; JP - 20070339937 - 28/12/2007	MITSUBISHI CHEMICAL MEDIENCE C ; OLYMPUS CORP	C12M 1/00 ; C12N 15/09 ; C12N 5/06 ; C12Q 1/04 ; C12Q 1/68	PROBLEM TO BE SOLVED: To Provide A Gene Marker Useful For Detecting And/Or Discriminating Cells In Each Step Of A Process For Differentiating Bone Marrow Cells Into Osteoblasts Through Mesenchymal Stem Cells, Especially The Mesenchymal Stem Cells. - SOLUTION: The Bone Marrow Cells, Cells After Culturing The Bone Marrow Cells And Before Selective Culture Solely Of The Mesenchymal Stem Cells, The Mesenchymal Stem Cells, Osteoblast Precursor Cells Or The Osteoblasts Are Detected And/Or Separated By Detecting The Expression Amount Or Difference In The Expression Amount Of At Least One Or More Genes Out Of Genes Having A Specific Base Sequence. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008179642	US - 20000245168P - 03/11/2000	KOURION THERAPEUTICS AG	A61K 35/12 ; A61K 35/14 ; A61K 35/44 ; A61K 35/50 ; A61P 1/16 ; A61P 21/00 ; A61P 25/00 ; A61P 25/16 ; A61P 3/10 ; A61P 41/00 ; A61P 43/00 ; A61P 7/00 ; A61P 9/00 ; C12N 5/06 ; C12N 5/08	PROBLEM TO BE SOLVED: To Provide A Stem Cell That Is Useful For Treating A Blood Vessel Disease, A Disease Of A Heart Or A Smooth Muscle, A Liver Disease, A Type 1 Diabetes, A Neurological Disease, A Parkinson's Disease Or A Blood Disease And Can Differentiate To A Different Precursor Cell Such As A Mesenchymal Cell, A Neurocyte, A Hemocyte Or An Endothelial Cell. - SOLUTION: An Unrestricted Somatic Stem Cell Has The Characteristics (I) To (Iv) As A Stem Cell That Can Differentiate To A Different Precursor Cell Such As A Mesenchymal Cell, A Neurocyte, A Hemocyte Or An Endothelial Cell. (I) Being Negative To CD 45 And CD 14 Surface Antigens; (Ii) Being Positive To CD 13, CD 29, CD 44 And CD 49e Antigens; (Iii) Expressing YB1, AML-1, RUNX-1 And Fibulin-2; And (Iv) Not Expressing Hyaluronan Synthase, Fibromodulin And INFLS. The Unrestricted Somatic Stem Cell Isolated From Human Cord Blood And Placental Blood Is Particularly Preferable. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008182912	JP - 20070017344 - 29/01/2007	NIPPON KAYAKU KK ; YASUMOTO SHIGERU	C12N 15/09 ; C12N 5/10 ; C12Q 1/02 ; C12Q 1/68	PROBLEM TO BE SOLVED: To Provide A Method For Selectively Culturing A Cancer Stem Cell, A Cancer Stem Cell Selected By The Culture Method, A Method For Screening A Specific Expression Gene And A Selectively Inhibitory Substance Using The Cancer Stem Cell, And The Specific Expression Gene And Selectively Inhibitory Substance Of The Cancer Stem Cell Selected By The Screening Method. - SOLUTION: The Method For Selectively Culturing A Cancer Stem Cell Employs Culture Solution Containing At Least Tumor Growth Factor [Beta] (TGF[Beta]) And Tumor Necrosis Factor [Alpha] (TNF[Alpha]). Also Disclosed Is The Method For Screening The Specific Expression Gene And Selectively Inhibitory Substance Using The Selected Cancer Stem Cell. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008188021	JP - 20030375026 - 04/11/2003 ; JP - 20040039099 - 16/02/2004 ; JP - 20080099668 - 07/04/2008	BIOMASTER INC	C12N 5/06 ; C12N 5/08	PROBLEM TO BE SOLVED: To Provide A Method For Preparing Homogeneous Stem Cells And/Or Precursor Cells In A Large Amount, In A Simple And Efficient Manner, From Human (Particularly, A Subject Per Se), And A Method For Preparing Tissue Implant Pieces Or Graft Pieces In A Large Amount By Using The Stem Cells And/Or Precursor Cells. - SOLUTION: It Was Unexpectedly Found That An Aspirate From Liposuction Contains A Large Number Of Stem Cells, And The Method For Preparing The Stem Cells From Such An Aspirate From Liposuction Was Achieved, And Thereby The Purpose Was Achieved. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008193897	JP - 20050120842 - 19/04/2005	DAINIPPON SUMITOMO PHARMA CO ; NARA INST SCIENCE & TECHNOLOGY ; SUMITOMO CHEMICAL CO	C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Growth Promoter For A Pluripotent Stem Cell Effectively Used In Research And Clinical Applications Of ES (Embryonic Stem) Cells In Regenerative Medicines Because The Pluripotent Stem Cell Can Be Cultured Even In The Absence Of Serum By Adding The Growth Promoter Thereof To A Serum-Free Culture Medium (Serum-Free Culture Solution). - SOLUTION: The Growth Promoter For The Pluripotent Stem Cell Comprises Visfatin Or A Visfatin Gene As An Active Ingredient. A Culture Solution Or A Culture Kit For The Pluripotent Stem Cell Comprises The Visfatin As The Ingredient. A Method For Culturing The Pluripotent Stem Cell Is Obtained Using The Culture Solution Or The Culture Kit. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008148625	JP - 20060339555 - 18/12/2006	TOKYO METROPOLITAN UNIV	C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Technology For Preparing Human ES Cells (Embryonic Stem Cells), Which Can Clear An Ethical Problem And A Technology Related To The Preparation Technology. - SOLUTION: A Somatic Cell-Derived Nucleus Is Transplanted Into An Enucleated Unfertilized Egg To Form A Cloned Embryo And The Cloned Embryo Is Treated To Generate A Divided Embryo. Then, The Blastomere Cells Of The Divided Embryo Generated By, E.G. An 8 Cell Period Are Co-Cultured Together With Separately Prepared ES Cells Of The Same Kind Of Animal Species So That Divided Embryo-Derived ES Cells, Namely, Blastomere Cell-Derived ES Cells Are Induced And Prepared. Then, The Cloned ES Cells Are Separately Cultured So As To Establish Cloned ES Cell Strains. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008194055	US - 20010314323P - 23/08/2001	RELIANCE LIFE SCIENCES PVT LTD	A61B 17/435 ; A61B 18/20 ; C12N 13/00 ; C12N 5/06 ; C12N 5/08	PROBLEM TO BE SOLVED: To Provide Isolation Of An Inner Cell Mass (ICM) By Using A Laser Ablation Technique, Safe And Simple And Commercially Practicable Without Using An Animal-Originated Antibody Or Animal-Originated Serum And Without Carrying Out Difficult Protocols Of Immunological Operations. - SOLUTION: The Method Is To Establish Human Embryonic Stem Cell Lines And Includes Following Processes: (A) A Process For Isolating Cells Of The Inner Cell Mass From The Blastocyst Stage Embryo By Preparing An Aperture In The Blastocyst Stage Embryo Through The Pellucid Zone And The Trophoblast By Laser Ablation And Taking Out The Cells Of The Inner Cell Mass From The Blastocyst Stage Embryo Through The Aperture, (B) A Process For Producing A Mass Originated From The Inner Cell Mass By Culturing The Cells Of The Inner Cell Mass Under A Condition Without Feeder And (C) A Process For Culturing The Mass Originated From The Inner Cell Mass To Produce The Isolated Human Embryonic Stem Cell Lines. - COPYRIGHT: (C)2008,JPO
JP2008307205	JP - 20070157389 - 14/06/2007	UNIV OSAKA	A61L 27/00 ; C12N 5/06 ; C12Q 1/02 ; G01N 33/15 ; G01N 33/50	PROBLEM TO BE SOLVED: To Provide A Method For Acquiring A Large Amount Of Cardiomyocytes, A Sheet Including Cardiomyocytes, And Also A Method For Screening Substances For Promoting Differentiation Into The Cardiomyocytes. - SOLUTION: In A Method, Fatty Tissue-Derived Stem Cells Are Cultivated Under Presence Of DMSO Or OP9 Cultivation Supernatant And Differentiated Into Cardiomyocytes, And Then, The Sheet Including Cardiomyocytes Is Formed. In The Method For Screening The Differentiation Promoting Substances, Candidate Substances For Promoting The Differentiation Into Cardiomyocytes Are Added In Cultivating Fatty Tissue-Derived Stem Cells So As To Screen The Differentiation Promoting Substances. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008195730	US - 20010309196P - 31/07/2001 ; US - 20020382155P - 20/05/2002	ANORMED INC	A61K 31/33 ; A61K 31/395 ; A61K 31/496 ; A61K 31/55 ; A61K 31/551 ; A61K 31/555 ; A61K 38/00 ; A61K 38/19 ; A61K 45/00 ; A61P 17/02 ; A61P 31/04 ; A61P 35/02 ; A61P 37/00 ; A61P 37/04 ; A61P 43/00 ; A61P 7/00 ; A61P 7/06	PROBLEM TO BE SOLVED: To Provide A Method For Increasing The Number Of Progenitor And Stem Cells In An Animal Subject By Using A Compound Which Binds To A Chemokine Receptor CXCR4. - SOLUTION: The Method Comprises A Step Of Prescribing A Compound Of The Formula: Z-Linker-Z' (1) Wherein Z Is A Cyclic Polyamine Containing A Ring Having 9 To 32 Ring Members (Of Which 3-8 Are Nitrogen Atoms), Or A Pharmaceutically Acceptable Salt Thereof, The Nitrogen Atoms Being Separated From Each Other By At Least 2 Carbon Atoms, And Wherein The Heterocycle May Optionally Contain An Additional Heteroatom Near The Nitrogen Atom And/Or May Be Condensed With An Additional Ring System. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008200033	JP - 20070011805 - 22/01/2007 ; JP - 20080008772 - 18/01/2008	UNIV OF SCIENCE TOKYO	A61K 35/12 ; A61P 1/02 ; C12N 15/09 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Mesenchymal Cell For Formation Of Tooth Capable Of Efficiently Obtaining Tooth Retaining Characteristic Cell Configuration And Efficiently Obtain The Tooth In Which Characteristic Cell Configuration Is Retained. - SOLUTION: A Totipotent Stem Cell, E.G. Embryonic Carcinoma Cell Is Cultured In The Presence Of A Differentiation-Inducing Agent Such As Dimethyl Sulfoxide, And The CD44-Positive And CD29-Positive Cell Or The CD44-Positive And CD106-Positive Cell Is Selected From The Differentiation-Induced Cell Population As A Tooth-Forming Mesenchymal Cell. A First Cell Population Comprising Substantially Only Either One Of A Mesenchymal Cell And An Epithelial Cell And A Second Cell Population Comprising Substantially Only The Other Are Placed In The Inside Of A Carrier Which Can Allow The Cells To Be In Contact With Each Other In A Closely Adhered State Without Mixing Them And The Cell Populations Are Cultured, Wherein The Mesenchymal Cell Comprises The Tooth-Forming Mesenchymal Cell. As A Result, The Tooth Having Characteristic Cell Configuration Is Obtained. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008201792	US - 20010970543 - 04/10/2001	HADASIT MED RES SERVICE ; NAT UNIV OF SINGAPORE ; UNIV MONASH	A61K 35/30 ; A61K 48/00 ; A61L 27/00 ; A61P 25/00 ; A61P 25/18 ; A61P 37/00 ; A61P 9/00 ; C12N 5/06 ; C12N 5/08	PROBLEM TO BE SOLVED: To Produce Human ES Cells Yielding Somatic Differentiated Cells In Vitro, As Well As Committed Progenitor Cells Such As Neural Progenitor Cells Giving Rise To Mature Somatic Cells Including Neural Cells And/Or Glial Cells. - SOLUTION: A Method Of Generating An In Vitro And In Vivo Model Of Controlled Differentiation Of ES Cells Toward The Neural Lineage, Is Provided. The Model And Cells That Are Generated Along The Pathway Of Neural Differentiation May Be Used For The Study Of The Cellular And Molecular Biology Of Human Neural Development, For The Discovery Of Genes, Growth Factors, Differential Factors That Play A Role In Neural Differentiation And Regeneration, For Drug Discovery And For The Development Of Screening Assays For Teratogenic, Toxic And Neuro-Protective Effects. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008207002	US - 20020414098P - 27/09/2002	VERIGEN AG	A61L 27/00 ; A61L 27/38 ; C12N 5/00	PROBLEM TO BE SOLVED: To Provide An Efficient And Effective Method For Repair And/Or Regeneration Of Tissue Defects Except For Cartilage. - SOLUTION: The Tissue Repair Structure Comprises A Cell-Free Collagen Support Matrix And Mesenchymal Stem Cells Located In Proximity Of The Matrix. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008212022	JP - 20070051609 - 01/03/2007	OLYMPUS CORP	C12M 1/00 ; C12N 5/06	PROBLEM TO BE SOLVED: To Readily And Rapidly Remove Erythrocytes From Cellular Suspension Containing Stem Cells That Originates From A Tissue And The Erythrocytes. - SOLUTION: This Device For Separating The Stem Cells C That Originate From The Tissue Is Provided With A Flow Passage 3 For Making The Cellular Suspension A Flow That Contains The Stem Cells C That Originate From The Tissues And Erythrocytes B, And Is Installed With A Multiple Recessed Parts 6, Which Are Narrower Than The Particle Diameter Of The Stem Cells C That Originate From The Tissues And Which Are Larger Than The Particle Diameter Of The Erythrocytes B, At The Bottom Surface 3a Of The Flow Passage 3. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008212150	US - 20010338885P - 07/12/2001	GERON CORP	A01N 63/00 ; A61K 35/12 ; A61K 38/22 ; A61K 38/26 ; A61K 38/28 ; A61K 48/00 ; A61P 1/18 ; A61P 3/10 ; C12M 1/00 ; C12M 3/00 ; C12N 15/17 ; C12N 15/18 ; C12N 15/85 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12P 21/02 ; C12Q 1/02 ; G01N 33/15 ; G01N 33/50	PROBLEM TO BE SOLVED: To Provide A Method For Producing Functioning Pancreas Islet Cells By Differentiating Embryonic Stem Cells, A Population Of Such The Cells And A Method For Treating Diseases By Using The Same. - SOLUTION: This Isolated Cell Population Is Obtained By Modifying A Gene So As To Express A Telomerase Reverse Transcriptase In A High Level, And Differentiating Primates Pluripotent Stem Cells So That At Least 5% Of The Cells Secrets One Or A Multiple Number Of Proteins (Insulin, Glucagon, Somatostatin Or A Pancreatic Polypeptide) Originated From Endogeneous Gene. It Is Possible To Produce The High Quality Pancreas Islet Cell Population Used For The Screening Of A Medicine Or A Regeneration Medicine, In A Commercial Scale. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008220205	JP - 20070059745 - 09/03/2007	SUMITOMO BAKELITE CO	C12M 3/00 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Container For Forming A Neural Stem Cell Aggregate, Capable Of Efficiently And Readily Affording The Neural Stem Cell Aggregate In A Step Of Forming The Neural Stem Cell Aggregate For Obtaining Neural Stem Cells From A Biological Tissue Containing The Neural Stem Cells, To Provide A Method For Producing The Container, And To Provide A Method For Preparing The Neural Stem Cell Aggregate. - SOLUTION: The Method For Producing The Container For Forming The Neural Stem Cell Aggregate Is Characterized By Comprising A Water-Soluble Resin Coating Step Of Coating The Inner Surface Of The Container With A Water-Soluble Resin And Forming A Water-Soluble Resin Coating Layer And A Water-Insoluble Cured Film-Modifying Step Of Curing The Water-Soluble Resin Coating Layer And Modifying The Coating Layer Into A Water-Insoluble Cured Film Layer After The Step. The Container For Forming The Neural Stem Cell Aggregate Is Produced By The Method For Production. The Method For Preparing The Neural Stem Cell Aggregate Is Characterized By Suspending A Tissue Containing Multifunctional Neural Stem Cells In A Culture Medium Containing At Least One Kind Of Stem Cell Growth Factor, Carrying Out Seeding And Culturing Thereof In The Container For Forming The Neural Stem Cell Aggregate And Thereby Forming The Neural Stem Cell Aggregate. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008220334	JP - 20070067259 - 15/03/2007	UNIV KYOTO	C12N 15/09 ; C12N 5/06 ; C12N 5/10 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/53	PROBLEM TO BE SOLVED: To Provide A Method For Performing The Quality Control Of A Mesenchymal Stem Cell By Using A Specific Marker, And To Provide A Method For Isolating A Cell Having Differentiation Potency Corresponding To Purposes From Mesenchymal Stem Cells Based On The Expression Of The Specific Marker. - SOLUTION: There Are Provided A Method Of Judging The Bone Differentiation Potency Of A Mesenchymal Stem Cell Comprising Measuring The Level Of Expression Of CD106 In The Mesenchymal Stem Cell And Judging The Bone Differentiation Potency Of The Mesenchymal Stem Cell Based On The Negative Correlation Between The Level Of Expression Of CD106 And The Bone Differentiation Potency Of The Mesenchymal Stem Cell. There Are Also Provided A Method For Producing A Mesenchymal Stem Cell Having A Bone Differentiation Potency Comprising Isolating A CD106 Negative Cell From A Mesenchymal Stem Cell Population. - COPYRIGHT: (C)2008,JPO&INPIT
JP2008220361	JP - 20060226212 - 23/08/2006 ; JP - 20070031630 - 13/02/2007 ; JP - 20070217174 - 23/08/2007	SUMITOMO ELECTRIC INDUSTRIES	A61L 27/00 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Technique For Selectively Differentiation-Inducing Mesenchymal Stem Cells, Which Can Differentiate To Cells That Constitute Various Tissues And Organs, To Osteoblasts, And To Provide A Technique For Differentiation-Inducing Mesenchymal Stem Cells To Osteoblasts With A Simple Operation That Needs Only Short Time And That Is Noninvasive. - SOLUTION: The Inventors Have Found That The Switch For The Differentiation Induction To Osteoblasts Is Turned On By Translocating Biological Clock-Relevant Factors Existing In Mesenchymal Stem Cells From The Cells' Cytoplasm To The Cells' Nucleus. The Inventors Have Also Found That The Switch Can Be Turned On By Irradiating The Cells For A Short Time With A Light That Is Noninvasive. - COPYRIGHT: (C)2008,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008228629	JP - 20070071252 - 19/03/2007	INOUE HAJIME	A61F 2/10 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Method For Easily Inducing The Differentiation Of An Epithelial Stem Cell Represented By Epidermal Stem Cell Highly Safely. - SOLUTION: A Differentiation Inducing Method For An Epithelial Stem Cell Includes Culturing An Epithelial Stem Cell In A Serum-Free Medium Added With Platelet-Rich Plasma. Also, The Differentiation Inducing Method Is Characterized By Having An Epidermal Stem Cell As For The Epithelial Stem Cell. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008228632	JP - 20070071416 - 19/03/2007	BAYER SCHERING PHARMA AG	A61K 35/54 ; A61P 15/12 ; C12N 15/09 ; C12N 5/10 ; G01N 33/15 ; G01N 33/50	PROBLEM TO BE SOLVED: To Provide A Method For Establishing A Somatic Stem Cell Of A Living Body Capable Of Inducing The Differentiation To Ovarian Granulosa Cell And Ovarian Theca Cell And Controlling The Differentiation Induction Of The Somatic Stem Cell Of A Living Body To Ovarian Granulosa Cell And Ovarian Theca Cell. - SOLUTION: The Invention Provides A Somatic Stem Cell Of A Living Body Differentiating To Ovarian Granulosa Cell And Ovarian Theca Cell By Collecting From A Mammalian, Subculturing In A Serum-Free Or Low Serum Content Medium For One To Eight Generations And Inducing The Expression Of A Transcription Factor Steroidogenic Factor-1, An Ovarian Granulosa Cell And An Ovarian Theca Cell Produced By The Differentiation, A Cell Therapeutic Agent Containing The Cells, A Method For Producing The Same, A Cell Producing The Same, And A Method For Searching A Factor Inducing The Differentiation To The Cells. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008228742	GB - 20020010539 - 08/05/2002	UNIV COURT OF THE UNIV OF EDIN	C12N 15/09 ; C12N 5/00 ; C12N 5/06 ; C12N 5/10	PROBLEM TO BE SOLVED: To Provide A Method For Culturing Pluripotent Stem Cells And A Culture Medium Suitable For The Pluripotent Stem Cells. - SOLUTION: A Composition For Promoting Self Renewal Of Pluripotent Cells During Culture Is Provided. The Composition Contains (A) A Bone Morphogenetic Protein (BMP) Receptor Agonist And (B) Cytokine Acting Through Gp130. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008241703	JP - 20070049374 - 28/02/2007 ; JP - 20080045507 - 27/02/2008	KUMAMOTO UNIV	C12N 5/06 ; G01N 33/574	PROBLEM TO BE SOLVED: To Provide A Method For Identifying A Marker Molecule Of A Pancreas Stem Cell, And Detecting The Pancreas Stem Cell By Utilizing It, And A Method For Isolating The Pancreas Stem Cell. - SOLUTION: This Method For Detecting The Pancreas Stem Cell, A Lung Villus Cell, A Liver Stem Cell Or Pancreatic Cancer Includes Detection Of Manifestation Of An Epiplakin 1 (EPPK1) Gene. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008263824	JP - 20070109539 - 18/04/2007	RIKAGAKU KENKYUSHO	A61K 45/00 ; A61P 35/00 ; C12N 15/09 ; C12N 5/10 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/15 ; G01N 33/50 ; G01N 33/574	PROBLEM TO BE SOLVED: To Provide A Method For Producing A Cancer Stem Cell, To Provide The Cancer Stem Cell Produced By The Method, To Provide A Method For Screening A Cancer Stem Cell-Targeting Substance And A Method For Screening An Anticancerous Substance Using The Cancer Stem Cell, To Provide A Pharmaceutical Composition Comprising The Substances Obtained By The Methods And To Provide A Diagnostic Method For Cancer Including A Step Of Detecting A Protein Or An Mrna Which Is Specifically Expressed In The Cancer Stem Cell. - SOLUTION: The Method For Producing The Cancer Stem Cell Includes A Step Of Feeding A Normal Cell To Ras Activation And P53 Deficiency. The Cancer Stem Cell Is Produced By The Method. Furthermore, The Method For Screening The Cancer Stem Cell-Targeting Substance And The Method For Screening The Anticancerous Substance Using The Cancer Stem Cell Are Provided. The Pharmaceutical Composition Comprises The Substances Obtained By The Methods. The Diagnostic Method For The Cancer Includes The Step Of Detecting The Protein Or The Mrna Which Is Specifically Expressed In The Cancer Stem Cell. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008273875	JP - 20070119579 - 27/04/2007	MARUZEN PHARMA	A61K 36/18 ; A61K 36/23 ; A61K 36/48 ; A61K 36/53 ; A61K 36/73 ; A61K 36/899 ; A61K 8/97 ; A61P 17/00 ; A61P 17/16 ; A61P 35/04 ; A61P 43/00 ; A61Q 19/02	PROBLEM TO BE SOLVED: To Provide An Agent For Suppressing The Increase Of Expression Of A Stem Cell Factor (SCF) By Finding A Substance Having An Action To Suppress The Increase Of Expression Of A Stem Cell Factor (SCF) From Natural Materials Having High Safety And Using The Substance As An Active Component Of The Agent, And To Provide A Prevention Or Treatment Agent Containing The Suppressing Agent. - SOLUTION: The Agent For Suppressing The Increase Of Expression Of SCF Comprises One Or More Vegetable Extracts Selected From The Extracts Of Averrhoa Carambola L., Glychyrrhiza Glabra, Rubus Ellipticus, Eriobotrya Japonica Lindley, Machilus Odoratissima, Melissa Officinalis, Alpinia Spesiosa, Coix Lachrymal-Jobi L., Ligusticum Wallichii Franch., Prunus Persica Seed And Gentiana Lutea, As An Active Component, And The Preventing Or Treating Agent Contains The Suppressing Agent. The Suppressing Agent Suppresses The Abnormal Growth Of Myeloblast And Is Useful For The Prevention Or Treatment Of Myelodysplastic Syndromes, Acute Myelocytic Leukemia, Etc. The Suppressing Agent Is Also Useful As A Cosmetic Effective For The Prevention Or Suppression Of Pigmentation, Spot, Freckle, Etc., After Sunburn By Suppressing The Growth Of Pigment Cell And The Excessive Production Of Melanin In The Skin. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008279238	JP - 20070159514 - 10/05/2007	FUNAYAMA MAKIKO	A61L 27/00	PROBLEM TO BE SOLVED: To Solve Issues That The Cause Of Disease Has High Probability Of Genetic Disposition And The Mechanism Of Disease Generation And Individual Difference Cannot Be Eludicated At Genetic Level Though The Cause Of Disease Can Be Explained By Genome In Genome And Gene Judgement, Genome Drug Creation, Etc. - SOLUTION: Though It Seems To Be Not Executed In Orthopedics, Cell-Regenerated Tissue, Erythropoietin, A Kind Of Hormone, Etc. And Gene Vector HGF Protein Etc. Autologously Transplanted, A Small Amount Of Appropriate Tissue Or Cell Collected From A Patient To Culture And Increase The Cell. Structure Of The Tissue Made According To Circumstances, Tissue Regeneration By Somatic Stem Cell, Somatic Stem Cell Separately Collected From Cells, And So Forth Are Applied. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008283963	GB - 20040006215 - 19/03/2004	PROCURE THERAPEUTICS LTD	C07K 16/18 ; C12N 15/09 ; C12N 5/06 ; C12Q 1/68 ; C40B 40/08 ; G01N 33/50 ; G01N 33/574	PROBLEM TO BE SOLVED: To Provide A Method For Identifying The Marker Of Normal Prostate Stem Cells And Isolating Prostate Stem Cells. - SOLUTION: Disclosed Are A Method For The Isolation Of Normal Prostate Stem Cells Comprising The Selective Enrichment Of Prostate Stem Cells Which Express CD133 Antigen; A Method Wherein The Stem Cells Also Express High Levels Of [Alpha]2[Beta]1 Integrin; Normal And Cancerous Prostate Stem Cells Isolated By The Methods; A Composition Comprising The Stem Cells; An Antibody And T Cells Obtained By Using The Stem Cells; And Their Use. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008283972	JP - 20050359537 - 13/12/2005 ; JP - 20080131577 - 20/05/2008	UNIV KYOTO	A61K 35/12 ; A61L 27/00 ; A61P 25/16 ; A61P 3/10 ; A61P 35/00 ; C12N 15/09 ; C12N 5/10	PROBLEM TO BE SOLVED: To Provide A Method For Producing Induced Pluripotent Stem Cells Having Pluripotency And Proliferation Capacity Similar To ES (Embryonic Stem) Cells Simply And With Good Reproducibility By Inducing The Initialization Of Differentiated Cells Without Utilizing Embryos Or The ES Cells. - SOLUTION: This Method For Producing The Induced Pluripotent Stem Cells From Somatic Cells Comprises A Process Of Introducing The Following 4 Kinds Of Genes: Oct3/4, Klf4, C-Myc And Sox2 Into The Somatic Cells. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008283991	JP - 20070014521 - 25/01/2007	NAT INST FOR MATERIALS SCIENCE	A61K 35/28 ; A61K 38/00 ; A61K 38/27 ; A61L 27/00 ; A61P 9/04	PROBLEM TO BE SOLVED: To Fabricate The 3-D Networks Of Nanofibers By Mixing A Growth Factor Solution With Aqueous Solution Of Peptide Amphiphile As An Injectable Carrier For Controlled Release Of Growth Factors And Used It For Feasibility Of Prevascularization By The Growth Factor Release From The 3-D Networks Of Nanofibers In Improving Efficiency Of ES Cells Transplantation In An Ischemic Cardiomyopathy Model. - SOLUTION: We Hypothesized That A Novel Approach To Promote ES Cells Differentiation And Vascularization Would Be To Create Injectable Three Dimensional (3-D) Scaffolds Containing Growth Factor That Enhance The Sustained Release Of The Growth Factor And Induce Angiogenesis. Then We Completed The Method. This Method Regenerates Cardiac Tissue By Combination Of Stem Cells, Growth Factor And Peptide-Amphiphile. As The Above Growth Factor, We Can Preferably Use Basic Fibroblast Growth Factor (Bfgf). - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008289476	JP - 20070120305 - 27/04/2007 ; JP - 20080114551 - 24/04/2008	TWO CELLS CO LTD ; UNIV HIROSHIMA	A61K 31/7088 ; A61K 38/00 ; A61K 48/00 ; A61P 19/08 ; A61P 43/00 ; C12N 15/09 ; C12N 5/10 ; C12Q 1/68	PROBLEM TO BE SOLVED: To Provide A New Composition For Controlling Bone Differentiation, And To Provide A New Composition For Measuring Bone Differentiation State And A New Composition For Controlling Bone Differentiation, Since A Composition For Measuring Bone Differentiation State Is Also In Demand. - SOLUTION: From Gene Expression Level Change Analysis Using A DNA Microarray, Based On A Gene Excited By Bone, Cartilage Or Fat Differentiation In MSC (Marrow Mesenchymal Stem Cells) Cultivation System, A Transcription Factor, Particularly Concerning Bone Differentiation Is Selected. The Transcription Factors Excited In Expression Within 24 H From Bone Differentiation Start Are Elucidated Comprehensively, And By Suppressing Expression Of These Transcription Factors, Gene-Encoding Transcription Factors Affecting The Bone Differentiation Are Identified. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008291040	US - 19990146233P - 28/07/1999 ; US - 20000188300P - 10/03/2000	UNIV LELAND STANFORD JUNIOR	A61K 31/44 ; A61K 31/445 ; A61K 31/465 ; A61K 45/00 ; A61P 1/04 ; A61P 17/02 ; A61P 31/12 ; A61P 31/18 ; A61P 37/04 ; A61P 37/06 ; A61P 43/00 ; A61P 7/00 ; A61P 7/02 ; A61P 7/04 ; A61P 9/00 ; A61P 9/08 ; A61P 9/10 ; A61P 9/14	PROBLEM TO BE SOLVED: To Provide A Method For Recruitment Of Bone Marrow-Derived Stem Cells (E.G., Endothelial Cell Precursors, Hematopoietic Stem Cells) By Administration Of Nicotine Or Another Nicotine Receptor Agonist. - SOLUTION: The Method Can Be Used In, For Example, The Treatment Of Conditions Amenable To Treatment By Recruitment Of Bone Marrow-Derived Stem Cells (E.G., Neutropenia). The Figure Is A Graph Showing The Capillary Density (Capillaries/Myocyte) And The Percentage Of New Vessels Incorporating Endothelial Progenitor Cells For Saline Control Animals And Nicotine Treated Animals. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008295396	JP - 20070146757 - 01/06/2007	OLYMPUS CORP	C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Method For Separating A Stem Cell Derived From An Adipose Tissue From A Cell Cluster Obtained By Digesting The Adipose Tissue In High Purity And Culturing The Stem Cell. - SOLUTION: The Method For Culturing The Stem Cell Derived From The Adipose Tissue Includes: An Extraction Step S1 Of Extracting A Cell From A Cell Suspension Obtained By Degrading The Adipose Tissue; A Seeding Step S2 Of Seeding The Extracted Cell Into A Culture Vessel In Which The Surface Treatment Is Not Carried Out For Improving Adhesiveness; And A Culturing Step S3 Of Culturing The Seeded Cell While Exchanging A Culture Medium. The Initial Exchange Of The Culture Medium In The Culturing Step S3 Is Carried Out After 16-24 H From The Start Of The Seeding Of The Cell. - COPYRIGHT: (C)2009,JPO&INPIT
JP2008295420	JP - 20070147906 - 04/06/2007	UNIV NIIGATA	A61L 27/00 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Human Periodontal Ligament Cell Line, To Provide An Osteoblast Dfferentiated From The Cell Line, And To Provide An Artificial Bone Produced From The Osteoblast. - SOLUTION: Provided Are The Human Periodontal Ligament Cell Line Originated From The Stem Cell Of A Human Periodontal Ligament Tissue And Has A Differentiation Ability To Osteoblast, And The Osteoblast Differentiated From The Cell Strain. The Human Periodontal Ligament Cell Line Increases The Density Of The Cells In Response To The Number Of Culture Days, And Remarkably Increases The Activity Of ALP In Response To The Increase. The Human Periodontal Ligament Cell Produces Type I Collagen, Osteopontin, And Osteocalcin In Large Amounts, And Exhibits Active Responsibility To Cell Proliferation Factors Such As Transforming Growth Factor-[Beta]1, Basic Fibroblast Growth Factor, Insulin-Like Growth Factor-1, And Epithelial Cell Proliferation Factor. This Artificial Bone Is Produced From Such The Osteoblast. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008297220	JP - 20070142412 - 29/05/2007	METABOLOME PHARMACEUTICALS INC ; SAITAMA MEDICAL UNIV	A61K 35/12 ; A61K 35/16 ; A61K 38/22 ; A61L 27/00 ; A61P 19/08 ; C12N 5/06	PROBLEM TO BE SOLVED: To Provide A Method For Not Only Boosting The Induction Of Differentiation From Mesenchymal Stem Cells And Mesenchymal Cells Other Than Osteoblast Cells To The Osteoblast Cells, But Also Markedly Promoting The Differentiation And Maturation Of The Osteoblast Cells, And Further A Preventing And Treating Agent Of The Bone Disorder Accompanied By Bone Fracture And The Reduction Of Bone Mass, Especially A Medicine Applicable To A Stent Device For Transplantation And Artificial Bone Prosthetic Material Necessary For The Treatment Of The Broken Bone And Regeneration Treatment In The Bone Disorder Such As The Reduction Of Bone Mass, Etc. - SOLUTION: This Method For Promoting The Differentiation From The Mesenchymal Cells To The Osteoblast Cells By Simultaneous Use Of Platelet Rich Plasma And Bone Formation-Inducing Protein; Similarly The Method For Promoting The Differentiation And Maturation Of The Precursor Cells Of The Osteoblast Cells And/Or The Osteoblast Cells; The Agent For Preventing And treating the bone disorder accompanied by the bone fracture and the reduction of the bone mass, comprising the simultaneous use of the platelet rich plasma and bone formation-inducing protein; and the osteoblast cells used for the prevention and treatment of the bone disorder accompanied by the bone fracture and reduction of the bone mass, prepared by culturing the mesenchymal cells in the presence of the platelet rich plasma and the bone formation-inducing protein are provided.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008301726	JP - 20070149833 - 06/06/2007	NIPPON MENAADE KESHOHIN KK	C12N 5/06	To Provide A Method For Preparing Stem Cells, By Which The Stem Cells Efficiently Proliferated In A State Maintaining The Undifferentiated State Of The Stem Cell Of A Mammal And Having A High Survival Rate On The Transplantation Of The Stem Cells Can Be Prepared, And/Or To Provide An Agent For Maintaining The Undifferentiated State Of The Stem Cells. - SOLUTION: A Solvent Extract Of Ganoderma Lucidum Is Used For The Embryonic Stem Cells Of A Mammal Or For The Somatic Stem Cells In A Living Tissue Including Marrow, Blood, Fat, And Skin Tissue To Promote The Proliferation Of The Cells In A State Maintaining The Undifferentiated State Of The Stem Cells, And Further Improve The Survival Rate Of The Stem Cells In The Living Tissue On The Transplantation Of The Stem Cells. The Cultured Stem Cells Are Useful For The Regenerative Treatment Of The Tissue. Thereby, The Present Invention Can Largely Contribute To The Field Of Tissue Regeneration, And Is Expected To Be Applied To The Fields Of Medical science, medicines, quasi-drugs, beauty, and health.
JP2008301821	US - 20010316368P - 30/08/2001 ; US - 20010339739P - 10/12/2001 ; US - 20020125852 - 19/04/2002	NUVELO INC	A61K 38/00 ; A61P 1/02 ; A61P 19/02 ; A61P 19/08 ; A61P 19/10 ; C07K 14/475 ; C12N 15/09 ; C12P 21/02	PROBLEM TO BE SOLVED: To Provide A Polypeptide Causing Various Kinds Of Cell Types (Including A Fat Cell, A Melanocyte And A Primordial Germ Cell) By Inducing Differentiation Of An Embryonal Stem Cell And An Adult Stem Cell, And A Polynucleotide Encoding The Polypeptide, And To Provide A Medicament Utilizing The Polypeptide And The Polynucleotide, And Usable For Treatment Of Bone/Cartilage Disease Or The Like. - SOLUTION: The Stem Cell Growth Factor-Like Polypeptide Has A Specific Amino Acid Sequence. The Isolated Polynucleotide Contains A Base Sequence Selected From The Group Consisting Of Matured Protein-Encoding Parts Thereof. The Medicament Contains The Polypeptide. - COPYRIGHT: (C)2009,JPO&INPIT

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
JP2008307007	JP - 20070159382 - 15/06/2007	BAYER SCHERING PHARMA AG	C12N 5/06	PROBLEM TO BE SOLVED: To Establish Human Pluripotent Stem Cells Having Resembling Properties With Human ES Cells Consisting Of The Genome Of Patient Himself And Capable Of Avoiding The Immunological Rejection Of Transplanted Cells, From Cells Originated From Human Tissue After Birth. - SOLUTION: It Is Found Out That The Human Pluripotent Stem Cells Can Be Induced By Introducing Three Genes Of Oct3/4, Sox2 And Klf4, Or Three Genes Of The Oct3/4, Sox2 And Klf4, And C-Myc Gene Or A Histone Deacetylase (HDAC) Inhibitor To The Undifferentiated Stem Cells In Which Each Of Genes Of Tert, Nanog, Oct3/4 And Sox2 Existing In Various Human Tissues After The Birth Has Not Received Epigenetic Inactivation. - COPYRIGHT: (C)2009,JPO&INPIT
KR100871165B	KR - 20070081948 - 14/08/2007	BOKWANG CHEMICAL CO LTD ; PICOBIO CO LTD	A61K 8/98 ; A61Q 19/00	Cosmetic composition containg stem cell secretion derived from umbilical cord blood
KR100848056B	KR - 20070076221 - 30/07/2007	PARK BYUNG SOON ; PROSTEMICS	A61K 8/64 ; A61K 8/98 ; A61Q 19/02	Inhibition of melanin synthesis using adult stem cells culture media
KR100874613B	KR - 20080000599 - 03/01/2008	PROSTEMICS	A61K 47/42 ; A61P 35/00	Inhibition of cancer cell proliferation using adult stem cells culture media
KR20080113279	EP - 20060009703 - 11/05/2006	HOFFMANN LA ROCHE	C07K 16/00 ; C12N 5/00 ; C12N 5/06 ; C12N 5/08	Mehod for the production of antibodies in immunodeficient animal injected with human fetal liver stem cells
KR20080060478	KR - 20060134619 - 27/12/2006	BACK EUN YEOUNG	A61K 35/28	The fixing method using the stem cell or the hematopoietic stem cell
KR20080063406	US - 20050727004P - 13/10/2005 ; US - 20060835628P - 04/08/2006	ANTHROGENESIS CORP	A61K 35/50 ; A61P 37/06 ; C12N 5/06	Immunomodulation using placental stem cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080063426	US - 19990123711P - 10/03/1999 ; US - 19990162462P - 29/10/1999	UNIV CALIFORNIA ; UNIV PITTSBURGH	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Adipose-derived stem cells and lattices
KR20080064915	US - 20000251900P - 06/12/2000	HARIRI ROBERT J	A61K 35/14 ; A61K 35/28 ; A61K 35/44 ; A61K 35/50 ; A61K 48/00 ; A61M 1/02 ; A61P 13/12 ; A61P 17/02 ; A61P 21/00 ; A61P 25/00 ; A61P 25/16 ; A61P 25/28 ; A61P 27/02 ; A61P 27/06 ; A61P 29/00 ; A61P 3/00 ; A61P 43/00 ; A61P 5/14 ; A61P 7/06 ; A61P 9/00 ; A61P 9/10 ; C12M 1/00 ; C12M 1/34 ; C12M 1/36 ; C12M 3/00 ; C12N 15/00 ; C12N 15/09 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Method of collecting placental stem cells
KR20080066362	KR - 20070003696 - 12/01/2007	SEOUL NAT UNIV IND FOUNDATION	C12N 5/00 ; C12N 5/06 ; C12N 5/08	Method for differentiating and proliferating of stem cell using patterened polydimetylysiloxan

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080068098	JP - 20050313971 - 28/10/2005	DNAVEC CORP	A61K 35/76 ; C12N 15/867 ; C12N 5/10	Gene transfer into airway epithelial stem cell by using lentiviral vector pseudo-typed with rna virus or dna virus spike protein
KR20080068351	KR - 20070006014 - 19/01/2007	SEOUL NAT UNIV IND FOUNDATION	C12N 5/00 ; C12N 5/06 ; C12N 5/08	Method of inducing differentiation of mesenchymal stem cells into neurons
KR20080068394	KR - 20070006130 - 19/01/2007	SEOUL NAT UNIV IND FOUNDATION	C12N 5/00 ; C12N 5/08	Adult stem cells having an ability of differentiation into pancreas beta; cells
KR20080070005	US - 20050728131P - 18/10/2005 ; US - 20060765993P - 06/02/2006	NAT JEWISH MED & RES CENTER ; UNIV COLORADO	A01N 63/00 ; C12N 15/09 ; C12N 5/00 ; C12N 5/02	Conditionally immortalized long-term stem cells and methods of making and using such cells
KR20080070015	US - 20050729177P - 21/10/2005 ; US - 20050733309P - 02/11/2005 ; US - 20060758443P - 11/01/2006 ; US - 20060813799P - 14/06/2006	INTERNAT STEM CELL CORP	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Parthenogenic activation of human oocytes for the production of human embryonic stem cells
KR20080071997	JP - 20050307741 - 21/10/2005 ; JP - 20050307742 - 21/10/2005 ; JP - 20050362413 - 15/12/2005	KANEGAFUCHI CHEMICAL IND	B01D 39/04 ; B01D 39/16 ; C12M 1/26	Stem cell separating material and method of separation
KR20080072748	US - 20050289004 - 29/11/2005	GAMIDA CELL LTD	A61K 48/00 ; C12N 5/00 ; C12N 5/02	Methods of improving stem cell homing and engraftment

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080075959	KR - 20070015211 - 14/02/2007	PARK BYUNG SOON ; PROSTEMICS	C12N 5/00 ; C12N 5/08	Composition of the injectable agents for tissues repair including adipose derived stem cells and optimized culture media
KR20080078204	KR - 20070017970 - 22/02/2007	CREAGENE INC	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression
KR20080079256	KR - 20050124320 - 16/12/2005	MODERN CELL & TISSUE TECHNOLOG	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Methods for culturing mesenchymal stem cell and compositions comprising mesenchymal stem cell for repairing skin defects
KR20080079302	US - 20050748951P - 09/12/2005	MASSACHUSETTS INST TECHNOLOGY	A61K 45/06 ; A61P 35/00 ; C12N 5/06	Methods for indentifying and targeting tumor stem cells based on nuclear morphology
KR20080081083	US - 20050754968P - 29/12/2005 ; US - 20060846641P - 22/09/2006	ANTHROGENESIS CORP	C12N 5/02 ; C12N 5/06 ; C12N 5/08	Placental stem cell populations
KR20080081088	US - 20050754692P - 29/12/2005	ANTHROGENESIS CORP	C12N 5/00 ; C12N 5/06 ; C12N 5/08	Co-culture of placental stem cells and stem cells from a second source
KR20080082595	US - 20050700859P - 19/07/2005	STEMGEN S P A	A61K 38/18 ; A61P 35/00	Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
KR20080086447	US - 20050735715P - 09/11/2005	SCRIPPS RESEARCH INST	A01N 1/02 ; C12N 5/00 ; C12N 5/02 ; G01N 33/567	Selection, propagation and use of mosaic aneuploid stem cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080087263	KR - 20070029235 - 26/03/2007	JB STEM CELL INST INC	A61K 35/32 ; C12N 5/00 ; C12N 5/02 ; C12N 5/08	Multipotent stem cell derived from human subacromial bursa and cellular therapeutic agents comprising the same
KR20080087264	KR - 20070029236 - 26/03/2007	JB STEM CELL INST INC	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Substrate for mesenchymal stem cells derived from human umbilical cord blood containing matrices derived from fibroblast of placenta
KR20080089157	KR - 20070031496 - 30/03/2007	MIRAEBIOTECH CO LTD	C12N 5/02 ; C12N 5/06 ; C12N 5/08 ; C12N 5/18	Method to differentiate brain cell of rat under cerebral infarction using human embryonic stem cell-derived neuronal precursor
KR20080091832	US - 20060763333P - 30/01/2006	UNIV VIRGINIA	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
KR20080091874	ES - 20020001540 - 02/07/2002	CHACQUES JUAN CARLOS ; INST CIENTIFICO TECNOL NAVARRA	A61K 31/198 ; A61K 31/727 ; A61K 35/16 ; A61K 35/34 ; A61K 38/00 ; A61K 38/16 ; A61P 21/00 ; A61P 9/00 ; A61P 9/10 ; C12N 1/02 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Medium for culturing autologous human progenitor stem cells and applications thereof
KR20080095467	KR - 20070039973 - 24/04/2007	HURIMBIOCELL CO LTD ; INFITRON INC ; KIM HAE KWON	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Method of differentiation of facial adipose- or umbilical cord-derived stem cells into hepatocytes and culture fluid therefore
KR20080095729	KR - 20070040578 - 25/04/2007	CATHOLIC UNIVERSITY INDUSTRY A	A61K 38/20 ; A61P 37/00	Composition comprising interleukin-10 for promoting self-renewal of hematopoietic stem cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080097190	US - 20050754969P - 29/12/2005	ANTHROGENESIS CORP	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Improved composition for collecting and preserving placental stem cells and methods of using the composition
KR20080097197	JP - 20060023770 - 31/01/2006	ASUBIO PHARMA CO LTD ; UNIV KEIO	C12N 5/00 ; C12N 5/06 ; C12N 5/08	Method for purifying cardiac myocyte and presumptive cardiac myocyte derived from stem cell and fetus
KR20080097593	KR - 20070042645 - 02/05/2007	RA JUNG CHAN	A61K 35/12 ; A61K 35/36 ; A61Q 7/00	Cellular therapeutic agent comprising multipotent stem cells derived from human adipose tissue and hair follicle cells
KR20080099052	KR - 20070044663 - 08/05/2007	HURIMBIOCELL CO LTD ; INFITRON INC ; KIM HAE KWON	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Method for the differentiation of human adult stem cells into insulin-secreting cells
KR20080100420	EP - 20060000452 - 11/01/2006 ; EP - 20060022458 - 27/10/2006	AXXAM SPA	C07K 14/435 ; C12N 15/12 ; C12N 5/06 ; C12N 5/08	Luminescent stem cells and uses thereof
KR20080101140	KR - 20070047472 - 16/05/2007	RNL BIO CO LTD ; SEOUL NAT UNIV IND FOUNDATION	A61K 35/12 ; A61P 1/16	Pharmaceutical composition for preventing and treating liver fibrosis or hepatic cirrhosis comprising mesenchymal stem cell
KR20080103637	KR - 20070050624 - 25/05/2007	RNL BIO CO LTD	A61K 35/34 ; A61P 9/10	Composition for treating of ischemic limb disease comprising stem cells derived from adipose tissue
KR20080104274	IT - 2006NA00017 - 20/02/2006	TESLAB S R L	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Collection and selection methods of an embryonic-like stem cell population from human adult periodontal follicular tissues
KR20080104844	KR - 20070052204 - 29/05/2007	CHABIOTECH CO LTD ; COLLEGE OF MEDICINE POCHON CHA	C12N 5/00 ; C12N 5/02 ; C12N 5/08	Process for the isolation of placenta-derived trophoblast stem cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080104850	KR - 20070052215 - 29/05/2007	CHABIOTECH CO LTD ; COLLEGE OF MEDICINE POCHON CHA	C12N 5/00 ; C12N 5/02 ; C12N 5/08	process for the high-purity isolation of mesenchymal stem cells derived from placental chorionic plate membrane
KR20080105555	KR - 20070053298 - 31/05/2007	INHA IND PARTNERSHIP INST	A61K 35/28 ; A61P 37/06	Therapeutic agent or method for treating graft-versus-host disease using mesenchymal stem cells
KR20080106152	KR - 20080108036 - 31/10/2008	CORESTEM CO LTD	A61K 35/28 ; A61P 21/00	Methods and compostions for treating motor neuron diseases comprising mesenchymal stem cells
KR20080106332	US - 20060844350P - 14/09/2006 ; IN - 2006DE00582 - 07/03/2006 ; IN - 2006DE01500 - 26/06/2006	SHROFF GEETA	A61K 35/12 ; A61K 35/48 ; A61P 25/00 ; C12N 5/06	Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
KR20080106686	KR - 20070054423 - 04/06/2007	JB STEM CELL INST INC	C12N 5/00 ; C12N 5/02 ; C12N 5/08	A distinguishing method of fibroblast from mesenchymal stem cell derived from human umbilical cord blood
KR20080106976	US - 20060783500P - 17/03/2006 ; US - 20060789132P - 05/04/2006 ; US - 20060862669P - 24/10/2006	STEM CELL THERAPEUTICS CORP	A61K 38/18 ; A61K 38/22 ; A61K 38/24 ; A61P 25/28	Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
KR20080109705	KR - 20080117836 - 26/11/2008	CREAGENE INC	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression
KR20080109725	KR - 20060008874 - 27/01/2006	PARK BYUNG SOON ; PROSTEMICS	C12N 5/02 ; C12N 5/06 ; C12N 5/08	Mass producing method of growth factor using adipose derived adult stem cells

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
KR20080109726	WO - 2006EP01427 - 16/02/2006	UNIV BRUXELLES	C12N 5/08	A method for osteogenic differentiation of bone marrow stem cells (bmsc) and uses thereof
KR20080109943	US - 20030498831P - 29/08/2003 ; US - 20030499570P - 02/09/2003	WISCONSIN ALUMNI RES FOUND	C12N 5/00 ; C12N 5/02 ; C12N 5/06	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
NO20084181	US - 20060844350P - 14/09/2006 ; IN - 2006DE00582 - 07/03/2006 ; IN - 2006DE01500 - 26/06/2006 ; WO - 2007IB02292 - 06/03/2007	SHROFF GEETA	A61K 35/48 ; A61P 25/00 ; C12N 5/06	Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
NZ537397	ES - 20020001540 - 02/07/2002 ; WO - 2003ES00285 - 11/06/2003	INST CIENTIFICO Y TECHNOLOGICO ; JUAN CARLOS CHACHQUES	A61K 31/198 ; A61K 31/727 ; A61K 35/16 ; A61K 35/34 ; A61K 38/00 ; A61K 38/16 ; A61P 21/00 ; A61P 9/10 ; C12N 1/02 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Provided Is A Method For The Preparation Of Autologous Culture Medium Of Autologous Human Progenitor Stem Cells Which Comprises: A) Between 0.1 % And 90% Weight Of Autologous Human Serum; B) Between 0.1 And 10,000 UI/Ml Heparin, C) Between 0.1 And 10,000 UI/Ml Protamine; And D) A Culture Medium With Basic Nutrients With Or Without Glutamine, In Sufficient Quantity Up To 100% Weight, Which Comprises Mixing Together Autologous Human Serum, Heparin, Protamine, Basic Nutrients With Or Without Glutamine. Further Provided Are Similar Methods For Preparing A Culture Medium Containing Additionally Specific Antibiotics And Use Of The Media For Culturing Said Stem Cells And For Obtaining Said Stem Cells From Muscle Or Blood Cells As Well As Pharmaceutical Compositions Comprising Said Cell Culture. Also Provided Is The Use Of Such Stem Cells In The Manufacture Of A Medicament To Treat Dysfunctional Myocardial Tissue.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
NZ546899	HU - 20030002888 - 09/09/2003 ; HU - 20030004124 - 31/12/2003 ; WO - 2004IB51711 - 08/09/2004	CRYO INNOVATION KFT	A01N 1/02	The Present Disclosure Relates To A Method For Improving Post-Thaw Survival Of Cryopreserved Biological Material Including Oocytes, Sperms, Zygotes, Blastocysts And Stem Cells. The Method Comprises Of Applying Hydrostatic Pressure To Said Biological Material; Keeping The Said Biological Material At The Hydrostatic Pressure For A Predetermined Time Period; Releasing The Hydrostatic Pressure; And Freezing The Said Biological Material Using Any Protocol Applicable Thereto. Further Disclosed Is The Use Of A Pressurizing Device For The Pretreatment Of A Biological Material That Is To Be Cryopreserved, As Well As To A Pressurizing Device For The Pretreatment Of A Biological Material That Is To Be Cryopreserved, Said Device Comprising A Pressure Chamber For Receiving Biological Material, Means To Produce Said Pressure, And Means To Maintain Said Pressure In Said Chamber.
NZ544828	US - 20030482001P - 25/06/2003 ; WO - 2004CA00940 - 25/06/2004	OTTAWA HEALTH RESEARCH INST	C07K 14/52 ; C12N 5/06	Disclosed Are Methods Of Promoting Stem Cell Proliferation Comprising Contacting The Cells With Cardiotrophin-1 (CT-1). The Methods May Further Comprise Contacting The Adult Stem Cells With One Or More Stem Cell Modulators That Promote Differentiation Of The Stem Cells. Methods Of Inhibiting Stem Cell Proliferation Comprising Contacting The Cells With One Or More CT-1 Inhibitor Are Also Disclosed.
RU2331670	RU - 20070119977 - 30/05/2007	G NTS RF I MEDIKO BIOLOG ROSSI	C12N 5/06	FIELD: Medicine. ^ SUBSTANCE: Invention Belongs To The Area Of Biotechnology And Medicine. Precursor Cells Are Recovered And Then Cultivated Till Obtaining Of Desired Cell Culture. Growth Of Cultured Cells Takes From 4 To 10 Days In Hypoxic Condition, With Oxygen Content No Less Than 5%, The Cells From 1st To 2nd Passages Are Being Used. Quantity Of Apoptosis And Necrotic Damaged Cells And Their Morphological Characteristics Are Determined. According To Markers CD90, CD54, CD44, CD73, CD11b, And CD45 Expression, Immune Type Of Cells Is Determined. If Aggregate Quantity Of Apoptosis And Necrotic Damaged Cells Is Reduced Two Times And More Compared To Representative Cultures In Normoxia Conditions, If MSC Immune Type Is Retained Completely, And If Quantity Of Rapidly Dividing Uniform Cells Exceeds Quantity Of Slow Proliferating Large Cells, Then Received Culture Is Reputed As A Culture Of Mesenchymal Cells With Low Heterogeneity And High Viability. ^ EFFECT: Increase Of Proliferative Activity Of Stromal Precursor cells culture, reduction of heterogeneity of culture. ^ 4 cl, 2 dwg, 2 tbl

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
RU2333737	RU - 20070114943 - 20/04/2007	FEDERAL NOE G UCHREZHDENI E MNT	A61F 9/00 ; A61K 35/28 ; A61P 27/02	FIELD: Medicine. ^ SUBSTANCE: Invention Relates To Medicine, In Particular Oculistics, And Can Be Used For Treatment Of "Dry" Form Of Age Macular Degeneration. Macular Retinal Area Is Exposed To Transpupillary Radiation By The Low-Intensity Laser Radiation. Intravenous Injection Of Autologous Incubate Mesenchymal Bone Marrow Stem Cell Is Carried Out In 3 Hours. ^ EFFECT: Microcirculation Enhancement And Activation Of Reparative Processes. ^ 2 Cl
RU2336901	RU - 20070130617 - 10/08/2007	BRJUKHOVETS KIJ ANDREJ STEPANOV ; CHEKHONIN VLADIMIR PAVLOVICH	A61K 39/395 ; A61K 9/127 ; A61P 35/00	FIELD: Medicine. ^ SUBSTANCE: Invention Concerns Biopharmacology And Medicine Area. The Antitumor Agent Representing A Immunoliposome Biological Structure, Including A Liposome Containing The Therapeutic Agent, Sewed With A Vector Of Peptide Nature, Thus For Treatment Of CNS Tumors Is Declared, The Liposome Contains The Therapeutic Agent In A Water Phase, As A Vector Contains Monoclonal Antibodies To CD34+, And A Linking Represents 2-Iminotiolan (IT) In 0.1% Concentration. As A Therapeutic Agent, Immunoliposome Contains The Substance Chosen From The Group: Daunomycin, Carminomycinum, Melphtalan, Methotrexatum, Cytarabinum, Doxorubicinum, Ricine. The Method Of Obtaining Of An Antitumoral Agent And Way Of Inhibition Of A Tumor Of The Brain, Consisting In Agent Administering Due To Item 1 In A Pharmaceutically Suitable Carrier In Effective Quantity Is Declared Also. Thus Preliminary Administer Parenterally A Preparation Of Hematological Stem Cells CD34+. ^ EFFECT: Provision Of Highly Effective Delivery Of An Antitumor agent to a CNS tumor. ^ 4 cl, 7 ex, 4 dwg
SG145530	IL - 19990129966 - 14/05/1999	TECHNION RES & DEV FOUNDATION ; YISSUM RES DEV CO	A61K 35/48 ; A61P 43/00 ; C12N 15/09 ; C12N 5/06 ; G01N 33/48	DIFFERENTIATED HUMAN EMBRYOID CELLS AND A METHOD FOR PRODUCING THEM A Process For Obtaining Human Derived Embryoid Bodies (Heb). Human Embryonic Stem Cells Are Incubated In Vitro In A Liquid Growth Medium Under Conditions In Which The Cells Undergo Differentiation, But Do Not Adhere To The Walls Of The Container. The Invention Also Provides Hebs Obtained By The Process. Figure I

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
SG144689	US - 20010970543 - 04/10/2001	HADASIT MED RES SERVICE ; UNIV MONASH ; UNIV SINGAPORE	A61K 35/30 ; A61K 48/00 ; A61L 27/00 ; A61P 25/00 ; A61P 25/18 ; A61P 37/00 ; A61P 9/00 ; C12N 5/06 ; C12N 5/08	EMBRYONIC STEM CELLS AND NEURAL PROGENITOR CELLS DERIVED THEREFROM The Present Invention Relates To Undifferentiated Human Embryonic Stem Cells, Methods Of Cultivation And Propagation And Production Of Differentiated Cells. In Particular It Relates To The Production Of Human ES Cells Capable Of Yielding Somatic Differentiated Cells In Vitro, As Well As Committed Progenitor Cells Such As Neural Progenitor Cells Capable Of Giving Rise To Mature Somatic Cells Including Neural Cells And/Or Glial Cells And Uses Thereof. This Invention Provides A Method That Generates An In Vitro And In Vivo Model Of Controlled Differentiation Of ES Cells Towards The Neural Lineage. The Model, And The Cells That Are Generated Along The Pathway Of Neural Differentiation May Be Used For The Study Of The Cellular And Molecular Biology Of Human Neural Development, For The Discovery Of Genes, Growth Factors, And Differentiation Factors That Play A Role In Neural Differentiation And Regeneration, For Drug Discovery And For The development of screening assays for teratogenic, toxic and neuroprotective effects.
SG146666	US - 20030503589P - 17/09/2003	MACROPORE BIOSURGERY INC	A01N 63/00 ; C12N 5/06	METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS Cells Present In Adipose Tissue Are Used To Treat Patients, Including Patients With PVD And Related Diseases Or Disorders. Methods Of Treating Patients Include Processing Adipose Tissue To Deliver A Concentrated Amount Of Stem Cells Obtained From The Adipose Tissue To A Patient. The Methods May Be Practiced In A Closed System So That The Stem Cells Are Not Exposed To An External Environment Prior To Being Administered To A Patient. Accordingly, In A Preferred Method, Cells Present In Adipose Tissue Are Placed Directly Into A Recipient Along With Such Additives Necessary To Promote, Engender Or Support A Therapeutic Benefit. [Figure 4]
SG148171	US - 20050651633P - 11/02/2005	AGENCY SCIENCE TECH & RES		Methods Of Proliferating Stem Cells The Invention Relates To Methods Of Proliferating Stem Cells. More Particularly, The Invention Relates To The Use Of Glycosaminoglycans Or Proteoglycans To Promote The Growth Of Stem Cells In Ex Vivo Culture, While Preserving Their Multipotentiality.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
SG146691	US - 20030509928P - 09/10/2003 ; US - 20030510021P - 08/10/2003 ; US - 20030510022P - 08/10/2003 ; US - 20030510072P - 09/10/2003	VET STEM INC	A01N 1/02 ; C12N 5/06	METHODS OF PREPARING AND USING STEM CELL COMPOSITIONS AND KITS COMPRISING THE SAME The Present Invention Provides Novel Stem Cell Compositions Having Significant Therapeutic And Practical Advantages, As Well As Methods Of Preparing And Using Such Compositions For The Treatment And Prevention Of Injury And Disease In Patients. The Invention May Be Applied To Stem Cell Populations Isolated From A Wide Variety Of Animals, Including Humans, And Tissues. In Particular Applications, The Invention Is Used To Prepare A Stem Cell Composition From A Collagen-Based Tissue, Such As Adipose Tissue, Isolated From A Patient, And The Stem Cell Composition Is Subsequently Provided To A Site Of Actual Or Potential Injury In The Patient. The Invention Further Includes Related Kits Comprising The Stem Cell Compositions, Which Are Remarkably Stable And Retain Viability And Efficacy During Storage And Shipment.
US2008159989	IT - 2003RM00125 - 21/03/2003 ; IT - 2003RM00370 - 29/07/2003 ; WO - 2004IT00133 - 19/03/2004	MINCHIOTTI GABRIELLA ; PARISI SILVIA ; PERSICO MARIA	A61K 35/12 ; A61K 35/30 ; A61K 35/34 ; A61K 38/00 ; A61K 38/18 ; A61K 39/395 ; A61P 25/28 ; A61P 9/00 ; C12N 5/06	A Method Is Described By Which Stem Cells Are Induced To Differentiate Into Cardiomycocytes; The Method Comprises Exposure For A Length Of Time And At Efficacious Quantities Of A Protein Of The EGF-CFC Family Or Its Derivitaies Having At Least The EGF And CFC Domains; Or To Differentiate Into Neuronal Cells, Comprising The Exposure To Cripto Protein Inhibitors. Compositions Are Described For Therapeutic Use In Treating Heart Disorders, Comprising A Therapeutically Efficacious Quantity Of A Protein Or Its Derivatives Having At Least The EGF And CFC Domains Of A Protein Of The EGF-CFC Family.
US2008159994	GB - 20050001637 - 28/01/2005 ; US - 20050647461P - 28/01/2005 ; WO - 2006GB50026 - 30/01/2006 ; US - 20070830378 - 30/07/2007	MANTALARIS SAKIS ; RANDLE WESLEY	A01N 1/00 ; A61K 35/12 ; A61P 19/00 ; A61P 19/10 ; A61P 35/00 ; C12M 1/00 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/02 ; C12Q 1/68	The Invention Relates To A Method Of Cell Culture Comprising Providing A Pluripotent ES Cell Encapsulated Within A Support Matrix To Form A Support Matrix Structure, Maintaining The Encapsulated Cell In 3-D Culture In Maintenance Medium, And Optionally Differentiating The Encapsulated Cell In 3-D Culture In Differentiation Medium. The Invention Further Relates To Screening Methods Incorporating The Use Of Encapsulated Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008159995	GB - 20060019500 - 03/10/2006 ; US - 20060867446P - 28/11/2006 ; US - 20070866511 - 03/10/2007	SPITERI MONICA SILVERSTONE ; WATTS KEIRA LOUISE	A61K 31/351 ; A61K 31/40 ; A61K 31/404 ; A61K 31/435 ; A61K 31/47 ; A61K 31/505 ; A61K 35/56 ; A61P 19/04	The Present Invention Relates To Methods And Compositions For Treating Fibrosis. In One Aspect The Invention Provides The Use Of An Agent Capable Of Increasing The Number Of Stem Cells And/Or Progenitor Cells Available To And/Or Engraftment At A Site Of Fibrosis In The Manufacture Of A Medicament For Use In Conjunction With An Anti-Fibrotic Agent For The Treatment Of Fibrosis. The Anti-Fibrotic Agent Can Be Supplied To The Subject Before, At The Same Time, Or After The Agent Capable Of Increasing The Number Of Stem Cells And/Or Progenitor Cells Available To And/Or Engraftment At A Site Of Fibrosis. The Fibrosis May Be Idiopathic Pulmonary Fibrosis. The Anti-Fibrotic Agent Can Be A Modulator Of Rhoa, Rhoa Gtpases, TGF-Beta1 Or CTGF, Or Any Other Member Of The Rhoa Signalling Pathway; Or Can Modulate The Effect Of Suppressor Of Cytokine Signalling 1 (SOCS 1), Suppressor Of Cytokine Signalling 3 (SOCS 3) Or TLR9; Or Can Be A Statin Compound Or Derivative Thereof.
US2008159998	US - 20060870572P - 18/12/2006 ; US - 20070959440 - 18/12/2007	MEDISTEM LABORTORIES	A61K 48/00	Disclosed Are Cells, Methods Of Modulating Cells, And Therapeutic Uses Of The Cells For The Immune Modulation Of Mammals In Need Thereof. Immune Modulation Including Alteration Of Cytokine Profile, Cytotoxic Activity, Antibody Production And Inflammatory States Is Achieved Through The Administration Of Various Cell Types That Have Been Unmanipulated Or Manipulated In Order To Endow Specific Biological Activity. Cellular Subsets And Administration Of The Subsets In Combination With Various Agents Are Also Provided. One Embodiment Teaches The Previously Unknown Finding That Adipose Tissue Derived Mononuclear Cells Contain T Cells With Immune Regulatory Properties That Alone Or Synergistically With Various Stem Cells Induce Immune Modulation Upon Administration. Another Embodiment Is The Finding That Stimulation Of Stem Cell Activation Results In Stem Cell Secondary Activation Of Immune Modulatory Cells, One Type Which Is T Regulatory Cells (Tregs). One Specific Embodiment Involves Extraction Of A Heterogenous Stem cell pool, which contains T regulatory cells, treatment in culture of the population with agents known to stimulate stem cell activation, then subsequent extraction and administration of the purified Tregs. Other embodiments include expansion of Tregs in the presence of antigen in order to generate anti-specific Tregs.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008159999	US - 20060853420P - 23/10/2006 ; US - 20070976321 - 23/10/2007	STEFANIDIS KONSTANTINOS	A61K 35/12 ; A61P 1/00 ; A61P 17/00 ; A61P 25/00 ; A61P 43/00 ; C12N 5/06 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/53	The Present Invention Is Directed To Pluripotent Embryonic Stem Cells Derived From Amniotic Fluid And The Methods For Isolating, Expanding And Differentiating These Cells, And Their Therapeutic Uses Such As Manipulating The Cells By Gene Transfection And Other Means For Therapeutic Applications.
US2008160563	US - 20010264796P - 29/01/2001 ; US - 20020059521 - 29/01/2002 ; US - 20080049815 - 17/03/2008	HEMOGENIX INC	C12Q 1/02 ; C12Q 1/66 ; G01N 33/50	The Present Invention Relates Generally To High-Throughput Assay Methods That Determine The Proliferative Status Of Hematopoietic Stem And Progenitor Cells. The Present Invention Further Relates To High-Throughput Assays For Screening Compounds That Modulate The Growth Of Hematopoietic Stem And Progenitor Cells And For Identifying Subpopulations Thereof That Are Suitable For Transplantation. The Assay Of The Present Invention Is Particularly Useful For Quality Control And Monitoring Of The Growth Potential In The Stem Cell Transplant Setting And Would Provide Improved Control Over The Reconstitution Phase Of Transplanted Cells.
US2008160564	US - 20020059521 - 29/01/2002 ; US - 20080049861 - 17/03/2008	HEMOGENIX INC	C12Q 1/02	The Present Invention Relates Generally To High-Throughput Assay Methods That Determine The Proliferative Status Of Hematopoietic Stem And Progenitor Cells. The Present Invention Further Relates To High-Throughput Assays For Screening Compounds That Modulate The Growth Of Hematopoietic Stem And Progenitor Cells And For Identifying Subpopulations Thereof That Are Suitable For Transplantation. The Assay Of The Present Invention Is Particularly Useful For Quality Control And Monitoring Of The Growth Potential In The Stem Cell Transplant Setting And Would Provide Improved Control Over The Reconstitution Phase Of Transplanted Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008160610	AU - 20040902337 - 03/05/2004 ; WO - 2005AU00636 - 03/05/2005	PETER MACCALLUM CANCER INST	C12N 5/06 ; C12N 5/08	The Present Invention Provides Methods, Culture Media, And Apparatus To Produce Useful Amounts Of Specific Cell Populations Ex Vivo By The Modulation Of Opn And/Or An Active Opn Fragment. The Present Invention Provides Ex Vivo Expanded Populations Of HSC For Use In Transplantation Therapy And In Clinical And Research Activities, Such As Drug Screening, Toxicity Testing, And Other Research Activities. Also Provided Are Methods, Devices And Culture Media Are Provided To Inhibit Opn Binding To HISC To Promote The Increased Production Of More Differentiated Cell Populations.
US2008160614	US - 20060882330P - 28/12/2006 ; US - 20070966427 - 28/12/2007	UNIV SOUTH FLORIDA	C12N 5/00 ; C12N 5/02	A Method Of Differentiating Adult Stem Cells, Such As Those Derived From A Teratocarcinoma Cell Line, The Ntera2/D1 Clone (NT2). The Developed Cells Exhibit A Stable Neurotransmitter Phenotype Without The Required Use Of Growth Factors Or Retinoic Acid In Differentiation Process, Which May Be Difficult To Completely Remove During Commercial Production. An Identification Of Specific Neurotransmitters Is Possible In These Differentiated NT2-Derived Neurons (NT2-N) After 30 Days In Culture Or 30 Days Survival In Vivo. The Invention Includes A Method To Stably Differentiate Neuronal Stem/Precursor Cells To A Neuronal Phenotype For Use In Cell Replacement Therapy For Neurodegenerative Disease, Stroke Or Spinal Cord Injury. At Least Four Different Types Of Neurons Are Produced From This Method Of Differentiation: Dopaminergic, Cholinergic, Gabaergic And Glutaminergic. Additionally, Since The Cells Are A Cancer Stem Cell Prior To Differentiation, They May Serve As A Model System For Developing Anti-Cancer Therapies

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008160617	JP - 20010350724 - 15/11/2001 ; WO - 2002JP11894 - 14/11/2002 ; US - 20040495567 - 14/05/2004 ; US - 20080030314 - 13/02/2008	IWATA HIROO ; KOBORI MASATO ; MURAKAMI YOSHINOBU ; SASAI YOSHIKI ; SATO MITSUO ; YANO KEIICHI	A61K 35/48 ; A61K 38/17 ; A61P 17/00 ; A61P 25/00 ; A61P 25/16 ; A61P 25/28 ; A61P 43/00 ; C12N 15/12 ; C12N 15/87 ; C12N 5/06 ; G01N 33/50 ; G01N 33/68	A Method For Obtaining A Solution Having Activity To Induce Differentiation Of An Embryonic Stem Cell Into An Ectodermal Cell Or Ectoderm-Derived Cell, Which Comprises Culturing A Stromal Cell In A Culture Comprising A Polyanionic Compound And Recovering The Culture; A Solution Having Activity To Induce Differentiation Of An Embryonic Stem Cell Into An Ectodermal Cell Or Ectoderm-Derived Cell, Which Is Obtainable By The Method; And An Agent For Inducing Differentiation Of An Embryonic Stem Cell Into An Ectodermal Cell Or Ectoderm-Derived Cell.
US2008166412	US - 20070883081P - 02/01/2007 ; US - 20080968393 - 02/01/2008	SEAL SUDIPTA ; SUGAYA KIMINOBU	A61K 33/24 ; A61K 35/12 ; A61K 9/16 ; C12N 5/02	Disclosed Herein Are Methods And Materials For Influencing Proliferation Of Stem Cells. Specifically Exemplified Herein Are Compositions Comprising Cerium Oxide Nanoparticles Which Can Be Used To Stimulate Proliferation Of Stem Cells Under Common Culture Conditions, Or Which Can Be Utilized To Improve Therapeutic Outcomes.
US2008166804	US - 20060830668P - 14/07/2006 ; US - 20070826539 - 16/07/2007	COHEN MICHAEL ; SHAMBLOTT MICHAEL J	C12N 5/06	Methods For Deriving And Cultivating Human Embryonic Stem (ES) Cells And Maintaining Their Pluripotency In Culture Is Provided By Utilizing Secreted Products Obtained From The Culture Medium Of Human Embryonic Germ (EG) Cell Derivatives, Such As Embryoid Body-Derived Cells. Substrates Include Compounds Such As Collagen I, Fibronectin, Or Superfibronectin, Or Extracellular Matrix, Typically Human Derived.
US2008166807	US - 20050059112 - 16/02/2005 ; US - 20070725197 - 15/10/2007	NAIR PADMANABHAN P	C12N 5/02	This Invention Relates To The Discovery Of Autologous Stem Cells Of Gastrointestinal Origin In Fecal Matter. More Particularly, The Invention Relates To The Isolation And Propagation Of Said Stem Cells In Continuous Culture. Furthermore, The Invention Describes A Method Of Directing And Converting These Gastrointestinal Progenitor Stem Cells Into Immunoglobulin Producing Cells That Secrete Autologous Antibodies To An Antigen. In Addition, The Invention Describes A Method Of Isolating Antibodies Secreted By Said Immunoglobulin Producing Cells. The Invention Also Describes A Method Of Generating A Lineage Of Antibody Producing Cells By Growing Said Progenitor Stem Cells Isolated From Fecal Matter On A Feeder Layer Of Tumor Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008171020	US - 20050657283P - 28/02/2005 ; US - 20050657288P - 28/02/2005 ; US - 20050657545P - 28/02/2005 ; US - 20060363592 - 27/02/2006 ; US - 20070894150 - 20/08/2007	RUDD DONNIE	A01N 63/00	The Present Invention Is Directed To The Expansion, Preferably TVEMF-Expansion, Of Mammalian Blood Adult Stem Cells, Wherein The Expansion Takes Place In A Rotating Bioreactor, Preferably A TVEMF-Bioreactor, To Compositions Resulting From The Expanded Cells, And To A Method Of Treating An Epithelial Cell/Tissue Related Disease Or Condition Or Repairing Tissue Of Skin, Mouth Or Ear With The Compositions.
US2008171022	US - 20060855984P - 31/10/2006 ; US - 20070932389 - 31/10/2007	ZECH HERBERT	A61K 35/12 ; A61P 35/00	Methods And Systems Are Provided To Facilitate Treatment For A Neoplastic Disease Include Providing Information Of Stem Cells That Can Be Isolated From An Individual Prior To Diagnosis With A Neoplastic Disease; Processing And Storing The Stem Cells, Such As Cord Blood Or Bone Marrow Stem Cells, In A Format Suitable For Transfusion; Providing Information That Treatment Of The Individual After Diagnosis With The Neoplastic Disease Includes Bone Marrow Ablation In Addition To At Least One Of Surgery, Chemotherapy, And Radiation Therapy; And Releasing The Stem Cells For Administration To The Individual To Repopulate The Bone Marrow After Ablation.
US2008171350	GB - 20040010011 - 05/05/2004 ; WO - 2005EP04886 - 04/05/2005	NOVARTIS FORSCHUNGSSTIFTUNG	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12Q 1/02	A Method For Inducing Differentiation Of Embryonic Stem Cells Into Neuronal Precursors Is Provided As Well As An Assay For Neuronal Precursor Or Progenitor Cells And A Method For Identifying Agents That Inhibit Or Reduce An Increase In Neurite Degeneration.
US2008171384	GB - 20050003918 - 25/02/2005 ; WO - 2006IB00745 - 27/02/2006	UNIV ERASMUS MEDICAL CT	C12N 5/06 ; C12N 5/08	The Present Invention Relates To A Method For The Isolation Of Large Numbers Of Hematopoietic Stem Cells. In Particular The Invention Relates To A Method For The Isolation Of Viable Haemopoietic Stem Cells From The Placenta. The Uses Of These Isolated Cells In Various Applications Are Also Described.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008171385	US - 20070880747P - 17/01/2007 ; US - 20080016066 - 17/01/2008	BERGENDAHL VEIT ; THOMSON JAMES A	C12N 5/02 ; C12N 5/08	While Culture Medium And Systems Have Been Described That Permit The Culture And Proliferation Of Human Embryonic Stem Cells In Feeder Free And Animal Product Free Conditions, These Conditions Will Not Readily Support Cloning Of An Embryonic Stem Cell Culture Meaning, At Least Here, The Initiation Of A Sub-Culture Using One Or A Very Few Originating Cells. It Has Been Found Here That A Class Of Small Molecules That Are Inhibitors Of Kinase Enzymes Will Increase The Efficiency Of Cloning Of Stem Cell Cultures Sufficiently To Make Such Cloning Practical In The Defined Medium And In Other Media As Well.
US2008171951	WO - 2005IB00747 - 23/03/2005 ; WO - 2006IB50895 - 23/03/2006	FELL CLAUDE	A61B 10/02 ; C12M 3/00	A System For The Extraction, Collection, Processing And Transplantation Of Cell Subsets, Including Adult Stem Cells And Platelets, In Particular For Tissue Repair In Regenerative Medicine, Comprises A Set Of Disposable Fluid-Transport Elements That Are Pre-Connected Or That Include Aseptic Connectors For Making Interconnections Between Them In An Aseptic Manner Or Are Adapted To Be Aseptically Connected. The Set Usually Includes Three Kits Of Disposable Sterile Elements, A Collection Kit, A Processing Kit, And A Transplantation Kit Packaged In A Blister Pack On A Support Such As A Tray, Having One Compartment For Receiving Each Inter-Connectable Kit Of The Set. The Set Includes An Extracting Device, For Example Including A Needle For Bone Puncture Or Vein Puncture, For Extracting Bone Marrow Or Other Sources Of Cell Subsets From A Patient.
US2008175816	US - 20070625763 - 22/01/2007	TRUSTEES OF THE UNIVERSITY OF	C12M 1/00 ; C12N 5/06	Various Embodiments Of The Present Invention Include Compositions, Materials And Methods For Maintaining And Propagating Mammalian Mesenchymal Stem Cells In An Undifferentiated State In The Absence Of Feeder Cells And Applications Of The Same.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008175824	US - 20020076180 - 13/02/2002 ; US - 20020437292P - 31/12/2002 ; US - 20030366671 - 13/02/2003 ; US - 20050754692P - 29/12/2005 ; US - 20060648802 - 28/12/2006 ; US - 20070982211 - 31/10/2007	DULANEY COLLEEN SUZANNE ; HEIDARAN MOHAMMAD ; WANG JIA-LUN ; YE QIAN ; ZEITLIN ANDREW	A61K 35/12 ; C12N 5/08	The Present Invention Relates To A Combination Of Placental Stem Cells And Stem Or Progenitor Cells Derived From A Second Source, Wherein The Combination Shows Improved Engraftment As Compared To Placental Stem Cells Or Stem Cells From A Second Source, Alone. The Combination Is Referred To As A Combined Stem Cell Population. The Invention Also Provides In Vitro And In Vivo Methods For Identifying And Producing Combined Stem Cell Populations, And Models Of Engraftment. In Accordance With The Present Invention, The Placental Stem Cells May Be Combined With, E.G., Umbilical Cord Blood-Derived Stem Or Progenitor Cells, Fetal Or Neonatal Stem Cells Or Progenitor Cells, Adult Stem Cells Or Progenitor Cells, Hematopoietic Stem Cells Or Progenitor Cells, Stem Or Progenitor Cells Derived From Bone Marrow, Etc.
US2008175828	US - 20020355157P - 08/02/2002 ; US - 20030359854 - 07/02/2003 ; US - 20070981945 - 31/10/2007	CAVIEDES PABLO ; CAVIEDES RAUL ; FREEMAN THOMAS B	A61K 35/12 ; A61P 1/00 ; A61P 25/00 ; C07K 14/00 ; C12N 5/00 ; C12N 5/06 ; C12Q 1/02	The Subject Invention Pertains To Tumor Cell Lines Useful For Increasing The Proliferation Potential Of Any Human Or Animal Cell In Culture, Thereby Providing Immortalized Or Continuous Cell Lines And Cultures. The Invention Also Concerns Proliferation Factors, And Compositions Containing The Factors, Which Are Capable Of Increasing The Proliferation Potential Of Any Human Or Other Animal Cell In Culture. The Subject Invention Further Pertains To A Method For Proliferating Cells In Culture By Containing Cells With The Proliferation Factors. The Proliferated Cells Can Range In Plasticity And Can Include, For Example, Blast Cells, Fertilized Ova, Non-Fertilized Gametes, Embryonic Stem Cells, Adult Stem Cells, Precursor Or Progenitor Cells, And Highly Specialized Cells. Optionally, The Cells Can Be Induced To Cease Proliferation. The Proliferated Cells Of The Subject Invention Are Useful For Cell Therapy, Cell/Gene Therapy, Biological Production Of Molecules, And As In Vitro Models For Research, Toxicity Testing
US2008175829	US - 20040873640 - 23/06/2004 ; US - 20080015367 - 16/01/2008	CHENG HENRICH ; TZENG SHUN-FEN	A61K 48/00 ; C12N 9/00	A Method For Inducing Neural Differentiation Includes Treating A Bone Marrow Stem Cell With A Neurotrophic Factor And/Or Dibutyryl Camp (Dbcamp), Wherein The Neurotrophic Factor Includes Or Is Glial Cell Line-Derived Neurotrophic Factor (GDNF) Or Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP).

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008175870	US - 20070881497P - 22/01/2007 ; US - 20070907180P - 23/03/2007 ; US - 20070924247P - 04/05/2007 ; US - 20070950714P - 19/07/2007 ; US - 20070972613P - 14/09/2007 ; US - 20080018126 - 22/01/2008	MATHER JENNIE P ; ROBERTS PENELOPE	A61K 35/00 ; A61K 39/00 ; A61P 37/00 ; C12N 5/06 ; G01N 33/574	This Invention Discloses Isolated Populations Of Human Cancer Stem Cells. Methods For Characterizing, Isolating And Culturing Human Cancer Stem Cells Are Also Disclosed. Uses For Human Cancer Stem Cells Are Provided.
US2008176207	US - 20050710028P - 19/08/2005 ; US - 20050711287P - 25/08/2005 ; US - 20060508010 - 21/08/2006 ; US - 20080008583 - 11/01/2008	DZAU VICTOR ; MIROTSOU MARIA	A01N 1/02	A Purified Paracrine Factor Of A Mesenchymal Stem Cell, Such As A Secreted Frizzled Related Protein (Sfrp) Is Useful To Reduce Cell Death An/Or Tissue Injury Associated With Ischemic Condtions.
US2008176325	US - 20060417719 - 04/05/2006 ; US - 20080047563 - 13/03/2008	BOB THOMAS H ; BOWERMASTER RUSSELL	C12N 5/08	The Invention Provides An Isolated Tissue Comprising A Source Of Millions Of Postnatal Stem Cells Expressing Embryonic Stem Cell Markers, And A Method Of Storing Or Banking Such Isolated Tissue To Provide Stems Cells For Later Therapeutic Use For The Donor Or For Allogeneic Transplant With Donor Permission.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008176328	US - 20070625252 - 19/01/2007	SEOUL NAT UNIV IND FOUNDATION	C12N 5/02	The Present Invention Relates To A Method For Inducing Differentiation Of Bone Marrow-Derived Mesenchymal Stem Cells Into Mature Neurons By Culturing Them In An Optimal Medium Supplemented With Necessary Composition. According To The Pre-Induction Method Of The Invention And A Method For Inducing Differentiation Of Mesenchymal Stem Cells Into Neurons By Culturing Them In Neuronal Induction Media (NIM) Containing Butyl Hydroxyanisole, Forskolin And VPA, Mesenchymal Stem Cells Can Be Effectively Differentiated Into Neurons Or Motor Neurons, Which Thereby Can Be Effectively Used As A Therapeutic Agent For Cell Therapy For Neurodegenerative Diseases.
US2008177329	US - 20060646750 - 28/12/2006 ; US - 20070757823 - 04/06/2007 ; US - 20070912869P - 19/04/2007	MI4SPINE LLC	A61B 17/70 ; A61F 2/00	A Method For Providing Disc Regeneration That Includes At Least Partially Restoring Disc Height Using A Vertebral Disc Annular Fibrosis Tensioning And Lengthening Device, And Then Injecting A Biologic Substance, Such As Stem Cells, Into The Disc That Differentiate Into Chondrocytes And/Or Notochordal Cells That Facilitate Disc Regeneration. Once The Biologic Substance Has Regenerated The Disc, It May Be Possible To Remove The Vertebral Disc Annular Fibrosis Tensioning And Lengthening Device.
US2008178305	US - 20000222794P - 03/08/2000 ; US - 20000240317P - 13/10/2000 ; US - 20010920517 - 01/08/2001 ; WO - 2001US24243 - 02/08/2001 ; US - 20030343692 - 25/08/2003 ; US - 20060529869 - 29/09/2006 ; US - 20070776935 - 12/07/2007	UNIV MICHIGAN	A01K 67/027 ; C12Q 1/02 ; G01N 33/574	A Small Percentage Of Cells Within An Established Solid Tumor Have The Properties Of Stem Cells. These Solid Tumor Stem Cells Give Rise Both To More Tumor Stem Cells And To The Majority Of Cells In The Tumor That Have Lost The Capacity For Extensive Proliferation And The Ability To Give Rise To New Tumors. Thus, Solid Tumor Heterogeneity Reflects The Presence Of Tumor Cell Progeny Arising From A Solid Tumor Stem Cell. We Have Developed A Xenograft Model In Which We Have Been Able To Establish Tumors From Primary Tumors Via Injection Of Tumor Cells In The Mammary Gland Of Severely Immunodeficient Mice. These Xenograft Assay Have Allowed Us To Do Biological And Molecular Assays To Characterize Clonogenic Solid Tumor Stem Cells. We Have Also Developed Evidence That Strongly Implicates The Notch Pathway, Especially Notch 4, As Playing A Central Pathway In Carcinogenesis.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008181849	WO - 2006BR00052 - 17/03/2006 ; US - 20070902064 - 18/09/2007	BAPTISTA GANDHI RADIS ; DA SILVA ALVARO ROSSAN B P ; DE OLIVEIRA EDUARDO BRANDT ; HAYASHI MIRIAN AKEMI FURUIE ; KERKIS ALEXANDRE ; KERKIS IRINA ; KONNO KATSUHIRO ; PEREIRA LYGIA DA VEIGA ; YAMANE TETSUO	A61K 31/70 ; A61K 38/00 ; A61K 47/00 ; A61K 49/00 ; A61P 43/00 ; C12N 5/06 ; C12Q 1/02	The Present Invention Refers To Uses Of Crotamine And Compositions Containing It, Based On Its Characteristic Of Interaction With Genetic Material. Under Submicromolar Quantities, The Polypeptide Is No Longer Toxic, Presenting The Characteristics Properties Of Cell Penetration, Transport Of Molecules To The Surface, Cytoplasm Or Cell Nucleus And Particularly, Selective Cell Penetration. The Invention Also Refers To Compositions Comprising A Pharmaceutically Effective Concentration Of Crotamine And Its Use For The Treatment Of Diseases And Dysfunctions, Based On Its Characteristics Of Interaction With Genetic Material, Such As DNA And RNA, And Cell Selectivity. Further, The Invention Refers To A Kit Comprising Crotamine As A Reagent To: (I) Transfect Or Carry Molecules To The Surface, Cytoplasm Or Nucleus Of The Cell Or (Ii) Identify And Select Actively Proliferating Cells In A Homogeneous And/Or Mixed Cell Population, Particularly The Ones Originated From The Umbilical Cord And/Or Bone Marrow And Others Undifferentiated cells such as progenitors and stem cells from different sources of organism and cancer cells.
US2008181873	US - 20010322514P - 14/09/2001 ; US - 20020231479 - 30/08/2002 ; US - 20020386404P - 07/06/2002 ; US - 20080051240 - 19/03/2008	STEM CELL THERAPEUTICS INC	A61K 31/565 ; A61K 35/12 ; A61K 35/30 ; A61K 38/00 ; A61K 38/22 ; A61K 38/27 ; A61K 38/30 ; A61L 27/00 ; A61P 21/00 ; A61P 25/00 ; A61P 25/14 ; A61P 25/16 ; A61P 25/28 ; C12N 5/06 ; C12N 5/08	The Present Invention Provides A Method Of Increasing Neural Stem Cell Numbers Or Neurogenesis By Using Prolactin. The Method Can Be Practiced In Vivo To Obtain More Neural Stem Cells In Situ, Which Can In Turn Produce More Neurons Or Glial Cells To Compensate For Lost Or Dysfunctional Neural Cells. The Method Can Also Be Practiced In Vitro To Produce A Large Number Of Neural Stem Cells In Culture. The Cultured Stem Cells Can Be Used, For Example, For Transplantation Treatment Of Patients Or Animals Suffering From Neurodegenerative Diseases Or Conditions. In Addition, Since Neural Stem Cells Are A Source For Olfactory Neurons, The Present Invention Also Provides Methods Of Increasing Olfactory Neurons And Enhancing Olfactory Functions.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008159978	US - 20030493000P - 07/08/2003 ; WO - 2004IL00727 - 05/08/2004 ; US - 20060348527 - 07/02/2006 ; US - 20080009567 - 18/01/2008	BRAIMAN-WIKSMAN LIORA ; SOLOMONIK INESSA	A61K 38/19 ; A61P 17/02	Methods For Inducing Or Accelerating A Healing Process Of A Damaged Skin Or Skin Wounds Are Described. The Methods Include Administering To The Skin Cells Colonizing The Damaged Skin Or Skin Wound A Therapeutically Effective Amount Of An Adipokine, An Adipocyte Or Preadipocyte Modulator, Adipocytes, Preadipocytes, Or Stem Cells, Or Transforming The Skin Cells Colonizing The Damaged Skin Or Skin Wound Such As To Express And Secrete An Adipokine, Thereby Inducing Or Accelerating The Healing Process Of The Damaged Skin Or Skin Wound.
US2008182278	US - 20060873722P - 07/12/2006 ; US - 20070001005 - 07/12/2007	CHANI KEITH S ; WEISSMAN IRVING L	C12N 5/06 ; C12Q 1/04 ; G01N 33/574	Transitional Cell Carcinoma Stem Cells (TCCSC) Are Identified. The Cells Can Be Prospectively Isolated Or Identified From Primary Tumor Samples, And Are Shown To Possess The Unique Properties Of Cancer Stem Cells In Functional Assays For Cancer Stem Cell Self-Renewal And Differentiation, And In Cancer Diagnosis.
US7465582	US - 19990132317P - 03/05/1999 ; WO - 2000EP03842 - 27/04/2000	NEURO THERAPEUTICS AB	A61K 35/30 ; A61K 45/00 ; A61P 25/28 ; C12N 15/00 ; C12N 5/06 ; C12N 5/10 ; C12Q 1/02 ; G01N 33/15 ; G01N 33/50	The Invention Relates To The Induction Of The Neuronal Fate In Neural Stem Cells Or Neural Progenitor Cells. The Inventors Have Found That A Neuronal Fate In A Neural Stem Cell Or Neural Progenitor Cell Can Be Induced By Expressing Nurr1 Above Basal Levels Within The Cell. Nurr1 Is A Transcription Factor Of The Thyroid Hormone/Retinoic Acid Nuclear Receptor Superfamily. It Is Shown Herein That The Expression Of Nurr1 Above Basal Levels In Neural Stem Cells Or Neural Progenitor Cells Increases The Proportion Of The Cells Which Differentiate Toward A Neural Fate. It Has Been Found That In Particular, Dopaminergic Neural Stem Cells Or Progenitor Cells By A Process Including Expression Of Nurr1 Above Basal Levels In The Cells And Contact Of The Cells With One Or More Factors Supplied By Or Derived From Type I Astrocytes Of The Ventral Mesencephalon.
US2008182328	US - 20060876004P - 19/12/2006 ; US - 20070004299 - 19/12/2007	BURNHAM INST	C12N 5/00 ; C12N 5/02	An Isolated Mammalian Extraembryonic Endoderm-Like Cell Line Is Provided. Methods For Producing Isolated Mammalian Extraembryonic Endoderm-Like Cell Line Derived From A Mammalian Pluripotent Stem Cell Culture Are Provided. Primate Or Human Embryonic Stem Cells (Escs) Spontaneously Generate The Primate Or Human Extraembryonic Endoderm-Like Cell Line Wherein The Extraembryonic Endoderm-Like Cells Sustain The Pluripotence Of The Primate Or Human Escs.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008182845	US - 20060859561P - 16/11/2006 ; US - 20070941196 - 16/11/2007	ABBOTT LAB	A61K 31/5377 ; C07D 413/02	Methods Of Preventing Or Treating Organ, Hematopoietic Stem Cell Or Bone Marrow Transplant Rejection Are Disclosed.
US2008187494	US - 20050716390P - 12/09/2005 ; US - 20050740462P - 29/11/2005 ; US - 20050753434P - 22/12/2005 ; US - 20060066624 - 12/09/2006 ; WO - 2006AU01333 - 12/09/2006	ES CELL INT PTE LTD	A61K 48/00 ; A61K 49/00 ; C12N 5/00 ; C12N 5/02	The Present Invention Provides A Process Of Differentiating Stem Cells, In Particular Hes Cells, Into Cardiomyocytes And Into Neural Progenitors By Growing The Hes Cells In The Presence Of A Defined Medium That Is Substantially Free Of Xeno- And Serum-Components And Thus Comprises A Clinically Compliant Medium. The Defined Media Comprises Defined Factors That Contribute To The Promotion Of Differentiation To Cardiomyocytes And Neural Progenitors. The Invention Also Includes Defined Culture Media And Cell Populations And Methods Of Using Them.
US2008187524	US - 20030423193 - 25/04/2003 ; US - 20080062230 - 03/04/2008	MEDTRONIC VASCULAR INC	A61F 2/06 ; A61K 35/12 ; A61P 7/00	The Present Invention Encompasses Methods And Apparatus For Minimizing The Risks Inherent In Endovascular Grafting For Blood Vessel Therapy And Repair. The Invention Involves Delivering Adult Stem Cells, Embryonic Stem Cells, Progenitor Cells, Fibroblasts, Or Smooth Muscle Cells To The Diseased Blood Vessel.
US2008187532	US - 20060847904P - 29/09/2006 ; US - 20070886260P - 23/01/2007 ; US - 20070905392 - 28/09/2007 ; US - 20070942542P - 07/06/2007	AXELROD FUMIKO ; GURNEY AUSTIN ; HOEY TIM ; SATYAL SANJEEV	A61K 39/395 ; A61P 43/00 ; C07K 16/18 ; C12N 15/00 ; C12N 5/06 ; C12P 21/04 ; G01N 33/574	An Isolated Antibody That Specifically Binds To An Extracellular Domain Of Human DLL4 And Affects Growth Of A Tumor Comprising Cancer Stem Cells Is Described. Also Described Is A Method Of Treating Cancer Comprising Administering A Therapeutically Effective Amount Of An Anti-DLL4 Antibody.
US2008187549	US - 20070703270 - 07/02/2007	MOREY WILLIAM A	A61K 39/00	Said Invention Is A Unique Modi Or Set Of Immunological Techniques/Methods, By Which To Develop Various Types Of Infertility Vaccines, Primarily Designed To Reduce Fertility Or To Produce Infertility In Animals And/Or In Humans. Said Reduced Fertility Or Infertility May Be Permanent Or Exists With Variable Duration. The Immunological Infertility

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
				Responses, Resulting From Said Uniquely Developed Vaccines (As Affected/Created By The Proposed Methodologies), May Be Superior To Currently Existing Infertility Vaccines {Referenced, Herein}, Since They (The Vaccines Resulting From The Proposed Methods, Herein) Would Contain A Far Greater Diversity/Variety Of Antigens; And Are Therefore, Considered As Polyantigenic Vaccines, Herein. A Larger Diversity/Variety Of Antigens May Better Elicit A Greater Diversity/Variety Of Endogenous Antibodies. A Greater Variety Of Antibody Types And Antibody Variable Sites May Enhance The Infertility Response. Correspondingly, The Proposed Methods May Result In Infertility Vaccines Which affect greater numbers and types of memory cells. While currently existing infertility vaccines use individual or limited numbers of identified antigens to sperm, or to sex-related hormones, etc. Said proposed modi or set of methods are unique, not only because they are polyantigenic, but because of some of the specified antigenic sources employed, besides sperm, i.e., ova, gamete germinal cells, gamete precursor cells, male ejaculate, liquor folliculi, certain differentiated stem cells, etc. The proposed modi does not use isolated/identified sperm antigens, as is currently used in infertility vaccines. Heretofore, the proposed modi has not been proposed. Because humans and many domesticated animals (cats, dogs, cattle, sheep, birds, etc.) are such out-bred species, in that they may possess a broad variety of gamete-based antigens, individual responsiveness to an immunologic vaccine which uses a single or highly limited number (one or two) of isolated/identified antigens, is apt to be ineffective. Limited antigen types may fail to adequately address the vaccine recipient's own gamete-based antigens. The use of the proposed polyantigenic modi may enhance vaccine efficacy by providing a greater diversity of antigens, and thereby affecting a broader spectrum of response antibodies, etc.
US2008187938	US - 20060846648P - 22/09/2006 ; US - 20070859901 - 24/09/2007	UNIV MICHIGAN	C12N 5/00 ; G01N 33/53	The Present Invention Relates To Compositions And Methods For Treating, Characterizing, And Diagnosing Cancer. In Particular, The Present Invention Provides A Novel Stem Cell Cancer Marker, ALDH1, Useful For The Diagnosis, Characterization, And Treatment Of Solid Tumor Stem Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008187950	US - 20060873653P - 07/12/2006 ; US - 20070999809 - 07/12/2007	HOSEN NAOKI ; WEISSMAN IRVING L	C12N 5/00 ; C12N 5/08 ; C12Q 1/02	Acute Myeloid Leukemia Stem Cells (AMLSC) Are Identified. The Cells Can Be Prospectively Isolated Or Identified From Patient Samples, And Are Shown To Possess The Unique Properties Of Cancer Stem Cells In Functional Assays For Cancer Stem Cell Self-Renewal And Differentiation, And In Cancer Diagnosis.
US2008187995	US - 20060848209P - 29/09/2006 ; US - 20070860886 - 25/09/2007	LILIENSIEK SARA J ; MCFARLIN DANIEL R ; MCKIE GEORGE A ; MURPHY CHRISTOPHER J ; NEALEY PAUL F	C12N 5/00 ; C12N 5/02	Surfaces, Kits, And Methods For The Modulation Of Cell Behavior In Vitro By Patterned Nanoscale Topography. The Invention Is Particularly Useful For Providing Means To Affect And Control The Growth And Differentiation Of Human Embryonic Stem Cells.
US2008188926	US - 20070670227 - 01/02/2007	MEDTRONIC VASCULAR INC	A61F 2/82 ; A61F 2/84	A Method Of Treating A Vascular Condition Includes Applying A Plurality Of Stem Cells To An Exterior Surface Of A Stent, And Enveloping The Applied Stem Cells With A Topcoat Layer. In Addition, The Method Includes Delivering The Stent With Applied Stem Cells And Topcoat To A Treatment Region Of A Vessel Within A Body; And Applying An Electrical Field To The Stent For A Predetermined Time. A System For Treating A Vascular Condition Includes A Catheter, A Stent Disposed On The Catheter, At Least One Layer Of Stem Cells Disposed On An Exterior Surface Of The Stent, And A Topcoat Layer Surrounding The Layer Of Stem Cells. In Addition, The System Includes At Least One Electrical Lead Attached To The Stent, The Electrical Lead Operable To Induce An Electrical Field Around The Stent.
US2008189045	US - 20070671967 - 06/02/2007	MOORE THOMAS E	G01N 33/48	The Present Invention Provides A Method For The Collection And Distribution Of Cord Blood Stem Cells, Particularly In Order To Increase The Number Of Usable Cord Blood Stem Cells That Are Collected Overall. By Using A Single Collection And Distribution Entity That Applies A Uniform Protocol To Obtain Cord Blood Stem Cell Samples At Each Of A Plurality Of Different Collection Facilities, A Greater Number Of Samples For Both Private And Public Cord Blood Stem Cell Banks Can Be Obtained.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008189799	US - 19990144942P - 20/07/1999 ; US - 19990157651P - 04/10/1999 ; US - 19990168358P - 01/12/1999 ; US - 20000179110P - 31/01/2000 ; US - 20000620607 - 20/07/2000 ; US - 20000680959 - 04/10/2000 ; US - 20000728445 - 30/11/2000 ; US - 20000750456 - 28/12/2000 ; US - 20010773476 - 31/01/2001 ; US - 20040770021 - 02/02/2004 ; US - 20040846839 - 14/05/2004 ; US - 20040964549 - 13/10/2004 ; US - 20050124617 - 06/05/2005 ; US - 20060488469 - 18/07/2006 ; US - 20070978234 - 26/10/2007	FAN LIANGFEN ; FRIEDRICH GLENN ; MINZE LAURIE JEANETTE ; MONTGOMERY CHARLES ; PAYNE BOBBY JOE ; RANGEL CAROLINA ; SANDS ARTHUR T ; SEVAUX TRACY ELLEN WILLIS ; SHI ZHENG-ZHENG ; SPARKS MARY JEAN ; VOGEL PETER ; ZAMBROWICZ BRIAN	A01K 67/027 ; C12N 15/11	The Current Invention Relates To Genetically Engineered Mice, Cells Derived From Those Mice, And Polynucleotides And Polypeptides Corresponding To Genes Affected By The Engineered Mutation. The Invention Also Relates To Antibodies Raised In A Mouse Of The Invention. The Invention Further Provides Methods For Using The Mice, Cells, Polynucleotides, Polypeptides And Antibodies Of The Invention.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008193420	DE - 200410017476 - 08/04/2004 ; WO - 2005EP03430 - 01/04/2005	FUHR GUNTER ; KRUSE CHARLI ; WEDEL THILO	A61K 35/24 ; A61K 35/26 ; A61K 48/00 ; C12M 1/00 ; C12M 3/04 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06	Disclosed Is A Method For Forming Epithelial Cells. Said Method Comprises The Steps Of Aggregating Stem Cells From Differentiated Exocrine Gland Tissue To Obtain An Organoid Body And Differentiating At Least One Portion Of The Organoid Body Or A Tissue Body Grown Therefrom To Obtain Epithelial Cells. Also Disclosed Is A Cultivation Device, Particularly For Forming Differential Epithelial Cells.
US2008193426	IL - 20010146970 - 06/12/2001 ; WO - 2002IL00988 - 05/12/2002 ; US - 20050497708 - 09/03/2005 ; US - 20060484772 - 12/07/2006 ; US - 20070948525 - 30/11/2007	YEDA RES & DEV	A61K 35/12 ; A61K 35/14 ; A61K 35/28 ; A61K 35/44 ; A61K 35/48 ; A61K 38/00 ; A61K 38/19 ; A61K 45/00 ; A61K 48/00 ; A61P 1/00 ; A61P 1/04 ; A61P 1/16 ; A61P 3/10 ; C07K 14/52 ; C12N 15/09 ; C12N 15/19	The Invention Relates To Transplantation Of Hematopoietic Stem Cells (HSC) And/Or Progenitor Cells (HPC) Into The Liver. More Specifically The Invention Relates To The Use Of Chemokines, Preferably SDF-1, For Enhancing Homing Of HSC/HPC To The Liver.
US2008193929	US - 20040625597P - 08/11/2004 ; US - 20050667280 - 08/11/2005 ; WO - 2005US40406 - 08/11/2005	CHUCK ROY S	C12M 1/00 ; C12Q 1/68	Methods And Systems For A) Identifying And Isolating Stem Cells, B) Assessing Mitochondrial Distribution And Structure In Living Cells And C) Performing Fluorescence Microscopy On Living Cells While The Cells Remain Within A Condition-Controlled Cell Culture Chamber.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008194022	US - 20000222794P - 03/08/2000 ; US - 20000240317P - 13/10/2000 ; WO - 2001US24243 - 02/08/2001 ; US - 20030343692 - 25/08/2003 ; US - 20060529869 - 29/09/2006 ; US - 20070788489 - 20/04/2007	AL-HAJJ MUHAMMAD ; CLARKE MICHAEL F ; MORRISON SEAN J ; WICHA MAX S	C12N 5/06 ; C12N 5/08 ; G01N 33/50 ; G01N 33/574	A Small Percentage Of Cells Within An Established Solid Tumor Have The Properties Of Stem Cells. These Solid Tumor Stem Cells Give Rise Both To More Tumor Stem Cells And To The Majority Of Cells In The Tumor That Have Lost The Capacity For Extensive Proliferation And The Ability To Give Rise To New Tumors. Thus, Solid Tumor Heterogeneity Reflects The Presence Of Tumor Cell Progeny Arising From A Solid Tumor Stem Cell. We Have Developed A Xenograft Model In Which We Have Been Able To Establish Tumors From Primary Tumors Via Injection Of Tumors In The Mammary Gland Of Severely Immunodeficient Mice. These Xenograft Assay Have Allowed Us To Do Biological And Molecular Assays To Characterize Clonogenic Solid Tumor Stem Cells. We Have Also Developed Evidence That Strongly Implicates The Notch Pathway, Especially Notch 4, As Playing A Central Pathway In Carcinogenesis.
US2008194710	US - 20040570811P - 14/05/2004 ; US - 20050596351 - 10/05/2005 ; WO - 2005US16284 - 10/05/2005	UNIV NEW YORK	A61K 47/00 ; A61P 13/00 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/04	Prostatic Stem Cells Have Been Isolated. Benign Prostatic Hyperplasia And Other Proliferative Diseases Of The Prostate May Arise In Prostatic Stem Cells. The Prostatic Stem Cells Are Used As A Research Tool For Studying Cancer And Other Proliferative Diseases Of The Prostate, And For Developing Diagnostics And Therapeutics For Proliferative Diseases Of The Prostate. Antibodies To The Antigens Expressed By Prostatic Stem Cells Can Be Used As Therapeutics Or Diagnostics Or Can Be Used To Deliver Therapeutic Or Diagnostic Agents Directly To The Prostatic Stem Cells.
US2008195007	US - 20070889355P - 12/02/2007 ; US - 20080029885 - 12/02/2008	LYUBICH MIKHAIL N ; PODRAZHANSKY YURY	A61H 23/00	A Method And Device For Using Topically Applied Acoustical Vibrations To Stimulate The Production Of Adult Stem Cells In Living Organisms. This Approach Is Non-Invasive, And More Specifically Does Not Involve Introducing Chemicals Or Physically Invading The Organisms. One Or More Acoustical Transducers Are Placed Directly On The Skin Of The Organism In Certain Locations, And Selected Vibration Profiles Are Applied To The Organism Through The Transducers. The Treatment Includes The Regular Application Of Various Vibration Pulse Profiles That Generally Include Sequences Of Pulses In Which Each Pulse Has A Duration In The Range Of One-Half To Ten Seconds, Is Separated By Rest Periods In The Range Of One-Tenth To Three Seconds, Is Modulated With An Oscillatory Signal In The Frequency Range Of 1 Hz To 1,500 Hz, And Has A Pulse Amplitude In The Range Of Range From About 20 To 5000 Microns.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008196110	US - 20040587044P - 13/07/2004 ; US - 20050571947 - 12/07/2005 ; WO - 2005US24788 - 13/07/2005	ANDEL RES INST VAN	A01K 67/027 ; C12N 15/00 ; C12N 5/06 ; C12P 21/00 ; G01N 33/53	A Transgenic Animal Model For Evaluating Growth, Survival And/Or Metastasis Of Xenotransplanted Normal Or Tumor Cells Or Tissue Is Disclosed, In Which A Human Growth Factor, Hhgf Stimulates Growth In Vivo Of Human Cells Or Tissue. A Strain Of Tg Mice On The C3H Background That Is Immunocompromised As A Result Of A Homozygous Scid Gene Has Been Bred Which Express A Nucleic Acid Encoding Hhgf/SE The Ectopically Expressed Hhgf/SF Ligand Significantly Enhances Growth Of Human Tumor Cell Lines And Explanted Tumor Cells Or Tissue That Express The Met Receptor For Hhgf. Such Animals Also Have An Enlarged Normal Livers And Greater Than Normal Liver Regenerative Capacity. Any Met-Expressing Hhgf-Dependent Human Cells, Including Hepatocytes And Various Stem Cells Can Survive And Grow In Such Animals.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008199495	AU - 1999PP09778 - 15/04/1999 ; US - 20000795286 - 13/10/2000 ; US - 20000795302 - 13/10/2000 ; WO - 2000AU00329 - 17/04/2000 ; AU - 2000PR00745 - 13/10/2000 ; US - 20010755965 - 05/01/2001 ; US - 20010965394 - 26/09/2001 ; US - 20010977479 - 12/10/2001 ; WO - 2001AU01291 - 15/10/2001 ; US - 20030418747 - 18/04/2003 ; US - 20030527001P - 05/12/2003 ; US - 20030748450 - 30/12/2003 ; US - 20040399213 - 13/02/2004 ; US - 20070805791 - 24/05/2007	UNIV MONASH	A61K 35/14 ; A61K 35/28 ; A61K 38/08 ; A61K 38/09 ; A61K 38/18 ; A61K 38/19 ; A61K 38/20 ; A61K 38/24 ; A61K 39/00 ; A61K 39/002 ; A61K 39/015 ; A61K 39/02 ; A61K 39/04 ; A61K 39/145 ; A61K 39/245 ; A61K 39/39	The Present Disclosure Provides Methods For Enhancing The Response Of A Patient's Immune System To Vaccination. This Is Accomplished By Reactivating The Thymus. Optionally, Hematopoietic Stem Cells, Autologous, Syngeneic, Allogeneic Or Xenogeneic, Are Delivered To Increase The Speed Of Regeneration Of The Patient's Immune System. In One Embodiment The Hematopoietic Stem Cells Are CD34<+>. The Patient's Thymus Is Reactivated By Disruption Of Sex Steroid Mediated Signaling To The Thymus. In One Embodiment, This Disruption Is Created By Administration Of LHRH Agonists, LHRH Antagonists, Anti-LHRH Receptor Antibodies, Anti-LHRH Vaccines Or Combinations Thereof.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008199849	US - 20050713992P - 02/09/2005 ; US - 20060065549 - 15/08/2006 ; WO - 2006SG00233 - 15/08/2006	AGENCY SCIENCE TECH & RES	C12N 5/00 ; C12N 5/02 ; C12Q 1/00	We Disclose A Method Comprising: (A) Providing An Embryonic Stem (ES) Cell; And (B) Establishing A Progenitor Cell Line From The Embryonic Stem Cell; In Which The Progenitor Cell Line Is Selected Based On Its Ability To Self-Renew. Preferably, The Method Selects Against Somatic Cells Based On Their Inability To Self-Renew. Preferably, The Progenitor Cell Line Is Derived Or Established In The Absence Of Co-Culture, Preferably In The Absence Of Feeder Cells, Which Preferably Selects Against Embryonic Stem Cells. Optionally, The Method Comprises (D) Deriving A Differentiated Cell From The Progenitor Cell Line.
US2008199959	SE - 20050001513 - 21/06/2005 ; WO - 2006SE00750 - 19/06/2006	GE HEALTHCARE BIO SCIENCES AB	C12M 1/00 ; C12N 1/00 ; C12N 1/20 ; C12N 5/06	The Present Invention Relates To A Method For Cell Culture, More Precisely Small Scale Cell Culture. In The Present Invention A Screening Tool Is Used Which Comprises Particulate Matter Or Microcarriers, Such As Beads, Attached To A Solid Support, Such As A Microtiter Plate, For The Cultivation Of Cells On Said Microcarriers. The Microcarriers Are Preferably Cultivation Beads, Such As CYTODEX(TM). According To The Invention, This Small Scale Format For Cell Cultivation May Be Used For Any Testing Involving Cells, For Example Testing Of Optimal Growth Conditions For A Specific Type Of Cell, Such As Stem Cells. Another Use Is Cell Expansion.
US2008200369	US - 20070888877P - 08/02/2007 ; US - 20080026810 - 06/02/2008	FUKUDA MICHIKO	A01N 1/02 ; A61K 31/70 ; A61K 38/00 ; C07H 21/04 ; C07K 16/00 ; C12N 15/00 ; C12N 5/00	Disclosed Herein Are Compositions And Methods Useful For Promoting Sperm Motility, Promoting Embryonic Stem Cell Formation, Promoting Trophoblast Formation, Or Promoting Neuronal Growth. The Compositions And Methods Are Based On Peptide Sequences That Bind Trophinin, Inhibit Bystin-Mediated Arrest Of Epidermal Growth Factor (EGF) Receptor, And Promotes EGF Receptor Autophosphorylation.
US2008200419	US - 20050652122P - 11/02/2005 ; US - 20060351953 - 10/02/2006 ; US - 20080043692 - 06/03/2008	SINAI SCHOOL MEDICINE	A61K 48/00 ; C12N 15/12 ; C12N 15/85 ; C12N 15/861 ; C12N 15/867 ; C12N 5/10	An Alternatively Spliced Form Of Transforming Growth Factor-Beta2 (TGF-Beta2), Herein Denoted Delta6-TGF-Beta2 Is Disclosed. Delta6-TGF-Beta2 Differs From TGF-Beta2 In The Sequence Of The Three C-Terminal Exons. This Novel Protein Is Secreted, Induced By Cytotoxic Stress In Hematopoietic Stem Cells, And Specifically Blocks The Enhancing Effects Of TGF-Beta2 On Adult Stem Cells. Delta6-TGF-Beta2 Can Be Used To Protect Stem Cells From Cytotoxic Stress, And To Enhance Maintenance Of These Cells In Vitro During Retroviral Transduction. In Addition, Delta6-TGF-Beta2 Can Be Used To Slow Aging And Extend Longevity.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008200663	US - 20040567952P - 03/05/2004 ; US - 20050121354 - 03/05/2005 ; US - 20080107015 - 21/04/2008	HOPE CITY	C07H 21/02 ; C07H 21/04 ; C12N 15/33 ; C12N 15/49 ; C12N 15/52 ; C12N 15/867	Murine Leukemia Virus (MLV) And Lentivirus Vectors Have Been Used Previously To Deliver Genes To Hematopoietic Stem Cells (Hscs) In Human Gene Therapy Trials. However, These Vectors Integrate Randomly Into The Host Genome, Leading To Disruption Or Inactivation Of Vital Host Genes. The Present Invention Discloses A Novel Lentiviral Vector System That Overcomes This Problem By Integrating Into A Host Genome In A Site-Specific Manner.
US2008200862	US - 20040626363P - 08/11/2004 ; US - 20050718882 - 08/11/2005 ; WO - 2005US40659 - 08/11/2005	IMARX THERAPEUTICS INC	A61M 37/00 ; A61N 7/00	The Invention Comprises A Method To Administer Stem Cells To A Patient In Need Thereof. The Method Provides Acoustically Active Material, Stem Cells, And An Ultrasound Energy Emitting Device. The Method Administers The Acoustically Active Material To The Patient, Administers The Stem Cells To The Patient, And Administers Ultrasound Energy To The Patient Using The Ultrasound Emitting Device.
US2008206202	US - 20010324362P - 24/09/2001 ; US - 20020252544 - 24/09/2002 ; US - 20070927399 - 29/10/2007	PACK SVETLANA ; REID CHRISTOPHER	A61K 48/00 ; C12N 5/06	We Propose Here That Endogenous Stem/Progenitor Cells Of The Developing Or Adult Nervous System Be Genetically Modified In Situ, To Express Therapeutically Advantageous Gene Products. Furthermore, We Propose Here That Endogenous Or Other Exogenous Stem Cells Or Their Progeny Be Genetically Modified When Appropriate To Express Advantageous Gene Products (And/Or Modified Through Culture Techniques), And That, If Exogenously Derived, They Be Transplanted Into The Ventricular System Of The Patient Nervous System, The Germinal Zone Of The Ventricular System, Into Postmitotic Regions Of The CNS Or Other Organs.
US2008206204	US - 20070711152 - 27/02/2007	BREVINI TIZIANA ; GANDOLFI FULVIO ; RAGNI GUIDO	C12N 5/08	The Invention Provides A Method For Establishing Pluripotent Cell Lines From Human Parthenotes, The Uses Of Said Cell Lines For Producing Differentiated Cells Or Tissues And For Therapeutic Applications Especially In Regenerative Medicine.
US2008206286	US - 20060826955P - 26/09/2006 ; US - 20070862135 - 26/09/2007	CEDARS SINAI MEDICAL CENTER	A61K 39/00 ; A61P 35/00	Method Of Stimulating An Immune Response (E.G., To Treat Cancer) Include Administering To A Patient A Composition Including Dendritic Cells That Present Cancer Stem Cell Antigens. Compositions Including Cancer Stem Cell Antigens Are Also Provided Herein.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008206343	US - 20070901066P - 12/02/2007 ; US - 20070901076P - 12/02/2007 ; US - 20070905664P - 07/03/2007 ; US - 20070906064P - 08/03/2007 ; US - 20070966577P - 23/05/2007 ; US - 20080030170 - 12/02/2008	ABRAMSON SASCHA DAWN ; EDINGER JAMES W ; HARIRI ROBERT J ; LABAZZO KRISTEN S ; PEREIRA MARIAN ; WANG JIA-LUN ; YE QIAN	A01K 67/00 ; A61K 35/12 ; A61K 9/14 ; C12N 5/00 ; C12N 5/06 ; C12Q 1/68 ; C12Q 1/70	Provided Herein Are Methods And Compositions For The Production Of Hepatocytes From Placenta Stem Cells. Further Provided Herein Is The Use Of Such Hepatocytes In The Treatment Of, And Intervention In, For Example, Trauma, Inflammation, And Degenerative Disorders Of The Liver. Also Provided Herein Are Compositions And Methods Relating To Combinations Of Nanofibrous Scaffolds And Adherent Placental Stem Cells And Methods Of Using The Same In Cartilage Repair. Finally, Provided Herein Are Compositions And Methods Relating To Nonadherent, CD34<+>CD45<-> Stem Cells From Placenta.
US2008206733	JP - 20050028200 - 03/02/2005 ; WO - 2006JP01762 - 02/02/2006	UNIV OKAYAMA NAT UNIV CORP	A01N 1/00 ; C12N 1/20 ; C12N 5/06 ; C12N 5/08	With Respect To A Method For Differentially Inducing Embryo-Stem Cells Into Hepatocytes, In Order To Obtain Safe Hepatocytes That Are Adequately Functionable And Able To Supply In Large Quantity, A Method For Differentially Inducing Embryo-Stem Cell Into Hepatocyte, Wherein The Embryo-Stem Cells Are Cultured In The Presence Of Deletion Type Hepatocyte Growth Factor Is Provided. Further, A Method For Differentially Inducing Embryo-Stem Cells Into Hepatocytes Comprising (A) A Step Of Forming The Embryoid Body Of The Embryo-Stem Cells And (B) A Step Of Culturing The Embryoid Body In The Presence Of Deletion Type Hepatocyte Growth Factor Is Provided.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008206863	US - 19930145175 - 03/11/1993 ; US - 19940333076 - 01/11/1994 ; US - 20020214903 - 08/08/2002 ; US - 20050249588 - 13/10/2005 ; US - 20080148059 - 16/04/2008	DIACRIN INC	C07K 14/475 ; C07K 14/715 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08 ; G01N 33/50	An Embryonic Stem Cell Which May Be Induced To Differentiate Homogeneously Into A Desired Primary Cell Line. The Embryonic Stem Cell May Be Engineered With DNA, Which Encodes A Protein Or Polypeptide Which Promotes Differentiation Of The Stem Cell Into A Specific Cell Line, Such As, For Example, A Neuronal Cell Line, A Muscle Cell Line, Or A Hematopoietic Cell Line. The DNA May Encode A Transcription Factor Found In The Particular Cell Line. In Another Alternative, A Desired Cell Line Is Produced From Embryonic Stem Cells By Culturing Embryonic Stem Cells Under Conditions Which Provide For A Three-Dimensional Network Of Embryonic Stem Cells, And Then Stimulating Embryonic Stem Cells With An Agent, Such As Retinoic Acid, Or Dimethylsulfoxide, Which Promotes Differentiation Of The Embryonic Stem Cells Into The Desired Cell Line, Such As, For Example, A Neuronal Cell Line, Or A Muscle Cell Line.
US2008206864	US - 20060866991P - 22/11/2006 ; US - 20070943312 - 20/11/2007	MENG GUOLIANG ; RANCOURT DERRICK	C12N 5/06	This Disclosure Provides Methods For Culturing Murine ES Cells In An Undifferentiated State Using Human Foreskin Fibroblasts (HFF) Feeder Layer Cells In The Absence Of Exogenous Leukemia Inhibitory Factor (LIF).
US2008206865	US - 20010970382 - 03/10/2001 ; US - 20030498831P - 29/08/2003 ; US - 20030499570P - 02/09/2003 ; US - 20040928805 - 27/08/2004 ; US - 20060594455 - 08/11/2006	DUNCAN IAN DAVID ; LI XUE-JUN ; THOMSON JAMES A ; ZHANG SU-CHUN	C12N 5/06 ; C12N 5/08	A Method Of Differentiating Embryonic Stem Cells Into Neural And Motor Cells Is Disclosed. In One Embodiment, The Invention Comprises Culturing A Population Of Cells Comprising A Majority Of Cells That Are Characterized By An Early Rosette Morphology And Are Sox1<->/Pax6<+> In The Presence Of FGF2, FGF4, FGF8, FGF 9, Or RA Wherein The Cells Are Characterized By An Neural Tube-Like Rosette Morphology And Are Pax6<+>/Sox1<+>.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008213214	US - 20040592871P - 30/07/2004 ; US - 20050572874 - 29/07/2005 ; US - 20050680775P - 12/05/2005 ; WO - 2005US26800 - 29/07/2005	MAYO FOUNDATION	A01N 1/02 ; A61K 35/12 ; A61K 38/20 ; A61P 9/00 ; C12N 5/06 ; C12Q 1/02	This Document Provides Methods And Materials For Treating Cardiovascular Tissue. For Example, Stem Cells, Compositions Containing Stem Cells, Methods For Obtaining Stem Cells, Compositions For Generating Stem Cells Expressing Particular Markers, And Methods For Repairing Cardiovascular Tissue Are Provided.
US2008213227	US - 20040555118P - 22/03/2004 ; US - 20050080298 - 15/03/2005 ; US - 20060541853 - 02/10/2006	AGGARWAL SUDEEPTA ; PITTENGER MARK F ; VARNEY TIMOTHY	A61K 35/14 ; A61K 45/00 ; C12N 5/00 ; C12N 5/06 ; H04Q 7/20	Methods Of Treating Autoimmune Diseases, Allergic Responses, Cancer, Or Inflammatory Diseases In An Animal, Promoting Would Healing, Repairing Epithelial Damage And Promoting Angiogenesis In An Organ Or Tissue Of An Animal By Administering To The Animal Mesenchymal Stem Cells In An Effective Amount.
US2008213228	US - 20060853971P - 23/10/2006 ; US - 20060855629P - 30/10/2006 ; US - 20070877475 - 23/10/2007 ; US - 20070997022P - 28/09/2007	ANTHROGENESIS CORP	A61K 35/12 ; A61P 19/00 ; C12N 5/06	Provided Herein Are Methods Of Using Adherent Placental Stem Cells And Placental Stem Cell Populations, And Methods Of Culturing, Proliferating And Expanding The Same. Also Provided Herein Are Methods Of Differentiating The Placental Stem Cells. Further Provided Herein Are Methods Of Using The Placental Stem Cells To Formulate Implantable Or Injectable Compositions Suitable For Administration To A Subject. Still Further Provided Herein Are Provides Methods For Treating Bone Defects With Stem Cells And Compositions Comprising Stem Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008213230	US - 20060857661P - 07/11/2006 ; US - 20070983431 - 07/11/2007	KECK GRADUATE INST	A61K 35/12 ; A61P 9/00 ; C12N 5/06 ; C12Q 1/04	The Present Invention Provides A Novel Method To Isolate And Expand Pure Progenitor/Stem Cells From A Primary Tissue Explant, Which Produces A Population Enriched In Multipotent Functional Progenitor/Stem Cells Free Of Contaminating Fibroblasts And Other Cell Types. Cardiac Progenitor/Stem Cells Isolated By This Method Maintain Their Self-Renewal And Clonogenic Character In Vitro And Differentiate Into Normal Cells In Myocardium, Including Cardiomyocytes, Endothelial Cells, And Smooth Muscle Cells, After Transplantation Into Ischemic Hearts. The Present Invention Also Includes Substantially Pure Populations Of Multipotent Progenitor/Stem Cells, E.G., Cardiac Progenitor/Stem Cells, And Their Use To Treat And Prevent Diseases And Injuries, Including Those Resulting From Myocardial Infarction.
US2008213231	JP - 20050207670 - 15/07/2005 ; WO - 2006JP314070 - 14/07/2006	UNIV KYOTO	A61K 35/12 ; A61P 9/00 ; C12N 5/06 ; C12Q 1/02	Techniques Are Provided Which Can Isolate Pluripotent Stem Cells At High Purity Capable Of Differentiation Into At Least A Myocardial Cell To Regenerate The Cardiac Muscle. The Pluripotent Stem Cells At High Purity Capable Of Differentiation Into At Least A Myocardial Cell To Regenerate The Cardiac Muscle Can Be Isolated Through The Following Steps: (I) Collecting A Skeletal Muscle Tissue From A Mammal And Enzymatically Treating The Obtained Skeletal Muscle Tissue To Prepare A Skeletal Muscle Tissue-Derived Cell; (Ii) Culturing The Obtained Skeletal Muscle Tissue-Derived Cell In A Culture Medium Containing An Epidermal Growth Factor And A Fibroblast Growth Factor; (Iii) Selecting And Separating A Colony That Is Floating In The Culture Medium.
US2008213233	US - 20050684958P - 27/05/2005 ; US - 20060915627 - 26/05/2006 ; WO - 2006SG00133 - 26/05/2006	WANG SHU ; ZENG JIEMING	A61K 35/54 ; A61P 43/00 ; C12N 15/31 ; C12N 15/85 ; C12N 5/10	There Is Provided A Method Of Delivering A Nucleic Acid Molecule To An Embryonic Stem Cell, Including A Human Embryonic Stem Cell, By Infecting The Embryonic Stem Cell With A Baculoviral Vector Comprising The Nucleic Acid Molecule. Embryonic Stem Cells Transduced By This Method Are Useful For Treating A Disease Or Disorder In A Subject.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008213235	US - 20050703591P - 29/07/2005 ; US - 20060995408 - 28/07/2006 ; WO - 2006US29686 - 28/07/2006	UNIV VIRGINIA	A61K 35/12 ; A61P 9/00 ; C12N 5/06	The Present Invention Provides Methods For Growing And Inducing Perivascular Cell Differentiation Of Adipose Tissue-Derived Stromal Cells. The Invention Further Provides Methods For Administering Such Adipose Tissue-Derived Cells To A Subject. The Cells Of The Invention Are Useful For Treating Diseases, Disorders, Conditions, And Injuries Requiring New Or Enhanced Angiogenesis, Vascular Remodeling, Drug Delivery, And Tissue Engineering.
US2008213276	US - 20020379114P - 08/05/2002 ; US - 20020393159P - 02/07/2002 ; US - 20030434943 - 08/05/2003 ; US - 20070880213 - 19/07/2007	LINDQUIST PER ; MERCER ALEX ; RONNHOLM HARRIET ; WIKSTROM LILIAN	A61K 31/00 ; A61K 31/66 ; A61K 39/395 ; A61P 25/00 ; G01N 33/50	The Invention Relates Generally To Methods Of Influencing Central Nervous System Cells To Produce Progeny Useful In The Treatment Of CNS Disorders. More Specifically, The Invention Includes Methods Of Exposing A Patient Suffering From Such A Disorder To A Reagent That Modulates The Proliferation, Migration, Differentiation And Survival Of Central Nervous System Cells Via S1P Or LPA Signaling. These Methods Are Useful For Reducing At Least One Symptom Of The Disorder.
US2008213387	GB - 20050007755 - 16/04/2005 ; GB - 20050012170 - 15/06/2005 ; GB - 20050022101 - 29/10/2005 ; WO - 2006GB01273 - 06/04/2006	AXORDIA LTD	A61K 35/12 ; A61K 35/23 ; A61K 35/32 ; A61K 35/34 ; A61K 35/39 ; A61K 35/54 ; A61P 41/00 ; C12N 15/06 ; C12N 5/02 ; C12N 5/08 ; C12N 5/22 ; C12Q 1/02 ; C12Q 1/68 ; C40B 50/06	The Invention Relates To Cytotrophoblast Stem Cells Derived From Embryonic Stem Cells; Their Differentiation Into Endovascular Cytotrophoblast Cells; And Uses Thereof.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008213839	US - 20010316368P - 30/08/2001 ; US - 20010339739P - 10/12/2001 ; US - 20010799451 - 05/03/2001 ; US - 20020125852 - 19/04/2002 ; WO - 2002US27746 - 30/08/2002 ; US - 20040488423 - 03/03/2004 ; US - 20080075686 - 13/03/2008	NUVELO INC	C07K 14/475 ; C12N 15/12 ; C12N 15/63 ; C12N 5/10 ; C12P 21/00 ; C40B 40/08	The Invention Provides Novel Polynucleotides And Polypeptides Encoded By Such Polynucleotides And Mutants Or Variants Thereof That Correspond To A Novel Human Secreted Stem Cell Growth Factor-Like Polypeptides. Other Aspects Of The Invention Include Vectors Containing Messes For Producing Novel Human Secreted Stem Cell Growth Factor-Like Polypeptides, And Antibodies Specific For Such Polypeptides.
US2008213885	US - 20070883406P - 04/01/2007 ; US - 20080969620 - 04/01/2008	DOMOGATSKAYA ANNA ; RODIN SERGEY ; TRYGGVASON KARL	C12N 5/06	The Present Disclosure Is Directed To The Development Of Compositions, Such As Extracellular Matrices, And Processes For Using The Same, For Culturing Stem Cells In Vitro In An Undifferentiated State. In This Regard, It Has Been Discovered That When Pluripotent Mouse And Human Embryonic Stem Cells Are Cultured On Plates Coated With Recombinant Laminin-10 (Laminin-511) Or Laminin-5 (Laminin-322), Or Their Functional Domains, The Embryonic Stem Cells Proliferated And Maintained Their Pluripotency.
US2008213888	DE - 19971056864 - 19/12/1997 ; WO - 1998DE03817 - 18/12/1998 ; US - 20000581890 - 28/08/2000 ; US - 20080048840 - 14/03/2008	BRUSTLE OLIVER	A61K 31/711 ; A61K 35/48 ; A61K 48/00 ; A61P 25/00 ; C12N 15/09 ; C12N 5/06 ; C12N 5/08	The Invention Relates To Isolated And Purified Neural Precursor Cells, To Methods For The Generation Of Such Precursor Cells In Unlimited Quantities From Embryonic Stem Cells, And To Their Use For The Therapy Of Neural Defects, Particularly In Mammals, Preferably In Human Beings, And For The Generation Of Polypeptides.
US2008213892	US - 20070904596P - 02/03/2007 ; US - 20080041538 - 03/03/2008	UNIV LELAND STANFORD JUNIOR	C12N 5/06	Mammalian Neural Progenitor Or Stem Cells Are Expanded In Vitro By Culture In The Presence Of One Or More Wnt Polypeptides. The Expanded Cells Substantially Maintain Their Original Phenotype Including The Ability To Give Rise To Multiple Types Of Differentiated Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008213893	US - 20010285407P - 20/04/2001 ; US - 20020128009 - 22/04/2002 ; US - 20070934597 - 02/11/2007	CHILDREN S HOSPITAL OF ORANGE	C12N 5/06 ; C12N 5/08	During The Growth And Study Of Nscs, A Range Of Molecules Present On The Surface Of Multipotent Neural Stem And Progenitor Cells (Nscs) Were Identified. These Markers Were Identified Using A Number Of Human And Murine Neural Stem Cell Lines, Including Retinal Stem Cells (Rscs). The NSC-Specific Markers Identified Included Gene Products As Well As Non-Protein Molecules And Sugar Epitopes Not Directly Coded In The Genome. Together With Surface Markers Which Were Determined To Be Absent From The Surface Of Hnscs, The Molecules Described Herein Provide A Means To Enrich For Neural Stem Cells, Or Neural Progenitor Subpopulations, Particularly Using Combinatorial Cell Sorting Strategies. These Same Molecules Also Represent Targets For Pharmacological Manipulation Of NSC Populations And Subpopulations, Both In Vivo And Ex Vivo. Furthermore, These Molecules Provide Potential Targets For Therapeutic Manipulation Of Other Neural Precursor-Related Cell Types Including Malignant Conditions As Well As Other Diseases Originating from, or preferentially affecting, various uncommitted or replication-competent cell types.
US2008215364	US - 20070881638P - 22/01/2007 ; US - 20080009793 - 22/01/2008	BREVNOVA ELENA ; LANCASTER J JUSTIN	G06Q 50/00	An Online Business Method And System Enables Donors Or Parents Or Guardians Of Donors To Order And Purchase Stem-Cells From Biological Tissue Sampled From The Donor, Such As, For Example, Cord-Blood Stem Cells Of A Newborn Baby, Wherein The Ordering Process Interfaces Directly With The Attending Medical Services, And The Service Steps Include Collection, Extraction, Preservation, Containment, Packaging, Delivery And Storage Of The Stem Cells In A Storage Medium That Can Be Cost-Effectively Maintained By The Donor, Parent Or Guardian At Home Or In A Custodial Location. In One Embodiment, Preservation Is By Freeze-Drying, Containment Is In A Vacuum Vial, And Storage Is At Room Temperature.
US2008216182	DE - 200510023342 - 17/05/2005 ; WO - 2006DE00893 - 17/05/2006	UNIV LEIPZIG	A01K 67/00 ; A01K 67/027	In A Method For Preparing An Animal Model For The Human Immune System In A Non-Human Mammal, Human Stem Cells With Hematopoietic Potential Are Transplanted Into A Non-Human Mammal. The Non-Human Mammal Is Conditioned With Cell Culture Supernatant Of A Culture Of Human Cell Lines, Cells And/Or Tissue. The Cell Culture Supernatant Is Derived From Cell Lines Producing Cytokines And Other Molecular Mediators.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008216185	US - 20070885843P - 19/01/2007 ; US - 20070969051P - 30/08/2007 ; US - 20080016415 - 18/01/2008	INVITROGEN CORP	C12N 15/00 ; C12N 15/87 ; C12Q 1/68	The Disclosure Relates Generally To Stem Cell Biology And More Specifically To Genetic Manipulation Of Stem Cells. Methods And Compositions Using Recombinational Cloning Techniques Are Disclosed Which Allow The Construction And Insertion Of Complex Genetic Constructs Into Embryonic And Adult Stem Cells And Progenitor Cells. The Methods Disclosed Will Allow The Harvesting Of Adult Stem Cells Pre-Engineered With Integration Sites To Facilitate Early Passage Genetic Modification.
US2008219955	US - 20070893780P - 08/03/2007 ; US - 20080038851 - 28/02/2008	SEKULA RAYMOND F	A61K 35/12 ; A61P 25/16 ; A61P 25/28 ; C12N 5/06	The Present Invention Provides A Method Of Producing Purified Neural Stem Cells, Comprising Harvesting Fluid Containing Neural Stem Cells From Cerebrospinal Fluid Surrounding The Spinal Cord Of An Individual, Isolating The Neural Stem Cells From The Fluid, Culturing The Neural Stem Cells In A Culture Medium Effective To Induce Proliferation Of The Neural Stem Cells And Purifying The Cultured Neural Stem Cells. Also Provided Is A Method Of Treating A Patient Afflicted With A Neurological Condition, In Which The Purified Neural Stem Cells Are Administered Autologously Into The Same Individual Or Heterologously To A Patient Other Than The Individual. Administration Of The Purified Neural Stem Cells Results In The Purified Neural Stem Cells Propagating In The Site Of The Brain Region Afflicted With The Neurological Condition.
US2008219957	US - 20050713992P - 02/09/2005 ; US - 20060065551 - 15/08/2006 ; WO - 2006SG00232 - 15/08/2006	AGENCY SCIENCE TECHNOLOGY AND	A61K 48/00 ; C12N 5/00 ; C12N 5/06	We Disclose A Method Comprising: (A) Providing An Embryonic Stem (ES) Cell; And (B) Establishing A Progenitor Cell Line From The Embryonic Stem Cell; In Which The Progenitor Cell Line Is Selected Based On Its Ability To Self-Renew. Preferably, The Method Selects Against Somatic Cells Based On Their Inability To Self-Renew. Preferably, The Progenitor Cell Line Is Derived Or Established In The Absence Of Co-Culture, Preferably In The Absence Of Feeder Cells, Which Preferably Selects Against Embryonic Stem Cells. Optionally, The Method Comprises (D) Deriving A Differentiated Cell From The Progenitor Cell Line.
US2008220085	US - 20060823460P - 24/08/2006 ; US - 20070844941 - 24/08/2007	DU YANSHENG ; JOHNSTONE BRIAN H ; MARCH KEITH LEONARD	A61K 35/12 ; A61P 25/00	A Method For Producing Stem Cell Conditioned Media For Treatment Of Neurological Insults Is Provided Herein. By Providing For The Culture Of Adipose Stem Cells, And Collecting The Supernatants Thereof, The Supernatants Have Been Shown To Effect Biological Activity In Preventing Neural Death When The Supernatants Are Administered To A Patient That Has Or Is About To Be Subjected To A Neural Insult.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008220453	US - 20060873765P - 08/12/2006 ; US - 20070001336 - 10/12/2007	AILLES LAURIE ; CLARKE MICHAEL ; WEISSMAN IRVING L	C12N 5/06 ; G01N 33/53	Squamous Carcinoma Stem Cells (SCSC) Are Identified. The Cells Can Be Prospectively Isolated Or Identified From Primary Tumor Samples, And Are Shown To Possess The Unique Properties Of Cancer Stem Cells In Functional Assays For Cancer Stem Cell Self-Renewal And Differentiation, And To Form Unique Histological Microdomains Useful In Cancer Diagnosis.
US2008220466	US - 20040576266P - 01/06/2004 ; US - 20040588520P - 15/07/2004 ; US - 20050628488 - 01/06/2005 ; WO - 2005IL00571 - 01/06/2005	BELKIN DANNY ; FULGA VALENTIN ; PORAT YAEL ; POROZOV SVETLANA ; SHIMONI-ZALK DAPHNA	C12N 5/06 ; C12Q 1/04 ; H04Q 7/00	A Method Is Provided For Use With Extracted Blood, Including (A) Applying Blood To A First Gradient Suitable For Selecting First-Pass Cells Having A Density Less Than 1.077 G/Ml; (B) Applying The First-Pass Cells To A Second Gradient Suitable For Selecting Second-Pass Cells Having A Density Between 1.055 And 1.074 G/Ml; (C) Increasing The Number Of Cells Having A Density Between 1.055 And 1.074 G/Ml, By Culturing The Second-Pass Cells For A Period Lasting Between 3 And 30 Days; And (D) Identifying Endothelial Progenitor Cells In The Cultured Cells. Other Embodiments Are Also Described.
US2008220520	US - 20030523343P - 19/11/2003 ; US - 20040993468 - 19/11/2004 ; US - 20060814975P - 20/06/2006 ; US - 20070765831 - 20/06/2007 ; US - 20080032986 - 18/02/2008	DEPABLO JUAN J ; JI LIN ; MOHR JEFFREY C ; PALECEK SEAN P	C12M 1/00 ; C12N 5/06	The Present Invention Relates To Methods And Structures For Preparing Stem Cells For Use In Cryopreservation Methods. Stem Cell Colonies Are Provided Between First And Second Matrix Portions And Are Exposed To A Carbohydrate-Containing Cryoprotecting Medium And A Freezing Medium. The Methods Of The Invention Yield Cryopreserved Cells That Maintain Cell Viability And Exhibit Limited Cell Differentiation After Freezing And Thawing, Facilitating Storage, Shipping And Handling Of Embryonic Stem Cell Stocks And Lines For Research And Therapeutics.
US2008226553	US - 20020414605P - 27/09/2002 ; US - 20030524690 - 29/09/2003 ; WO - 2003US30901 - 29/09/2003	COLD SPRING HARBOR LAB	A01K 67/027 ; A61K 35/12 ; A61K 48/00 ; A61K 49/00 ; C12N 15/00 ; C12N 15/11	This Invention Provides, Among Other Things, Methods For Performing RNA Interference In Stem Cells And Methods For Using Stem Cells In Vivo.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008226595	US - 20070901067P - 12/02/2007 ; US - 20080030161 - 12/02/2008	EDINGER JAMES W ; FALECK HERBERT ; HARIRI ROBERT J ; WANG JIA-LUN ; YE QIAN	A61K 35/12 ; A61K 38/21	Provided Herein Are Methods Of Treatment Of Individuals Having An Immune-Related Disease, Disorder Or Condition, For Example, Inflammatory Bowel Disease, Graft-Versus-Host Disease, Multiple Sclerosis, Rheumatoid Arthritis, Psoriasis, Lupus Erythematosus, Diabetes, Mycosis Fungoides (Alibert-Bazin Syndrome), Or Scleroderma Using Placental Stem Cells Or Umbilical Cord Stem Cells.
US2008226613	US - 20030464084P - 18/04/2003 ; US - 20030504576P - 18/09/2003 ; US - 20040826082 - 15/04/2004 ; US - 20080069072 - 07/02/2008	UNIV MASSACHUSETTS	A61K 45/00 ; C12Q 1/02 ; C12Q 1/04 ; C12Q 1/68 ; G01N 33/567 ; G01N 33/574	The Present Invention Is Based On The Unexpected Discovery That The Loss Of Cells In Inflamed Tissue During Chronic Inflammation Leads To The Influx And Long-Term Re-Population Of The Tissue With Bone Marrow Derived Stem Cells, And That It Is These Stem Cells That Are The Primary Source Of Metaplasia And Cancer. Accordingly, The Invention Relates To Various Methods, Reagents And Kits For Prognosing, Diagnosing, Staging, Monitoring, Preventing And Treating Cancers, Particularly Cancers Associated With Chronic Inflammation.
US2008226726	US - 20040555815P - 24/03/2004 ; US - 20050593823 - 23/03/2005 ; WO - 2005IB00752 - 23/03/2005	JACONI MARISA E E ; ZAMMARETTI-SCHAER PRISCA	A61K 9/14 ; A61L 27/38 ; A61P 9/00 ; C12N 5/06 ; C12N 5/16	A Pharmaceutical Composition Comprising Biodegradable Gel-Based Matrix, At Least One Active Agent And Stem Cells Able To Differentiate Into Cardiac Tissue Under The Form Of A Patch, For The Treatment Of Heart Failure Due To Myocardial Infarction Is Disclosed.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008227137	US - 20010970382 - 03/10/2001 ; US - 20030498831P - 29/08/2003 ; US - 20030499570P - 02/09/2003 ; US - 20040928805 - 27/08/2004 ; US - 20060594455 - 08/11/2006 ; US - 20070932582 - 31/10/2007	LI XUE-JUN ; ZHANG SU-CHUN	C12N 5/02 ; C12Q 1/02	A Method Of Differentiating Embryonic Stem Cells Into Ventral Spinal Progenitor Cells Is Disclosed. In One Embodiment, The Invention Comprises Culturing A Population Of Cells Comprising A Majority Of Cells That Are Characterized By An Early Rosette Morphology And Are Sox1<->/Pax6<+> In The Presence Of Retinoic Acid, Wherein The Cells Express Hoxb4, But Not Otx2 Or Bf1.
US2008227197	US - 20020357308P - 14/02/2002 ; US - 20030367339 - 13/02/2003 ; US - 20080110850 - 28/04/2008	STEMCYTE INC	A61K 35/16 ; A61K 35/28 ; A61K 35/50 ; C12N 5/08 ; G06F 19/00	This Invention Provides Methods For Supplying A Therapy For Individuals Exposed To Radiation Following A Nuclear Event, Through The Prospective Establishment Of An Undesignated Allogeneic Stem Cell Bank With Prospective HLA Typing Of Healthy Potential Recipients.
US2008227200	US - 20010297286P - 11/06/2001 ; WO - 2002JP05807 - 11/06/2002 ; US - 20040478926 - 17/06/2004 ; US - 20070986709 - 26/11/2007	DRMANAC RADOJE T ; LABAT IVAN ; LEE JUHI ; NISHIKAWA MITSUO ; STACHE-CRAIN BIRGIT ; TANG Y TOM	C07K 14/00 ; C07K 14/475 ; C07K 16/18 ; C12N 15/00 ; C12N 15/11 ; C12N 5/06 ; C12N 5/08	A Gene Encoding A Polypeptide Having An Activity To Support Proliferation Or Survival Of Hematopoietic Stem Cells Or Hematopoietic Progenitor Cells Is Isolated By Comparing Expressed Genes Between Cells Which Support Proliferation Or Survival Of Hematopoietic Stem Cells Or Hematopoietic Progenitor Cells And Cells Which Do Not Support The Proliferation Or Survival. Proliferation Or Survival Of Hematopoietic Stem Cells Or Hematopoietic Progenitor Cells Is Supported By Using Stromal Cells In Which The Isolated Gene Is Expressed Or A Gene Product Of The Isolated Gene.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008227202	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; TW - 20050208663U - 26/05/2005 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; US - 20060440158 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20070003074 - 19/12/2007	DANCU MICHAEL	C12N 5/00	A Method Of Promoting Differentiation Of One Or More Human Stem Cells Into Human Coronary Endothelial Cells On At Least One Surface Of A Synthetic Tubular Structure To Be Used To Make A Human Hybrid Hemodialysis Access Graft Is Provided. The Method Includes Arranging A Plurality Of Human Stem Cells On The Synthetic Tubular Structure To Yield A Hybrid Stem Cell/Synthetic Tubular Structure And Subjecting Ex Vivo, The Hybrid Stem Cell/Synthetic Tubular Structure To Three Dimensional Dynamic Conditions Effective To Promote Differentiation Of The One Or More Human Stem Cells Into Human Coronary Endothelial Cells On The At Least One Surface.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008227707	US - 20020433573P - 16/12/2002 ; WO - 2003US39873 - 16/12/2003 ; US - 20050539634 - 09/12/2005 ; US - 20080022745 - 30/01/2008	UNIV WAYNE STATE	A61K 38/00 ; C07K 14/00 ; C07K 16/00	Three Novel Low Molecular Weight (LMW) Polypeptide Fragments Of A Proteolipid Protein Human PLP/DM20 Are Designated PIRP-M, PIRP-L And PIRP-J, And Are Growth Factors For Oligodendrocytes With Anti-Apoptotic Activity. They Are Encoded By Mrna From An IRES. Fusion Polypeptides Of Such A LMW Polypeptide, DNA Encoding The LMW Polypeptide And Fusion Polypeptide, Expression Vectors Comprising Such DNA, And Cells Expressing Such Polypeptides, Or Pharmaceutical Compositions Thereof, Are Useful For Stimulating Neural Stem Cell Differentiation, Maturation Along The Oligodendrocytic Pathway And Proliferation Of Oligodendrocytes Or Precursors. These Compositions Can Protect Oligodendrocytes (And Nonneural Cells) From Apoptotic Death. Thus, The Present Composition Is Used To Treat A Disease Or Condition In Which Such Differentiation, Maturation And Proliferation Or Inhibition Of Cell Death, Including Remyelination Or Stimulation Of Oligodendroglia Or Schwann Cells, Is Desirable. Disorders Include Multiple Sclerosis, Trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma.
US2008227712	US - 20010316368P - 30/08/2001 ; US - 20010339739P - 10/12/2001 ; US - 20010799451 - 05/03/2001 ; US - 20020125852 - 19/04/2002 ; WO - 2002US27746 - 30/08/2002 ; US - 20040488423 - 03/03/2004 ; US - 20080080606 - 03/04/2008	NUVELO INC	A61K 38/00 ; C07K 14/475 ; C07K 16/00 ; C12P 21/04	The Invention Provides Novel Polynucleotides And Polypeptides Encoded By Such Polynucleotides And Mutants Or Variants Thereof That Correspond To A Novel Human Secreted Stem Cell Growth Factor-Like Polypeptides. Other Aspects Of The Invention Include Vectors Containing Processes For Producing Novel Human Secreted Stem Cell Growth Factor-Like Polypeptides, And Antibodies Specific For Such Polypeptides.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008233166	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080019558 - 24/01/2008	DANCU MICHAEL	A61F 2/04 ; C12M 3/00 ; C12N 5/02	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Coat A Hybrid Graft With A Confluent Monolayer Of Endothelial Cells By Immobilizing Stem Cells On A Hybrid Hemodialysis Access Graft Or A Hybrid Femoral Artery Bypass Graft, And Placing The Hybrid Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote The Stem Cells To Form A Confluent Monolayer On The Hybrid Graft And In An Environment To Promote The Stem Cells To Differentiate Into Endothelial Cells.
US2008233640	GB - 20040006215 - 19/03/2004 ; WO - 2005GB01142 - 18/03/2005	PROCURE THERAPEUTICS LTD	C12N 5/06 ; G01N 33/50 ; G01N 33/574	We Describe A Method For The Isolation Of Prostate Stem Cells, Typically Prostate Stem Cells Which Express CD 133 Antigen; Stem Cells And Cancer Stem Cells Isolated By The Method And Their Use.
US2008233648	US - 20070891354P - 23/02/2007 ; US - 20080036722 - 25/02/2008	ALVAREZ ANGEL ; SUGAYA KIMINOBU	C12N 5/06	Methods Are Described That Bias Cells, Such As Potent And Multipotent Stem Cells, By Transfection With A Nucleic Acid Sequence, To Differentiate To A Desired End-Stage Cell Or A Cell Having Characteristics Of A Desired End-Stage Cell. In Particular Embodiments, Human Neural Stem Cells Or Mesenchymal Stem Cells Are Transfected With Vectors Comprising Genes In The Homeobox Family Of Transcription Factor Developmental Control Genes, And This Results In A Greater Percentage Of Resultant Transformed Cells, Or Their Progeny, Differentiating Into A Desired End-Stage Cell Or A Cell Having Characteristics Of A Desired End-Stage Cell.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008233649	US - 20040550056P - 05/03/2004 ; CA - 20042460602 - 10/03/2004 ; US - 20050072630 - 07/03/2005 ; US - 20080052505 - 20/03/2008	SEABERG RAEWYN ; SMUKLER SIMON ; VAN DER KOOY DEREK	A61K 35/30 ; A61K 35/39 ; A61P 1/18 ; A61P 25/00 ; A61P 5/48 ; C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Pancreatic Progenitor Cells Isolated From The Pancreas Of A Mammal. The Invention Also Includes Pancreatic Cells Or Neural Cells Differentiated From The Pancreatic Progenitor Cells.
US2008234542	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080018997 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Coat A Hybrid Graft With A Confluent Monolayer Of Endothelial Cells By Immobilizing Stem Cells On A Hybrid Lower Limb Artery Bypass Vascular Graft, Placing The Hybrid Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote The Stem Cells To Form A Confluent Monolayer On The Surface Of The Hybrid Vascular Graft And In An Environment To Promote The Stem Cells To Differentiate Into Endothelial Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008234803	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080018919 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Promote Endothelialization Of A Hybrid Carotid Bypass Vascular Graft By Placing The Hybrid Carotid Bypass Vascular Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote Stem Cells To Differentiate Into Endothelial Cells On A Surface Of The Hybrid Carotid Bypass Vascular Graft.
US2008234804	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080018925 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Coat A Hybrid Graft With A Confluent Monolayer Of Endothelial Cells By Immobilizing Stem Cells On A Hybrid Carotid Bypass Vascular Graft, Placing The Hybrid Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote The Stem Cells To Form A Confluent Monolayer On The Surface Of The Hybrid Vascular Graft And In An Environment To Promote The Stem Cells To Differentiate Into Endothelial Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008234807	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080018982 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Promote Endothelialization Of A Hybrid Lower Limb Artery Bypass Vascular Graft By Placing The Hybrid Lower Limb Artery Bypass Vascular Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote Stem Cells To Differentiate Into Endothelial Cells On A Surface Of The Hybrid Lower Limb Artery Bypass Vascular Graft.
US2008241110	US - 20050741015P - 29/11/2005 ; US - 20060606619 - 29/11/2006 ; US - 20070809871 - 01/06/2007	NEVADA CANCER INST	A61K 31/7052 ; A61K 31/7068 ; A61K 35/12 ; A61K 38/07 ; C07H 21/04 ; C12Q 1/02 ; C12Q 1/68	The Present Invention Discloses Nucleic Acids, Proteins, And Antibodies For SALL4 (Including Isoforms SALL4A, SALL4B, And SALL4C), A Zinc Finger Transcriptional Factor. Further, Methods Are Disclosed Which Demonstrate That Constitutive Expression Of SALL4 Increases Leukemogenic Potential In Cells Of Model Animal Systems. Moreover, Constitutive Expression Of Select Isoforms (E.G., SALL4B) In Transgenic Mice Demonstrate That These Animals Develop Myelodysplastic Syndrome (MDS)-Like Signs And Symptoms, Including Subsequent Acute Myeloid Leukemia (AML), Which Is Transplantable. The Disclosure Also Provides Methods For Identifying And Purifying Embryonic Stem Cells, Adult Stem Cells, Cancer Stem Cells, Including Leukemia Stem Cells, Methods For Identifying Substances Which Bind To And/Or Modulate SALL4, Methods For Diagnosing MDS In A Subject, And Methods Of Treating A Subject Presenting MDS, AML And Other Forms Of Leukemia.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241111	JP - 20050060831 - 04/03/2005 ; WO - 2006JP04111 - 03/03/2006	UNIV KYOTO	A61K 35/12 ; A61P 43/00 ; C12N 5/00 ; C12N 5/02 ; C12N 5/08	An Object Of The Present Invention Is To Provide A Stem Cell Applicable To Regenerative Therapeutic Method, And To Provide A Technique To Carry Out Regenerative Therapy Using The Cell. A Collected Cardiac Tissue Fragment Is Enzymatically Treated To Prepare A Cell Suspension. Then Using The Cell Suspension, Following Steps Are Carried Out: (1) Separation Of Cells By The Density Gradient Method, (2) Suspension-Culture In A Culture Medium Containing Fibroblast Growth Factor And Epidermal Growth Factor And (3) Selection And Separation Of Cells Forming A Floating Sphere To Obtain Pluripotent Stem Cells. Thus-Obtained Pluripotent Stem Cells Are Used To Carry Out Regenerative Therapy.
US2008241112	WO - 2005US16489 - 10/05/2005	WESTENFELDER CHRISTOF	A61K 35/12 ; A61P 13/12 ; A61P 17/02 ; A61P 29/00	Methods And A Composition For The Treatment Of Organ Dysfunction, Acute Renal Failure, Multi-Organ Failure, Early Dysfunction Of Kidney Transplant, Graft Rejection, Chronic Renal Failure, Wounds, And Inflammatory Disorders Including Media Conditioned By Mesenchymal Stem Cells Are Provided. Methods For Modulation Of Growth Factor And Cytokine Expression Including Administering A Therapeutic Amount Of Mesenchymal Stem Cells, Endothelial Cells Derived From Mesenchymal Stem Cells, Or Media Conditioned By Mesenchymal Stem Cells Are Also Provided.
US2008241113	US - 20070904836P - 01/03/2007 ; US - 20070918961P - 20/03/2007 ; US - 20070994166P - 17/09/2007 ; US - 20070998255P - 09/10/2007 ; US - 20080011881P - 22/01/2008 ; US - 20080067849P - 29/02/2008 ; US - 20080074423 - 03/03/2008	CRYO CELL INT	A61K 35/12 ; C12M 1/00 ; C12N 5/06 ; C12Q 1/02	Compositions Comprising Menstrual Stem Cells (Mscs) And Methods, Processes, And System Therefor Are Provided By The Invention. Mscs Are Processed From Menstrual Flow Collected During Menses. Mscs May Be Cryopreserved, Processed Through Various Culturing And Selection Steps In Preparation For Cryopreservation, Or Processed For Therapeutic Or Cosmeceutical Use. Cryopreserved Mscs May Be Thawed In Preparation For Therapeutic And Cosmeceutical Use. Mscs Express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, And HLA Class I, And Have Low Or No Expression Of CD3 And HLA Class II.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241115	KR - 20050091155 - 29/09/2005 ; WO - 2006KR03928 - 29/09/2006	AJOU UNIVERSITY INDUSTRY ACADE	A61K 35/12 ; A61P 43/00	Mesenchymal Stem Cells Expressing A Suicide Gene Show Excellent And Highly Selective Anticancer Effects Against Cancer Tissues Through The Selective Conversion Of A Prodrug Of An Anticancer Agent To The Anticancer Agent At Around The Cancer. Also Disclosed Herein Are A Pharmaceutical Composition For Treating A Cancer Comprising The Mesenchymal Stem Cell; A Kit For Treating A Cancer Comprising An Expression Vector Comprising The Suicide Gene, The Mesenchymal Stem Cell And The Prodrug; And A Method For Treating A Cancer Patient, Which Comprises Successively Administering The Mesenchymal Stem Cell And The Prodrug To The Patient.
US2008241171	US - 20040543607P - 11/02/2004 ; US - 20040544038P - 12/02/2004 ; US - 20040589173 - 04/05/2004 ; WO - 2004US13747 - 04/05/2004	ALDAGEN INC	A61K 35/28 ; A61P 25/00 ; A61P 35/00 ; A61P 37/00 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/02 ; G01N 33/53	Populations Of Stem Cells And Methods For Their Isolation And Use Are Provided. These Stem Cell Populations Comprise Aldehyde Dehydrogenase Positive (ALDH) Cells Isolated From Bone Marrow, And ALDH CD105<+> Cells Derived From Any Stem Cell Source. These Populations May Also Comprise Cells Expressing Such Surface Markers As CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, And HLA-DR, And/Or Are Substantially Free From Such Cell Surface Markers As CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, And Glycophorin A. The Population May Also Comprise Cells Expressing CD90. The Stem Cell Populations Of The Invention Are Isolated From A Stem Cell Source Such As Bone Marrow, Peripheral Blood, Umbilical Cord Blood, And Fetal Liver. Methods Of The Invention Comprise Isolating And Purifying Stem Cell Populations From Stem Cell Sources, And Methods Of Using These Cells To Reconstitute, Repair, And Regenerate Tissues.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241207	US - 20000215733P - 28/06/2000 ; US - 20000496914 - 03/02/2000 ; US - 20000543774 - 05/04/2000 ; US - 20010266614P - 05/02/2001 ; US - 20010282397P - 05/04/2001 ; US - 20010757562 - 09/01/2001 ; US - 20010894912 - 28/06/2001 ; US - 20040968674 - 19/10/2004 ; US - 20070985996 - 19/11/2007	CHAO CHENG-CHI ; DRMANAC RADOJE T ; LABAT IVAN ; MIZE NANCY ; NISHIKAWA MITSUO ; TANG Y TOM	A61K 31/711 ; A61K 35/12 ; A61K 38/18 ; A61L 27/54 ; A61P 43/00 ; C07K 14/475 ; C07K 16/22 ; C12N 5/00 ; C12N 5/02 ; C12N 5/22 ; C12Q 1/68 ; C40B 40/08 ; G01N 33/53	The Invention Provides Novel Polynucleotides And Polypeptides Encoded By Such Polynucleotides And Mutants Or Variants Thereof That Correspond To A Novel Human Stem Cell Growth Factor-Like Protein. These Polynucleotides Comprise Nucleic Acid Sequences Isolated From Cdna Libraries From Human Testis Cells (Hyseq Clone Identification Numbers 2880984 And 2881695), From Human Fetal Skin (Hyseq Clone Identification Number 15375176), Adult Spleen (Hyseq Clone Identification Number 14856094), And Human Endothelial Cells (Hyseq Clone Identification Numbers 13804756, 13687487, 13804756). Other Aspects Of The Invention Include Vectors Containing Processes For Producing Novel Human Stem Cell Growth Factor-Like Polypeptides, And Antibodies Specific For Such Polypeptides.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241882	US - 20000215733P - 28/06/2000 ; US - 20000496914 - 03/02/2000 ; US - 20000543774 - 05/04/2000 ; US - 20010266614P - 05/02/2001 ; US - 20010282397P - 05/04/2001 ; US - 20010757562 - 09/01/2001 ; US - 20010894912 - 28/06/2001 ; US - 20040968674 - 19/10/2004 ; US - 20070985824 - 16/11/2007	CHAO CHENG-CHI ; DRMANAC RADOJE T ; LABAT IVAN ; MIZE NANCY ; NISHIKAWA MITSUO ; TANG Y TOM	C07H 21/04 ; C07K 14/475 ; C12N 15/63 ; C12N 5/06 ; C12P 21/00	The Invention Provides Novel Polynucleotides And Polypeptides Encoded By Such Polynucleotides And Mutants Or Variants Thereof That Correspond To A Novel Human Stem Cell Growth Factor-Like Protein. These Polynucleotides Comprise Nucleic Acid Sequences Isolated From Cdna Libraries From Human Testis Cells (Hyseq Clone Identification Numbers 2880984 And 2881695), From Human Fetal Skin (Hyseq Clone Identification Number 15375176), Adult Spleen (Hyseq Clone Identification Number 14856094), And Human Endothelial Cells (Hyseq Clone Identification Numbers 13804756, 13687487, 13804756). Other Aspects Of The Invention Include Vectors Containing Processes Fro Producing Novel Human Stem Cell Growth Factor-Like Polypeptides, And Antibodies Specific For Such Polypeptides.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241919	US - 20030533506P - 31/12/2003 ; US - 20040027395 - 31/12/2004 ; US - 20070980166 - 29/10/2007	BURNHAM INST OF MEDICAL RES	C12N 5/06 ; C12N 5/08	Stem Cells, Including Mammalian, And Particularly Primate Primordial Stem Cells (Ppscs) Such As Human Embryonic Stem Cells (Hescs), Hold Great Promise For Restoring Cell, Tissue, And Organ Function. However, Cultivation Of Stem Cells, Particularly Undifferentiated Hescs, In Serum-Free, Feeder-Free, And Conditioned-Medium-Free Conditions Remains Crucial For Large-Scale, Uniform Production Of Pluripotent Cells For Cell-Based Therapies, As Well As For Controlling Conditions For Efficiently Directing Their Lineage-Specific Differentiation. This Instant Invention Is Based On The Discovery Of The Formulation Of Minimal Essential Components Necessary For Maintaining The Long-Term Growth Of Ppscs, Particularly Undifferentiated Hescs. Basic Fibroblast Growth Factor (Bfgf), Insulin, Ascorbic Acid, And Laminin Were Identified To Be Both Sufficient And Necessary For Maintaining Hescs In A Healthy Self-Renewing Undifferentiated State Capable Of Both Prolonged Propagation And Then Directed Differentiation. Having Discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a "biologics"-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241920	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20070000894 - 18/12/2007	DANCU MICHAEL	C12N 5/08	A Method Of Promoting Differentiation Of One Or More Human Stem Cells Into Human Coronary Endothelial Cells On At Least One Surface Of A Synthetic Tubular Structure To Be Used To Make A Human Hybrid Carotid Graft Is Provided. The Method Includes Arranging A Plurality Of Human Stem Cells On The Synthetic Tubular Structure To Yield A Hybrid Stem Cell/Synthetic Tubular Structure And Subjecting Ex Vivo, The Hybrid Stem Cell/Synthetic Tubular Structure To Three Dimensional Dynamic Conditions Effective To Promote Differentiation Of The One Or More Human Stem Cells Into Human Coronary Endothelial Cells On The At Least One Surface.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008241921	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20070000907 - 18/12/2007	DANCU MICHAEL	C12N 5/08	A Method Of Promoting Differentiation Of One Or More Human Stem Cells Into Human Coronary Endothelial Cells On At Least One Surface Of A Synthetic Tubular Structure To Be Used To Make A Human Hybrid Coronary Graft Is Provided. The Method Includes Arranging A Plurality Of Human Stem Cells On The Synthetic Tubular Structure To Yield A Hybrid Stem Cell/Synthetic Tubular Structure And Subjecting Ex Vivo, The Hybrid Stem Cell/Synthetic Tubular Structure To Three Dimensional Dynamic Conditions Effective To Promote Differentiation Of The One Or More Human Stem Cells Into Human Coronary Endothelial Cells On The At Least One Surface.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008242594	US - 20050715935P - 08/09/2005 ; US - 20060066075 - 07/09/2006 ; WO - 2006US34988 - 07/09/2006	ANDROUTSELLIS-THEOTOKIS ANDREAS ; MCKAY RONALD D G	A61K 38/18 ; A61K 38/28 ; C12N 5/02 ; C12N 5/08 ; G01N 33/53 ; G01N 33/574	It Is Disclosed Herein That STAT3 Phosphorylated At Serine 727 Is A Key Regulator Of Proliferation And Survival Of Stem Cells And Precursor Cells. Methods For Increasing The Survival And Proliferation Of Stem Cells And/Or Precursor Are Disclosed Herein. In One Embodiment, The Method Includes Contacting A Mammalian Stem Cell Mammalian Precursor Cell With A JAK Inhibitor, A P38 Inhibitor, Or Both. Methods Are Also Disclosed For Increasing The Survival And Proliferation Of Neuronal Precursor Cells In A Subject. The Method Includes Administering A Therapeutically Effective Amount Of A Notch Ligand And A Growth Factor. Methods Are Also Disclosed For Identifying An Agent That Increases The Proliferation Of Stem Cells And/Or Precursor Cells. The Method Includes Contacting A Stem Cell Or A Precursor Cell With An Agent Of Interest, Wherein The Stem Cell Or The Precursor Cell Expresses STAT3; And Determining The Phosphorylation Status Of Serine 727 Of STAT3 In The Cell. Phosphorylation Of Serine 727 Indicates That The agent increases the survival and/or proliferation of stem cells and/or precursor cells. An isolated population of cells is disclosed, wherein the cells express nestin and STAT3, wherein serine 727 of STAT3 is phosphorylated.
US2008242611	US - 19990378567 - 19/08/1999 ; US - 20000492935 - 27/01/2000 ; US - 20000641587 - 17/08/2000 ; US - 20020050190 - 15/01/2002 ; US - 20080029332 - 11/02/2008	FELKER THOMAS S ; PASKELL STEFAN ; PERNET ANDRE ; TWARDZIK DANIEL R	A61K 38/18 ; C07K 14/495	Disclosed Are TGF-Alpha Polypeptides, Related Polypeptides, Fragments And Mimetics Thereof Useful In Stimulating Stem Cell Or Precursor Cell Proliferation, Migration And Differentiation. The Methods Of The Invention Are Useful To Treat Tissue Injury As Well As Expand Stem Cell Populations In, Or Obtained From, Gastrointestinal, Musculoskeletal, Urogenital, Neurological And Cardiovascular Tissues. The Methods Include Ex Vivo And In Vivo Applications.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008242920	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; TW - 20050208663U - 26/05/2005 ; US - 20060440091 - 25/05/2006 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20070000792 - 17/12/2007	DANCU MICHAEL	A61F 2/06	A Method Of Yielding A Functional Human Hybrid Coronary Bypass Graft Is Provided. The Method Includes Conditioning A Hybrid Synthetic Tubular Structure Having Stem Cells And/Or Endothelial Cells On At Least One Surface To Yield The Functional Human Hybrid Coronary Bypass Graft. Specifically, The Method Includes Placing The Hybrid Synthetic Tubular Structure In A System Capable Of Producing Three Dimensional Dynamic Conditions For A Sufficient Time To Yield Said Functional Human Hybrid Coronary Bypass Graft.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008243236	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; WO - 2001US42576 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; US - 20060440158 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20070003076 - 19/12/2007	DANCU MICHAEL	A61F 2/04	A Method Of Yielding A Functional Human Hybrid Hemodialysis Access Graft Is Provided. The Method Includes Conditioning A Hybrid Synthetic Tubular Structure Having Stem Cells And/Or Endothelial Cells On At Least One Surface To Yield The Functional Human Hybrid Hemodialysis Access Graft. Specifically, The Method Includes Placing The Hybrid Synthetic Tubular Structure In A System Capable Of Producing Three Dimensional Dynamic Conditions For A Sufficient Time To Yield Said Functional Human Hybrid Hemodialysis Access Graft.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008243237	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; US - 20060440158 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080018922 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Promote Endothelialization Of A Hybrid Carotid Bypass Vascular Graft By Placing The Hybrid Carotid Bypass Vascular Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote Stem Cells To Form A Confluent Monolayer On The Hybrid Vascular Graft.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008243239	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080019548 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holders Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Promote Endothelialization Of A Hybrid Hemodialysis Access Graft Or A Hybrid Femoral Artery Bypass Graft By Placing The Hybrid Hemodialysis Access Graft Or The Hybrid Femoral Artery Bypass Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote Stem Cells To Form A Confluent Monolayer On The Hybrid Graft.
US2008247998	US - 20030532363P - 24/12/2003 ; WO - 2004US42953 - 22/12/2004 ; US - 20050584303 - 14/07/2005	TRUSTEE OF COLUMBIA UNIVERSITY ; UNIV NEW YORK	A61K 35/12 ; A61L 27/38 ; A61N 1/18 ; A61P 9/00 ; C12N 5/06	A Method Of Creating An Atrioventricular Bypass Tract For A Heart Comprises Growing Mesenchymal Stem Cells Into A Strip With Two Ends, Attaching One End Of The Strip Onto The Atrium Of The Heart, And Attaching The Other End Of The Strip To The Ventricle Of The Heart, To Create A Tract Connecting The Atrium To The Ventricle To Provide A Path For Electrical Signals Generated By The Sinus Node To Propagate Across The Tract And Excite The Ventricle.
US2008248000	IT - 2004FI00238 - 15/11/2004 ; WO - 2005EP55950 - 14/11/2005	AZIENDA OSPEDALIERO UNIVERSITA	A01N 1/02 ; A61K 35/12 ; A61P 43/00 ; C12N 5/06 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/53	Herein Is Described A New Population Of Circulating CD14+Cells, With A Low Density Surface Expression Of CD34 And Endowed With Stem Capacity, A Method For Their Purification And Identification, And Their Therapeutic Use.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008248003	US - 20050715025P - 08/09/2005 ; US - 20050716337P - 12/09/2005 ; US - 20060066348 - 08/09/2006 ; WO - 2006US34915 - 08/09/2006	UNIV VIRGINIA	A61K 35/12 ; A61P 43/00 ; C12N 5/06	The Present Invention Relates To Adipose Tissue-Derived Stem Cells And To Methods And Compositions For Enhancing Growth And Differentiation Of Such Cells. The Invention Further Relates To Growing Such Cells In Serum-Free Or Low Serum Growth Medium, And Formulations Thereof.
US2008248005	US - 20050729172P - 21/10/2005 ; US - 20060091018 - 11/10/2006 ; WO - 2006SG00301 - 11/10/2006	CELLRES CORP PTE LTD	A01N 1/02 ; A61K 35/12 ; A61P 11/00 ; A61P 19/00 ; A61P 3/10 ; C12N 5/06	The Present Invention Relates To A Skin Equivalent And A Method For Producing The Same, Wherein The Skin Equivalent Comprises A Scaffold And Stem/Progenitor Cells Isolated From The Amniotic Membrane Of Umbilical Cord. These Stem/Progenitor Cells May Be Mesenchymal (UCMC) And/Or Epithelial (UCEC) Stem Cells, Which May Then Be Further Differentiated To Fibroblast And Keratinocytes. Further Described Is A Method For Isolating Stem/Progenitor Cells From The Amniotic Membrane Of Umbilical Cord, Wherein The Method Comprises Separating The Amniotic Membrane From The Other Components Of The Umbilical Cord In Vitro, Culturing The Amniotic Membrane Tissue Under Conditions Allowing Cell Proliferation, And Isolating The Stem/Progenitor Cells From The Tissue Cultures. The Invention Also Refers To Therapeutic Uses Of These Skin Equivalents. Another Aspect Of The Invention Relates To The Generation Of A Mucin-Producing Cell Using Stem/Progenitor Cells Obtained From The Amniotic Membrane Of Umbilical Cord And Therapeutic Use

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008248078	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080019543 - 24/01/2008	DANCU MICHAEL	A61F 2/04 ; C12M 1/00 ; C12N 5/02	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Promote Endothelialization Of A Hybrid Hemodialysis Access Graft Or A Hybrid Femoral Artery Bypass Graft By Placing The Hybrid Hemodialysis Access Graft Or The Hybrid Femoral Artery Bypass Graft In A System Embodiment According To Tie Invention Under Conditions Effective To Promote Stem Cells To Differentiate Into Endothelial Cells On A Surface Of The Hybrid Graft.
US2008248567	US - 20060876843P - 22/12/2006 ; US - 20070002971 - 19/12/2007	UNIV VERMONT	C12N 5/06	The Invention Relates To Methods And Media For Preparing And Maintaining Self-Renewing Pluripotent Embryonic Stem Cells. The Methods Include, In Some Embodiments, Culturing Embryonic Stem Cells In Culture Medium That Includes Culture Medium Conditioned By Cells That Express Wnt3a.
US2008248582	US - 19990261068 - 02/03/1999 ; US - 20000514686 - 28/02/2000 ; US - 20010949314 - 07/09/2001 ; US - 20030371837 - 20/02/2003 ; US - 20080054383 - 24/03/2008	QUALIGEN INC	G01N 1/34 ; G01N 33/49 ; G01N 33/50	A Method Of Separating A Cell-Containing Sample Into A Substantially Cell-Depleted Portion, And A Cell-Containing Portion Comprising At Least One Of A Stem Cell, A Lymphocyte, And A Leukocyte Comprises A Step In Which The Sample Is Received In A Vessel With At Least One Flexible Wall. In Another Step, An Additive And Particles Are Added To The Sample, Wherein The Additive Substantially Binds To The At Least One Of The Stem Cell, Lymphocyte, And Leukocyte, And The Particles And Wherein The Particles Substantially Bind To The At Least One Of The Stem Cell, Lymphocyte, And Leukocyte, And The Additive, Thereby Producing A Cell-Containing Network. In A Further Step, The Network Is Separated From The Substantially Cell-Depleted Portion By Applying A Magnetic Force.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008253999	US - 20050722321P - 30/09/2005 ; US - 20060088668 - 28/09/2006 ; WO - 2006DK00533 - 28/09/2006	CLAUSEN CHRISTIAN ; OSTHER KURT ; PEDERSEN KLAUS RISKAER	A61K 45/00 ; C12N 5/08	The Present Invention Relates To A Method For Propagating And/Or Differentiating Mammalian Cells, The Method Comprising Exposing Or Co-Culturing Mammalian Cells With One Or More Of Periodontal Ligament Tissue, Periodontal Ligament Proteins Or Factors Derived From Periodontal Ligament Tissue, To Obtain Cells Having PDL Characteristics And Fulfilling At Least One Of The Following: I) Show Periodontal Characteristics As Evidenced With Von Kossa Method In Which Calcium Phosphate Deposits Are Stained Brown To Black, Ii) Show Increased Osteopontin And Osteocalcin And At The Same Time Decreased Bone Sialoprotein (Bone Sialoprotein II Or BSP), Iii) Are Capable Of Being Implanted To Repair And/Or Regenerate Periodontal Tissue, Iv) Are Capable Of Repairing Disorders Such As Paradentitis Also Called Paradentosis, Or Periodontitis By Healing Of The Gum Line Towards The Teeth, And V) Are Accepted By The Host Without Significant Immune Reaction Or Cell Rejection.
US2008254002	US - 20040607127P - 03/09/2004 ; US - 20050661773 - 02/09/2005 ; WO - 2005US31547 - 02/09/2005	EDELBERG JAY M ; PALLANTE BENEDETTA A	A61K 35/12 ; A61P 9/00 ; C12N 5/06	The Invention Provides Bone-Marrow Derived Stem Cells, E.G., Cardiomyocyte Precursor Cells, Differentiated Cardiomyocytes Generated From The Precursor Cells, And A Method For Treating Cardiac Dysfunction In A Subject By Administering Such Cells.
US2008254003	AU - 20040907294 - 22/12/2004 ; WO - 2005AU01921 - 21/12/2005	MUMMERY CHRISTINE LINDSAY ; PASSIER ROBERT	A01K 67/027 ; A61K 35/12 ; A61P 9/00 ; C12N 5/06	The Present Invention Provides A Method To Improve Current Culturing Methods For The Differentiation Of Cardiomyocytes From Hes Cells. The Method Includes Culturing The Hes Cells In The Presence Of Ascorbic Acid Or A Derivative Thereof. Preferably The Culturing Is Conducted In Serum Free Conditions. The Invention Also Includes Isolated Cardiomyocytes And Cardiac Progenitors Differentiated By The Methods As Well As The Use Of These Cells In Methods Of Treating And Preventing Cardiac Diseases And Conditions. Culture Media And Extracellular Media Are Also Provided Which Include Ascorbic Acid For The Differentiation Of Hes Cells To Cardiomyocytes.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008254004	US - 20050651932P - 09/02/2005 ; US - 20060815786 - 09/02/2006 ; WO - 2006US04957 - 09/02/2006	BURNHAM INST FOR MEDICAL RES	A61K 35/12 ; A61P 35/00 ; C12N 5/06	This Invention Provides Pure Populations Of Neural Precursor Cells, Capable Of Differentiation Into Neurons, Glial Cells, And Astrocytes. The Populations Are Obtained By Culturing Stem Cell Populations (Such As Embryonic Stem Cells) In A Cocktail Of Growth Conditions That Initiates Differentiation, And Establishes The Neural Precursor Population. The Precursors Can Be Further Differentiated In Culture Into A Variety Of Different Neural Phenotypes. The Neural Precursors Can Be Generated In Pure Form (At Least 99%) And In Large Quantities For Use In Drug Screening And The Treatment Of Neurological Disorders.
US2008254005	US - 20070910605P - 06/04/2007 ; US - 20080098420 - 05/04/2008	MEDISTEM LABORTORIES	A61K 35/12 ; A61P 43/00	Disclosed Are Methods, Compositions Of Matter, And Cells, Useful For The Treatment Of Autism, Social Integrative Disorders, And Various Cognitive Abnormalities. The Invention Discloses, Inter Alia, Means Of Inducing Angiogenesis And Immune Modulation Either In Sequence Or Parallel In Order To Substantially Ameliorate Or Reverse The Progression Of Autism. The Use Of Stem Cells, And Cells Naturally Possessing Or Endowed With Angiogenic And Anti-Inflammatory Activity Are Disclosed For Autism Either Alone Or In Combination With Various Therapeutic Interventions.
US2008254006	US - 20070911796P - 13/04/2007 ; US - 20080102739 - 14/04/2008	RELIANT TECHNOLOGIES INC	A61K 48/00 ; A61N 1/30 ; A61P 17/14	A Method Of Restoring Hair To Skin That Has Suffered Hair Loss Includes Optically Ablating An Array Of Spaced-Apart Microchannels Or Voids Into The Skin And Transplanting Into The Voids Stem Cells, A Scaffold And A Differentiation Factor For Causing The Stem Cells To Differentiate Into Hair Follicles.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008254019	JP - 20040105890 - 31/03/2004 ; WO - 2005JP06320 - 31/03/2005	KATO YUKIO ; NISHIMURA MASAHIRO ; OZAKI YOSHIE ; TSUJI KOICHIRO	A61K 31/728 ; A61K 35/12 ; A61K 35/28 ; A61K 38/00 ; A61K 38/16 ; A61K 38/22 ; A61K 38/27 ; A61K 38/46 ; A61K 38/48 ; A61K 45/00 ; A61L 27/00 ; A61P 1/02 ; A61P 17/02; A61P 19/00; A61P 19/02; A61P 9/10; C07K 14/00; C12N 9/74	This Invention Provides Therapeutic Agents, Transplants And Therapeutic Methods That Can Enhance The Regeneration Of Injured Tissue. This Invention Relates To Agents, Transplants And Therapeutic Methods For Enhancing The Migration And Accumulation Of Mesenchymal Stem Cells In Injured Tissues And/Or Suppressing The Diffusion Of Mesenchymal Stem Cells From Injured Tissues.
US2008254092	US - 20050734584P - 08/11/2005 ; US - 20060092863 - 08/11/2006 ; WO - 2006US43711 - 08/11/2006	GEORGIA TECH RES INST	A61F 2/04 ; A61K 35/12 ; A61P 25/00 ; A61P 9/00 ; C12N 5/06	Compositions Containing Acellularized Biomaterial Derived From Differentiating Pluripotent Cells, For Example, Embryonic Stem Cells Are Provided. The Acellularized Biomaterial Can Be Used To Promote Wound Healing, Promote Tissue Regeneration, Or Inhibit Scarring. Methods For Using The Acellularized Biomaterial For Treating Degenerative Diseases Are Also Provided.
US2008254138	US - 20060775913P - 22/02/2006 ; US - 20070004332 - 22/02/2007 ; US - 20070708231 - 20/02/2007 ; US - 20070865023 - 30/09/2007 ; US - 20070876963 - 23/10/2007 ; US - 20070925907 - 27/10/2007	FIRESTONE LEIGH H	A61K 35/12 ; A61K 35/36 ; A61K 35/37 ; A61K 35/38 ; A61P 35/00	The Invention Is To A Method Of Recruiting Stem Cells To A Site Of Malignancy By Contacting The Site With Exogenous Mammalian Extracellular Matrix In The Form Of A Sheet Article, Or A Composition Comprising Particulate Extracellular Matrix, Or Emulsion Or Gel Extracellular Matrix.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008255163	US - 20020348473P - 14/01/2002 ; US - 20020357783P - 19/02/2002 ; US - 20020376257P - 29/04/2002 ; US - 20020381138P - 08/05/2002 ; US - 20020404361P - 19/08/2002 ; US - 20020430381P - 02/12/2002 ; US - 20030341683 - 14/01/2003 ; US - 20080053429 - 21/03/2008	TRUSTEES OF THE UNIVERSITY OF	A61K 31/519 ; A61K 31/7088 ; A61P 43/00 ; C12N 5/06	This Invention Provides Cells And Methods For Stimulating Proliferation And Migration Of Endogenous And Exogenous Mammalian Stem Cells In Vivo And In Vitro. The Invention Provides Reagents And Methods For Efficiently Proliferating Mammalian Stem Cells In An Animal In Need Thereof And Producing Stem Cells That Can Be Re-Introduced Into An Animal In Need Thereof To Alleviate Neurological And Corporal Disorders.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008255197	US - 20030462736P - 11/04/2003 ; US - 20030505688P - 23/09/2003 ; US - 20040823494 - 12/04/2004 ; US - 20070936047 - 06/11/2007	BAIRD IAN ; BRIDGER GARY J ; CHEN GANG ; HARWIG CURTIS ; KALLER AL ; MCEACHERN ERNEST J ; SCHOLS DOMINIQUE ; SKERLJ RENATO ; SKUPINSKA KRYSTYNA ; ZHU YONGBAO	A61K 31/44 ; A61K 31/444 ; C07D 213/38 ; C07D 213/61 ; C07D 213/65 ; C07D 213/69 ; C07D 213/70 ; C07D 213/73 ; C07D 213/74 ; C07D 213/75 ; C07D 213/76 ; C07D 213/80 ; C07D 213/82 ; C07D 213/89 ; C07D 401/12 ; C07D 401/14 ; C07D 409/14 ; C07D 413/14 ; C07D 417/12 ; C07D 417/14 ; C07D 451/04 ; C07D 471/06	The Present Invention Relates To Compounds That Bind To Chemokine Receptors, And Having The Formula Wherein Each A, X, Y, R<1>, R<2 >And R<3 >Are Substituents. The Present Invention Also Relates To Methods Of Using Such Compounds, Such As In Treating HIV Infection And Inflammatory Conditions Such As Rheumatoid Arthritis. Furthermore, The Present Invention Relates To Methods To Elevate Progenitor And Stem Cell Counts, As Well As Methods To Elevate White Blood Cell Counts, Using Such Compounds.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008255408	US - 20000239015P - 06/10/2000 ; US - 20010973433 - 09/10/2001 ; US - 20060440091 - 25/05/2006 ; US - 20060440148 - 25/05/2006 ; US - 20060440152 - 25/05/2006 ; US - 20060440155 - 25/05/2006 ; US - 20060440156 - 25/05/2006 ; WO - 2006US45715 - 30/11/2006 ; US - 20080018990 - 24/01/2008	DANCU MICHAEL	A61F 2/06	Hybrid Synthetic Grafts And Embodiments Of Systems And Methods For Producing Hybrid Vascular Grafts That Can Yield Implantable Grafts That Combine Synthetic Grafts With Living Cells. Embodiments Of Systems Can Include A Pressure/Flow Loop Subsystem Having An External Flow Loop System Coupled To A Specimen Holder, Where The Pressure/Flow Loop Subsystem Is Capable Of Adjusting At Least Two Dynamic Conditions In The Specimen Holder Or A Diameter Of A Specimen In The Specimen Holder. Embodiments Of Methods Can Promote Endothelialization Of A Hybrid Lower Limb Artery Bypass Vascular Graft By Placing The Hybrid Lower Limb Artery Bypass Vascular Graft In A System Embodiment According To The Invention Under Conditions Effective To Promote Stem Cells To Form A Confluent Monolayer On The Hybrid Vascular Graft.
US2008260707	US - 20000253943P - 30/11/2000 ; US - 20010997240 - 30/11/2001 ; US - 20020179959 - 26/06/2002 ; US - 20080078799 - 04/04/2008	STEMRON INC	A61K 35/12 ; A61K 48/00 ; A61P 43/00 ; C12N 15/63 ; C12N 5/06 ; C12N 5/08	The Present Invention Discloses And Describes Pluripotent Homozygous Stem (HS) Cells, And Methods And Materials For Making Same. The Present Invention Also Provides Methods For Differentiation Of HS Cells Into Progenitor (Multipotent) Cells Or Other Desired Cells, Groups Of Cells Or Tissues. Further, The Applications Of The HS Cells Disclosed Herein, Include (But Are Not Limited To) The Diagnosis And Treatment Of Various Diseases (For Example, Genetic Diseases, Neurodegenerative Diseases, Endocrine-Related Disorders And Cancer), Traumatic Injuries, Cosmetic Or Therapeutic Transplantation, Gene Therapy And Cell Replacement Therapy.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008260722	US - 20040640692P - 30/12/2004 ; US - 20050675520P - 28/04/2005 ; US - 20050794455 - 30/12/2005 ; WO - 2005US47481 - 30/12/2005	JOHNS HOPKINS UNIVERSITY JOHNS	A61B 17/435 ; A61K 39/395 ; A61P 43/00 ; C12N 5/06	The Present Invention Provides A Role For Neurotrophins In Hes Cell Survival And Important New Insights Into The Molecular Mechanisms Controlling The Growth Of These Cells. Although Previous Studies Identified Growth Factors That Affect Self-Renewal Of Hes Cells, The Novelty Of The Present Invention Is The Identification Of Factors That Act Through Specific Receptors Present On Hes Cells And Activate The Receptors At Physiological Concentrations To Promote Survival And Proliferation.
US2008261244	US - 20070897190P - 24/01/2007 ; US - 20080019339 - 24/01/2008	UNIV MICHIGAN	C12N 5/06 ; G01N 33/574	The Present Invention Relates To The Field Of Oncology And Provides Novel Compositions And Methods For Diagnosing And Treating Pancreatic Cancer. In Particular, The Present Invention Provides Pancreatic Cancer Stem Cells Useful For The Study, Diagnosis, And Treatment Of Solid Tumors.
US2008261305	US - 20070919349P - 21/03/2007 ; US - 20080050034 - 17/03/2008	HANTASH BASIL M ; ZHAO LONGMEI	C12N 5/02	Methods And Compositions Are Provided For The Culture Of MSC To Provide Osteogenic Progenitor Cells.
US2008267874	US - 20070920457P - 28/03/2007 ; US - 20080056823 - 27/03/2008	BUCK INST FOR AGE RES	A01K 67/027 ; A61K 49/00 ; A61P 43/00 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/68 ; C40B 30/06	The Present Invention Is Related To Human Stem Cells Lines Comprising A Targeted Gene Construct, And In Particular To Human Embryonic Stem Cells Lines (Hesc) Comprising A Reporter Gene Inserted Into The Olig2 Locus Via Homologous Recombination. The Hesc Line Remains Pluripotent And Maintains A Normal Karyotype, And Allows For Visualization Of Olig2 Expression By Fluorescence Microscopy And Sorting By FACS. Since Olig2 Is Important Is The Development Of Motor Neurons And Oligodendrocytes, The Present Invention Provides A Means To Study Differentiation Of Stem Cells Into Motor Neurons And Oligodendrocytes, As Well As The Study Of Intrinsic And Extrinsic Factors That Affect Such Differentiation. The Hescs Of The Present Invention Also Provide A Means To Study And Determine Optimal Factors And Conditions For Cell Differentiation.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008267921	US - 20040625695P - 08/11/2004 ; US - 20050666685 - 08/11/2005 ; WO - 2005US40359 - 08/11/2005	UNIV JOHNS HOPKINS	A61K 45/00 ; A61P 9/02 ; C12N 5/06 ; C12N 5/08	Human Cardiac Stem Cells Can Be Isolated From Endomyocardial Biopsies. Such Cells Mediate Cardiac Regeneration And Improve Heart Function In A Mouse Infarct Model. The Cells Can Be Used For Autologous, Allogeneic, Syngeneic, Or Xenogeneic Therapeutic Applications In Patients. The Stem Cells Can Be Genetically Modified To Enhance Their Therapeutic Activity.
US2008267922	US - 20060873196P - 06/12/2006 ; US - 20070951761 - 06/12/2007	MILDE TILL ; RAFII SHAHIN ; SHMELKOV SERGEY V	A61K 35/12 ; C12N 5/00 ; C12N 5/06 ; G01N 33/567	The Present Invention Relates To Slitrk Proteins As Markers Of Stem And Progenitor Cells, Including Embryonic Stem Cells And Hematopoietic Stem And Progenitor Cells, And Also As A Marker Of Leukemia And Lymphoma Cells, And Of Endothelial Cells. The Invention Provides, Inter Alia, Methods For Purifying Slitrk-Positive Cells, Methods For Detecting Slitrk-Positive Cells, Purified Preparations Of Slitrk-Positive Cells, Therapeutic Compositions Containing Purified Slitrk-Positive Cells, Methods For Targeting Therapeutic Agents To Slitrk-Positive Cells, And Methods Of Treatment, Including But Not Limited To, Methods Of Administering Slitrk-Positive Cells To Subjects In Need Thereof.
US2008267927	US - 20040636204P - 15/12/2004 ; US - 20050304865 - 15/12/2005 ; US - 20080214660 - 20/06/2008	DORNIER MEDTECH SYSTEMS GMBH	A61K 35/12 ; A61P 9/10	Improving Cell Therapy And Tissue Regeneration In A Patient Suffering From A Cardiovascular Or A Neurological Disease By Treating A Tissue Of The Patient With Shock Waves And/Or Applying To The Patient A Therapeutically Effective Amount Of Stem Cells And/Or Progenitor Cells. Such Treatment Increases Expression Of Chemoattractants, Pro-Angiogenic Factors, And Pro-Survival Factors. The Chemoattractants Can Be, For Example, Vascular Endothelial Growth Factor (VEGF) Or Stromal Cell Derived Factor 1 (SDF-1). For Example, The Treated Tissue Can Be Located In The Patient's Heart Or In A Skeletal Muscle Of The Patient, And The Shock Waves Can Be Extracorporeal Shock Waves (ESW) Or Intracorporeal Shock Waves. The Cardiovascular Disease Can Have An Ischemic Or Non-Ischemic Etiology. For Example, The Cardiovascular Disease Can Be A Myocardial Infarction, Ischemic Cardiomyopathy, Or A Dilatative Cardiomyopathy. For Example, The Neurological Disease Can Be A Peripheral Neuropathy Or Neuropathic Pain.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008267929	US - 20030519712P - 13/11/2003 ; US - 20040605746P - 31/08/2004 ; US - 20040989649 - 15/11/2004 ; US - 20070953797 - 10/12/2007	EDGE ALBERT ; HELLER STEFAN ; LI HUAWEI	A61K 35/30 ; A61K 38/17 ; A61K 48/00 ; A61P 27/16 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/68 ; G01N 33/53	This Invention Relates Generally To Methods And Compositions For Inducing Stem Cell Or Progenitor Cell Differentiation, And More Particularly To Methods And Compositions For Inducing Differentiation Of Stem Cells And/Or Progenitor Cells Into Cells That Function Within The Inner Ear.
US2008268054	US - 20000251125P - 04/12/2000 ; US - 20000256614P - 18/12/2000 ; US - 20010005053 - 04/12/2001 ; US - 20010256593P - 29/05/2001 ; US - 20010901786 - 09/07/2001 ; US - 20030400753 - 27/03/2003 ; US - 20030430041 - 05/05/2003 ; US - 20060610021 - 13/12/2006 ; US - 20070678143 - 23/02/2007 ; US - 20070907131P - 22/03/2007 ; US - 20070924729P - 29/05/2007 ; US - 20080053435 - 21/03/2008	BANU NAHEED ; BELL EUGENE ; BELL NUILIANT ; RUSSAKOVSKY VLADIMIR	A61K 35/12 ; A61K 9/14 ; A61P 43/00 ; C12N 5/06	This Application Discloses Dermal Derived Human Stem Cells (Ddhscs) And Methods Of Making And Using Thereof. More Specifically, The Invention Relates To Ddhscs Derived From Subsets Of Dedifferentiated Dermal Fibroblasts That Can Give Rise To A Series Of Cell Lineages. The Ddhscs May Be Used, For Example, In Cell Therapy And In The Search For And Development Of Novel Medicaments.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008268533	US - 20040604453P - 25/08/2004 ; US - 20050574280 - 25/08/2005 ; WO - 2005US30488 - 25/08/2005	UNIV GEORGIA	C12N 5/06	The Present Invention Provides Methods For Stabilizing Pluripotent Cells Through The Transcriptional Activation Of C-Myc. Alternatively, The Cells Are Stabilized Through The Transcriptional Activation Of C-Myc, And The Stabilization Of C-Myc Protein Levels. C-Myc Protein Can Be Stabilized Through The Inhibition Of GSK3beta Or Through Other Components Of The Cellular Machinery That Impact On C-Myc Stability. The Invention Contemplates The Stabilized Pluripotent Cells Produced Using The Methods Described Herein. Methods For The Identification Of Compounds That Modulate The Stabilization Of Pluripotent Cells Through Modulating Transcriptional Activation Of C-Myc, Stabilization Of C-Myc Protein Levels, And/Or Inhibition Of GSK3beta Activity Are Also Contemplated.
US2008274054	US - 20070742963 - 01/05/2007	TAIPEI VETERANS GENERAL HOSPIT	A61K 35/12 ; A61K 49/00 ; A61P 17/02 ; C12Q 1/02	A Composite Comprising A Stem Cell; A Biodegradable Layer, Which Can Provide An Environment For The Stem Cell To Grow And To Differentiate, And; A N-Isopropylacrylamide (Nipaam), Which Can Polymerize With The Biodegradable Layer And Possess The Temperature-Responsive Character For Easy Stripping. This Invention Also Provides A Method Of Treating A Subject With A Skin Defect By Covering The Composite Of The Present Invention On The Skin Defect Of The Subject In Need Of Such Treatment. Furthermore, Using This Composite With Different Growth Factors, Stem Cells Can Be Induced To Differentiate Into Skin-Related, Neuronal Cells, Neuron, And Insulin-Positive Cells In Biodegradable Scaffolds As Well As Transplanted Graft. Finally, This Invention Also Provides A Quick And Convenient Method Of Monitoring Cell Growth Or Tissue Engineering In An Animal.
US2008274086	US - 20030509105P - 06/10/2003 ; US - 20040598468 - 17/09/2004 ; WO - 2004US30607 - 17/09/2004	CEDARS SINAI MEDICAL CENTER	A61K 35/12 ; A61P 35/00 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/68 ; G01N 33/50	The Present Invention Relates To Tumor Tropic Stem Cells, And Particularly To Neural Stem Cells, And Their Use As Delivery Vehicles For Therapeutic Gene Products To Neoplastic Foci. The Stem Cells With Tumor Tropic Potential Are Selected Based On The Stem Cells Exhibiting CXCR4 Receptors Or An Affinity For The Chemokine SDF-1. The Stem Cells May Additionally Exhibit Markers Characteristic Of Astrocytic Progenitors. The Stem Cells May Be Administered As Part Of A Treatment Regimen Including The Chemokine SDF-1.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008274089	GB - 20050014300 - 12/07/2005 ; WO - 2006IB02896 - 12/07/2006	MARTINO GIANVITO ; PLUCHINO STEFANO	A61K 35/12 ; A61P 25/00 ; C12N 5/06	This Invention Provides Adult Neural Stem Cell (Ansc) Materials And Methods For Treating Central Nervous System Disorders.
US2008274090	US - 19990406253 - 27/09/1999 ; WO - 2000US26469 - 27/09/2000 ; US - 20020088806 - 17/09/2002 ; US - 20080020265 - 25/01/2008	UNIV FLORIDA	A61K 35/12 ; A61P 3/10 ; C12N 5/06 ; C12Q 1/02 ; C12Q 1/68	The Subject Invention Concerns New Methods Which Make It Possible, For The First Time, To Grow Functional Islet-Producing Stem Cells (Ipscs), Islet Progenitor Cells (Ipcs) And IPC-Derived Islets (Idis) In In Vitro Cultures. The Subject Invention Also Concerns The Use Of The In Vitro Grown Ipscs, Ipcs And/Or Idis For Implantation Into A Mammal For In Vivo Therapy Of Diabetes. The Subject Invention Further Concerns A Process Of Using The Implanted Cells For Growing A Pancreas-Like Structure In Vivo That Has The Same Functional, Morphological And Histological Characteristics As Those Observed In Normal Pancreatic Endocrine Tissue. The Ability To Grow These Cells In Vitro And Pancreas-Like Structures In Vivo Opens Up Important New Avenues For Research And Therapy Relating To Diabetes.
US2008274125	FR - 20040013058 - 08/12/2004 ; WO - 2005EP56608 - 08/12/2005	VIVALIS	A61K 39/00 ; A61P 37/00 ; C12N 5/06 ; C12N 7/00 ; C12P 21/04 ; C12Q 1/02	The Present Invention Concerns The Field Of Biology And Virology. In Particular, The Invention Concerns A Method For Obtaining Human Cell Lines, In Particular Human Stem Cells Derived From Human Embryonic Stem Cells, The Method Comprising Separation From The Serum, The Feeder Layer And At Least One Growth Factor. The Cell Lines Are Capable Of Proliferating Indefinitely In A Basic Culture Medium. The Invention Also Concerns The Use Of The Cells Derived From Such Cell Lines For Virus Replication, And More Particularly For Producing Human Or Veterinary Vaccines, As Well As For Producing Recombinant Proteins Of Therapeutic Interest.
US2008274185	US - 20040584657P - 30/06/2004 ; US - 20050571180 - 30/06/2005 ; WO - 2005US23318 - 30/06/2005	MAO JEREMY	A61K 35/12 ; A61K 9/14 ; A61P 19/00 ; C12N 5/06	Methods And Compositions For De Novo And In Vivo Synthesis Of Soft Tissue In Predefined Shape And Dimensions From Adult Mesenchymal Stem Cells (Mscs) Within A Biocompatible Scaffold Are Described. Scaffolds Are Implanted In Vivo In A Host Animal And Fabricated Therein, Or Maintained Ex Vivo. Inducing Angiogenesis Enhances Success Of Soft Tissue Implants.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008274202	US - 20050704639P - 01/08/2005 ; US - 20050723189P - 03/10/2005 ; US - 20060997476 - 01/08/2006 ; WO - 2006US29774 - 01/08/2006	KAMINSKI MICHAEL ; KRAIG RICHARD P	A61K 31/7088 ; A61K 35/12 ; A61K 39/395 ; A61K 9/51 ; A61P 25/00	Disclosed Are Methods And Compositions For Delivering A Therapeutic Agent To Target Organs Or Tissues, Such As Brain. The Methods And Compositions Use Bone Marrow Stem Cells, Monocytes, Macrophages Or Microglial Cells To Deliver The Therapeutic Agent Associated With Nanoparticles To The Target Organ Or Tissue.
US2008274446	US - 20070927851P - 04/05/2007 ; US - 20080150818 - 01/05/2008	UNIV GEORGIA	A01N 1/02 ; C12N 5/08	Cryopreserved Cultures Of Post-Mitotic Neuronal Or Neural-Like Cells Are Provided Having A Viability After Thaw Of Greater Than 10%, Typically Greater Than 50%. Once Thawed, The Cells Are Capable Of Further Differentiation. In One Embodiment, Less Than 20% Of The Cryopreserved Cells Are Self-Proliferating Cells. The Cells Can Be Provided In A Kit Including A Container Of The Cryopreserved Neuronal Or Neural-Like Cells, Optionally Including Additional Cell Culture Reagents And Materials. Method For Preparing The Cryopreserved Neuronal Or Neural-Like Cells Derived From Embryonic Stem Cells, Preferably Human Embryonic Stem Cells, Are Also Provided.
US2008274491	US - 20050685269P - 27/05/2005 ; US - 20060915687 - 29/05/2006 ; WO - 2006CA00868 - 29/05/2006	COLES JOHN G ; HANNIGAN GREGORY ; LU HUANZHANG	C12N 15/861 ; C12N 5/06	Modulation Of The Integrin-Linked Kinase (ILK) Signaling Pathway Is Used To Enhance The Remodeling Process Relevant To A Wide Range Of Cardiac Diseases. More Specifically, A Process To Instigate Beneficial Human Cardiac Hypertrophy Or For Post Myocardial Infarction (MI) Remodeling Comprising Illiciting An Overexpression Of ILK, Is Described. The ILK Signaling Pathway Is Also Used As A Means For Cardiac Stem Cell Proliferation And Self-Renewal

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008279833	US - 20070747004 - 10/05/2007	MATHENY ROBERT G	A61K 35/12 ; A61P 17/02	The Invention Is To Articles Of Extracellular Matrix. The Articles Comprise One Or More Sheets Of Mammalian Extracellular Matrix Laminated Together. A Single Sheet Can Be Folded Over And Laminated On 3 Sides. Two Or More Sheets Can Be Laminated To Each Other At Their Edges. The Sheets Can Further Encase A Composition Comprising A Cell Or Cells, Such As For Example, A Stem Cell. A Single Sheet Can Be Folded Over To Encase A Composition, Or Rolled To Encase A Composition With Lamination At Either End Of The Roll, For Example. The Invention Also Includes Methods Of Using These Articles To Regenerate Tissue At Tissue Defects, Or Heal Wounds In Damaged Tissue.
US2008279835	US - 20050735027P - 08/11/2005 ; WO - 2006US60692 - 08/11/2006 ; US - 20080117197 - 08/05/2008	UNIV SOUTH FLORIDA	A61K 35/14 ; A61P 9/10	A Method Of Treating Acute Myocardial Infarction Has The Steps Of Providing Human Umbilical Cord Blood Cells (HUCBC); And Administering The HUCBC To The Individual With The Acute Myocardial Infarction At Particular Time Intervals After Said Myocardial Infarction. Preferably The Intervals Are About One To About Three Hours Or About 12 To About 48 Hours After The Acute Myocardial Infarction.
US2008279956	US - 20070797929 - 09/05/2007	LIN TUNG-HO	A61K 35/14	The Present Invention Discloses A Method For Collecting A Live Placenta Cord Stem Cell, In Which The Live Placenta Cord Stem Cells Are Required To Be Healthy And Plenty Of Endocrine. The Cord Is First Picked With A Proper Length, Then Dipped In The Sodium Citrate Solution Of A Specific Concentration As An Anticoagulant And Then Preserved In A Refrigerator To Maintain Natural Activity Thereof. The Collected Stem Cells Can Be Implanted Into Human Bodies Without Synthetic Chemicals, Side Effects And Rejection, And Therefore Are Suitable For Treating Many Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008279961	US - 20070917398P - 11/05/2007 ; US - 20080118394 - 09/05/2008	BURGER ANGELIKA M	A61K 31/282 ; A61K 31/351 ; A61K 31/4188 ; A61K 31/427 ; A61K 31/435 ; A61K 31/4353 ; A61K 31/437 ; A61K 31/4375 ; A61K 31/513 ; A61K 31/675 ; A61K 31/704 ; A61K 33/24 ; A61K 33/36 ; C12N 5/06 ; C12Q 1/04 ; G01N 33/574	It Is Demonstrated In The Present Invention That G-Quadruplex Ligands Can Be Used To Both Shorten Telomeres And Inhibit Telomerase By Causing Telomere Uncapping. The Invention Relates To Compositions And Methods Of Treating Cancer Stem Cells Comprising The Administration Of G-Quadruplex Ligands, Such As 3,11-Difluoro-6,8,13-Trimethyl-8H-Quino [4,3,2-Kl]Acridinium Methosulfate (RHPS4), Which Can Effectively Inhibit Or Reduce The Growth Of Cancer Stem Cells. The Invention Also Relates To A Synergistic Effect In Inhibiting Or Reducing The Growth Cancer Stem Cells When A G-Quadruplex Ligand Is Combined With A Mitotic Spindle Poison, Such As Paclitaxel, Or Other Agents Used In The Treatment Of Cancer And Disease. The Invention Also Relates To RHPS4 Inducing Non-Cancerous Cell And Non-Cancerous Stem Cell Proliferation.
US2008286243	KR - 20060062807 - 05/07/2006 ; WO - 2007KR03259 - 04/07/2007	RNL BIO CO LTD ; SEOUL NAT UNIV IND FOUNDATION	A61K 35/12 ; A61P 17/14 ; C12N 5/02	The Present Invention Relates To A Method For Isolating Hair Follicle Stem Cells And A Composition For Inducing Hair Growth. More Specifically, Relates To A Method For Isolating Hair Follicle Stem Cells Showing A Positive Immunological Response To CD34, By Chemically Degrading Hair Follicle-Containing Scalp Tissue And Then Culturing The Degraded Tissue In A Serum-Containing Medium And A Serum-Free Medium, As Well As A Composition For Inducing Hair Growth, Which Contains, As An Active Ingredient, CD34-Positive Hair Follicle Stem Cells Isolated By The Method. The Hair Follicle-Derived Stem Cells, Which Are Obtained According To The Disclosed Method, Are Classified As Autologous Adult Stem Cells, Have Self-Renewal Capability, The Ability To Differentiate Into Adult Hair Follicle Cells And The Ability To Induce Hair Growth, And Can Be Used As A Novel Cell Therapeutic Agent Against Hair Loss. In Addition, The Present Invention Relates To A Method For Culturing Hair Follicle Cells, Which Has High Yield Compared To that of the prior art, as well as a method for identifying hair follicle stem cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008286246	JP - 20030185260 - 27/06/2003 ; JP - 20030432329 - 26/12/2003 ; US - 20040562202 - 25/06/2004 ; WO - 2004JP09386 - 25/06/2004 ; US - 20060377610 - 17/03/2006 ; US - 20080149646 - 06/05/2008	HITACHI LTD	A61K 35/12 ; A61P 7/00	Intravenous Administration Of Bone Marrow Cells Collected From Rat Bone Marrow Or Peripheral Blood To A Rat Cerebral Infarction Model Was Found To Be Effective In Treating Cerebral Infarction. Human And Murine Bone Marrow Stem Cells Showed Similar Effects. Mesenchymal Cells Such As Bone Marrow Cells, Cord Blood Cells, Or Peripheral Blood Cells Can Be Used As Agents For In Vivo Administration Against Cranial Nerve Diseases.
US2008286249	US - 20060758387P - 12/01/2006 ; US - 20070651878 - 10/01/2007 ; US - 20080042487 - 05/03/2008	DANILKOVITCH ALLA ; MILLS CHARLES RANDAL ; VARNEY TIMOTHY R	A61K 35/12 ; A61P 37/02	A Method Of Treating A Genetic Disease Or Disorder Such As, For Example, Cystic Fibrosis, Wilson's Disease, Amyotrophic Lateral Sclerosis, Or Polycystic Kidney Disease, In An Animal Comprising Administering To Said Animal Mesenchymal Stem Cells In An Amount Effective To Treat The Genetic Disease Or Disorder In The Animal.
US2008286324	US - 20070748315 - 14/05/2007	CARDIAC PACEMAKERS INC	A61F 2/82 ; A61K 9/16 ; C12M 1/00 ; C12N 5/02	The Invention Provides A Composition For Cold Storage Of Cells Which Includes A Population Of Isolated Stem Cells, A Cell Medium, And Isolated Trophic Factors, As Well As Devices Having A Plurality Of The Trophic Factors.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008286745	US - 20040630118P - 22/11/2004 ; US - 20050575900 - 15/11/2005 ; WO - 2005US41532 - 15/11/2005	CEDARS SINAI MEDICAL CENTER	A01N 1/02	Described Herein Are Compositions And Methods Particularly Useful In The Medical Arts. The Compositions And Methods May Be Used In Connection With The Preservation Of A Portion Of A Mammal, For Example, Tissues, Organs, Appendages, Limbs, Extremities, Stem Cells, Myocytes, Bone Marrow, Skeletal Muscle As Well As An Array Of Other Medical Procedures, Such As Cardiac Surgery, Transplantation And/Or Preservation. In Various Embodiments, The Inventive Composition May Be Hyperoxygenated And Be Formulated To Resemble The Biochemistries Of Natural Intracellular Fluids. The Inventive Composition Includes Active Ingredients To Reduce Ischemic, Hypothermic And Reperfusion Injury During Transplantation, Thereby Resulting In Improved Post-Transplant Graft Function And Quality, When Used In Connection With Organ Transplantation And Storage Procedures, For Example Cardiac Transplantation.
US2008286862	US - 20030458815P - 28/03/2003 ; US - 20040811423 - 26/03/2004 ; US - 20080110015 - 25/04/2008	LUDWIG TENNEILLE E ; THOMSON JAMES A	C12N 5/06 ; C12N 5/08	Physiochemical Parameters To Improve The Culturing And Sub-Culturing (Here Called Cloning) Of Human Embryonic Stem Cells Have Been Investigated. Low Levels Of Oxygen And Higher Than Expected Levels Of Osmolarity In The Culture Medium Have Both Been Found To Contribute To The Improved Culture Of Human Stem Cells.
US2008286867	CN - 20051064431 - 15/04/2005 ; WO - 2006CN00683 - 14/04/2006	UNIV BEIJING	C12N 5/06	The Present Invention Provided A Simple Three-Step Approach Based On The Combinational Induction With Activin A, All-Trans Retinoic Acid And, Optionally, Other Maturation Factors Which Are Able To Induce Embryonic Stem Cells To Differentiate Into Insulin-Producing Cells. A Kit Used To Induce Embryonic Stem Cells To Differentiate Into Insulin-Producing Cells Was Also Provided.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008287391	JP - 20040218243 - 27/07/2004 ; WO - 2005JP12799 - 12/07/2005	HIRATA AKIO ; KITAKAZE MASAFUMI ; MINAMINO TETSUO	A61K 31/70 ; A61P 9/00 ; C12N 5/06	It Is Intended To Provide A Regeneration Promoter For Regenerating A Tissue With The Use Of Somatic Stem Cells. It Is Also Intended To Provide A Cell Fusion Promoter Safely Usable In Vivo. Namely, It Is Intended To Provide A Cell Fusion Promoter Comprising ATP Or Its Metabolite. A Cell Fusion Promoter Comprising ATP Or Its Metabolite And A Method Of Producing Fused Cells In The Presence Of ATP Or Its Metabolite. A Medicinal Composition For Regenerating Or Improving The Function Of A Tissue Or An Organ, Which Suffers From Dysfunction Or Hypofunction Due To Injury Or Denaturation, By Using Stem Cells. This Composition Comprises ATP Or Its Metabolite And A Pharmaceutically Acceptable Carrier.
US2008287855	US - 19960699552 - 19/08/1996 ; US - 19980008636 - 16/01/1998 ; US - 20000690947 - 18/10/2000 ; US - 20020053750 - 21/01/2002 ; US - 20040575121P - 28/05/2004 ; US - 20050141403 - 31/05/2005 ; US - 20080060334 - 01/04/2008	MOWER MORTON M	A61N 1/30 ; A61N 1/362	A System And Method For Managing And Inhibiting Cardiac Remodeling In MI Patients. Bi-Ventricular Stimulation Is Constantly Provided With And Without Sensing To Encourage Normal Pumping Of The Heart On A Consistent Basis. Pulses Are Administered Using An Anodal Pulse Followed By A Cathodal Pulse To Stimulate Cardiac Muscle Contraction. Stem Cells Are Administered To MI Areas To Encourage Regeneration Of Cardiac Tissue In The Damaged Area. Stimulation May Be Provided To Both Healthy And Compromised Cardiac Tissue.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008292052	US - 20050054000 - 10/02/2005 ; US - 20060884158 - 10/02/2006 ; WO - 2006US04733 - 10/02/2006	ANCHEL DAVID J ; DILMANIAN F AVRAHAM ; GAUDETTE GLENN ; HAINFELD JAMES ; ROMANELLI PANTALEO	A61N 5/10	A Method Of Assisting Recovery Of An Injury Site Of The Central Nervous System (CNS) Or Treating A Disease Includes Providing A Therapeutic Dose Of X-Ray Radiation To A Target Volume Through An Array Of Parallel Microplanar Beams. The Dose To Treat CNS Injury Temporarily Removes Regeneration Inhibitors From The Irradiated Site. Substantially Unirradiated Cells Surviving Between Beams Migrate To The In-Beam Portion And Assist Recovery. The Dose May Be Staggered In Fractions Over Sessions Using Angle-Variable Intersecting Microbeam Arrays (AVIMA). Additional Doses Are Administered By Varying The Orientation Of The Beams. The Method Is Enhanced By Injecting Stem Cells Into The Injury Site. One Array Or The AVIMA Method Is Applied To Ablate Selected Cells In A Target Volume Associated With Disease For Palliative Or Curative Effect. Atrial Fibrillation Is Treated By Irradiating The Atrial Wall To Destroy Myocardial Cells While Continuously Rotating The Subject.
US2008292546	US - 20030477228P - 09/06/2003 ; US - 20030477235P - 09/06/2003 ; US - 20040864207 - 09/06/2004 ; US - 20080127636 - 27/05/2008	UNIV MICHIGAN	A61K 39/395 ; A61K 51/00 ; A61P 31/00 ; C12Q 1/68 ; G01N 33/574	The Present Invention Relates To Compositions And Methods For Treating, Characterizing, And Diagnosing Cancer. In Particular, The Present Invention Provides Gene Expression Profiles Associated With Solid Tumor Stem Cells, As Well As Novel Stem Cell Cancer Markers Useful For The Diagnosis, Characterization, And Treatment Of Solid Tumor Stem Cells.
US2008292583	US - 20020380842P - 17/05/2002 ; US - 20020424600P - 06/11/2002 ; US - 20030438213 - 15/05/2003 ; US - 20080151758 - 08/05/2008	CELGENE CORP	A61K 31/00 ; A61K 31/40 ; A61K 31/425 ; A61K 31/445 ; A61K 31/45 ; A61K 31/454 ; A61K 31/515 ; A61K 38/18 ; A61K 38/20 ; A61K 38/21 ; A61K 45/06 ; A61P 35/00	Methods Of Treating, Preventing And/Or Managing Cancer As Well As And Diseases And Disorders Associated With, Or Characterized By, Undesired Angiogenesis Are Disclosed. Specific Methods Encompass The Administration Of An Immunomodulatory Compound Alone Or In Combination With A Second Active Ingredient. The Invention Further Relates To Methods Of Reducing Or Avoiding Adverse Side Effects Associated With Chemotherapy, Radiation Therapy, Hormonal Therapy, Biological Therapy Or Immunotherapy Which Comprise The Administration Of An Immunomodulatory Compound. Pharmaceutical Compositions, Single Unit Dosage Forms, And Kits Suitable For Use In Methods Of The Invention Are Also Disclosed.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008292597	US - 20040592167P - 29/07/2004 ; US - 20050658327 - 28/07/2005 ; WO - 2005US26992 - 28/07/2005	STEENBLOCK DAVID A	A61K 35/12 ; A61P 25/00	A Neurological Disease Is Treated By Administering To A Patient A Therapeutically Effective Amount Of A Composition Including Human Umbilical Cord Stem Cells. The Composition May Include Growth Factors Mixed With The Stem Cells Immediately Prior To Being Administered. A Specific Pre And Post Transplantation Protocol Provides Optimal Methods For Obtaining Favorable Clinical Results.
US2008292598	US - 20070914122P - 26/04/2007 ; US - 20080110227 - 25/04/2008	BROTMAN HARRIS F	A61K 35/50 ; A61P 43/00 ; C12Q 1/02	Compositions Comprising Amniotic Fluid Stem Cells Which Are Derived From Non-Identical Donor Sources. Donors May Be Non-Identical Siblings, Non-Identical Twins, And/Or Donors Which Are Unrelated By A Familial Relationship. Also Disclosed Are Methods For Making Such Amniotic Stem Cell Compositions, And Methods For Their Use, Such As Therapeutic Stem Cell Transplantation.
US2008292600	KR - 20070053298 - 31/05/2007 ; US - 20070940349P - 25/05/2007 ; US - 20080127734 - 27/05/2008	KIM CHUL SOO ; LEE MOON HEE ; SONG SUN UK	A61K 35/12 ; A61P 37/02	This Present Application Describes A Therapeutic Agent For Treating Acute Or Chronic Graft-Versus-Host Disease Using Clonal Marrow Stem Cells (Cmscs) As Active Ingredient.
US2008292601	KR - 20070053298 - 31/05/2007 ; US - 20070940349P - 25/05/2007 ; US - 20080127743 - 27/05/2008	SONG SUN UK	A61K 35/12 ; A61P 37/02 ; C12N 5/08	This Present Application Describes A Therapeutic Agent For Treating Acute Or Chronic Graft-Versus-Host Disease Using Clonal Marrow Stem Cells (Cmscs) As Active Ingredient.
US2008293056	JP - 20070109539 - 18/04/2007	RIKEN	C12N 15/87 ; C12N 5/06 ; C12Q 1/02 ; C12Q 1/68	The Present Invention Provides A Method For Preparing Cancer Stem Cells Including The Step Of Subjecting Normal Cells To Ras Activation And P53 Deficiency; The Cancer Stem Cells Prepared By The Preparation Method; A Method For Screening A Cancer Stem Cell-Targeting Substance And A Method For Screening An Anti-Cancer Substance Using The Cancer Stem Cells; A Method For Treating A Cancer Comprising Administering To A Patient The Substances Obtainable By The Screening Methods; And A Diagnostic Method For Cancers Including The Step Of Detecting Proteins Specifically Expressed In The Cancer Stem Cells Or Mrnas Of The Protein.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008293140	GB - 19980019912 - 11/09/1998 ; WO - 1999GB03031 - 13/09/1999 ; US - 20010786817 - 08/06/2001 ; US - 20050084166 - 21/03/2005 ; US - 20080098037 - 04/04/2008	UNIV EDINBURGH	C12N 5/00 ; C12N 5/06	Embryonic Stem (ES) Cells Are Cultured In The Presence Of A Compound Which Selectively Inhibits Propagation Or Survival Of Cells Other Than ES Cells. The ES Cells Have Not Been Genetically Altered. Instead, The Compound Inhibits A Signalling Pathway Which Is Essential For Propagation Of Differentiated Cells But Is Not Essential For Propagation Of ES Cells-Hence ES Cells Are Selectively Maintained In The Culture.
US2008293936	US - 20070805579 - 23/05/2007	BURCHARDT ELMAR REINHOLD	C07D 231/08 ; C07D 403/04	The Present Invention Concerns Novel Pyridazine-3-On- And Pyrazol-3-On Derivatives, Methods Of Synthesizing Such, A Pharmaceutical Agent Containing Pyridazine-3-On- And Pyrazol-3-On Derivatives As Well As The Use Of The Compounds For The Prophylaxis Or Treatment Of Fibrotic Diseases And/Or Pathologic Remodelling And The Use Of Said Compounds For The Expansion Of Stem Cells.
US2008294096	US - 20050734035P - 04/11/2005 ; US - 20050742224P - 05/12/2005 ; US - 20060092448 - 06/11/2006 ; US - 20060460635 - 28/07/2006 ; US - 20060771206P - 07/02/2006 ; WO - 2006US43133 - 06/11/2006	MEDRAD INC	A61M 5/168	A System For Delivering A Fluid Comprising Cells To Tissue Of A Patient, Includes: A Least A First Container For Holding An Injection Fluid In Which The Agent Is Carried; A First Powered Drive In Operative Connection With The Container, The First Powered Drive Being Operable To Pressurize Contents Of The Container; A Control System In Operative Connection With The First Powered Drive And Operative To Control The First Powered Drive; A Fluid Path In Fluid Connection With The Container, The Fluid Path Including A Patient Interface Adapted To Deposit The Cells Within Tissue Of The Patient; A Sensor System; And A Communication System In Connection With At Least The Control System And The Sensor System. The Communication System Is Adapted To Provide Information To The Control System. The Control System In Adapted To Transmit A Control Signal To At Least The First Powered Drive Based At Least In Part On Information Provided To The Control System. The Cells Can For Example Be Pregenitor Cells Or Stem Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008299077	US - 20070809871 - 01/06/2007 ; US - 20080050131P - 02/05/2008 ; US - 20080130656 - 30/05/2008	NEVADA CANCER INST	A01K 67/02 ; A61K 38/20 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/53	The Present Invention Describes Stem Cells And Progenitor Cells Derived From Hemangiomas, Including Testing Of Angiogenic Inhibitors Using These Cells. The Invention As Described Is Useful In Providing A Process To Culture And Propagate Hemangioma Stem Cells And Generate Xenograft Models To Develop Treatments For Infantile Hemangiomas And Other Types Of Vascular Lesions.
US2008299090	US - 20020083779 - 25/02/2002 ; US - 20030647361 - 25/08/2003 ; US - 20070919375P - 22/03/2007 ; US - 20080053167 - 21/03/2008	COGNATE BIOSERVICES INC ; UNIV KANSAS STATE	A61K 35/12 ; A61P 9/00	The Invention Relates To The Isolation And Use Of Stem Cells From Amniote Species (Potentially Any Animal With An Umbilical Cord, Including Humans). More Particularly The Invention Relates To Obtaining Stem Cells That Are At Least Multipotent And May Be Totipotent Or Nearly Totipotent And Are Envisaged To Have A Variety Of End Uses. The Cells Of The Present Invention Are Immunosuppressive And May Be Used To Inhibit The Immune Response In A Subject.
US2008299091	US - 20070922244P - 06/04/2007 ; US - 20080082028 - 07/04/2008	INTERNAT STEM CELL CORP	A61K 35/12 ; A61P 43/00 ; C12N 5/02 ; C12N 5/08 ; C40B 40/02	Methods Are Disclosed For Generating HLA Homozygous Parthenogenetic Human Stem Cell (Hpsc-Hhom) Lines From Both HLA Homozygous And HLA Heterozygous Donors. These Hpsc-Hhom Lines Demonstrate Typical Human Embryonic Stem Cell Morphology, Expressing Appropriate Stem Cell Markers And Possessing High Levels Of Alkaline Phosphatase And Telomerase Activity. Additionally, Injection Of These Cell Lines Into Immunodeficient Animals Leads To Teratoma Formation. Furthermore, In The Case Of HLA Heterozygous Donors, The Hpsc-Hhom Lines Inherit The Haplotype From Only One Of The Donor's Parents. SNP Data Analysis Suggests That Hpsc-Hhom Lines Derived From HLA Heterozygous Oocyte Donors Are Homozygous Throughout The Genome As Assessed By Single-Nucleotide Polymorphism (SNP) Analysis. The Protocol As Disclosed Minimizes The Use Of Animal-Derived Components, Which Makes The Stem Cells More Practical For Clinical Application.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008299092	CH - 20070000701 - 27/04/2007	MIBELLE AG	A61K 36/73 ; A61K 9/127	The Present Invention Relates To The Use Of Dedifferentiated Plant Cells In Cosmetic Preparations For Protecting Of Stem Cells Against Intrinsic And Extrinsic Stress Factors, In Particular For Promoting Proliferation Of Stem Cells And For Protecting Them Against Apoptosis. In Particular, The Invention Relates To The Use Of Dedifferentiated Plant Cells From Fruits Of Malus Domestica (Apple) Cultivar Uttwiler Spaetlauber. Further, The Invention Relates To A Method For Cultivating Of Dedifferentiated Plant Cells, As Well As To The Preparation Of Extracts Of Plant Cell Cultures Which Are Suitable For Such Applications.
US2008299095	US - 20040586917P - 09/07/2004 ; US - 20050632091 - 16/05/2005 ; WO - 2005CA00755 - 16/05/2005	BC CANCER AGENCY ; UNIV MONTREAL	A61K 31/7088 ; A61K 35/12 ; A61P 31/00 ; C12N 15/11 ; C12N 5/06	Nucleic Acid Constructs Encoding Homeobox-Nucleoporin Fusions Are Disclosed, Compositions Comprising Same, And Methods Which Provide Enhanced Expansion Of Stem Cells. In Particular, An Isolated Nucleic Acid Construct Encoding A NUP98-HOX Fusion Is Provided, Which When Introduced Into Hemopoietic Stem Cells Provides Enhanced Expansion Of These Cells. Methods Of Expanding Stem Cells In Vivo Or Ex Vivo And Methods Of Treatment Using The Stem Cells Are Also Described.
US2008299097	US - 20060864847P - 08/11/2006 ; US - 20070937089 - 08/11/2007	TULANE UNIVERSITY HEALTH SCIEN	A61K 35/12 ; A61P 43/00	Multipotent Stromal Cells "Mscs" Have Been Described As Consisting Of At Least Two Populations Of Cells, Rapidly Self-Renewing Stem Cells (RS-Mscs), And Larger, Slowly Replicating Cells (Mmscs). The Present Invention Provides Methods For Enhancing Engraftment Of Mscs In Vivo By Administering An Enriched Fraction Of RS-Mscs That Express Certain Cell Surface Markers.
US2008299106	US - 20060560167 - 15/11/2006 ; US - 20060804060P - 06/06/2006 ; US - 20080189442 - 11/08/2008	ZOLTAN LAB LLC	A61K 38/46	Embodiments Of The Present Invention Include The Use Of Placental Alkaline Phosphatase And Other Members Of The Alkaline Phosphatase Family Alone Or In Combination With Human Transferrin And, Optionally, Human Alpha1-Antitrypsin To Enhance The Proliferation And Survival Of Adult Or Embryonic Stem Cells And Stem Cell-Derived Progenitor Cells In Vivo.
US2008299107	US - 20060560167 - 15/11/2006 ; US - 20060804060P - 06/06/2006 ; US - 20080189446 - 11/08/2008	ZOLTAN LAB LLC	A61K 38/46 ; A61P 43/00	Embodiments Of The Present Invention Include The Use Of Placental Alkaline Phosphatase Alone Or In Combination With Human Transferrin And, Optionally, Human Alpha1-Antitrypsin To Enhance The Proliferation And Survival Of Transplanted Stem Cells And Stem Cell-Derived Progenitor Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008299540	US - 20040569005P - 07/05/2004 ; US - 20040630934P - 24/11/2004 ; US - 20050123612 - 06/05/2005	BRIGHAM & WOMENS HOSPITAL ; WHITEHEAD BIOMEDICAL INST	C12N 5/02 ; C12N 5/08 ; C12Q 1/00 ; C12Q 1/68	The Invention Provides Tissue Culture System For Primary Cells (E.G. Normal Mammalian Primary Epithelial Progenitors). This System Includes: A) A Serum-Free, Chemically Defined Cell Culture Media; And, B) Methods For Isolation And In Vitro Long-Term Propagation Of Primary Cells (E.G. Primary Epithelial Cells). Primary Cells So Isolated And Cultured Can Be Kept Undifferentiated And Proliferate For Many Weeks (>15 Weeks) Or Population Doubling (>35 PD) Without Senescence, Or Any Detectable Genetic Alterations. Upon Changing Media/Culture Conditions, These Cells Can Be Induced To Differentiate. The Invention Also Provides Methods To Transform Normal Primary Cells So Cultured Into "Cancer Stem Cells." The Genetically Defined Cancer Stem Cell Tumor Model Mimics The Behavior Of The Disease Closely, E.G., The Cells Are Invasive, Hormone Responsive And Metastatic When Injected Into Mice. The Tumor Cells Express Genes That Are Specific To Cancer Stem Cells Identified In Patient Samples.
US2008299582	WO - 1998US22619 - 23/10/1998 ; US - 20000530346 - 29/08/2000 ; US - 20010317478P - 05/09/2001 ; US - 20020235094 - 04/09/2002 ; US - 20020330873 - 24/12/2002 ; US - 20080170219 - 09/07/2008	GERON CORP	C12N 15/10 ; C12N 15/87 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/02 ; C12Q 1/68	This Disclosure Provides An Improved System For Culturing Human Pluripotent Stem Cells. Traditionally, Pluripotent Stem Cells Are Cultured On A Layer Of Feeder Cells (Such As Mouse Embryonic Fibroblasts) To Prevent Them From Differentiating. In The System Described Here, The Role Of Feeder Cells Is Replaced By Components Added To The Culture Environment That Support Rapid Proliferation Without Differentiation. Effective Features Are A Suitable Support Structure For The Cells, And An Effective Medium That Can Be Added Fresh To The Culture Without Being Preconditioned By Another Cell Type. Culturing Human Embryonic Stem Cells In Fresh Medium According To This Invention Causes The Cells To Expand Surprisingly Rapidly, While Retaining The Ability To Differentiate Into Cells Representing All Three Embryonic Germ Layers. This New Culture System Allows For Bulk Proliferation Of Pps Cells For Commercial Production Of Important Products For Use In Drug Screening And Human Therapy.
US2008299656	US - 20070755320 - 30/05/2007	SONG SUN U	C12N 5/06	The Present Application Discloses A Method Of Manipulating A Biological Sample Of Cells, Which Includes Multi-Lineage Stem Cells, Progenitor Cells, Other Marrow Stromal Cells: Allowing The Sample Of Cells To Settle In A Container; Transferring Supernatant From The Container To Another Container; And Isolating Cells From The Supernatant, Which Has Comparatively Lower Density In The Sample.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008301822	US - 20050734076P - 07/11/2005 ; WO - 2006US43015 - 03/11/2006 ; US - 20080151594 - 07/05/2008	CLEVELAND CLINIC FOUNDATION	A01K 67/027 ; C07H 21/04 ; C12N 15/09 ; C12N 5/06 ; G01N 33/53	The Present Invention Is Directed To A Transgenic Non-Human Mammal (E.G., A Rodent Such As A Mouse) Whose Genome Comprises A Recombinant Nucleic Acid Sequence Comprising An Alpha1a-Adrenergic Receptor (AR) And A Marker Peptide (E.G., A Fluorescent Peptide Such As Green Fluorescent Protein And An Enhanced Green Fluorescent Protein) Operably Linked To All Or A Functional Portion Of An Alpha1a-AR Promoter, Wherein The Alpha1a-AR (E.G., Human Alpha1a-AR) And The Marker Peptide Are Expressed As A Fusion Protein In The Transgenic Non-Human Mammal. The Present Invention Also Provides Methods Of Producing A Transgenic Non-Human Mammal Whose Genome Comprises A Recombinant Nucleic Acid Sequence Comprising An Alpha1a-AR And A Marker Peptide, As Well As Targeting Constructs For Use In Such Methods. The Invention Also Provides A Source Of Cells (For Example, Tissue, Cells, Cellular Extracts, Organelles) And Animals Useful For Elucidating The Function Of Alpha1a-AR In Intact Animals. Further Aspects Of The Invention Provide methods for the identification of agents that modulate neural stem cell or progenitor cell differentiation by alpha1A-AR; methods of determining whether a cell is a neural stem cell; methods of regulating differentiation or proliferation of a neural stem cell or progenitor cell; and methods of treating neurodegenerative diseases, cognitive impairment or conditions.
US2008305074	US - 19890422383 - 16/10/1989 ; US - 19900537198 - 11/06/1990 ; US - 19900573616 - 24/08/1990 ; US - 19900589701 - 01/10/1990 ; US - 19910684535 - 10/04/1991 ; US - 19920982255 - 25/11/1992 ; US - 19930172329 - 21/12/1993 ; US - 19950486546 -	AMGEN INC	A61K 35/12 ; A61K 35/14 ; A61K 35/28 ; A61K 38/00 ; A61K 38/16 ; A61K 38/17 ; A61K 38/18 ; A61K 38/19 ; A61K 38/20 ; A61K 47/48 ; A61K 48/00 ; A61P 13/02 ; A61P 15/00 ; A61P 35/00 ; A61P 37/04 ;	Novel Stem Cell Factors, Oligonucleotides Encoding The Same, And Methods Of Production, Are Disclosed. Pharmaceutical Compositions And Methods Of Treating Disorders Involving Blood Cells Are Also Disclosed.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
	07/06/1995 ; US - 20000643652 - 21/08/2000 ; US - 20030620642 - 16/07/2003 ; US - 20070702389 - 05/02/2007		A61P 7/00 ; A61P 7/06 ; C07K 1/113 ; C07K 1/16 ; C07K 1/20 ; C07K 14/00 ; C07K 14/435 ; C07K 14/475 ; C07K 14/52 ; C07K 16/00 ; C07K 16/22 ; C07K 16/24 ; C12N 1/21 ; C12N 15/02 ; C12N 15/03 ; C12N 15/09 ; C12N 15/10 ; C12N 15/12 ; C12N 15/18 ; C12N 15/19 ; C12N 15/63 ; C12N 15/65 ; C12N 15/85 ; C12N 15/87 ; C12N 5/00 ; C12N 5/06 ; C12N 5/08 ; C12N 5/10 ; C12P 21/00 ; C12P 21/08 ; C12Q 1/68	
US2008305085	US - 20040629626P - 19/11/2004 ; US - 20050791147 - 18/11/2005 ; WO - 2005US41927 - 18/11/2005	SCADDEN DAVID T ; STIER SEBASTIAN	A61K 35/12 ; A61K 38/00 ; A61P 31/00 ; C12N 5/06	The Present Invention Features Methods And Compositions That Are Useful For Promoting Stem Cell Survival And Expansion. In Addition, The Invention Also Provides Compositions And Methods For The Treatment Of Neoplasia.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008305086	US - 20070896758P - 23/03/2007 ; US - 20080054245 - 24/03/2008	CALIFORNIA STEM CELL INC	A61K 35/12 ; A61P 25/00 ; C12N 5/06 ; C12Q 1/02	Motor Neuron Progenitor (MNP) Cells And Populations Of MNP Cells, Are Provided, In Particular, Populations Of Human Late Stage MNP Cells Having A Purity Of Greater Than About 65% Late Stage MNP Cells And High-Purity Populations Of MNP Cells Having Greater Than 95% Viable Cells, As Well As Method Of Making And Using The Same, Including Deriving Late Stage MNP Cells From Pluripotent Embryonic Stem Cells, Producing High-Purity Populations Of Late Stage MNP Cells, Producing Populations Of Viable MNP Cells, Transporting Viable MNP Cells, And Transplanting MNP Cells.
US2008305148	US - 20070895510P - 19/03/2007 ; US - 20080047417 - 13/03/2008	NAT YANG MING UNIVERSITY	A61F 2/00 ; A61K 35/12 ; A61P 25/00	Transplantation Of Human Umbilical Mesenchymal Stem Cells (Humscs) To An Area Of A Spinal Injury Is Therapeutically Effective In Treating The Spinal Injury. Methods For Treating Spinal Injuries Based On Such Transplantation Are Described.
US2008305544	JP - 20040199609 - 06/07/2004 ; WO - 2005JP12472 - 06/07/2005	IWATA HIROO ; KOBORI MASATO ; SASAI YOSHIKI ; SATOH MITSUO ; YAMAZOE HIRONORI ; YANO KEIICHI	C12N 5/06	An Object Of The Present Invention Is To Provide A Process For Producing A Nerve Cell By Inducing Differentiation Of An Embryonic Stem Cell, A Method For Inducing Differentiation Of The Embryonic Stem Cell Into A Nerve Cell, A Medium To Be Used In The Production Process Or Differentiation Induction Method, Or A Method For Improving Purity Of The Nerve Cell Obtained By Inducing Differentiation Of The Embryonic Stem Cell. The Present Invention Provides A Process For Producing A Nerve Cell Which Is Applicable To Treatment Of Neurodegenerative Disease Or The Like Easily, Selectively Or Inexpensively By Inducing Differentiation Induction Of An Embryonic Stem Cell Using Vitamin B12 Or A Salt Thereof And Heparin, A Substance Having Heparin-Like Activity Or A Salt.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008305545	US - 20000208285P - 31/05/2000 ; WO - 2001EP06210 - 31/05/2001 ; US - 20030297147 - 28/07/2003 ; US - 20080081104 - 10/04/2008	MNEMOSCIENCE GMBH	A61L 27/18 ; A61L 27/38 ; A61L 27/58 ; B29C 61/06 ; C08L 67/04 ; C12N 5/06 ; C12N 5/08	Methods And Compositions Are Described Herein For Reconstruction Of Different Functional Tissues. Dissociated Cells, Differentiated Cells, Adult Mesenchymal Stem Cells Or Embryonic Stem Cells Are Seeded On A Scaffold. The Scaffold Will Consist Of A Biocompatible, Biodegradable Shape Memory ("SM") Polymers. In Addition Bioactive Substances May Be Incorporated In The Scaffold. Thermoplastic As Well As Thermoset Materials With SM-Effect Can Be Used. The Shape Memory Effect Will Be Applied As An Interactive Link Between The Cells And The Used Polymeric Scaffold. The Degradation Kinetics As Well As Shape Memory Transition Temperature Will Be Tailored By Adjusting To Monomer Ratios Of The Co-Oligomers. The Shape Memory Effect Will Be Used To Create A Degradation Or Release Of Bioactive Substances On Demand, Induce Forces On Seeded Cells Or Induce Proliferation And Differentiation Of Cells.
US2008306004	US - 20010316368P - 30/08/2001 ; US - 20010799451 - 05/03/2001 ; US - 20020125852 - 19/04/2002 ; US - 20060356373 - 15/02/2006 ; US - 20080069560 - 11/02/2008	NUVELO INC	A61K 31/70 ; A61K 38/00 ; A61P 43/00 ; C07K 14/00 ; C07K 14/47 ; C07K 14/475 ; C07K 16/18 ; C12N 15/00 ; C12N 15/11 ; C12N 5/06 ; C12P 21/04 ; C12Q 1/68 ; C40B 40/08 ; G01N 33/53	The Invention Provides Novel Polynucleotides And Polypeptides Encoded By Such Polynucleotides And Mutants Or Variants Thereof That Correspond To A Novel Human Secreted Stem Cell Growth Factor-Like Polypeptides. In Particular, The Invention Relates To Novel Stem Cell Growth Factor-Like Polypeptides, Including Novel Proteins Named SCGF3248Fk081_Aa2, SCGF3248Fk081_Aa1, Scgffk081_Aa3, And SCGF323401Fe131_Aa1. Other Aspects Of The Invention Include Vectors Containing Processes For Producing Novel Human Secreted Stem Cell Growth Factor-Like Polypeptides, And Antibodies Specific For Such Polypeptides.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008311092	EP - 20050076219 - 24/05/2005 ; WO - 2006IB01969 - 24/05/2006	PEREZ-CARO MARIA ; SANCHEZ-GARCIA ISIDRO ; VOCES-SANCHEZ FELIPE	A01K 67/027 ; A61K 35/12 ; A61P 35/00 ; C12N 15/11 ; C12N 5/02 ; C12N 5/10 ; C12Q 1/02 ; C12Q 1/68 ; G01N 33/574	The Invention Relates To Animal Solid Tumour Models Which Comprise A Transgenic Non-Human Mammal Containing In Its Genome A DNA Construct That Comprises A Gene Created And/Or Activated By A Genetic Anomaly Associated With Human Cancer Operatively Bound To A Promoter That Directs The Expression Of The Gene In Sca1+ Cells. The Invention Also Relates To Stem Cells Capable Of Specifically Expressing In Stem Cells Human Genetic Anomalies Associated With Human Pathologies. Applications Of These Models And Stem Cells, Such As Diagnostic, Therapeutic And Prophylactic Applications For Human Diseases, And Products And Methods Are Provided.
US2008311093	US - 20060868971P - 07/12/2006 ; US - 20070945014P - 19/06/2007 ; US - 20070952535P - 27/07/2007 ; US - 20070952898 - 07/12/2007	AMERICAN SYMBOLIC LLC	A61K 35/12 ; A61Q 90/00	Stem Cell Secretions Are Derived From Epithelial Cells Conditioned Media. The Stem Cell Secretions Are Then Applied Topically, Orally, Or Rectally, Etc., To Derive Health Benefits From The Growth Factors And Other Molecules Comprising The Stem Cell Secretion. The Stem Cell Secretion May Optionally Be Modified By Covalently Bonding Fatty Acids To Protect The Molecules Through The Delivery Process And To Make Them More Readily Available To Cells.
US2008311094	EP - 20050447286 - 21/12/2005 ; WO - 2006EP10014 - 17/10/2006 ; WO - 2006EP12046 - 14/12/2006	UNIV LOUVAIN	A61K 35/12 ; A61P 1/16 ; C12N 5/08 ; C12P 21/00 ; C12Q 1/02 ; C12Q 1/70	Isolated Liver Progenitor Stem Cells And Cell Populations Of Isolated Liver Progenitor Stem Cells Are Disclosed. The Progenitor Stem Cells Originate From Adult Liver, Especially Human Adult Liver. The Isolated Progenitor Stem Cells Have Uses In Medicine, Hepatology, Inborn Errors Of Liver Metabolism Transplantation, Infectious Diseases And Liver Failure. Methods Of Isolating These Cells And Their Culture Is Described. The Isolated Cells Are Characterized Before And After Differentiation. Their Use For Transplantation And As Animal Models Of Human Disease, Toxicology And Pharmacology Is Disclosed.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008311607	US - 20040600924P - 12/08/2004 ; US - 20050573508 - 12/08/2005 ; WO - 2005US28823 - 12/08/2005	UNIV TEXAS	C12N 5/02 ; C12Q 1/02	Compositions And Methods For Regulating In Vitro Cell Growth Are Disclosed, And For Providing Undifferentiated Stem Cells Or Embryonic Cells That Are Suitable For Transplantation Into Damaged Tissues Or Organs, Or For Use In Tissue Repair. A Representative Method Includes Causing The Overexpression Or Underexpression Of Galt Binding Protein (Gtbp), Also Referred To As Galt Associated Protein (GTAP), In A Cell Such That Ubiquitination Of At Least One Cellular Protein Associated With Cell Adhesion And/Or Cell-To-Cell Interaction Is Correspondingly Increased Or Decreased, Causing Inhibition Of Cell Growth When GTAP Is Overexpressed And Causing Enhanced Cell Growth When GTAP Is Underexpressed By The Cell. As A Result, Growth Of The Cell Is Altered Or Regulated.
US2008311625	IT - 2005TO00819 - 18/11/2005 ; WO - 2006IB54288 - 16/11/2006	GENNERO LUISA ; PONZETTO ANTONIO ; SAVARINO ANDREA	C12N 5/08 ; C12P 21/04	The Present Invention Relates To Immortal Pluripotent Stem Cells Derived From A Human Leukaemia Cell Line, Preferably A Human Monocytoid Cell Line And More Preferably The Human Monocytoid Cell Line, THP1. The Present Invention Further Relates To Cell Lines Derived From The Immortal Pluripotent Stem Cell Line Having The Phenotype Of Cell Strains Characteristic Of Human Tissues, Particularly Having A Human Hepatocyte Phenotype, As Well As The Methods For Preparing Thereof. The Present Invention Further Relates To The Use Of The Derived Cell Line With A Human Hepatocytic Phenotype For The Production Of Albumin And Blood Coagulation Factors.
US2008312187	US - 20050677133P - 02/05/2005 ; US - 20050735311P - 12/11/2005 ; US - 20050736735P - 14/11/2005 ; WO - 2006US05745 - 17/02/2006 ; US - 20070934534 - 02/11/2007	KIM TAE-WAN ; LANDMAN NATALIE	A61K 31/661 ; A61P 25/28 ; C12N 9/99 ; C12Q 1/02	The Present Invention Relates To Methods Of Treating Alzheimer's Disease Which Utilize Agents That Increase Neuronal Phosphotidylinositol 4,5-Biphosphate (PIP2), And To Differentiated Stem Cell-Based Assay Systems That May Be Used To Identify Agents That Modulate Phosphoinositide Levels And Thereby Treat A Variety Of Diseases. It Is Based, At Least In Part, On The Discovery That Edelfosine, An Agent That Increases PIP2 Levels By Inhibiting An Enzyme That Catalyzes PIP2 Breakdown, Decreases Levels Of Neurotoxic Abeta42 Peptide, Particularly In Cells Expressing A Mutant Presenilin Gene Associated With Familial Alzheimer's Disease.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008313752	JP - 20040058406 - 03/03/2004 ; WO - 2005JP02548 - 18/02/2005	MIYAMOTO KAORU ; UMEZAWA AKIHIRO ; YAZAWA TAKASHI	A01K 67/027 ; C12N 15/09 ; C12N 5/06 ; C12N 5/08 ; C12N 5/10 ; C12P 33/00	To Control The Differentiation Of Mesenchymal Stem Cells Into Steroid Hormone Producing Cells. Mesenchymal Stem Cells Can Be Differentiated Into Steroid Hormone-Producing Cells By Being Stimulated By A Transcriptional Factor (SF-1), Preferably By The Transcriptional Factor (SF-1) And Camp. The Present Invention Is A Method For Differentiating Mesenchymal Stem Cells Into Steroid Hormone Producing Cells, Comprising Stimulating The Mesenchymal Stem Cells By The Transcriptional Factor (SF-1). The Mesenchymal Stem Cells May Be Further Stimulated By Camp.
US2008317719	US - 20070820975 - 20/06/2007	FULGA VALENTIN ; PORAT YAEL ; POROZOV SVETLANA ; SHIMONI-ZALK DAPHNA	A61K 45/00 ; A61P 15/00 ; C12N 5/00	A Method Is Provided, Including In Vitro Stimulating An Initiating Cell Population (ICP) Of At Least 5 Million Cells That Have A Density Of Less Than 1.072 G/Ml, And At Least 1% Of Which Are CD34+CD45-/Dim, To Differentiate Into A Progenitor/Precursor Cell Population (PCP). A Method Is Provided, Including In Vitro Stimulating An Initiating Cell Population (ICP) Of At Least Ten Thousand Cells That Have A Density Of Less Than 1.072 G/Ml To Differentiate Into A Progenitor/Precursor Cell Population (PCP). A Method Is Provided, Including Separating Lower Density Cells From Higher Density Cells, The Lower Density Cells Defining An Initiating Cell Population (ICP), And In Vitro Stimulating The ICP To Differentiate Into A Progenitor/Precursor Cell Population (PCP). Other Embodiments Are Also Described.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US2008317721	US - 20050656122P - 24/02/2005 ; US - 20060884973 - 24/02/2006 ; WO - 2006US06744 - 24/02/2006	SCRIPPS RESEARCH INST	A61K 35/12 ; A61K 35/48 ; A61P 27/02	The Present Invention Provides A Method For Treating Retinopathy Of Prematurity (ROP) And Related Retinopathic Diseases. The Method Comprises Administering To The Retina Of A Mammal Suffering From, Or At Risk Of Developing, Retinopathy Of Prematurity Or A Related Retinopathic Disease An Amount Of Cells From A Vasculotrophic Lineage Negative Hematopoietic Stem Cell Population, Effective To Promote Beneficial Physiological Revascularization Of Damaged Areas Of The Retina And To Ameliorate Damage To The Retina Caused By The Disease. Preferably, The Mammal Is A Human Patient. In One Preferred Embodiment, The Lineage Negative Hematopoietic Stem Cell Population Is A Lineage Negative Hematopoietic Stem Cell Population Comprising Hematopoietic Stem Cells And Endothelial Progenitor Cells (I.E., Lin-HSC). In Another Preferred Embodiment, The Lineage Negative Hematopoietic Stem Cell Population Is An Isolated Myeloid-Like Bone Marrow (MLBM) Cell Population In Which The Majority Of The Cells Are Lineage Negative And Express CD44 antigen and CD11b antigen. As an alternative, for treatment of newborn infants, a lineage negative hematopoietic stem cell population can be isolated from umbilical cord vein blood.
US2008318804	JP - 20040170587 - 08/06/2004 ; WO - 2005JP10436 - 07/06/2005	CARNA BIOSCIENSES INC ; UNIV OSAKA	A01K 67/027 ; C12N 13/00 ; C12N 15/01 ; C12N 15/85 ; C12N 15/87 ; C12N 5/06 ; C12N 5/10 ; C12N 9/14 ; C40B 40/02	This Is Intended To Provide A Technique For Providing A Stem Cell Having A Mutation In Both Alleles (A Pair Of Alleles). A Method For Producing A Stem Cell Having A Mutation In Both Chains Of Alleles Which Comprises: A) The Step Of Providing A Stem Cell; B) The Step Of Preventing Blm Alleles From Functioning In The Stem Cell; And C) The Step Of Inducing Mutation In The Stem Cell. It Is Also Intended To Provide A Library Of Stem Cells Having A Mutation In Both Chains Of Alleles Wherein Stem Cells Involved In The Library Have The Mutation Transferred Thereinto Over The Entire Genome.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
US7393686	US - 20000569259 - 11/05/2000 ; US - 20000654462 - 01/09/2000	UNIV CALIFORNIA ; UNIV COLUMBIA	C12N 15/00 ; C12N 5/00 ; C12N 5/02	This Invention Provides A Method Of Converting A Stem Cell Into A Ventral Neuron Which Comprises Introducing Into The Stem Cell A Nucleic Acid Which Expresses Homeodomain Transcription Factor Nkx6.1 Protein In The Stem Cell So As To Thereby Convert The Stem Cell Into The Ventral Neuron. Provided Are Methods Of Diagnosing A Motor Neuron Degenerative Disease In A Subject. Also Provides Is A Method Of Treating Neuronal Degeneration In A Subject Which Comprises Implanting In Diseased Neural Tissue Of The Subject A Neural Stem Cell Which Comprises An Isolated Nucleic Acid Molecule Which Is Capable Of Expressing Homeodomain Nkx6.1 Protein Under Conditions Such That The Stem Cell Is Converted Into A Motor Neuron After Implantation, Thereby Treating Neuronal Degeneration In The Subject.
US7396537	US - 20020360820P - 28/02/2002 ; US - 20020408448P - 05/09/2002 ; US - 20030378015 - 28/02/2003	TRUSTEES OF THE UNIVERSITY OF	A61K 9/00	A Patch For Cardiac Tissue Engineering Includes A Gel Layer Supported By An Intermediate Layer, Which Is Attached To A Reinforcement Layer. These Patches May Be Implanted In A Heart To Treat Pediatric Congenital Malformations Of The Heart As Well As Adult Ischemic Myopathies. The Gel Layer May Include Cells Such As, For Example, Stem Cells; The Intermediate Layer May Be Biodegradable Porous Mesh And The Reinforcement Layer May Be Polytetrafluoroethylene. Included Are Methods For Making Patches According To The Invention And For Tissue Engineering Using Patches Of The Invention.
US7455962	JP - 19990320234 - 10/11/1999 ; WO - 2000JP07817 - 07/11/2000	TOUDAI TLO LTD	A01K 67/027 ; A01N 1/02 ; C07K 16/18 ; C07K 16/28 ; C12N 15/12 ; C12N 15/85 ; C12N 5/06 ; C12P 21/08	Mouse PCLP1 Was Identified By Expression Cloning With The Use Of A Monoclonal Antibody Against A Surface Antigen Of A Cell Line Derived From Mouse AGM. By Fractionating PCLP1-Positive/CD45-Negative Cells And Culturing Them In Vitro, It Was Clarified That These Cells Differentiate Into Endothelial-Like Cells, Angioblast-Like Cells, And Hematopoietic Cells. By Transferring The PCLP1-Positive/CD45-Negative Cells Into A Mouse Defective In The Hematopoietic Function, The Hematopoietic System Was Reconstructed Over A Long Period Of Time. These Facts Indicate That The PCLP1-Positive/CD45-Negative Cells Contain Mammalian Hemangioblasts Capable Of Expressing The Activity As Long-Term Repopulating Hematopoietic Stem Cells (LTR-HSC). The Present Invention Provides A Method For Preparing A Cell Fraction Containing Hemangioblasts, The Cell Fraction Prepared By The Method, And Use Of This Cell Fraction.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008081457	US - 20070878389P - 04/01/2007	BARBASH ISRAEL ; ITZHAKI-ALFIA AYELET ; LEOR JONATHAN ; TEL HASHOMER MEDICAL RES INFRA ; UNIV RAMOT	A61K 35/00 ; C12N 5/00 ; C12N 5/06	A Method Of Isolating Cardiac Stem Cells Is Disclosed. The Method Comprises Contacting A Tissue Which Comprises The Cardiac Stem Cells With A Composition Which Comprises Dispase II Under Conditions Sufficient To Induce Cell Dissociation. Banks Of The Isolated Cardiac Stem Cells Are Also Disclosed.
WO2008082523	US - 20060875560P - 19/12/2006	COHEN JACOB ; COHEN MICHAEL ; NAT STEM CELL INC	A61K 35/12 ; A61K 35/48	Compositions Including Formulations Comprising Secreted Products Obtained From The Culture Medium Of Stem Cells, Such As Umbilical Cord Blood Stem Cells, Or Embryonic Germ Cell Derivatives, Or Embryonic Stem Cells, Are Provided For Enhancement Of Wound Healing. Further Compositions Contain Components Identified In Such Culture Medium To Enhance Wound Healing. Methods For Using The Compositions And Formulations For Enhancing Wound Healing Are Also Provided. Wounds To Both Soft And Bony Tissues Are Encompassed, And Include Wounds Created By Surgical Procedures.
WO2008082525	US - 20060875558P - 19/12/2006	COHEN JACOB ; COHEN MICHAEL ; NAT STEM CELL INC	A61K 8/02 ; C12N 5/00	Compositions Including Topical Formulations Comprising Secreted Products Obtained From The Culture Medium Of Human Umbilical Cord Stem Cells And Particular Combinations Of Components Therefrom Are Provided For Treatment Of Various Dermatological Conditions, Such As Adverse Consequences Of Aging, Wrinkling, Altered Pigmentation, Altered Viscoelasticity, And Altered Thickness, Among Others. Methods For Using The Compositions And Topical Formulations For Treating Adverse Or Undesirable Dermatological Conditions Are Also Provided, As Well As Preventing The Appearance Of Undesirable Dermatological Conditions.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008083251	US - 20060877530P - 27/12/2006 ; US - 20060882948P - 31/12/2006	LAIRD PETER W ; USC STEVENS UNIVERSITY OF SOUT ; WIDSCHWENDTER MARTIN	C12Q 1/68	In Particular Aspects, Stem-Cell Polycomb Group (Pcg) Targets Are More Likely To Have Cancer-Specific Promoter DNA Methylation Than Non-Targets, Indicating A Stem-Cell Origin Of Cancer, Where Reversible Gene Repression Is Replaced By Permanent Silencing, Locking The Cell Into A Perpetual State Of Self-Renewal And Predisposition To Subsequent Malignant Transformation. Exemplary Aspects Provide Methods For Identifying Preferred DNA Methylation Markers For A Cellular Proliferative Disorder And/Or Cancer And Markers For Developmental Lineages And/Or Stages, Based On Identifying Pcg Protein Or Pcg Repressive Complex Genomic Target Loci Within A Precursor Cell (E.G., Stem Or Progenitor Cell) Population, And Determining, In Cells Of The Proliferative Disorder And/Or Cancer Or Cell Of The Particular Developmental Lineages And/Or Stages, A Characteristic Methylation Status Of The Pcg Target Loci. Additional Aspects Provide Methods For Validating And/Or Monitoring A Precursor Cell (E.G., Stem Cell) Population. Diagnostic and prognostic methods for ovarian and breast cancer are provided.
WO2008083401	US - 20070883081P - 02/01/2007	SEAL SUDIPTA ; SUGAYA KIMINOBU ; UNIV CENTRAL FLORIDA RES FOUND	A61K 33/00	Disclosed Herein Are Methods And Materials For Influencing Proliferation Of Stem Cells. Specifically Exemplified Herein Are Compositions Comprising Cerium Oxide Nanoparticles Which Can Be Used To Stimulate Proliferation Of Stem Cells Under Common Culture Conditions, Or Which Can Be Utilized To Improve Therapeutic Outcomes.
WO2008083987	US - 20070879799P - 11/01/2007	CELLARTIS AB ; HYLLNER SVEN JOHAN ; STREHL RAIMUND ; UDDENBERG KATARINA ; WESSBERG FREDRIK	C12N 5/06 ; C12N 5/08	The Present Invention Relates To A Novel Mesenchymal Human Progenitor (Hbs- MP) Cell Population Derived From Human Blastocyst-Derived Stem (Hbs) Cells And The Method To Obtain The Progenitor Cell Population In Which Is Eliminated The Need Of Co-Culture Steps, Cell Sorting, Manual Selection, And Transfections. Furthermore, The Present Invention Relates To The Use Of The Hbs-MP Cells In Drug Discovery And Specifically For Toxicity Testings As Well As For Therapeutic Use.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008084401	US - 20070883406P - 04/01/2007	DOMOGATSKAYA ANNA ; RODIN SERGEY ; TRYGGVASON KARL	C12N 5/06	The Present Disclosure Is Directed To The Development Of Compositions, Such As Extracellular Matrices, And Processes For Using The Same, For Culturing Stem Cells In Vitro In An Undifferentiated State. In This Regard, It Has Been Discovered That When Pluripotent Mouse And Human Embryonic Stem Cells Are Cultured On Plates Coated With Recombinant Laminin-10 (Laminin-51 1) Or Laminin-5 (Laminin-322), Or Their Functional Domains, The Embryonic Stem Cells Proliferated And Maintained Their Pluripotency.
WO2008084566	JP - 20070003398 - 11/01/2007	FUJII TOMOAKI ; RES ORGANIZATION OF INFORMATIO ; SHIROISHI TOSHIHIKO ; TAMURA MASARU	A01K 67/027 ; C12N 15/09 ; C12Q 1/02 ; G01N 33/15 ; G01N 33/50	It Is Intended To Provide A Model Mouse Which Is To Be Used For Clarifying The Functions Of Gsdmd On Intestinal Epithelial Cells And Gsdmd Gene Encoding The Same. A Mouse Having A Homozygote In Which Gsdmd Gene Encoding Gsdmd Has Been Knock-Out On Chromosome And Not Expressing Gsdmd Is Referred To As The Model Mouse. First, A Targeting Vector Having A Fragment Which Contains The Exon 2 Of Gsdmd Gene In Mouse Genomic DNA Is Transferred Into Mouse Embryonic Stem Cells And Chimeric Embryonic Cells Are Constructed From The Embryonic Stem Cells Having The Gsdmd Gene Knock-Out By Homologous Recombination. Next, These Chimeric Cells Are Transplanted Into A Host Mouse. The Gsdmd Gene-Knock Out Chimeric Mice Thus Bred Are Mated And Heterozygous Mice Are Selected. By Mating These Heterozygous Mice With Each Other, A Model Mouse Of The Gsdmd Gene-Knockout Homozygote Can Be Obtained.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008085564	US - 20060845934P - 20/09/2006	KUNDRA VIKAS ; UNIV TEXAS	A01K 67/027 ; A61K 48/00 ; A61K 49/00 ; A61K 51/08 ; A61K 51/12 ; C07K 14/72 ; G01N 33/569	Disclosed Are Methods For Tracking The Location Of A Cell And/Or Its Progeny In A Subject, Such As A Stem Cell, That Involve (A) Obtaining A Cell; (B) Trans Fecting The Cell With An Expresison Construct Comprising A First Coding Region Encoding A First Reporter Comprising A Truncated Recombinant Seven Transmembrane G-Protein Associated Receptor (GPCR) Amino Acid Sequence Operatively Linked To A First Promoter Sequence; (C) Introducing The Cell To The Subject; And (D) Detecting The Location Of The Cell In The Subject By Contacting The Cell With A Detectable Moiety That Binds To The Truncated Recombinant GPCR And Imaging The Detectable Moiety Using A Non-Invasive Imaging Technique. The Cell, For Example, May Be A Stem Cell Or An Immune Cell. Also Disclosed Are Non-Human Transgenic Animals Whose Genome Comprises A Nucleic Acid Encoding A Truncated Recombinant GPCR Amino Acid Sequence. Also Disclosed Are Methods Of Producing Stem Cells That Express A Truncated Recombinant GPCR, Comprising Obtaining A Transgenic Animal of the present invention and isolating stem cells from the transgenic animal.
WO2008085879	US - 20070883281P - 03/01/2007	CALIFORNIA STEM CELL INC ; NISTOR GABRIEL	C12N 5/00	The Invention Provides Media Formulations. A Complete Media Formulation Of The Invention Includes, For Example, The Following Components: Albumin, An Iron Carrier, Glutamine, A Glycosidase Or Hydrolase, Fibroblast Growth Factor (FGF), A Salt Or Mineral, And Essential Amino Acids, At An Osmolarity Of About 220-330 Mosm/Liter.
WO2008086426	US - 20070013243P - 12/12/2007 ; US - 20070884162P - 09/01/2007 ; US - 20070889893P - 14/02/2007 ; US - 20070938564P - 17/05/2007	CLEVELAND BIOLABS INC ; SHAKHOV ALEXANDER ; STROM EVGUENIA	A61K 38/14 ; C12N 5/00	A Method Is Provided For Increasing The Number Of Hematopoietic Stem Cells In The Bone Marrow, Increasing The Mobilization Of These Cells To Migrate From The Bone Marrow To The Bloodstream And Elsewhere, And Increasing The Number Of Differentiating Hematopoietic Stem Cells In The Bloodstream.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008087256	FI - 20070005030 - 18/01/2007	GLYKOS FINLAND LTD ; HEISKANEN ANNAMARI ; JAATINEN TAINA ; LAINE JARMO ; NATUNEN JARI ; NYSTEDT JOHANNA ; SATOMAA TERO ; SUOMEN PUNAINEN RISTI VERIPALV	C08B 37/00 ; C12N 5/08 ; C12N 9/10 ; C12N 9/24 ; C12Q 1/48 ; G01N 33/50	The Invention Describes Specific Sialylated Structures Present On Human Stem Cells And Cell Populations Derived Thereof. The Invention Is Especially Directed To Methods To Control The Status Of Stem Cells By Changing Sialylation And/Or Fucosylation Levels Of The Cells. The Invention Is Further Directed To Novel Stem Cells, The Glycosylation Of Which Has Been Specifically Altered. The Control Methods Are Preferably Mass Spectrometric Methods.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008087257	FI - 20070005033 - 18/01/2007 ; FI - 20070005034 - 18/01/2007	BLOMQVIST MARIA ; GLYKOS FINLAND LTD ; HEISKANEN ANNAMARI ; IMPOLA ULLA ; LAINE JARMO ; MIKKOLA MILLA ; NATUNEN JARI ; OLONEN ANNE ; SAARINEN JUHANI ; SATOMAA TERO ; SUOMEN PUNAINEN RISTI VERIPALV ; TIITINEN SARI ; TIITTANEN MINNA ; VALMU LEENA	C12N 5/06 ; C12N 5/08	The Present Invention Provides Methods And Mate Rials To Modulate And Grow Stem Cells By Contacting Stem Cells With A Binder Recognizing Te Rminal Glycan Structures Of Stem Cells. The Modulation Can Be Morphological Change, Change In Differentiation Status, Biological Status Or Adherence. The Materials Provided In The Present Invention Are Also Useful To Screen Such A Binding Agents And Binders.
WO2008087258	FI - 20070000205 - 13/03/2007 ; FI - 20070005033 - 18/01/2007	AITIO OLLI ; ANDERSON HEIDI ; BLOMQVIST MARIA ; GLYKOS FINLAND LTD ; HEISKANEN ANNAMARI ; IMPOLA ULLA ; JAATINEN TAINA ; LAINE JARMO ;	C12N 5/06 ; C12N 5/08 ; G01N 33/50	The Invention Describes Reagents And Methods For Specific Binders To Glycan Structures Of Stem Cells. Furthermore The Invention Is Directed To Screening Of Additional Binding Reagents Against Specific Glycan Epitopes On The Surfaces Of The Stem Cells. The Preferred Binders Of The Glycans Structures Includes Proteins Such As Enzymes, Lectins And Antibodies.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
		NATUNEN JARI ; OLONEN ANNE ; PARTANEN JUKKA ; PITKAENEN VIRVE ; SAARINEN JUHANI ; SATOMAA TERO ; SUOMEN PUNAINEN RISTI VERIPALV ; TIITINEN SARI ; VALMU LEENA		

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008087259	FI - 20070000200 - 08/03/2007 ; FI - 20070000205 - 13/03/2007 ; FI - 20070000368 - 10/05/2007 ; FI - 20070000369 - 10/05/2007 ; FI - 20070000650 - 28/08/2007 ; FI - 20070005033 - 18/01/2007 ; FI - 20070005034 - 18/01/2007 ; WO - 2007FI50405 - 29/06/2007	AITIO OLLI ; ANDERSON HEIDI ; BLOMQVIST MARIA ; GLYKOS FINLAND LTD ; HEISKANEN ANNAMARI ; HIRVONEN TIA ; IMPOLA ULLA ; JAATINEN TAINA ; LAINE JARMO ; MIKKOLA MILLA ; NATUNEN JARI ; NATUNEN SUVI ; OLONEN ANNE ; PARTANEN JUKKA ; PITKAENEN VIRVE ; SAARINEN JUHANI ; SALO HANNA ; SATOMAA TERO ; SUOMEN PUNAINEN RISTI VERIPALV ; TIITINEN SARI ; TIITTANEN MINNA ; VALMU LEENA	C12N 5/08 ; G01N 33/50	The Invention Describes Reagents And Methods For Specific Binders To Glycan Structures Of Stem Cells. Furthermore The Invention Is Directed To Screening Of Additional Binding Reagents Against Specific Glycan Epitopes On The Surfaces Of The Stem Cells. The Preferred Binders Of The Glycans Structures Includes Proteins Such As Enzymes, Lectins And Antibodies.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008087260	FI - 20070000368 - 10/05/2007 ; FI - 20070000650 - 28/08/2007 ; FI - 20070005033 - 18/01/2007	AITIO OLLI ; BLOMQVIST MARIA ; GLYKOS FINLAND LTD ; HEISKANEN ANNAMARI ; IMPOLA ULLA ; LAINE JARMO ; NATUNEN JARI ; NATUNEN SUVI ; OLONEN ANNE ; SAARINEN JUHANI ; SALO HANNA ; SATOMAA TERO ; SUOMEN PUNAINEN RISTI VERIPALV ; TIITINEN SARI ; VALMU LEENA	C12N 5/08 ; G01N 33/50	The Invention Describes Reagents And Methods For Speficic Binders To Glycan Structures Of Stem Cells. Furthermore The Invention Is Directed To Screening Of Additional Binding Reagents Against Specific Glycan Epitopes On The Surfaces Of The Stem Cells. The Preferred Binders Of The Glycans Structures Includes Proteins Such As Enzymes, Lectins And Antibodies.
WO2008087917	JP - 20070009617 - 18/01/2007	IKEDA HANAKO ; MANDAI MICHIKO ; OSAKADA FUMITAKA ; RIKEN ; TAKAHASHI MASAYO ; UNIV KYOTO	C12N 15/09 ; C12N 5/06	Disclosed Is A Method For The Production Of A Retinal Progenitor Cell Of A Primate, Which Comprises The Steps Of: Culturing An Embryonic Stem Cell From A Primate In A Serum-Free Culture Medium In The Form Of A Floating Aggregate; And Collecting The Retinal Progenitor Cell From The Culture. Also Disclosed Is A Method For The Production Of A Photoreceptor Progenitor Cell, Which Comprises The Steps Of: Culturing An Isolated Retinal Progenitor Cell (Which Has Been Differentiated And Induced From An Embryonic Stem Cell) In The Presence Of A Gamma-Secretase Inhibitor Under Adhesive Culture Conditions; And Collecting The Retinal Progenitor Cell From The Culture.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008088863	US - 20070881226P - 19/01/2007	FEHLING HANS JOERG ; GADUE PAUL ; IRION STEFAN ; KELLER GORDON ; LUCHE HERVE ; SINAI SCHOOL MEDICINE	A01K 67/00 ; A01K 67/027 ; A01K 67/033 ; C07H 21/00 ; C07H 21/02 ; C07H 21/04 ; C12N 15/00 ; C12N 5/00 ; C12N 5/02	(A2 A3 A9) The Invention Provides A Method For Generating A Transgenic Eukaryotic Cell Population Having A Modified Human Rosa26 Locus, Which Method Includes Introducing A Functional DNA Sequence Into The Human Rosa26 Locus Of Starting Eukaryotic Cells. Also Provided Are Targeting Vectors Useful In The Method, As Well As A Cell Population And A Transgenic Non-Human Animal Comprising A Modified Human Rosa26 Locus. Finally, The Invention Provides An Isolated DNA Sequence Corresponding To The Human Rosa26 Locus.
WO2008089351	US - 20070880747P - 17/01/2007	BERGENDAHL VEIT ; THOMSON JAMES A ; WISCONSIN ALUMNI RES FOUND	C12N 5/06 ; C12N 5/08	While Culture Medium And Systems Have Been Described That Permit The Culture And Proliferation Of Human Embryonic Stem Cells In Feeder Free And Animal Product Free Conditions, These Conditions Will Not Readily Support Cloning Of An Embryonic Stem Cell Culture Meaning, At Least Here, The Initiation Of A Sub-Culture Using One Or A Very Few Originating Cells. It Has Been Found Here That A Class Of Small Molecules That Are Inhibitors Of Kinase Enzymes Will Increase The Efficiency Of Cloning Of Stem Cell Cultures Sufficiently To Make Such Cloning Practical In The Defined Medium And In Other Media As Well.
WO2008089396	US - 20070885843P - 19/01/2007 ; US - 20070969051P - 30/08/2007	BENNETT ROBERT ; BURRIER ROBERT ; CHESNUT JONATHAN ; INVITROGEN CORP ; LIEU PAULINE ; RAO MAHENDRA ; TALIANA ANTJE ; THYAGARAJAN BHASKAR	C12N 15/09	The Disclosure Relates Generally To Stem Cell Biology And More Specifically To Genetic Manipulation Of Stem Cells. Methods And Compositions Using Recombinational Cloning Techniques Are Disclosed Which Allow The Construction And Insertion Of Complex Genetic Constructs Into Embryonic And Adult Stem Cells And Progenitor Cells. The Methods Disclosed Will Allow The Harvesting Of Adult Stem Cells Pre-Engineered With Integration Sites To Facilitate Early Passage Genetic Modification.
WO2008090355	GB - 20070001321 - 24/01/2007	BIRNIE RICHARD ; MAITLAND	A61K 39/00 ; A61P 35/00	The Invention Relates To Agents That Target Cancer Stem Cell Specific Gene Products And Includes Medicaments And Methods To Treat Cancer, In Particular Prostate Cancer.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
		NORMAN ; MISTRY ROSHNA ; PROCURE THERAPEUTICS LTD		
WO2008090826	JP - 20070011805 - 22/01/2007	MORITA RITSUKO ; OTSUKA CHEMICAL CO LTD ; TOKYO UNIVERSITY OF SCIENCE ED ; TSUJI TAKASHI	A61K 35/32 ; A61K 6/00 ; A61P 1/02 ; C12N 15/09 ; C12N 5/06	Disclosed Is A Mesenchymal Cell Production Method For Producing A Mesenchymal Cell For Use In The Formation Of A Tooth, Which Comprises The Steps Of: Culturing A Totipotent Stem Cell In The Presence Of A Differentiation-Inducing Agent To Produce A Differentiation-Induced Cell Population Containing A CD44-Positive And CD29-Positive Cell Or A CD44-Positive And CD106-Positive Cell; And Selecting The CD44-Positive And CD29-Positive Cell Or The CD44-Positive And CD106-Positive Cell From The Differentiation-Induced Cell Population As A Tooth-Forming Mesenchymal Cell. Also Disclosed Is A Tooth Production Method Comprising The Steps Of Placing A First Cell Population Comprising Substantially Only Either One Of A Mesenchymal Cell And An Epithelial Cell And A Second Cell Population Comprising Substantially Only The Other In The Inside Of A Carrier Which Can Allow The Cells To Be Contacted With Each Other In A Closely Adhered State Without Mixing Them And Culturing The Cell Populations, Wherein The Mesenchymal Cell Comprises the tooth-forming mesenchymal cell.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008091043	KR - 20070006409 - 22/01/2007	HONG HYUNSOOK ; KOREA INST OF RADIOLOGICAL & M ; LEE JUNGSUN ; MODERN CELL & TISSUE TECHNOLOG ; SON YOUNGSOOK ; UNIV KYUNG HEE UNIV IND COOP	A61K 38/14 ; A61P 19/00	Disclosed Herein Are A Composition For Prevention Or Treatment Of Bone Marrow Damage Comprising Substance-P As An Active Ingredient; A Use Of Substance-P For The Preparation Of A Medicament For Prevention Or Treatment Of Bone Marrow Damage; A Method For Prevention Or Treatment Of Bone Marrow Damage Comprising Administering A Therapeutically Effective Amount Of Substance-P To A Mammal; An Anticancer Supplement Comprising Substance-P As An Active Ingredient; A Use Of Substance-P For The Preparation Of An Anticancer Supplement; And A Method For Prevention Or Treatment Of Cancer Comprising Administering A Therapeutically Effective Amount Of Substance-P As An Anticancer Supplement To A Mammal. Substance-P Stimulates Proliferation Of Mesenchymal Stem Cells (Mscs) Within The Bone Marrow To Thereby Facilitate Protection And Regeneration Of Bone Marrow Cells And Hematopoietic Stem Cells. Therefore, The Composition Of The Present Invention Can Be Therapeutically Used For Treatment And/Or Prevention Of Bone Marrow Damage. Further, the composition of the present invention can be used as an anticancer supplement for anticancer therapy.
WO2008091680	US - 20070897399P - 25/01/2007	GEN HOSPITAL CORP ; LEE JEANNIE T	A61K 48/00 ; C12N 5/00 ; C12N 5/02	Disclosed Herein Are Methods For Controlling Stem Cell Differentiation Through The Introduction Of Transgenes Having Xic, Tsix, Xite, Or Xic Flanking Region Sequences To Block Differentiation And The Removal Of The Transgenes To Allow Differentiation. Also Disclosed Are Small RNA Molecules And Methods For Using The Small RNA Molecules To Control Stem Cell Differentiation. Also Disclosed Are Stem Cells Genetically Modified By The Introduction Of Xic, Tsix, Xue, Or Xic Flanking Region Sequences.
WO2008091830	US - 20070625763 - 22/01/2007	CHEN XIAO-DONG ; JILKA ROBERT L ; TRUSTEES OF THE UNIVERSITY OF	C12M 1/00 ; C12N 5/06	The Present Invention Encompasses Compositions, Materials, And Methods For Maintaining And Propagating Mammalian Mesenchymal Stem Cells In An Undifferentiated State In The Substantial Absence Of Feeder Cells, And Applications Of The Same.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008091908	US - 20070881497P - 22/01/2007 ; US - 20070907180P - 23/03/2007 ; US - 20070924247P - 04/05/2007 ; US - 20070950714P - 19/07/2007 ; US - 20070972613P - 14/09/2007	MATHER JENNIE P ; RAVEN BIOTECHNOLOGIES ; ROBERTS PENELOPE	A61K 35/00 ; A61K 39/00 ; A61P 37/00 ; C12N 5/06 ; G01N 33/574	This Invention Discloses Isolated Populations Of Human Cancer Stem Cells. Methods For Characterizing, Isolating And Culturing Human Cancer Stem Cells Are Also Disclosed. Uses For Human Cancer Stem Cells Are Provided.
WO2008092002	US - 20070897190P - 24/01/2007	CLARKE MICHAEL F ; SIMEONE DIANE M ; UNIV MICHIGAN ; WICHA MAX S	A61K 48/00 ; C12N 5/00 ; C12N 5/02 ; G01N 33/53	The Present Invention Relates To The Field Of Oncology And Provides Novel Compositions And Methods For Diagnosing And Treating Pancreatic Cancer. In Particular, The Present Invention Provides Pancreatic Cancer Stem Cells Useful For The Study, Diagnosis, And Treatment Of Solid Tumors.
WO2008092440	DE - 200710005946 - 01/02/2007	DEGISTIRICI OEZER ; STIFTUNG CAESAR ; THIE MICHAEL	A61K 35/12 ; A61K 35/32 ; A61L 27/36 ; C12N 5/06	The Invention Relates To A Therapeutic Composition, A Method For Producing A Therapeutic Composition, And The Use Of A Cell-Free Substance, Especially A Cell-Free Bone Or Cartilage Matrix. The Disclosed Therapeutic Composition Comprises At Least A Cell-Free Substance Obtained From Stimulated Stem Cells And/Or Precursor Cells. Immunogenic Reactions During In Vivo Therapeutic Use Are Prevented By The Fact That The Therapeutic Composition Is Free From Cells And Contains No Typically Antigenic Cell Components. The Disclosed Composition Can Therefore Be Universally Used For Therapeutic Purposes Regardless Of The Origin Of The Stem Cells And/Or Precursor Cells And Utilize The Natural Regenerative Potency Thereof In A Highly Efficient Manner For Replacing Tissue, E.G. For A Suitable Bone And/Or Cartilage Structure.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008093225	IT - 2007MI00175 - 02/02/2007	ABRIGNANI SERGIO ; CROSTI MARIACRISTINA ; ISTITUTO NAZ DI GENETICA MOLEC ; MORO MONICA	A61K 35/14 ; C07K 16/28 ; C12N 5/08 ; C12Q 1/68	The Subject Of The Present Invention Is A Sub- Population Of Isolated Hematopoietic Stem Cells That Express The CRISP-1 Gene And Produce The CRISP-1 Protein On The Cytoplasmic Membrane Of The Cell, Their Isolation And Their Application In The Therapeutic/Diagnostic/Progno Stic Field.
WO2008093646	JP - 20070023073 - 01/02/2007	KAJIWARA KAZUMI ; NAT UNIV CORP NARA INSTSTITUTE ; PHG CORP ; TANIHARA MASAO	A61K 38/00 ; A61P 25/00 ; A61P 25/08 ; A61P 25/16 ; A61P 25/18 ; A61P 25/28 ; A61P 3/10 ; A61P 35/00 ; A61P 43/00 ; A61P 9/10 ; C07K 14/47 ; C12N 15/09 ; C12N 5/06	Disclosed Is A Peptide Or A Salt Thereof Which Has A Relatively Low Molecular Weight And Is Useful For The Regulation Of Proliferation Or Differentiation Of A Stem Cell Such As A Neural Stem Cell And A Hematopoietic Stem Cell Or The Treatment Of Cancer, A Neurological Disease Or Other Diseases Such As Diabetes. Specifically Disclosed Is A Peptide Of The Following Item (1) Or (2) Or A Salt Thereof: (1) A Peptide Comprising The Amino Acid Sequence Depicted In SEQ ID NO:1; Or (2) A Peptide Which Comprises An Amino Acid Sequence Having The Substitution, Deletion Or Addition Of One Or Several Amino Acid Residues In The Amino Acid Sequence Depicted In SEQ ID NO:1, And Which Has At Least One Wnt Signaling Activation Activity Selected From The Group Consisting Of An Activity Of Inducing The Adhesion Of A PC12 Cell, An Activity Of Promoting The Differentiation Of A Neural Stem Cell And An Activity Of Accelerating The Intracellular Accumulation Of Ss-Catenin.
WO2008093827	JP - 20070023442 - 01/02/2007	JING XUEFENG ; MIWA HIDETO ; OSAKA IND PROMOTION ORG ; SAKAGUCHI KAZUSHIGE ; SAWADA TAKAHIRO	A61K 38/00 ; A61K 39/395 ; A61K 45/00 ; A61P 25/00 ; A61P 25/14 ; A61P 25/16 ; A61P 25/28	A Ligand For An Epha Receptor Is Injected Into A Lateral Ventricle Or A Striate Body To Induce The Differentiation, Proliferation Or Migration Of A Neural Stem Cell In The Central Nervous System, Thereby Recovering A Disorder Caused By The Degeneration Of The Central Nervous System Such As Parkinson's Disease And Striatonigral Degeneration. An Example Of The Ligand Is An Ephrin-A Multimer, Such As An Ephrin-A1 Multimer Produced By The Polymerization Of Ephrin-A1-Fc (Which Is Produced By Fusing The C-Terminus Of The Extracellular Domain Of Ephrin-A1 To An Igg(Fc) Fragment) And An Ephrin-A1 Multimer Which Is Polymerized Using A Coiled-Coil Domain Derived From Human Thrombospondin-5 (Htsp5cc).

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008094689	US - 20070898803P - 01/02/2007	NEPHROGEN LLC ; WESTENFELDER CHRISTOF	A61K 31/44	The Invention Provides Methods And Compositions For The Treatment Of Multi-Organ Failure Or Kidney Dysfunction, Such As Acute Renal Failure, By Mesenchymal Stem Cells And A CD26 Inhibitor, Where Inhibition Of CD26 Increases Homing Of The Mesenchymal Stem Cells To A Target Tissue.
WO2008094936	US - 20070670227 - 01/02/2007	MEDTRONIC VASCULAR INC ; REA SUSAN	A61F 2/06 ; A61L 29/08 ; A61L 29/12 ; A61L 29/16 ; A61L 31/10 ; A61L 31/16	A Method Of Treating A Vascular Condition Includes Applying A Plurality Of Stem Cells To An Exterior Surface Of A Stent, And Enveloping The Applied Stem Cells With A Topcoat Layer. In Addition, The Method Includes Delivering The Stent With Applied Stem Cells And Topcoat To A Treatment Region Of A Vessel Within A Body; And Applying An Electrical Field To The Stent For A Predetermined Time. A System For Treating A Vascular Condition Includes A Catheter, A Stent Disposed On The Catheter, At Least One Layer Of Stem Cells Disposed On An Exterior Surface Of The Stent, And A Topcoat Layer Surrounding The Layer Of Stem Cells. In Addition, The System Includes At Least One Electrical Lead Attached To The Stent, The Electrical Lead Operable To Induce An Electrical Field Around The Stent.
WO2008095096	US - 20070898610P - 31/01/2007	HU XIAOQU ; IMMUNE DISEASE INST ; LIEBERMAN JUDY ; SONG ERWEI ; YU FENGYAN	A61K 31/7088 ; C12N 15/11	(A2 A3 A9) The Present Invention Relates To Methods To Treat Or Prevent Cancers In A Subject, In Particular The Present Invention Relates To A Method Of Treating And/Or Preventing Cancer Comprising Targeting Cancer Stem Cells By Administering Mirnas Which Have Reduced Expression Or Are Lacking In The Cancer Stem Cells. In Some Embodiments, The Mirnas That Are Reduced Or Lacking In Cancer Stem Cells Are Let-7 Mirnas. In Alternative Embodiments, The Present Invention Relates To A Method Of Treating And/Or Preventing Cancer Comprising Targeting Cancer Stem Cells By Administering Mirnas Which Have Increased Expression Levels In The Cancer Stem Cells. Another Aspect Of The Present Invention Relates To Methods To Enrich For A Cancer Stem Cell Population. Another Aspect Of The Present Invention Relates To Methods To Identify Mirnas Which Contribute To The Self-Renewal Capacity Of Cancer Stem Cells.
WO2008096118	GB - 20070002401 - 08/02/2007	ARCHER CHARLES WILLIAM ; DOWTHWAITE GARY ; HAVEN	A61L 27/38 ; C12N 5/08	The Invention Concerns A Human Stem Cell Isolated From The Full Depth Of Human Cartilage Tissue And/Or Isolated From Aged Human Cartilage; And Uses Thereof.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
		SAMANTHA NICHOLA ; UNIV CARDIFF		
WO2008096781	JP - 20070028186 - 07/02/2007	KOJIMA ITARU ; NAT UNIVERSITY CORP GUNMA UNIV ; SENO MASAHARU ; UNIV OKAYAMA NAT UNIV CORP	A61K 38/27 ; A61P 3/10 ; A61P 43/00 ; C07K 14/485 ; C12N 1/15 ; C12N 1/19 ; C12N 1/21 ; C12N 15/18 ; C12N 5/10	Disclosed Is A Betacellulin Mutein Which Is A Stable Protein, Has Low Antigenicity, Retains An Activity Of Causing The Differentiation Of An Undifferentiated Pancreatic Stem Cell Into An Islet Beta-Cell, And Has A Reduced Cell Proliferation Activity. Specifically Disclosed Is A Betacellulin Mutein Having An Amino Acid Sequence Corresponding To An Amino Acid Sequence Lying Between Position-38 And Position-62 In The Amino Acid Sequence Depicted In SEQ ID NO:1 (Provided That Glu At Position-57 Is Substituted By A Basic Or Aromatic Amino Acid Residue, And The Amino Acid Sequence Corresponding To An Amino Acid Sequence Lying Between Position-38 And Position-50 May Have The Substitution, Insertion And/Or Deletion Of One Or More Amino Acid Residues).
WO2008097155	SE - 20070000333 - 08/02/2007	AXEN ANDREAS ; BELETSKII ANTON ; ELWINGER FREDRIK ; GE HEALTHCARE BIO SCIENCES AB ; HAGSTROEM GUNNAR ; NELSON DEIDRE A	B01J 20/28 ; B01J 20/285 ; C12N 5/00 ; G01N 33/543 ; G01N 33/569	The Present Invention Relates To A Separation Media And A Method For Separation Of Cells From Different Cell Sources, Such As Umbilical Cord Blood, Using Said Separation Media To Obtain The Desired Cells, Such As Stem Cells. The Separation Media Has Beads With A Diameter Of 200-500 [Mu]M And Is Provided With Cell Separation Ligands. The Cell Specific Ligands Are Preferably CD3 And CD 19 For Depletion B And T Cells And Production Of A Stem Cell Rich Product.
WO2008097875	US - 20070900157P - 08/02/2007	MOUSSATOV SERGUEI ; NEUROLOGIX INC	A61K 48/00 ; C07K 14/705 ; C12N 15/62	The Invention Pertains To The Use Of Synthetic Compounds To Dimerize And Activate Chimeric Proteins Within Cells, Specifically Within Neural Cells. The Invention Also Pertains To The Use Of Adeno-Associated Virus As A Vector To Specifically Deliver The Gene For The Chimeric Protein To Cells In A Specific Region Of The Brain Or To Neural Progenitor And/Or Stem Cells Used For The Treatment Of Neurodegenerative Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008098000	US - 20070671967 - 06/02/2007	CBR SYSTEMS INC ; MOORE THOMAS E	A01N 1/02 ; A61B 5/00 ; G01N 33/48 ; G06F 12/00 ; G06F 17/00 ; G06F 17/30 ; G06F 7/00 ; G06Q 10/00 ; G06Q 50/00	The Present Invention Provides A Method For The Collection And Distribution Of Cord Blood Stem Cells, Particularly In Order To Increase The Number Of Usable Cord Blood Stem Cells That Are Collected Overall. By Using A Single Collection And Distribution Entity That Applies A Uniform Protocol To Obtain Cord Blood Stem Cell Samples At Each Of A Plurality Of Different Collection Facilities, A Greater Number Of Samples For Both Private And Public Cord Blood Stem Cell Banks Can Be Obtained.
WO2008099006	US - 20070902017P - 16/02/2007	GALLI ROSSELLA ; SAN RAFFAELE CENTRO FOND	C12N 5/06	The Present Invention Is Directed To A Method For Isolating And Establishing Growth Factor-Independent (GF-I) Tumor Stem Cells (Tscs) From Tumor Biopsies Or Tumor Cell Lines Consisting In Culturing Cells In Serum-Free Mitogen-Free Culture Medium. The Method Discloses Cell Growth In A Culture Medium, Which Does Neither Comprise Serum, Nor EGF (Epidermal Growth Factor) And FGF-2 (Fibroblast Growth Factor), Nor Both, Nor EGF Or FGF-2 Derivatives With The Same Mitogenic Characteristics Of The Parent Molecules. According To A Preferred Embodiment, The Method Is Directed To The Isolation Of Tumor Stem Cells (Tscs) From Glioblastoma Multiforme (GBM) Or From Other Brain Tumors Or Brain Tumor Cell Lines. GF-Lndependent Tscs Can Be Identified And Expanded In Vitro Providing A Homogeneous Population Of Multipotent, Self-Renewing And Highly Tumorigenic Growth Factor-Independent Tscs, Distinguishable From Tumor Stem Cells Derived With Other Methods, Grown In Parallel, For The Above Characteristics. The Invention Also Encompasses therapeutic methods based on Tumor Stem Cells isolated as described.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008099561	JP - 20070033318 - 14/02/2007	HIROMOTO NOBUE ; JAPAN SCIENCE & TECH AGENCY ; NIKAWA HIROKI ; NISHIMURA MASAHIRO ; TSUJI KOICHIRO ; TWO CELLS CO LTD ; UNIV HIROSHIMA	A61K 38/00 ; C07K 7/08 ; C12N 5/10	In Order To Perform Large-Scale Proliferation Of Synoviocytes And Amnion-Derived Cells Which Are Superior To Stem Cells In Terms Of Differentiation Into Chondrocytes Or Neurons, It Is Intended To Provide A Peptide Which Has Much Fewer Side Effects Or Inhibitory Effects On The Living Body And Has A Useful Activity. The Invention Relates To An Agent For Promoting Proliferation Of Amnion-Derived Cells Or Synoviocytes, Comprising A Peptide Consisting Of The Following Amino Acid Sequence: (1) The Following Amino Acid Sequence: Lys-Arg-Leu-Phe-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Tyr (SEQ ID NO: 1), Or (2) An Amino Acid Sequence In Which One Or Several Amino Acids Have Been Deleted, Substituted Or Added In The Amino Acid Sequence Represented By SEQ ID NO: 1, And Which Has Substantially The Same Activity Of Promoting Cell Proliferation As A Peptide Consisting Of The Amino Acid Sequence Represented By SEQ ID NO: 1.
WO2008099696	JP - 20070036574 - 16/02/2007	KARASAWA CHISATO ; OLYMPUS CORP	C12M 1/34 ; G01N 21/03	It Becomes Possible To Obtain Fat-Origin Stem Cells Having Constant Qualities Regardless Of The Difference In Fat Tissue Form Individual To Individual. It Is Intended To Provide An Apparatus For Determining The Termination Of Fat Digestion (1) Which Is To Be Used In An Apparatus For Digesting Fat Tissue, Whereby A Fat Tissue Is Digested By Introducing Into A Container A Physiological Saline, A Lactate Ringer Solution Or A Buffer Solution Containing The Fat Tissue And An Enzyme And Stirring, And Comprises A Boundary Detection Unit (8) Whereby The Boundary Between A Fat Tissue Layer Formed In The Container After Stirring And Then Allowing To Stand And A Cell Suspension Layer Located Below The Fat Tissue Layer Is Detected From Outside The Container, A Layer Thickness-Measuring Unit (10) Whereby The Thickness Of The Fat Tissue Layer Is Measured Based On The Position Of The Boundary Detected By The Boundary Detection Unit (8), A Fat Volume-Calculating Unit (12) Whereby The Volume Of The Fat Tissue Layer Is Calculated by multiplying the thickness of the fat tissue layer measured above by the cross-section area of the container, and a termination-determining unit (13) whereby the termination of the digestion is determined based on the fat tissue layer volume calculated above.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008100083	KR - 20070015211 - 14/02/2007	PARK BYUNG-SOON ; PARK JEONG-SOO ; PROSTEMICS CO LTD	C12N 5/08	The Present Invention Provides An Injectable Composition For Tissue Regeneration, Which Contains Components Optimizing The Tissue Regeneration Ability Of Human Mesenchymal Stem Cells. The Injectable Composition For Tissue Regeneration Contains A Culture Medium, Obtained By Culturing Mesenchymal Stem Cells In A Serum-Free Medium, Containing Cell-Activating Compounds, For At Least One Day, In Order To Optimize The Effect Of Mesenchymal Stem Cells On The Correction Of Morphological Or Histological Defects In Skin, Soft Tissue, Bone, Etc. When The Disclosed Injectable Composition For Tissue Regeneration Is Administered, It Increases The Tissue Adhesion Of Mesenchymal Stem Cells And Improves The Tissue Regeneration Ability Of The Stem Cells, Thus Improving The Therapeutic Ability Of The Stem Cells, Compared To The Case Where Only Mesenchymal Stem Cells Are Used As Injectable Compositions.
WO2008100168	US - 20070890256P - 16/02/2007	AGASSE FABIENNE ; BERNARDINO LILIANA INACIO ; CT DE NEUROCIENCIAS E BIOLOG C ; MALVA JOAO JOSE OLIVEIRA ; SILVA BRUNO ALEXANDRE CORDEIRO ; UNIV COIMBRA	G01N 33/50	The Present Invention Relates To A Method For The Functional Identification Of New Neurons, Neural Progenitors, Astrocytes And Immature Cells From Stem Cell Cultures And Pharmacological Characterization Of Different Cell Types Differentiating From Stem Cell Cultures Comprising The Steps Of : A) Stimulating Said Stem Cells Cultures With Compounds Able To Increase The Intracellular Calcium Concentrations Specifically In Neurons, B) Stimulating Said Stem Cells Cultures With Compounds Able To Increase The Intracellular Calcium Concentration Specifically In Immature And Neural Progenitor Cells, C) Monitoring Intracellular Calcium Concentrations By The Use Of A Probe, And D) And Using Ratios Of Fluorescence Values Following Stimulations To The Direct Evaluation Of The Level Of Differentiation Of Cells. The Invention Refers Also To The Use Of The Method Of The Invention In Laboratorial Or Pharmacological Studies, For Example On Undifferentiated Nestin Positive Cells, GFAP Positive Nest In Negative Astrocytes, Doublecortin positive neuroblasts, MAP-2 positive neurons, in different stages of differentiation.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008100497	US - 20070901066P - 12/02/2007 ; US - 20070901076P - 12/02/2007 ; US - 20070905664P - 07/03/2007 ; US - 20070906064P - 08/03/2007 ; US - 20070966577P - 23/05/2007	ABRAMSON SASCHA DAWN ; ANTHROGENESIS CORP ; EDINGER JAMES W ; HARIRI ROBERT J ; LABAZZO KRISTEN S ; PEREIRA MARIAN ; WANG JIA-LUN ; YE QIAN	A01K 67/027 ; A61F 2/30 ; A61K 35/50 ; A61L 27/38 ; A61P 1/16 ; A61P 19/00 ; C12N 5/08	Provided Herein Are Methods And Compositions For The Production Of Hepatocytes From Placenta Stem Cells. Further Provided Herein Is The Use Of Such Hepatocytes In The Treatment Of, And Intervention In, For Example, Trauma, Inflammation, And Degenerative Disorders Of The Liver. Also Provided Herein Are Compositions And Methods Relating To Combinations Of Nanofibrous Scaffolds And Adherent Placental Stem Cells And Methods Of Using The Same In Cartilage Repair. Finally, Provided Herein Are Compositions And Methods Relating To Nonadherent, CD34<+>CD45<-> Stem Cells From Placenta.
WO2008100498	US - 20070901067P - 12/02/2007	ANTHROGENESIS CORP ; ANTHROGENESIS CORPARATION ; EDINGER JAMES W ; FALECK HERBERT ; HARIRI ROBERT J ; WANG JIA-LUN ; YE QIAN	A61K 35/44 ; A61K 35/50 ; A61K 35/64 ; A61K 38/21 ; A61P 37/06 ; C12N 5/06	Provided Herein Are Methods Of Treatment Of Individuals Having An Immune-Related Disease, Disorder Or Condition, For Example, Inflammatory Bowel Disease, Graft-Versus-Host Disease, Multiple Sclerosis, Rheumatoid Arthritis, Psoriasis, Lupus Erythematosus, Diabetes, Mycosis Fungoides (Alibert-Bazin Syndrome), Or Scleroderma Using Placental Stem Cells Or Umbilical Cord Stem Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008100936	US - 20070889442P - 12/02/2007	CEDARS SINAI MEDICAL CENTER ; SHAH PREDIMAN K ; SHARIFI BEHROOZ ; WANG LAI	C12N 5/00 ; C12N 5/08	The Invention Relates To The Isolation And Use Of Hematopoietic And Embryonic Stem Cells. Additionally, The Inventors Identified The Peritoneal Cavity As A New Source Of Hematopoietic Stem Cells. In One Embodiment, The Invention Provides Methods Of Isolating Progenitor And/Or Stem Cells From The Peritoneal Cavity. In Another Embodiment, The Invention Provides Methods Of Transporting Progenitor And/Or Stem Cells From The Peritoneal Cavity To Another Organ. In Another Embodiment, The Present Invention Provides Methods Of Regenerating Bioengineered Tissues And/Or Reconstituting An Hematopoietic System.
WO2008101272	US - 20070902355P - 21/02/2007	ADELAIDE RES & INNOVATION PTY ; BARRY SIMON C ; D ANDREA RICHARD JAMES ; HUTTON JONATHON F ; WOMEN S AND CHILDREN S HEALTH	A61K 35/12 ; C12N 5/08	A Method For Generating A Population Of Functional Regulatory T Cells (TREG- Cells), Which Are A Subset Of The T Cell Lineage Having The Ability To Actively Suppress Immune Activation And Maintain Peripheral Immune Tolerance, Is Described. The Method Comprises The Steps Of First Culturing Haemopoietic Stem Cells (HSC) And/ Or Haemopoietic Progenitor Cells In The Presence Of A Notch Ligand That Supports T Cell Differentiation, And Then Isolating T Cells Having A TREG-Cell Surface Marker Phenotype. A Suitable Source Of HSC Is Cord Blood (CB) And A Suitable Culture Medium Is OP9 Cells Engineered To Express The Notch Ligand Delta-Like 1 (DL1) (OP9-DL1 Cell Line). Examples Of TREG-Cell Surface Marker Phenotypes Are CD4+CD25+, CD45RO+, CD45RA+, CD127Low-, LAG-3 And/ Or CD39+.
WO2008102118	GB - 20070003188 - 19/02/2007 ; GB - 20070006917 - 10/04/2007	KERBY JULIE ; STEM CELL SCIENCES UK LTD ; THOMPSON HAZEL	C12N 5/06 ; C12N 5/08	Methods For Large-Scale Production Of Stem Cells, Including Embryonic Stem Cells, Are Provided. Also Provided Are Methods For Large-Scale Production Of Differentiated Cells Derived From Stem Cells And Use Of Stem Cells Or The Differentiated Progeny Thereof In Assays.
WO2008102460	WO - 2007JP53991 - 23/02/2007	DEZAWA MARI ; KODA MASAO ; MORI KEITA ; SANBIO INC ; YAMAZAKI MASASHI	A61K 35/28 ; A61K 35/30 ; C12N 5/06	There Is Provided A Method And A Pharmaceutical Composition For Neurotransplantation Of Bone Marrow Stromal Cell-Induced Neural Stem Cells (BMSC-Nscs) For Promoting Functional Recovery After Spinal Cord Injury In A Patient.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008102937	KR - 20070017970 - 22/02/2007	BAE YONG SOO ; CREAGENE INC ; JEONG JU AH ; KANG MI-SUN ; LEE HYUN SOO ; LIM DAE SEOG	A61P 37/02 ; C12N 5/00 ; C12N 5/06 ; C12N 5/08	The Present Invention Relates To A Method For Preparing Dendritic Cells Which Have An Enhanced Potential To Suppress Immune Responses, Dendritic Cells Carrying A Potential To Suppress Immune Responses, And A Pharmaceutical Composition Comprising The Dendritic Cells Capable Of Inducing Immunosuppressive Responses. The Present Dendritic Cells Having An Enhanced Potential To Suppress Immune Responses Can Be Utilized For Treating Various Diseases Or Disorders Through The Suppression Of Immune Responses. In Addition, The Enhanced Immunotolerance Potential Of The Dendritic Cells Of This Invention Ensures The Cells To Be Effectively Used As An Immunosuppressive Agent.
WO2008103462	US - 20070009432P - 28/12/2007 ; US - 20070902970P - 23/02/2007 ; US - 20070918543P - 16/03/2007 ; US - 20070993772P - 14/09/2007	ADVANCED CELL TECH INC ; CHUNG YOUNG ; LANZA ROBERT	C12N 15/00 ; C12N 5/00 ; C12N 5/02 ; C12N 5/08	The Present Invention Relates Generally To The Field Of Somatic Cell Nuclear Transfer (SCNT) And To The Creation Of Cloned Animals And Cells. The Disclosure Relates To A Method Of Cloning A Mammal, Obtaining Pluripotent Cells Such As Embryonic Stem Cells, Or For Reprogramming A Mammalian Cell Using An Oocyte And A Fertilized Embryo.
WO2008103810	US - 20070890958P - 21/02/2007	UNIV TEXAS ; WANG DACHUN ; WETSEL RICK A	C12N 5/02 ; C12N 5/08	A Method Of Preparing A Population Of In Vitro Cultured Cells Of Alveolar Epithelial Type II (ATII) Cell Lineage Derived From At Least One Embryonic Stem Cell Is Disclosed Which Comprises (A) Culturing Said At Least One Embryonic Stem Cell In Vitro In A Medium Comprising Matrigel TM , To Produce Differentiated Cells Without Formation Of An Embryonic Body, Wherein At Least Some Of The Differentiated Cells Are Of ATII Cell Phenotype; (B) Identifying The Differentiated Cells Of ATII Cell Phenotype By Detecting Expression Of At Least One Biomarker Of ATII Cells; (C) Isolating The Differentiated Cells Having ATII Cell Phenotype; And (D) Cloning The Isolated Cells To Produce A Population Of Cells Having ATII Cell Phenotype. The Resulting Cells Are Preferably >99% Pure ATII Phenotype Lineage And Are Potentially Useful Therapeutically For Treating Lung Injury And Disease.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008105630	US - 20070891824P - 27/02/2007	JO DAE WOONG ; KIM JIN SOOK ; PARK YUN KYUNG ; UNIV NAT CHONNAM IND FOUND	C07K 14/71	The Present Invention Discloses Cell Permeable Nanog And Oct4 Recombinant Proteins That Comprise A Kaposi Fibroblast Growth Factor 4 (Kfgf4)-Derived Macromolecule Transduction Domain (MTD). Also Disclosed Are Polynucleotides Encoding The Cell Permeable Nanog And Oct4 Recombinant Proteins, A Method Of Increasing Self-Renewal And Suppressing Differentiation Of Stem Cells By Treating The Cells In Combination With The Cell Permeable Nanog And Oct4 Recombinant Proteins, And The Combined Use Of The Cell Permeable Nanog And Oct4 Recombinant Proteins For Increasing Self-Renewal And Suppressing Differentiation Of Stem Cells.
WO2008106771	US - 20070892653P - 02/03/2007 ; US - 20070943351P - 12/06/2007 ; US - 20070974677P - 24/09/2007	UNGRIN MARK ; ZANDSTRA PETER	B01L 3/00 ; C12M 1/00 ; C12M 1/26 ; C12M 1/32 ; C12M 3/00 ; C12N 5/00 ; C12N 5/06 ; C12N 5/08 ; C12Q 1/24	The Present Application Provides Methods And Devices For The Production And Recovery Of Cell Aggregates. In One Embodiment, The Device Is A Microwell Device With A High Density Of Microwells. The Application Also Provides A Device For Extracting Cell Aggregates Such As Stem Cells Or Embryoid Bodies From Well Plates. Such Cell Aggregates Are Used For The Differentiation Of Pluripotent Stem Cells Such As Embryonic Stem Cells, In The Fields Of Developmental Biology And Regenerative Medicine / Tissue Engineering.
WO2008107695	GB - 20070004406 - 07/03/2007 ; GB - 20070009552 - 18/05/2007	KERBY JULIE ; STEM CELL SCIENCES UK LTD ; THOMPSON HAZEL	C12M 3/00 ; C12N 5/06	Methods Are Provided For Large-Scale Automated Production Of Stem Cells, Including Embryonic Stem Cells, And Differentiated Cells Derived From Stem Cells In Culture. Also Provided Are Populations Of Stem Cells Or Differentiated Cells And Apparatus Adapted For The Large-Scale Production Of Stem Cells Or The Differentiated Progeny Thereof.
WO2008107912	IN - 2007MU00654D - 06/03/2007	KHANNA APAMA ; RELIANCE LIFE SCIENCES PVT LTD	G01N 33/50	The Present Disclosure Provides Methods Useful For Screening Compounds And/Or Compositions, For Example Potential Drug Candidates. The Results Of The Screening Assays Correlate To The Effects Of The Compounds On The Molecular And/Or Cellular Level Of The Human Body. Also Disclosed Are Screening Assays Utilizing Human Embryonic Stem Cells RELICELL TM Hes Of Indian Origin. The Methods Disclosed Herein Correlate Well With Animal Preclinical Toxicity Studies Done In A Clinical Trial Setup.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008109063	US - 20070904836P - 01/03/2007 ; US - 20070918961P - 20/03/2007 ; US - 20070994166P - 17/09/2007 ; US - 20070998255P - 09/10/2007 ; US - 20080011881P - 22/01/2008 ; US - 20080067849P - 29/02/2008	ALLICKSON JULIE G ; CRYO CELL INT ; WALTON MERCEDES A	A61K 35/12 ; C12M 1/00 ; C12N 5/00 ; C12N 5/06 ; C12Q 1/02	Compositions Comprising Menstrual Stem Cells (Mscs) And Methods, Processes, And System Therefor Are Provided By The Invention. Mscs Are Processed From Menstrual Flow Collected During Menses. Mscs May Be Cryopreserved, Processed Through Various Culturing And Selection Steps In Preparation For Cryopreservation, Or Processed For Therapeutic Or Cosmeceutical Use. Cryopreserved Mscs May Be Thawed In Preparation For Therapeutic And Cosmeceutical Use. Mscs Express CD9, Cdlo, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, And HLA Class I, And Have Low Or No Expression Of CD3 And HLA Class II.
WO2008109320	US - 20070893780P - 08/03/2007	SEKULA RAYMOND F JR	A01N 63/00	The Present Invention Provides A Method Of Producing Purified Neural Stem Cells, Comprising Harvesting Fluid Containing Neural Stem Cells From Cerebrospinal Fluid Surrounding The Spinal Cord Of An Individual, Isolating The Neural Stem Cells From The Fluid, Culturing The Neural Stem Cells In A Culture Medium Effective To Induce Proliferation Of The Neural Stem Cells And Purifying The Cultured Neural Stem Cells. Also Provided Is A Method Of Treating A Patient Afflicted With A Neurological Condition, In Which The Purified Neural Stem Cells Are Administered Autologously Into The Same Individual Or Heterologously To A Patient Other Than The Individual. Administration Of The Purified Neural Stem Cells Results In The Purified Neural Stem Cells Propagating In The Site Of The Brain Region Afflicted With The Neurological Condition.
WO2008109839	US - 20070905513P - 07/03/2007	BEHFAR ATTA ; MAYO FOUNDATION ; NELSON TIMOTHY J ; TERZIC ANDRE	A61K 48/00 ; C12N 5/08	This Document Provides Methods And Materials Related To Treating Cardiovascular Tissue (E.G., Heart Tissue Or Vascular Tissue). For Example, Stem Cells (E.G., CXCR4+/Flk-1+ Stem Cells), Compositions Containing Stem Cells, Methods For Obtaining Stem Cells, And Methods For Repairing Cardiovascular Tissue Are Provided.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008110624	EP - 20070106119 - 13/04/2007 ; IT - 2007PD00088 - 14/03/2007	GRASSILLI EMANUELA ; HELIN KRISTIAN ; LAVITRANO MARIALUISA ; UNI DEGLI STUDI DI MILANO BICO	A61K 48/00 ; A61P 35/00 ; C12N 15/11 ; G01N 33/50	(A2 A3 A9) The Use Of Compounds Is Described Which Are Capable Of Functionally Blocking At Least One Of The Genes Chosen From The Group Composed Of Epha1, Epha2, Epha8, Ephb2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 And SERPINE1, For The Manufacture Of A Medicament Destined To Diminish The Resistance To Chemotherapeutic Drugs In The Therapeutic Treatment Of Epithelial Tumour Pathologies. Also Described Is A Method For The Determination Of The Drug Resistance In Tumour Cells, As Well As A Method Forthe Identification Of Tumour Stem Cells.
WO2008111161	WO - 2007JP54869 - 12/03/2007	HARA MAIKO ; IGARASHI AKIRA ; KANAWA MASAMI ; KATO YUKIO ; TSUJI KOICHIRO ; TWO CELLS CO LTD ; UNIV HIROSHIMA	C12N 15/09 ; C12N 5/06 ; C12Q 1/68	It Is Intended To Provide A Method Of Identifying Uniformity Of Mesenchymal Stem Cells Capable Of Identifying Whether Or Not A Subcultured Mesenchymal Stem Cell Is A Cell (Multipotent Mesenchymal Stem Cell) Which Has An Ability To Differentiate To Three Directions Of Fat Differentiation, Bone Differentiation And Cartilage Differentiation And Does Not Cause Any Differentiation Unless Differentiation Is Induced. The Invention Provides A Method Of Determining Uniformity Of Mesenchymal Stem Cells Comprising The Steps Of: (A) Generating A Plurality Of Clones From A Mesenchymal Stem Cell Population; (B) Determining The Expression Level Of Mrna Related To A Predetermined Gene Group In Terms Of The Clones And The Population; (C) Schematizing The Relationship Between The Expression Level Of Mrna Determined In The Step (B) And The Gene Group; And (D) Determining The Uniformity Of The Population Based On The Obtained Scheme.
WO2008112246	US - 20070906626P - 12/03/2007	GEN HOSPITAL CORP ; LEE JEANNIE T ; SILVA SUSANA SANTOS	A61K 31/4745 ; C12Q 1/00	Disclosed Herein Are Methods And Compositions That Include Markers Of XCI, Such As Xic, Xic Flanking Region, Xist, Xit E, Or - (A3) Disclosed Herein Are Methods And Compositions That Include Markers Of XCI, Such As Xic, Xic Flanking Region, Xist, Xit

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008112542	US - 20070906169P - 09/03/2007	UNIV MISSOURI	A01K 67/00 ; A01K 67/033 ; C12N 15/00	Methods Are Disclosed In Which The Expression Of A Specific Gene, Or Combinations Of Genes, Is Controlled Spatially And Temporally To Develop Intra- And Interspecies Chimeras. A Transgenic EC/ES/P/Ips Cell Line Is Created Which Conditionally Expresses A Suicide Or Compromiser Gene Configured To Compromise All Cell Lineages Except That Corresponding To A Target Tissue/Organ. The EC/ES/P/Ips Cell Line Is Injected Into Donor Embryos Having A Specific Target Gene Deficiency Or Embryos Genetically Engineered To Be Complementary Compromised In Lineages Corresponding To The Target Tissue/Organ Cell Lineages Of The EC/ES/P/Ips Line. One Or More Stimuli Is Provided To The Embryo To Activate Compromiser Genes For Ablation Of Non-Target Tissues/Organs Of The EC/ES/P/Ips Line And Target Tissues/Organs Of The Host Embryo, Resulting In A Chimeric Animal Having Target Tissues/Organs Derived From The Genotype Of The Transgenic Cell Line And All Remaining Tissues/Organs Derived From The Donor Embryo.
WO2008112560	US - 20070906012P - 09/03/2007	DING JUN ; LAHANN JOERG ; NANDIVADA HIMABINDU ; SMITH GARY D ; UNIV MICHIGAN	C12N 5/00 ; C12N 5/08	The Present Invention Provides Methods And Compositions For Establishing And Maintaining Growth Of Undifferentiated Stem Cells. In Particular, The Present Invention Provides Synthetic Growth Matrices For Stem Cells, Wherein Said Cells Are Capable Of Going Through Multiple Passages While Remaining In An Undifferentiated State.
WO2008115087	WO - 2007RS00009 - 20/03/2007	STOJKOVIC MIODRAG	C12N 5/06	Embryonic Stem Cells, Particularly Human Embryonic Stem Cells Are In High Demand As Objects Of Research Due To Their Ability To Reproduce And Differentiate Into Many, If Not All, Cell Types In The Body. The Present Application Discloses A Process By Which Arrested Embryos May Be Used To Derive Embryonic Stem Cells.
WO2008115517	US - 20070918808P - 19/03/2007	GOSTJEVA ELENA V ; MASSACHUSETTS INST TECHNOLOGY ; THILLY WILLIAM G	G01N 33/50	Methods Are Disclosed For The Characterization Of The Stage Of Development Or Pathology Of A Tissue Sample, And For Identifying Pluripotent Stem Cells, Comprising Detecting Autofluoresence Of Cells And Syncytia.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008115601	US - 20070919384P - 22/03/2007	BERMAN DAVID M ; HE XIAOBING ; MATSUI WILLIAM ; UNIV JOHNS HOPKINS	C08K 5/41 ; G01N 33/48	The Present Invention Provides A Method Of Treating Cancer In A Patient (E.G., A Human Patient) In Need Thereof, The Method Comprising Administering A Therapeutically Effective Regimen, The Regimen Comprising Administering To A Patient In Need Thereof A Compound That Targets 67 Laminin Receptor (67LR). In A Particular Embodiment, The Compound That Targets 67LR Is An Antibody Or Antibody Fragment. In Particular, The Present Invention Provides A Method Of Treating Cancer Comprising Administering To A Patient In Need Thereof An Antibody That Binds To 67LR. The Present Invention Also Provides A Method Of Treating Cancer Comprising Administering To A Patient In Need Thereof An Antibody Conjugate, Wherein The Antibody Conjugate Comprises An Antibody That Binds To 67LR Linked To A Therapeutic Agent, A Protein Toxin, A Cytotoxic Agent Or Other Moiety. The Present Invention Provides Pharmaceutical Compositions For The Treatment Of Cancer Comprising An Antibody That Binds To 67LR In An Amount Effective To Reduce Cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.
WO2008115799	US - 20070896105P - 21/03/2007	HACKER MICHAEL C ; MIKOS ANTONIOS G ; SARAF ANITA ; UNIV RICE WILLIAM M	A61K 48/00 ; A61K 9/127 ; A61K 9/32 ; C12N 15/00	Novel Gene Delivery Vector Compositions That Interact With Human Mesenchymal Stem Cells Are Provided, As Well As Methods Of Synthesizing And Using Such Compositions. Such Compositions May Comprise A Plurality Of Hyaluronic Acid Hexamers Covalently Attached To A Branched Polyethylenimine. Such Methods Of Synthesis May Comprise Providing A Plurality Of Hyaluronic Acid Hexamers And A Branched Polyethylenimine, Andallowing A Hexamer Of Hyaluronic Acid To Covalently Attach To A Branched Polyethylenimine To Form A Conjugate. Such Methods Of Use May Comprise Providing A Conjugate Comprising A Plurality Of Hyaluronic Acid Hexamers Covalently Attached To A Branched Polyethylenimine, And Administering The Conjugate To A Cell.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008116157	US - 20070726676 - 22/03/2007	AGGARWAL SUDEEPTA ; DANILKOVITCH ALLA ; OSIRIS THERAPEUTICS INC ; PITTENGER MARK F ; VARNEY TIMOTHY	A61K 35/14 ; A61K 35/24 ; A61K 35/28 ; A61P 17/06 ; A61P 35/00 ; A61P 37/06 ; A61P 37/08 ; C12N 5/00 ; C12N 5/06 ; H04Q 7/20	Methods Of Treating Autoimmune Diseases, Allergic Responses, Cancer, Inflammatory Diseases, Or Fibrosis In An Animal, Promoting Would Healing, Repairing Epithelial Damage And Promoting Angiogenesis In An Organ Or Tissue Of An Animal By Administering To The Animal Mesenchymal Stem Cells In An Effective Amount.
WO2008116160	US - 20070919375P - 22/03/2007	ANDERSON CAMERON ; COGNATE BIOSERVICES INC ; MCINTOSH KEVIN R ; MEDICETTY SATISH ; UNIV KANSAS STATE ; VANDERWERFF IRENE ; WEISS MARK ; WEISS RITA	A61K 35/50 ; A61P 37/02	The Invention Relates To The Isolation And Use Of Stem Cells From Amniote Species (Potentially Any Animal With An Umbilical Cord, Including Humans). More Particularly The Invention Relates To Obtaining Stem Cells That Are At Least Multipotent And May Be Totipotent Or Nearly Totipotent And Are Envisaged To Have A Variety Of End Uses. The Cells Of The Present Invention Are Immunosuppressive And May Be Used To Inhibit The Immune Response In A Subject.
WO2008116213	US - 20070907131P - 22/03/2007 ; US - 20070924729P - 29/05/2007	BANU NAHEED ; BELL EUGENE ; RUSSAKOVSKY VLADIMIR ; TEI BIOSCIENCES INC	A61K 35/14 ; A61K 35/28 ; A61K 35/36 ; C12N 5/00	This Application Discloses Dermal Derived Human Stem Cells (Ddhscs) And Methods Of Making And Using Thereof. More Specifically, The Invention Relates To Ddhscs Derived From Subsets Of Dedifferentiated Dermal Fibroblasts That Can Give Rise To A Series Of Cell Lineages. The Ddhscs May Be Used, For Example, In Cell Therapy And In The Search For And Development Of Novel Medicaments.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008080154	US - 20060871484P - 22/12/2006	RAABE TOBIAS D ; TRUSTEES OF THE UNIVERSITY OF	C12N 5/00 ; C12N 5/06 ; C12P 21/06	Compositions And Methods Are Provided Which Improve The Growth Rate, Self- Renewal Potential And Capacity Of Germ Line Transmission Of Mouse Embryonic Stem Cells.
WO2008117813	JP - 20070085369 - 28/03/2007	FURUSAWA SHUICHI ; HIROSHIMA IND PROMOTION ORG ; HORIUCHI HIROYUKI ; MATSUDA HARUO ; NAKANO MIKIHARU ; NISHIMOTO MAKI ; UNIV HIROSHIMA ; YAMASHITA YUSUKE	A01K 67/027 ; C12N 15/00 ; C12N 15/09 ; C12N 5/10 ; C12Q 1/68	A Chicken Embryonic Stem Cell Is Established, Which Steadily Has A Pluripotency And An Ability Of Being Differentiated Into A Germ Cell. For Evaluating On Whether Or Not The Chicken Embryonic Stem Cell Can Be Applied To Gene Modification Technique, Detection Is Made On A Protein Which Serves As A Measure Of The Ability Of Being Differentiated Into A Germ Cell. It Becomes Possible To Provide A Chicken Embryonic Stem Cell Applicable To Genetic Modification Technique And A Method For Evaluation Of The Chicken Embryonic Stem Cell.
WO2009002559	US - 20070937571P - 27/06/2007	CARDOZO DAVID LOPES ; HARVARD COLLEGE ; JHA RUCHIRA	C12N 5/06	The Invention Provides Compositions And Methods For Obtaining Neural Stem Cells From Post-Natal Subjects And Their Use In Treating Neurological Disorders.
WO2008118020	EP - 20070105060 - 27/03/2007	IPD THERAPEUTICS B V ; SPANHOLTZ JAN	C12N 5/08	The Invention Is Related To Methods For Expanding And Differentiating Hemopoietic Progenitor Cells In A Medium Comprising A Collection Of Cytokines, Desulphated Glycosaminoglycan And Human Serum. The Invention Further Relates To A Collection Of Cells Obtainable By A Method Of The Invention, Use Of The Collection Of Cells, And A Kit Of Parts For Expanding And Differentiating Hemopoietic Progenitor Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008118410	US - 20070919627P - 23/03/2007 ; US - 20070936873P - 22/06/2007	BRINK PETER R ; COHEN IRA S ; GAUDETTE GLENN ; ROBINSON RICHARD B ; ROSEN AMY B ; ROSEN MICHAEL R ; UNIV COLUMBIA ; UNIV NEW YORK	B82B 1/00 ; C01G 11/00 ; C12Q 1/68	The Present Invention Provides Methods And Compositions Relating To The Labeling Of Target Cells With Nanometer Scale Fluorescent Semiconductors Referred To As Quantum Dots (Qds). Specifically, A Delivery System Is Disclosed Based On The Use Of Negatively Charged Qds For Delivery Of A Tracking Fluorescent Signal Into The Cytosol Of Target Cells Via A Passive Endocytosis-Mediated Delivery Process. In A Specific Embodiment Of The Invention The Target Cell Is A Stem Cell, Preferably A Mesenchymal Stem Cell (MSC). Such Labeled Mscs Provide A Means For Tracking The Distribution And Fate Of Mscs That Have Been Genetically Engineered To Express, For Example, A Hyperpolarization-Activated Cyclic Nucleotide-Gated ("HCN") Channel And Administered To A Subject To Create A Biological Pacemaker. The Invention Is Based On The Discovery That Mscs Can Be Tracked Invitro For Up To At Least 6 Weeks. Additionally, Qds Delivered In Vivo Can Be Tracked For Up To At Least 8 Weeks, Thereby Permitting For The First Time, The Complete 3-D reconstruction of the locations of all MSCs following administration into a host.
WO2008118421	US - 20070896758P - 23/03/2007	CALIFORNIA STEM CELL INC ; POOLE ALEKSANDRA JOVANOVIC	C12N 5/06 ; C12N 5/08	Motor Neuron Progenitor (MNP) Cells And Populations Of MNP Cells, Are Provided, In Particular, Populations Of Human Late Stage MNP Cells Having A Purity Of Greater Than About 65% Late Stage MNP Cells And High-Purity Populations Of MNP Cells Having Greater Than 95% Viable Cells, As Well As Method Of Making And Using The Same, Including Deriving Late Stage MNP Cells From Pluripotent Embryonic Stem Cells, Producing High-Purity Populations Of Late Stage MNP Cells, Producing Populations Of Viable MNP Cells, Transporting Viable MNP Cells, And Transplanting MNP Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008118957	US - 20070920215P - 26/03/2007	FALCO GEPPINO ; GOVERNMENT OF U S A AS REPRESE ; KO MINORU S H ; LEE SUNG-LIM ; MONTI MANUELA ; STANGHELLINI ILARIA	C12N 15/00 ; C12N 5/00	Described Herein Is Zscan4, A Gene Exhibiting 2-Cell Embryonic Stage And Embryonic Stem Cell Specific Expression. Identification Of Nine Zscan4 Co-Expressed Genes Is Also Described. Inhibition Of Zscan4 Expression Inhibits The 2-Cell To 4-Cell Embryonic Transition And Prevents Blastocyst Implantation, Expansion And Outgrowth. Provided Herein Are Methods Of Inhibiting Differentiation Of A Stem Cell, Promoting Blastocyst Outgrowth Of Embryonic Stem Cells And Identifying A Subpopulation Of Stem Cells Expressing Zscan4. Further Described Is The Identification Of Trim43 As A Gene Exhibiting Morula-Specific Expression. Also Provided Are Isolated Expression Vectors Comprising A Zscan4 Promoter, Or A Trim43 Promoter Operably Linked To A Heterologous Polypeptide And Uses Thereof. Further Provided Are Transgenic Animals Comprising Transgenes Encoding Marker Proteins Operably Linked To Zscan4 And Trim43 Promoters.
WO2008120218	US - 20070730560 - 02/04/2007	HADASIT MED RES SERVICE ; REUBINOFF BENJAMIN ; STEINER DEBORA	C12N 5/08	The Present Disclosure Provides Methods For Maintaining And Propagating Undifferentiated Pluripotent Stem Cells (SC) In Suspension. The Methods Comprise Culturing Such SC In A Non-Adherent Culture Dish Under Conditions Comprising A Basic Serum Free Medium And One Or More Of A Basic Medium, A Serum Replacement, An Extra Cellular Matrix Component And A Factor Supporting Expansion Of Said SC. A Specific And Preferred Culture Condition Comprise Supplementing Neurobasal Medium With KO Serum Replacement (KOSR). These Conditions Allowed For Large Scale And Long Term Propagation Of Undifferentiated Pluripotent SC. The Culture System Comprising Suspended Undifferentiated Pluripotent SC Were Found To Have Many Applications Including In Methods For Directed As Well As Spontaneous Differentiation Of The SC Into Somatic Cells. Also Disclosed Herein Is A Method Of Deriving SC, Preferably Human Embryonic SC From Human Embryos Via The Formation Of Cell Clusters.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008120832	WO - 2007KR01577 - 30/03/2007	IND ACADEMIC COOP ; PARK KOOK-IN	C12N 15/07 ; C12N 5/08	The Present Invention Relates To A Human Neural Stem Cell Secreting SMAC, A Preparation Method Thereof And A Use Thereof, More Particularly To A Human Neural Stem Cell Secreting SMAC Transformed By A SMAC-Encoding Nucleotide, A Preparation Method Thereof And A Use Thereof. The SMAC Secreting Human Neural Stem Transformed By A SMAC Encoding Nucleotide Provided By The Present Invention Proliferates And Grows On A Plate In Undifferentiated State, Without Inducing Cytotoxicity, And Is Capable Of Differentiating Into Nerve Cells Such As Neuron, Oligodendrocyte And Astrocyte In Vivo And In Vitro. Further, The Neural Stem Cell Of The Present Invention Secretes SMAC In The Human Body And Assists The Action Of TRAIL, Thereby Inducing Apoptosis Of Tumor Cells And Reduction Of Tumor Volume. Accordingly, The Neural Stem Cell Of The Present Invention Can Be Effectively Used For The Treatment Or Prevention Of Tumors.
WO2008121120	US - 20070664212 - 28/03/2007	BAKER BRUCE A ; CHAPMAN JOHN R ; CHILDERS ROBERT S ; COELHO PHILIP H ; EMMANUEL PRINCE ; LI JUNZHI ; THERMOGENESIS CORP	C12N 5/00	The Invention Includes Compositions Of Stem And Progenitor Cells Recovered From Bone Marrow Or Cord Blood Containing Most Of The Viable CD34+ Cells And Substantially Depleted Of Red Blood Cells Resident In The Original Sample, Without Any Xenobiotic Additives To Aid Cell Separation. The Invention Also Includes A System And Method For Preparing The Compositions. The System Includes A Bag Set And A Processing Device, Which Utilizes An Optical Sensor, Microcontroller, Servo Motor, Accelerometer, Load Cell, And Battery. The System And Method Utilize Centrifugation To Stratify The Cells Into Layers And Then Separate And Transfer The Stem Cells Into A Stem Cell Bag. The Processing Device's Microcontroller Receives Input From The Device's Accelerometer, Load Cell And Optical Sensor To Direct The Metering Valve In The Bag Set To Open And Close To Permit The Transfer Of As Many Stems Cells As Possible With As Few Red Cells As Possible.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008121417	US - 20070920922P - 30/03/2007 ; US - 20080036739P - 14/03/2008	DJORDJEVIC BOZIDAR ; LANGE CHRISTOPHERS ; ROTMAN MARVIN Z	C12N 5/06	The Present Invention Is Directed To Methods Of Measuring The Proliferative Ability Of Individual Patient Cancer Stem Cells. The Present Invention Provides A Method For Treating A Cancer Patient According To An Assay Of The Individual Patient's Tumor's Cancer Stem Cell Sensitivity, By Measuring The Proliferative Ability Of Cancer Stem Cells From The Patient. By The Methods Of The Present Invention It Is Possible To Treat Individual Cancer Stem Cells Presented In Tumor Cells. Methods Of Detecting And Enumerating Cancer Stem Cells In Hybrid Spheroids Comprised Of Fibroblasts And Tumor Cells Are Also Provided By The Present Invention. The Present Invention Also Contemplates A Method For Drug And Other Treatment Development, Wherein The Effects Of A Drug Or Combination Of Drugs Or Other Treatments Are Determined On The Individual Patient's Cancer Stem Cells.
WO2008121437	US - 20070888877P - 08/02/2007	BURNHAM INST FOR MEDICAL RES ; FUKUDA MICHIKO	A61K 38/04 ; C07K 14/435 ; G01N 33/50 ; G01N 33/68	(A2 A3 A9) Disclosed Herein Are Compositions And Methods Useful For Promoting Sperm Motility, Promoting Embryonic Stem Cell Formation, Promoting Trophoblast Formation, Or Promoting Neuronal Growth. The Compositions And Methods Are Based On Peptide Sequences That Bind Trophinin, Inhibit Bystin-Mediated Arrest Of Epidermal Growth Factor (EGF) Receptor, And Promotes EGF Receptor Autophosphorylation.
WO2008122354	DE - 200710016534 - 05/04/2007	BOLES ECKHARD ; UNIV JW GOETHE FRANKFURT MAIN ; WIEDEMANN BEATE	C12N 15/81 ; C12N 9/90 ; C12P 7/10	The Invention Relates To Novel Expression Cassettes And Expression Vectors, Having Three Nucleic Acid Sequences For Araa, Arab And Arad, Each Coding For A Polypeptide Of An L-Arabinose Metabolic Pathway, In Particular, A Bacterial L-Arabinose Metabolic Pathway. The Invention Particularly Relates To Expression Cassettes And Expression Vectors, Having Codon-Optimised Nucleic Acid Sequences For Araa, Arab And Arad. The Invention Further Relates To Host Cells, In Particular, Modified Yeast Stem Cells Containing The Expression Cassettes Or Expression Vectors And Expressing The Polypeptides For The L-Arabinose Metabolic Pathway, In Particular, For The Bacterial L-Arabinose Metabolic Pathway. Arabinose Is More Effectively Fermented By These Cells,In Particular To Give Ethanol, By Means Of Said Modified Host Cells. The Invention Is Amongst Other Things Important In The Production Of Biochemicals From Biomasses Such As, For Example, Bioethanol.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008123741	KR - 20070034482 - 09/04/2007	HAN HO JAE ; LEE MIN YOUNG ; UNIV NAT CHONNAM IND FOUND	C12M 1/00	The Present Invention Relates To A Cell Culture Dish For The Erabryoid Body Formation From Embryonic Stem Cells, Which Facilitates Efficient And Stable Differentiation Of Embryonic Stem Cells By Forming Embryoid Body In Grooves On The Bottom Of A Support Adhered On The Back Of The Lid For The Culture Dish By Hanging Drop Culture.
WO2008123887	US - 20070733050 - 09/04/2007	DONNENBERG ALBERT DAVID ; DONNENBERG VERA SVOBODOVA ; UNIV PITTSBURGH	G01N 33/574	The Invention Provides A Method Of Identifying Circulating Clonogenic Cancerous Cells, Specifically Multiply-Drug Resistant (MDR) Cancer Stem Cells.
WO2008124142	US - 20070922244P - 06/04/2007	INTERNAT STEM CELL CORP ; JANUS JEFFREY D ; KUZMICHEV LEONID N ; REVAZOVA ELENA S ; TUROVETS NIKOLAY A	C12N 5/08	Methods Are Disclosed For Generating HLA Homozygous Parthenogenetic Human Stem Cell (Hpsc-Hhom) Lines From Both HLA Homozygous And HLA Heterozygous Donors. These Hpsc-Hhom Lines Demonstrate Typical Human Embryonic Stem Cell Morphology, Expressing Appropriate Stem Cell Markers And Possessing High Levels Of Alkaline Phosphatase And Telomerase Activity. Additionally, Injection Of These Cell Lines Into Immunodeficient Animals Leads To Teratoma Formation. Furthermore, In The Case Of HLA Heterozygous Donors, The Hpsc-Hhom Lines Inherit The Haplotype From Only One Of The Donor's Parents. SNP Data Analysis Suggests That Hpsc-Hhom Lines Derived From HLA Heterozygous Oocyte Donors Are Homozygous Throughout The Genome As Assessed By Single-Nucleotide Polymorphism (SNP) Analysis. The Protocol As Disclosed Minimizes The Use Of Animal-Derived Components, Which Makes The Stem Cells More Practical For Clinical Application.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008124166	US - 20070922433P - 09/04/2007	GENSURE ROBERT C ; MATSUSHITA OSAMU ; NAT UNIVERSITY CORP KAGAWA UNI ; OCHSNER CLINIC FOUNDATION ; SAKON JOSHUA ; TECHNO NETWORK SHIKOKU CO LTD ; TRUSTEES OF THE UNIVERSITY OF	A61K 38/48 ; A61K 48/00 ; C12N 15/09 ; C12N 5/06	(A2 A3 A8) Fusion Proteins Containing Active Agonist Or Antagonist Fragments Of Parathyroid Hormone (PTH) And Parathyroid Hormone Related Peptide (Pthrp) Coupled To A Collagen- Binding Domain Are Presented. The Fusion Proteins Can Be Used To Promote Bone Growth, To Promote Hair Growth, To Prevent Cancer Metastasis To Bone, To Promote Immune Reconstitution With A Bone Marrow Stem Cell Transplant, To Promote Mobilization Of Bone Marrow Stem Cells For Collection For Autologous Stem Cell Transplant, And To Treat Renal Osteodystrophy. Pharmaceutical Agents Comprising A Collagen-Binding Polypeptide Segment Linked To A Non-Peptidyl PTH/Pthrp Receptor Agonist Or Antagonist Are Also Presented.
WO2008124494	US - 20070921517P - 03/04/2007	CARALLA TONYA ; CLEVELAND CLINIC FOUNDATION ; HASCALL VINCENT ; MIDURA RONALD ; MUSCHLER GEORGE	A61K 48/00 ; C12M 1/26 ; C12N 5/08	Methods For Enriching, Detecting, Or Using Adult Stem Cells Through The Use Of Recognition Ligands That Specifically Bind To ECM Components Retained To The Surfaces Of Adult Stem Cells Are Described. An ECM Component Such As Hyaluronan That Is Retained To The Surfaces Of Adult Stem Cells When Removed From Animal Tissues Can Be Used To Detect A Diverse Population Of Adult Stem Cells Based On The Nature Of The ECM Niche Region In Which The Adult Stem Cells Normally Reside. For Example, A Separation Method Such As Magnetic Separation Can Be Used To Detect And Isolate Or Enrich Adult Stem Cells Based On A Recognition Ligand That Is Specific For An ECM Component That Is Retained To The Surfaces Of Adult Stem Cells To A Greater Degree Than To Other Cells In The Population.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008124872	AU - 20070901902 - 11/04/2007	BARTLETT PERRY FRANCIS ; UNIV QUEENSLAND ; WALKER TARA LOUISE	C12N 5/06 ; C12N 5/08	The Present Invention Relates To A Latent Neural Stem Cell Population Which Is Capable Of Activation By Membrane Depolarization Of A Neural Cell Population, Isolation And Culture Of Same, And Uses Thereof.
WO2008125279	US - 20070923092P - 11/04/2007	UNIVERSITAET SKLINIKUM HEIDELBE ; ZEHELEIN JOERG	A61K 35/28 ; A61P 9/00	The Present Invention Provides Mesenchymal Stem Cells (Mscs) For The Treatment Of Heart Diseases In A Mammal, Characterized In That The Treatment Comprises An Administration Of The Mscs Or A Pharmaceutical Preparation Comprising Mscs And That Before The Administration Lesions Are Introduced Into The Myocardium Of Said Mammal, Wherein Said Lesions Do Not Essentially Impair The Function Of Said Myocardium. The Present Invention Also Provides Mscs For The Provision Of A Biological Cardiac Pacemaker In A Mammal. Furthermore, The Present Invention Relates To A Method For Controllably Introducing Mesen Not Chymal Stem Cells (Mscs) Into The Myocardial Tissue Of A Mammal, Comprising The Steps Of: A) Providing A Pharmaceutical Preparation Comprising Mscs To Be Introduced Into Said Mammal, B) Introducing Lesions Into The Myocardium Of Said Mammal, Wherein Said Lesions Do Not Essentially Impair The Function Of Said Myocardium, And C) Infunding Said Pharmaceutical Preparation Comprising Mscs Into Said Mammal. The Present invention further relates to a method for providing a biological cardiac pacemaker in a mammal, a method for treating a pacemaker dysfunction and/or a degenerative disease of the sinoatrial and/or atrioventricular node in the myocardium, and related complications and conditions in a mammal on the basis of said method for controllably introducing mesenchymal stem cells (MSCs) into the myocardial tissue of a mammal. - (A9) The present invention provides mesenchymal stem cells (MSCs) for the treatment of heart diseases in a mammal, characterized in that the treatment comprises an administration of the MSCs or a pharmaceutical preparation comprising MSCs and that before the administration lesions are introduced into the myocardium of said mammal, wherein said lesions do not essentially impair the function of said myocardium. The present invention also provides MSCs for the provision of a biological cardiac pacemaker in a mammal. Furthermore,

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
				the present invention relates to a method for controllably introducing mesenchymal stem cells (MSCs) into the myocardial tissue of a mammal, comprising the steps of: a) providing a pharmaceutical preparation comprising MSCs to be introduced into said mammal, b) introducing lesions into the myocardium of said mammal, wherein said lesions do not essentially impair the function of said myocardium, and c) infunding said pharmaceutical preparation comprising MSCs into said mammal. The present invention further relates to a method for providing a biological cardiac pacemaker in a mammal, a method for treating a pacemaker dysfunction and/or a degenerative disease of the sinoatrial and/or atrioventricular node in the myocardium, and related complications and conditions in a mammal on the basis of said method for controllably introducing mesenchymal stem cells (MSCs) into the myocardial tissue of a mammal.
WO2008126083	US - 20070907619P - 11/04/2007	GEPSTEIN LIOR ; HUBER IRIT ; TECHNION RES & DEV FOUNDATION	C12N 15/85 ; C12N 5/06	A Nucleic Acid Construct Is Disclosed, The Nucleic Acid Comprising A Polynucleotide Comprising A Nucleic Acid Sequence Encoding A Detectable Expression Product, The Nucleic Acid Sequence Being Operably Linked To A Human Tissue Specific Promoter. A Method Of Lineage Tracing Of Human Stem Cells And Isolated Human Embryonic Stem Cell Comprising The Nucleic Acid Construct Are Also Disclosed.
WO2008127256	US - 20060809908P - 01/06/2006	FRIGOLA LLUIS QUINTANA ; GARRETA ELENA ; GRODZINSKY ALAN ; KAMM ROGER ; MASSACHUSETTS INST TECHNOLOGY ; ROLAUFFS BERND ; SEMINO CARLOS E	A01N 1/00 ; C12N 5/00	Methods For Wound Healing Or Tissue Regeneration By Means Of Cell And Tissue Engineering, Including Using Three-Dimensional Matrices With Cells Therein. A Three-Dimensional Matrix, Optionally Containing Cells Such As Fibroblasts, Is Inserted Into The Wound Of A Subject. An Anti-Inflammatory Factor May Also Be Used To Reduce Or Suppress The Immune Response. The Wound May Be Covered To Limit Exposure To Gaseous Oxygen, For Example, Using A Membrane. An Anticoagulant May Also Be Applied. In Addition, Cells, Such As Fibroblasts Or Stem Cells, When Cultured Within A Three-Dimensional Matrix, Under Certain Conditions, Can Be Induced To Form Non- Fibroblast Multipotent Cells. When Stem Cells Are Cultured In The Three-Dimensional Matrix, At Least Some Of The Stem Cells Remain As Stem Cells And Do Not Differentiate. Kits For Promoting The Control Of Cells Within Three-Dimensional Matrices Are Also Disclosed.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008127735	US - 20070923499P - 13/04/2007	BERGSTEIN IVAN ; STEMLINE THERAPEUTICS INC	A61K 39/395 ; C07K 16/00 ; C12N 5/06	The Present Invention Provides Antibodies That Bind To The IL-3 Receptor Alpha Subunit Alpha (113 Ra) Chain, And Compositions Comprising Such Antibodies. The Present Invention Provides Methods For Inhibiting Or Reducing An IL3Ra-Expressing Cell Population, The Methods Comprising Contacting A Population Of IL3Ra-Expressing Cells (E.G., Cancer Cells And/Or Cancer Stem Cells) With An Antibody That Binds To IL3Ra. The Present Invention Also Provides Antibody Conjugates Comprising An Antibody That Binds To An IL3Ra Chain Linked To A Cytotoxic Agent Or Anticellular Agent And Compositions Comprising Such Conjugates. The Present Invention Also Provides Methods For Preventing, Treating And/Or Managing A Disorder Associated With IL3Ra-Expressing Cells (E.G., A Hematological Cancer), The Methods Comprising Administering To A Subject In Need Thereof An Antibody That Binds To IL3Ra.
WO2008127974	US - 20070911824P - 13/04/2007 ; US - 20070915837P - 03/05/2007	JESSELL THOMAS M ; NAGAI MAKIKO ; PRZEDBORSKI SERGE ; UNIV COLUMBIA ; WICHTERLE HYNEK	C12N 5/08	The Present Invention Relates To Culture Systems, Comprising Differentiated Stem Cells, That May Be Used For Identifying Agents Useful In Treating Degenerative Nervous System Disorders And Are Suitable For High-Throughput Screening Applications. It Is Based, At Least In Part, On The Discovery That Co-Cultures Of (I) Astrocytes Expressing A Mutated Sodl Gene And (Ii) Stem-Cell Derived Motor Neurons Manifested Cell Death Via A Bax-Dependent Mechanism, And Modeled Motor Neuron Death In Amyotrophic Lateral Sclerosis.
WO2008128031	US - 20070911350P - 12/04/2007	HALL JOHN K ; OLWIN BRADLEY BRUCE ; TANAKA KATHLEEN KELLY ; UNIV COLORADO	A01N 63/00	Embodiments Herein Relate To Compositions And Methods For Engraftment Of And Increasing Survival Of Muscle Cells In A Subject In Need Thereof. In Certain Embodiments, Compositions Including Myofibers And/Or Satellite Stem Cells May Be Administered To A Subject. Other Embodiments Relate To Compositions And Methods For Introducing One Or More Compounds To A Subject Using Cell Compositions Disclosed Herein. Still Other Embodiments Relate To Uses Of These Compositions In Kits For Portable Applications And Methods.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008128069	US - 20070923091P - 11/04/2007	DEUTSCH ROGER	C12N 5/06	The Present Invention Relates To A Method For Diagnosing The Compatibility Of A Biological Sample Containing Stem Cells From A Donor With The Immune System Of A Recipient. Furthermore, The Present Invention Relates To A Method For Determining The Quality Of A Stem Cell Preparation Based On The Inventive Method, As Well As Methods Of Diagnosing An Immune Disorder Affecting Stem Cell Recognition. The Present Invention Further Relates To A Method For Producing An Improved Stem Cell Preparation, And An Apparatus That Is Equipped For Performing The Method According To The Invention. The Invention Can Be Used In The Field Of Stem Cell-Based Transplantation And Respective Diseases. The Invention Also Includes A Method For Testing The Efficacy Of Donor Immune Cells As Treatments For Disease Such As Cancer In A Host Patient. A Method For Testing The Immune Response Of A Patient To Recall Antigens Is Also Disclosed.
WO2008129058	EP - 20070300979 - 24/04/2007	ESNAULT MAGALI ; GUEHENNEUX FABIENNE ; MEHTALI MAJID ; MOREAU KARINE ; VIVALIS	A61K 39/145	The Present Invention Relates To The Development And Manufacturing Of Viral Vaccines. In Particular, The Invention Relates To The Field Of Industrial Production Of Viral Vectors And Vaccines, More In Particular To The Use Of Avian Embryonic Stem Cells, Preferably The Ebx< TM > Cell Line Derived From Duck Embryonic Stem Cells, For The Production Of Viral Vectors And Viruses. The Invention Is Particularly Useful For The Industrial Production Of Viral Vaccines To Prevent Viral Infection Of Humans And Animals.
WO2008129554	US - 20070907818P - 18/04/2007	ALPER-PINUS RUSLANA ; BANIN EYAL ; HADASIT MED RES SERVICE ; IDELSON MASHA ; OBOLENSKY ALEX ; REUBINOFF BENJAMIN	A61K 35/44 ; C12N 5/06	The Present Invention Concerns RPE Cells Obtainable By Directed Differentiation From Stem Cell, Particularly, Human Stem Cells. It Has Been Specifically Found That Culturing Stem Cells In The Presence Of One Or More Member Of The TGF Superfamily, Such As Activin A) Induced Directed Differentiation Into Mature And Functional RPE Cells. This Was Evidenced By The Expression Of Markers Specific To Mature RPE Cells, Including Mitf-A, RPE65 Or Bestrophin). In Accordance With One Particular Embodiment, The Cells Are A Priori Cultured With Nicotinamide (NA) Which Was Found To Augment The Cells' Response To The Inductive Effect Of The One Or More Member Of The TGF Superfamily. The Invention Also Provides Methods Of Performing The Directed Differentiation, As Well As Methods For Use Of The Resulting RPE Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008129560	IN - 2007CH00855 - 20/04/2007	DEB KAUSHIK DILIP ; STEMPEUTICS RES PRIVATE LTD ; TOTEY SATISH MAHADEO	C12N 5/06 ; C12N 5/08	The Present Invention Relates To The Field Of Stem Cells Particularly Development Of A Novel Human Embryonic Model Using Human Embryoid Bodies Obtained From The Human Embryonic Stem Cell. The Novel Human Embryonic Model Disclosed Thus Can Provide A Screening Assay For Determining The Toxic Activity Of The Compound And/Or Drug.
WO2008129563	IN - 2007CH00861 - 23/04/2007	HANWATE MADHURI ; KOLKUNDKAR KUMAR UDAY ; PAL RAKHI ; STEMPEUTICS RES PRIVATE LTD ; TOTEY MAHADEORAO SATISH	C12N 5/00 ; C12N 5/06	The Present Invention Provides A Process Of Isolation, Proliferation And/Or Maintenance Of Mesenchymal Stem Cells (Mscs). The Invention Further Provides A Culture Medium For Proliferation And/Or Maintenance Of Human Mesenchymal Stem Cells In Xeno-Free Conditions. The Culture Medium Provided In The Present Invention Proliferates And/Or Maintains Mesenchymal Stem Cell Expansion While Maintaining A Multipotent Phenotype.
WO2008130568	US - 20070907761P - 16/04/2007	ONCOMED PHARMACEUTICALS INC ; WANG XINHAO	C12Q 1/68	The Present Invention Relates To Compositions And Methods For Treating, Characterizing, And Diagnosing Cancer. In Particular, The Present Invention Provides Gene Expression Profiles Associated With Solid Tumor Stem Cells, As Well As Novel Stem Cell Cancer Gene Signatures Useful For The Diagnosis, Characterization, Prognosis And Treatment Of Solid Tumor Stem Cells.
WO2008133536	PL - 20070382287 - 25/04/2007 ; PL - 20070383134 - 11/08/2007	AKADEMIA MEDYCZNA IM PIASTOW S ; BOCHNIA MAREK ; CALKOSINSKI IRENEUSZ ; CEGIELSKI MAREK ; DZIEWISZEK WOJCIECH	A61L 27/36 ; C12N 5/00 ; C12N 5/06	New Lines Of Stem Cells From The Growing Antlers Of Deer (Cervidae) And The Application Of Said Cells In The Reconstruction Of Connective Tissue, Preferentially Bone, Cartilage Or Adipose Tissue, In Humans And Animals; As Well As A Method Of Culturing Them And The Application Of Tissues From Growing Deer Antlers In The Production Of The MIC-1 Stable Stem Cell Line.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008133904	US - 20070926065P - 23/04/2007 ; US - 20080066693P - 22/02/2008	GRINDLEY JUSTIN C ; LI LINHENG ; PERRY JOHN M ; STOWERS INST FOR MEDICAL RES	A01N 63/00 ; C12N 5/08	The Present Invention Relates To Methods For Expanding A Stem Cell Population. More Particularly, The Invention Relates, Inter Alia, To Methods And Compositions For Expanding A Stem Cell Population, Particularly A Hematopoietic Stem Cell Population.
WO2008134406	US - 20070926429P - 25/04/2007	BLISS TONYA ; STEINBERG GARY K ; UNIV LELAND STANFORD JUNIOR	A61K 35/30 ; A61K 38/19 ; A61K 48/00	The Invention Provides Methods For Inducing Or Enhancing Neovascularization Following Ischemia By Transplanting An Effective Amount Of Human Central Nervous System Stem Cells. The Human Central Nervous System Stem Cells Can Be Grown As Neurospheres Or In Adherent Culture. Also Provided Are Methods For Inducing The Repair Of Ischemic Tissue In A Patient And Methods For Treating Stroke In A Patient Suffering Therefrom.
WO2008134522	US - 20070926525P - 26/04/2007	EGGAN KEVIN ; EGLI DIETER ; HARVARD COLLEGE	C12N 5/06 ; C12N 5/08	In Certain Embodiments, The Present Disclosure Provides Methods And Compositions Useful For The Generation A Transgenic Cell Comprising Transfer Of Nuclear-Derived Genetic Material From A Donor Cell Into A Fertilized Zygote Or A Blastomere From Which Nuclear- Derived Genetic Material Has Been Removed. Also Disclosed Are Methods And Compositions For The Generation Of Pluripotent Transgenic Embryonic Stem Cells And Transgenic Animals, As Well As Methods Of Using Such Transgenic Embryonic Stem Cells And Transgenic Animals For Disease Modeling, Drug Screening And/Or Cell Replacement Therapy.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008134759	US - 20070915069P - 30/04/2007 ; US - 20070915341P - 01/05/2007	CEDARS SINAI MEDICAL CENTER ; GERY SIGAL ; KOEFFLER H PHILLIP	A61K 38/17 ; C07K 16/00 ; C12P 21/08	Janus Kinase 2 (JAK2) Associates With Cytokine Receptors And Is Essential For Signal Transduction In Hematopoietic Cells. The JAK2 Mutation, JAK2 V617F, Prevalent In Myeloproliferative Disorders, Confers Cytokine-Independent Proliferation And Constitutive Activation Of Downstream Signaling Pathways, When Co-Expressed With Homodimeric Type I Cytokine Receptors. The Adaptor Protein Lnk Is A Negative Regulator Of Hematopoietic Cytokine Receptors, Including EPOR And MPL. Lnk Attenuates Wild Type JAK2 Signaling In Hematopoietic Ba/F3 Cells Expressing MPL. Lnk Also Inhibits Cytokine-Independent Growth And Signaling Conferred By JAK2 V617F In Those Cells. Lnk, Via Its SH2 Domain, PH Domain, And Other Regions, Associates With JAK2 And JAK2 V617F. Additional Lnk Domains Are Involved In Lnk Downregulation Of JAK2 V617F Constitutive Activation. Elucidating The Pathways That Attenuate JAK2 And JAK2 V617F Signaling Provides Insight Into Myeloproliferative Disorders And Helps To Develop Therapeutic Approaches. Inhibition Of Lnk enhances the expression of hematopoetic stem cells and hematopoetic progenitor cells.
WO2008136656	WO - 2007NL50193 - 02/05/2007	UNIV ERASMUS MEDICAL CT ; VAN TIL NICO PETER ; VERSTEGEN MONIQUE MARIA ANDREA ; WAGEMAKER GERARD	C12N 15/09	The Invention Relates To The Field Of Gene Therapy And More In Specific To Lentiviral Gene Delivery Vehicles And Methods For Efficient Transduction Of Lentiviral Gene Delivery Vehicles Into Hematopoietic Stem Cells And Their Descendants. Preferably, The Invention Provides In One Of Its Embodiments A Method Of Gene Transfer Into E.G. Pluripotent Hematopoietic Stem Cells And Their Descendants, Enabling Successful Transduction Of Cells, Including Transplantable Cell Populations Comprising Hematopoietic Stem Cells That Give Rise To Progeny Expressing The Transduced Gene(S). The Invention Further Comprises A Method For Treating A Variety Of Hereditary And Acquired Human Disease By Transfer Of Therapeutically Active Genes Into Hematopoietic Stem Cells.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008136670	EP - 20070118404 - 12/10/2007 ; WO - 2007NL50193 - 02/05/2007	UNIV ERASMUS MEDICAL CT ; VAN TIL NICO PETER ; VERSTEGEN MONIQUE MARIA ANDREA ; WAGEMAKER GERARD	C12N 15/09	The Invention Relates To The Field Of Gene Therapy And More In Specific To Lentiviral Gene Delivery Vehicles And Methods For Efficient Transduction Of Lentiviral Gene Delivery Vehicles Into Hematopoietic Stem Cells And Their Descendants. Preferably, The Invention Provides In One Of Its Embodiments A Method Of Gene Transfer Into E.G. Pluripotent Hematopoietic Stem Cells And Their Descendants, Enabling Successful Transduction Of Cells, Including Transplantable Cell Populations Comprising Hematopoietic Stem Cells That Give Rise To Progeny Expressing The Transduced Gene(S). The Invention Further Comprises A Method For Treating A Variety Of Hereditary And Acquired Human Disease By Transfer Of Therapeutically Active Genes Into Hematopoietic Stem Cells. As A Non-Limiting Example, The Invention Shows That Symptoms Associated With Pompe Disease Are (Completely) Reduced And/Or Alleviated By Treatment Of A Subject Suffering From Pompe Disease Withjiematopoietic Stem Cell Transduced With An Alpha- Glucosidase Comprising lentiviral vector.
WO2008136733	SE - 20070001078 - 04/05/2007	ASCENDIA AB ; BUSCH CHRISTER	A61K 35/12 ; A61L 27/38 ; A61P 19/08 ; A61P 19/10 ; C12N 5/06 ; C12N 5/08	A Method Of Culturing Human Or Mammalian Mesenchymal Stem Cells (MSC) Or Osteoblastic Cells To Form Corresponding Cell Aggregates Evenly Distributed In The Culturing Medium Having A Reduced Content Of Cells With Fibroblast Morphology Comprises Contacting MSC Or OC With A Water-Soluble Cellulose Derivative Over A Period Of From 1 Day To One Or Two Weeks. Also Disclosed Are A Corresponding Aggregates, A Culture Medium And A Pharmaceutical Composition, And Uses Of The Aggregate, The Culturing Medium And The Composition.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008137115	US - 20070927596P - 03/05/2007	BRIGHAM & WOMENS HOSPITAL ; CRAWFORD KEITH W	C12N 5/08 ; C12N 5/22 ; C12Q 1/68	The Invention Provides A Quiescent Stem Cell Having The Capacity To Differentiate Into Ectoderm, Mesoderm And Endoderm, And Which Does Not Express Cell Surface Markers Including MHC Class I, MHC Class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 And CD90. The Invention Further Provides A Proliferative Stem Cell, Which Expresses Genes Including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 And TWIST But Does Not Express Cell Surface Markers Including MHC Class I, MHC Class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 And CD90. The Cells Of The Invention Can Be Isolated From Adult Mammals, Have Embryonic Cell Characteristics, And Can Form Embryoid Bodies. Methods For Obtaining The Stem Cells, As Well As Methods Of Treating Diseases And Differentiated The Stem Cells, Are Also Provided.
WO2008137122	US - 20070916269P - 04/05/2007	PRIMIANO THOMAS ; SHILOH LAORATORIES INC	C12N 5/08 ; C12N 5/10	The Present Invention Provides Stem Cell Feeder Layer Cell Lines That Contain Are Readily Triggered To Differentiation. The Expression Vector Encodes The Senescence-Triggering Factors (Stfs) Consisting Of Cip/Kip, INK4A, Cy Protein Or Ankyrin-Binding Protein Motifs. Each Expression Vector Also Contains An Inducible Transcription Regulation Element For Conditional Expression Of The Stfs.
WO2008137629	US - 20070927568P - 03/05/2007	LIN HSIN CHIEH ; MACDONALD LYNN ; REGENERON PHARMA ; WEI YI	C12N 5/06 ; C12Q 1/68 ; G01N 33/50	(A2 A3 A4) Methods And Compositions For Selecting ES Cells That Are Germline Competent Are Provided, Including Gene Expression Arrays Of From One To About 300 Or More Genes. Selecting ES Cells That Are Competent For Germline Transmission By Comparing The Expression Of One Or More Genes Between An ES Cell That Is Competent At Germline Transmission With An ES Cell Of Interest Is Described. Selecting ES Cells Likely To Be Competent At Germline Transmission, Based On Their Level Of Expression Of Gtl2, Is Also Described.
WO2008137641	US - 20070014006P - 14/12/2007 ; US - 20070927668P - 04/05/2007	LODISH HARVEY ; WHITEHEAD BIOMEDICAL INST ; ZHANG CHENGCHENG	C12N 5/00 ; C12N 5/08	Methods And Kits For Expanding The Number Of Hematopoietic Stem Cells Are Provided. The Methods Comprise Incubating Cells In Medium Comprising Isolated IGFBP-2 And An Angiopoietin-Like Protein (Angpt1). Expanded Hscs Are Provided As Well As Culture Media And Kits For The Expansion Of Human Hscs In A Defined Medium. Methods Of Administering Expanded Human Hscs To And Individual Are Provided As Well As Methods Of Treating An Individual By Administering Certain Growth Factors And Cytokines.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008140141	WO - 2007KR02397 - 16/05/2007	KANG KYUNG SUN ; RA JUNG CHAN ; RNL BIO CO LTD ; SEO JU YEON ; SHIN IL SEOB	A61K 35/12 ; A61K 35/14 ; A61P 1/16	Provided Is A Pharmaceutical Composition For Preventing And Treating Liver Fibrosis And Hepatic Cirrhosis Including A Mesenchymal Stem Cell. The Composition Substitutes For A Damaged Liver Cell, Thereby Recovering Liver Functions And Reducing Collagen Fibrils Deposited On The Liver, And Thus May Be Used For Preventing And Treating Liver Fibrosis Or Hepatic Cirrhosis.
WO2008140413	SE - 20070001168 - 15/05/2007 ; US - 20070924434P - 15/05/2007	NEUROGEN MEDICAL INNOVATION I ; TERENGHI GEORGIO ; WIBERG MIKAEL	A61B 17/11 ; A61F 2/02 ; A61L 31/04	A Bioresorbable Fibrin-Based Nerve Repair Conduitproduced From Tissue Glueis Disclosed. The Nerve Repair Conduit May Be In The Form Of A Sheet Or A Tube, And May Additionally Comprise A Serine Protease, And/Or Factor XIII And/Orcalcium Ions. The Serine Protease Is Chosen From The Group Consisting Of Trombin, Plasmin, Elastases, And Plasminogen Activators, Or Combinations Thereof. The Nerve Repair Conduit May Moreover Be Loaded With Schwann Cells And/Or Stem Cellsand/Orgrowth Factors, For Better Nerve Regeneration. Further,A Method Of Producing The Above-Mentioned Nerve Repair Conduit Is Provided, Comprising Curing Fibrinogenand Serine Protease Containing Fluids In The Form Of Afibrinogen-Containing Tissue Glue, In A Mould Equipped With A Central Shaft Creating A Channel In The Nerve Repair Conduit When Removed.Moreover, Use Ofa Fibrinogen-Basedtissue Glue For The Preparation Of A Fibrin-Based Nerve Repair Conduit Is Described. A Method Of Treating Nerve Damage By Placing A Nerve Repair Conduit According To The invention around at least one nerve stump and allowing the nerve repair conduit to guide the nerve stump during regeneration is also provided.
WO2008140586	US - 20060860606P - 21/11/2006 ; US - 20060860607P - 21/11/2006	BISSELL MINA J ; LAWSON HEALTH RES INST ; TURLEY EVA A ; UNIV CALIFORNIA	A61K 38/00 ; A61K 39/395	Herein Is Described The Methods And Compositions For Modulation Of Rhamm, Also Known As CD 186, And Its Effects On Wound Repair, Muscle Differentiation, Bone Density And Adipogeneisis Through Its Ability To Regulate Mesenchymal Stem Cell Differentiation. Compositions And Methods Are Provided For Blocking Rhamm Function For Selectively Increasing Subcutaneous, But Not, Visceral Fat. Compositions And Methods For Modulating Rhamm In Wound Repair Are Also Described.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008140808	US - 20070917226P - 10/05/2007	GERBER MICHAEL J ; MATSUURA JAMES E ; PEAK BIOSCIENCES INC ; WARREN STEPHEN L	A01N 43/42	A Method Is Provided For Treatment Of Disorders Involving Hyperproliferative Cells, Such As Malignancies, Advanced Stage Solid Tumors Like Glioblastoma Multiforme, And Non-Malignant Hyperproliferative Pathological Conditions Such As Adult Macular Degeneration. A Short Range, Unselective Cell Killing Radiotherapeutic Substance Is Administered, Optionally In A Spatially Defined Volume Of Tissue, Optionally In Combination With A Mitogenic Agent That Stimulates Or Induces DNA Biosynthesis. In This Way, The Percentage Of Hyperproliferative That Are Susceptible To Killing By The Radiotherapeutic Agent Is Increased. Cancer Stem Cells Can Be Induced To Enter S Phase With The Mitogenic Agent, Then Killed With The Radiotherapeutic Agent. Thus, Not Only Does The Combination Effectively Kill The Transit Amplifying Cell Population, The Most Rapidly Replicating Type Of Cell In A Tumor, But It Also Effectively Kills The Tumor Stem Cells, Which Give Rise To The Transit Amplifying Cells, For A Longer Lasting Anticancer Effect.
WO2008141177	US - 20070917506P - 11/05/2007	LEE FRANCIS Y ; UNIV COLUMBIA	C12Q 1/68	The Present Invention Is Directed To Compositions And Methods Useful In The Treatment Of Sarcomas, Such As Chondrosarcomas, That Are Typically Resistant To Conventional Treatment Modalities, Such As Radiotherapy Or Chemotherapy. Various Aspects Of The Invention Involve Increasing The Sensitivity Of A Sarcoma To Chemotherapy And/Or Radiotherapy By Exposing It To A Transformed Stem Cell, Such As A Mesenchymal Stem Cell, That Expresses Rnai Molecules Specific For One Or More Anti-Apoptotic Genes And/Or Multi-Drug Resistance Genes, And Optionally Expresses A Connexin Protein That Facilitates Transfer Of The Rnai Molecules To Sarcomal Cells.
WO2008142124	EP - 20070301058 - 21/05/2007 ; US - 20080032786P - 29/02/2008	MEHTALI MAJID ; VIVALIS	A61K 38/00 ; A61K 39/395 ; C07K 16/00 ; C12N 5/06 ; C12N 5/10	The Invention Generally Relates To The Field Of Recombinant Protein Production. More Particularly, The Invention Relates To The Use Of Avian Embryonic Derived Stem Cell Lines, Named Ebx TM , For The Production Of Proteins And More Specifically Glycoproteins Such As Antibodies. The Invention Is Useful For The Production Of Monoclonal Igg1 Antibody Subtype Having High Cell-Mediated Cytotoxic Activity. The Invention Relates To The Use Of Such Antibodies As A Drug To Treat Cancers And Inflammatory Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008143884	US - 20070748315 - 14/05/2007	CARDIAC PACEMAKERS INC ; GIROUARD STEVEN D ; STOLEN CRAIG		The invention provides a composition for cold storage of cells which includes a population of isolated stem cells, a cell medium, and isolated trophic factors, as well as devices having a plurality of the trophic factors.
WO2008144052	US - 20070939046P - 18/05/2007	WALIA RAMPYARI	A61K 49/00 ; C12N 5/10 ; C12Q 1/66	Methods And Compositions For Detecting And Localizing Light Originating From Cultured Stem Cells Or Stem Cells Injected Into Tissue Or An Animal, Especially A Mammal, Are Described. Also Disclosed Are Methods For Localization Of Stem Cells In Selected Regions, As Well As For Tracking Stem Cells Within The Mammal, And For Causing Stem Cell Differentiation.
WO2008144580	US - 20070938683P - 17/05/2007 ; US - 20070940316P - 25/05/2007 ; US - 20070942427P - 06/06/2007	BYRNE JAMES ; MITALIPOV SHOUKHRAT M ; UNIV OREGON HEALTH & SCIENCE ; WOLF DON P	C12N 15/00 ; C12N 15/87 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	Purified Totipotent Stem Cells And Pluripotent Stems Cells Derived By Somatic Cell Nuclear Transfer Are Disclosed Herein, As Well As Cell Lines, Multipotent Cells And Differentiated Cells Produced From These Stem Cells. The Stem Cells Are Produced From An Enucleated Host Cell From A First Donor And Nuclear Genetic Material From A Somatic Cell Of A Second Donor. Methods For Making And Using Such Compositions Of Such Stem Cells Are Also Provided.
WO2008144820	AU - 20070902844 - 28/05/2007	ILANCHERAN SIVAKAMI ; JENKIN GRAHAM ; MANUELPILLAI URSULA ; MOODLEY YUBEN ; TROUNSON ALAN OSBORNE ; UNIV MONASH ; WALLACE EUAN MORRISON	A61K 31/01 ; A61K 35/12 ; A61K 35/48 ; A61K 35/56 ; A61P 11/00	A Method Of Cellular Therapy For A Lung Disease Or Condition In A Subject Is Disclosed, Wherein The Method Involves The Administration Of Multipotent Epithelial Stem Cells Derived From Amnion Tissue (Aecs). In A Particular Application, The Method Is Used For The Treatment Of Lung Diseases And Conditions Such As Chronic Lung Diseases Including Chronic Obstructive Pulmonary Disease (COPD), Acute Lung Conditions Such As Acute Respiratory Distress Syndrome (ARDS), And Ventilator Associated Lung Injury (VALI).

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008146956	WO - 2007KR02215 - 06/05/2007	CHOI BYUNG HYUNE ; JIN CHENG ZHE ; MIN BYOUNG-HYUN ; PARK SO RA	A61L 27/56	The Present Invention Relates To A Method For Preparing A Cell-Derived ECM Scaffold To Which Chondrocytes Or Stem Cells Are Attached, A Method For Cartilage Regeneration By Tissue Engineering, Which Comprises Using The Cell-Derived ECM Scaffold, And A Therapeutic Composition For Treating Cartilage Disorder, Which Contains The ECM Scaffold As An Effective Component. More Specifically, The Present Invention Relates To A Method For Cartilage Regeneration By Tissue Engineering, Which Comprises Transplanting ECM Scaffold, Having Chondrocytes Or Stem Cells Attached Thereto, Into Cartilage Defects, And A Therapeutic Composition For Treating Cartilage Disorder, Which Contains The ECM Scaffold, Having Chondrocytes Or Stem Cells Attached Thereto, As An Effective Component. According To The Present Invention, When The Inventive ECM Scaffold Having Chondrocytes Or Stem Cells Attached Thereto Is Transplanted Into A Cartilage Defect, Mature Articular Cartilage Having The Same Appearance And Characteristics As Those Of Natural cartilage tissue, can be regenerated without side effects such as inflammatory responses.
WO2008146991	KR - 20070052204 - 29/05/2007	CHABIOTECH CO LTD ; COLLEGE OF MEDICINE POCHON CHA ; KIM GI-JIN ; NA KYU-HWAN ; SHIN KYUNG-SUN	C12N 5/06 ; C12N 5/08	The Present Invention Provides A Method For Isolating Trophoblast Stem Cells, The Method Including: (A) Harvesting Placental Villi From A Detached Normal Placenta; (B) Adding An Enzyme Solution Containing Trypsin, Dmase I, And Dispase To The Placental Villi Of Step (A) To Perform An Enzymatic Reaction And Adding A Fetal Bovine Serum Thereto To Terminate The Enzymatic Reaction; (C) Centrifuging The Reaction Solution Of Step (B) And Separating Cytotrophoblasts From The Recovered Cells By A Density-Gradient Separation Method; And (D) Culturing The Cytotrophoblasts Of Step (C) In A Medium Containing A Fetal Bovine Serum And An Antibiotic.
WO2008147057	KR - 20070050624 - 25/05/2007	HAN HAE JUNG ; KIM HYO EUN ; LEE HANG YOUNG ; RA JEONG CHAN ; RNL BIO CO LTD	A01N 63/00 ; A61K 35/34 ; A61K 45/00 ; A61P 25/02 ; C12N 5/06	Disclosed Herein Is A Cell Therapeutic Composition For Treating Ischemic Limb Diseases, More Specifically, Disclosed Is A Cell Therapeutic Composition For Treating Ischemic Diseases, Which Contains Adipose Tissue-Derived Mesenchymal Stem Cells And Sucrose Or Mannose As An Excipient. The Composition Induces Angiogenesis Around Closed Blood Vessels In The Ischemic Limb Lesions, And Thus Is Useful To Treat Ischemic Diseases.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008147304	US - 20070930453P - 16/05/2007 ; US - 20080151814 - 09/05/2008	B & L DEV AB ; ERICSSON PETER	A61K 38/28 ; A61P 25/28 ; C07K 14/62 ; C07K 7/06	The Field Of The Present Invention Is A Novel Neuroprotective Peptide, Pentinin, Having Neuroprotective Properties. Pentinin Consists Of The Five C-Terminal Amino Acids Of Insulin Chain B (B26-30). More Particularly, The Field Of The Present Invention Relates To The Ability Of Pentinin, YTPKT (SEQ ID NO: 1), To Affect Endogenous Undifferentiated Stem Cells To Positively Modulate Neural Damage And The Use Of Such Peptide For The Treatment Of Disorders Of The Neural System. The Present Invention Also Relates To The Manufacture Of Medicaments, Methods Of Formulation And Uses Thereof. An Intranasal Delivery System For Administration Of Pentinin Is Also Described.
WO2008148105	US - 20070940364P - 25/05/2007 ; US - 20070987880P - 14/11/2007	ICHIM THOMAS E ; MEDISTEM LAB INC ; MENG XIAOLONG ; RIORDAN NEIL H	A61K 38/00 ; C12N 5/06 ; C12N 5/08	The Invention Provides Pluripotent Stem Cells And Methods For Making And Using Pluripotent Stem Cells. Pluripotent Stem Cells, Among Other Things, Can Differentiate Into Various Cell Lineages In Vitro, Ex Vivo And In Vivo. Pluripotent Stem Cells, Among Other Things, Can Also Be Used To Produce Conditioned Medium.
WO2008148831	EP - 20070450104 - 06/06/2007 ; US - 20070942416P - 06/06/2007	BAGLEY JESSAMYN ; BARANYI ULRIKE ; BIOMAY AG ; GATTRINGER MARTINA ; IACOMINI JOHN ; LINHART BIRGIT ; PILAT NINA ; VALENTA RUDOLF ; WEKERLE THOMAS	C12N 15/86 ; C12N 5/06	The Present Invention Relates To A Method For Inducing Specific Long-Lasting Robust Immunological Tolerance Towards At Least One Polypeptide Derived From At Least One Allergen By Transplanting A Hematopoietic (Stem) Cell Which Is Produced To Display The Said At Least One Polypeptide Derived From At Least One Allergen.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008149356	US - 20070924865P - 04/06/2007 ; US - 20070929865P - 16/07/2007	BARZILAY RAN ; BEN-ZUR TALI ; BULVIK SHLOMO ; MELAMED ELDAD ; OFFEN DANIEL ; UNIV RAMOT	C12N 5/08	An Isolated Mesenchymal Stem Cell Expressing An Exogenous Polynucleotide Is Disclosed. The Exogenous Polynucleotide Comprises A Nucleic Acid Sequence Encoding A LIM Homeobox Transcription Factor 1 Alpha (Lmx1a) Polypeptide. Methods Of Generating Same, Uses Of Same And Pharmaceutical Compositions Comprising Same Are Also Disclosed.
WO2008149803	JP - 20070150912 - 06/06/2007 ; JP - 20070159355 - 15/06/2007	MORIMOTO CHIKAO ; NISHIDA HIROKO ; UNIV TOKYO ; YAMAZAKI HIROTO	C12N 5/06 ; C12Q 1/02 ; C12Q 1/04 ; G01N 33/574	By Finding Surface Antigen Markers Being Positive Specifically To Cancer Stem Cells In Acute Lymphocytic Leukemia, It Is Intended To Provide A Novel Method For Sorting And Identifying Cancer Stem Cells In Acute Lymphocytic Leukemia With The Use Of The Above Markers And A Kit Therefor. By Using Surface Antigen Markers CD90 And CD110 As Indications, Cancer Stem Cells In T Cell Acute Lymphocytic Leukemia (T-ALL) Are Sorted. By Using Surface Antigen Markers CD9 Or CD9 With CD90 As Indications, Cancer Stem Cells In B Cell Acute Lymphocytic Leukemia (B-ALL) Are Sorted.
WO2008150001	JP - 20070153424 - 08/06/2007	BIOMASTER INC ; FUJITA YUKO ; KIKUCHI TOSHIYUKI ; MURASE SHOKO ; NAGASE TAKASHI ; NAT HOSPITAL ORGANIZATION	A61K 35/12 ; A61L 27/00 ; A61P 25/00 ; A61P 43/00 ; C12M 3/00 ; C12N 15/09 ; C12N 5/06	An Object Is To Examine Whether Or Not The Requirement Of A Clone Property Is Needed In The Preparation Of A Neural Stem Cell Preparation. Another Object Is To Provide A Method For Preparing A Neural Stem Cell In A Simple Manner. Thus, Disclosed Is A Method For Producing Cells Containing A Cell Derived From A Musashi-Positive Adipose Tissue, Which Comprises The Steps Of: Providing A Cell Derived From An Adipose Tissue; And Subjecting The Cell To The Floating Culture For A Sufficient Period For Producing An Aggregate.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008150498	US - 20070932328P - 30/05/2007	BOYD NOLAN ; STICE STEVEN ; UNIV GEORGIA	C12N 5/08 ; C12N 5/22	Human Embryonic Stem Cells (Hesc) Have The Potential To Produce All Of The Cells In The Body. They Are Also Able To Self-Renew Indefinitely, Sparking The Hope They Could Be Used As A Source For Large Scale Production Of Therapeutic Cell Lines. The Present Invention Relates To A Monolayer Differentiation Culture System That Induces Hesc (WA09 And BG0l) To Form Epithelial Sheets With Mesodermal Gene Expression Patterns (BMP4, Runxl, GAT A4). These E-Cadherin+ CD90lovv Cells Then Undergo Apparent Epithelial-Mesenchymal Transformation (EMT) For The Derivation Of Mesenchymal Progenitor Cells (Hes-MC) That By Flow Cytometry Are Negative For Hematopoietic (CD34, CD45 And CD 133) And Endothelial (CD31 And CD 146) Markers, But Positive For Markers Associated With Mesenchymal Stem Cells (MSC) (CD73, CD90, CD105 And CD166). To Determine Their Functionality, We Tested Their Capacity To Produce The Three Lineages Commonly Associated With MSC And Found They Could Form Osteogenic And Chondrogenic, But Not Adipogenic Lineages. The derived hES-MC were able to remodel and contract collagen I lattice constructs to an equivalent degree as keloid fibroblast control cells and were induced to express aSMA when exposed to TGF-ss1, but not PDGF-B. This data suggests the derived hES-MC cells are multipotent cells with potential uses in tissue engineering/regenerative medicine and for providing a highly reproducible cell source for adult-like progenitor cells.
WO2008151021	US - 20070809871 - 01/06/2007 ; US - 20080050131P - 02/05/2008	FINK LOUIS M ; MA YUPO ; NEVADA CANCER INST ; WANER MILTON E ; WARD DAVID C	C12N 5/08	The Present Invention Describes Stem Cells And Progenitor Cells Derived From Hemangiomas, Including Testing Of Angiogenic Inhibitors Using These Cells. The Invention As Described Is Useful In Providing A Process To Culture And Propagate Hemangioma Stem Cells And Generate Xenograft Models To Develop Treatments For Infantile Hemangiomas And Other Types Of Vascular Lesions.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008151035	US - 20070809871 - 01/06/2007	MA YUPO ; NEVADA CANCER INST	A61K 31/7052 ; A61K 31/7068 ; A61K 35/12 ; A61K 38/07 ; C12Q 1/00 ; C12Q 1/02 ; C12Q 1/68	The Present Invention Discloses Nucleic Acids, Proteins, And Antibodies For SALL4 (Including Isoforms SALL4A, SALL4B, And SALL4C), A Zinc Finger Transcriptional Factor. Further, Methods Are Disclosed Which Demonstrate That Constitutive Expression Of SALL4 Increases Leukemogenic Potential In Cells Of Model Animal Systems. Moreover, Constitutive Expression Of Select Isoforms (E.G., SALL4B) In Transgenic Mice Demonstrate That These Animals Develop Myelodysplastic Syndrome (MDS)-Like Signs And Symptoms, Including Subsequent Acute Myeloid Leukemia (AML), Which Is Transplantable. The Disclosure Also Provides Methods For Identifying And Purifying Embryonic Stem Cells, Adult Stem Cells, Cancer Stem Cells, Including Leukemia Stem Cells, Methods For Identifying Substances Which Bind To And/Or Modulate SALL4, Methods For Diagnosing MDS In A Subject, And Methods Of Treating A Subject Presenting MDS, AML And Other Forms Of Leukemia.
WO2008151058	US - 20070932267P - 30/05/2007	GEN HOSPITAL CORP ; HOCHEDLINGER KONRAD ; MAHERALI NIMET	C12N 5/06	Disclosed Herein Are Methods To Select For The Generation Of Mouse And Human Pluripotent Stem Cells During Developmental Reprogramming. The Methods Described Herein Relate To The Selection Of Induced Pluripotent Stem Cells, I.E., Pluripotent Stem Cells Generated Or Induced From Differentiated Cells Without A Requirement For Genetic Selection. Described Herein Are Particular Embodiments For Selection Of Reprogrammed Cells Based On 1) Colony Morphology, Or 2) X Chromosome Reactivation In Female Cells.
WO2008151386	AU - 20070903224 - 15/06/2007	AUSTRALIAN STEM CELL CT LTD ; ELEFANTY ANDREW ; NG ELIZABETH ; STANLEY EDUOARD	C12N 5/08	The Present Invention Provides A Method For Generating Megakaryocytes And/Or Megakaryocyte Precursors From A Population Of Embryonic Stem Cells (Escs), The Method Comprising: (I) Culturing Escs In A Serum-Free, Stromal/Feeder Cell-Free Medium For A Time And Under Conditions Sufficient For Formation Of Mesoderm And/Or Mesendoderm; And (Ii) Differentiating The Cells Cultured In Step (I) In A Medium Comprising Thrombopoietin (TPO), Stem Cell Factor (SCF) And Interleukin 3 (IL-3), Or Any Functional Fragment, Variant Or Mimetic Of TPO, SCF And/Or IL-3, For A Time And Under Conditions Sufficient For Formation Of Megakaryocytes And/Or Megakaryocyte Precursors.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008151390	AU - 20070903225 - 15/06/2007	AUSTRALIAN STEM CELL CT LTD ; ELEFANTY ANDREW ; NG ELIZABETH ; STANLEY EDUOARD	A61K 35/14 ; A61P 7/00 ; C07K 14/705 ; C07K 14/71 ; C12N 5/06 ; C12N 5/08	The Present Invention Provides A Method For Detecting Hematopoietic Progenitor Cells In A Population Of Cells Comprising Differentiating Pluripotent Cells, The Method Comprising Detecting The Presence Of Pdgfra On The Surface Of Cells In Said Population, Wherein The Presence Of Pdgfra Is Indicative Of Hematopoietic Progenitor Cells.
WO2008153231	WO - 2007KR02840 - 13/06/2007	CHABIOTECH CO LTD ; CHUNG HYUNG-MIN ; COLLEGE OF MEDICINE POCHON CHA ; KIM JU-MI ; LEE SOO-HONG ; MOON SUNG-HWAN	C12N 5/00 ; C12N 5/02 ; C12N 5/06 ; C12N 5/08	The Present Invention Provides A Process For Isolating Vascular Endothelial Cells From Embryoid Bodies Differentiated From Embryonic Stem Cells, Which Comprises: (A) Treating Embryoid Bodies Differentiated From Embryonic Stem Cells With 0.005 - 0.015% Trypsin And 0.05 - 0.15 Mm Ethylenediaminetetraacetate (EDTA) To Obtain Vascular Endothelial Cell Clusters; And (B) Treating The Vascular Endothelial Cell Clusters With 0.1 - 0.5% Trypsin And 0.5 - 2 Mm EDTA So As To Separate The Vascular Endothelial Cell Clusters Into Single Cells.
WO2008156512	US - 20070919593P - 23/03/2007 ; US - 20070936874P - 22/06/2007	BRINK PETER R ; COHEN IRA S ; GAUDETTE GLENN ; ROBINSON RICHARD B ; ROSEN AMY B ; ROSEN MICHAEL R ; TRUSTEES OF COLUMIBA UNIVERSIT ; UNIV NEW YORK	A61K 35/12 ; G01N 21/76	The Present Invention Provides Methods And Compositions Relating To The Labeling Of Target Cells With Nanometer Scale Fluorescent Semiconductors Referred To As Quantum Dots (Qds). Specifically, A Delivery System Is Disclosed Based On The Use Of Negatively Charged Qds For Delivery Of A Tracking Fluorescent Signal Into The Cytosol Of Target Cells Via A Passive Endocytosis-Mediated Delivery Process. In A Specific Embodiment Of The Invention The Target Cell Is A Stem Cell, Preferably A Mesenchymal Stem Cell (MSC). Such Labeled Mscs Provide A Means For Tracking The Distribution And Fate Of Mscs That Have Been Administered To A Subject To Promote Cardiac Repair. The Invention Is Based On The Discovery That Mscs Can Be Tracked In Vitro For Up To At Least 6 Weeks. Additionally, Qds Delivered In Vivo Can Be Tracked For Up To At Least 8 Weeks, Thereby Permitting For The First Time, The Complete 3-D Reconstruction Of The Locations Of All Mscs Following Administration Into A Host. - (A3) The Present Invention Provides Me

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2008156685	US - 20070934606P - 14/06/2007	BI YANMING ; SHI SONGTAO ; US GOVERNMENT ; YOUNG MARIAN F	A61P 17/02 ; A61P 19/02 ; A61P 21/00 ; A61P 9/00 ; C12N 5/06	The Invention Relates To Tendon Stem Cells Useful For Treating A Variety Of Diseases And Condition, Including Tendon Repair And Attachment Of Tendon To Bone. The Invention Is Also Directed To Treatment And/Or Inhibition Of Bone Formation By Use Of Biglycan And/Or Fibromodulin.
WO2008156708	US - 20070934742P - 15/06/2007 ; US - 20080125041P - 22/04/2008	COLTON CLARK K ; MASSACHUSETTS INST TECHNOLOGY ; MILLMAN JEFFREY R ; POWERS DARYL E	C12N 5/00 ; C12N 5/08	The Invention Provides Methods For Differentiating Pluripotent Stem Cells Such As ES Cells With Improved Progenitor And Differentiated Cell Yield Using Low Oxygen Conditions And Optionally In The Absence Of Exogenously Added Differentiation Factors.
WO2008157324	US - 20070013145P - 12/12/2007 ; US - 20070943821P - 13/06/2007	BRINCHMANN JAN ENGELSEN ; FMC CORP ; FRONSDAL KATRINE BJORNEBEK ; MELVIK JAN EGIL	A61K 48/00 ; C12N 5/00 ; C12N 5/08	Biostructures That Comprises Modified Alginates Entrapping One Or More Stem Cells Are Discloses. The Modified Alginates Comprise At Least One Alginate Chain Section To Which Is Bonded By Covalent Bonding At Least One Cell Attachment Peptide. Pluralities Of Stem Cells Are Also Disclosed. Methods Of Preventing Death Of Stem Cells And Cells Differentiated There From Are Disclosed. Methods Of Preparing A Plurality Of Stem Cells Are Disclosed. Methods Of Treating An Individual Who Has A Degenerative Disease, Such As A Neurological Disorder, Or Injury Involving Nerve Damage By Administering Stem Cells To Said Individual Are Disclosed.
WO2009000347	DE - 200710029699 - 27/06/2007	FRAUNHOFER GES FORSCHUNG ; GUERLEYIK EMEL ; KRUSE CHARLI	C12N 5/06	The Invention Relates To A Method For The Preparation Of Isolated Proliferating Cells With Stem Cell Properties And To The Corresponding Stable Cell Cultures From Adult Tissue Of Poikilothermic Animals, In Particular Fish (Pisces), And To The Cells And Cell Cultures Prepared Therewith. In A Preferred Embodiment Of The Invention, The Cells Are Obtained From The Anterior Kidney Tissue Of Fish.

Nº DO PEDIDO	PRIORIDADE	DEPOSITANTE	CLASSIFICAÇÃO	TÍTULO OU RESUMO
WO2009002223	RU - 20070123281 - 21/06/2007	CHUPIKOVA NATALIYA IGOREVNA ; SHARIFULLINA SVETLANA ZAGIROVNA ; SINGINA GALINA NIKOLAEVNA ; TEPLYASHIN ALEXANDER SERGEEVICH	C12N 15/07 ; C12N 5/22	The Invention Relates To Cell Engineering And Can Be Used For Producing A Human Hybrid Stem Cell. The Inventive Method Consists In Producing A Hybrid Stem Cell By Carrying Out The Inter-Species Transplantation Of A Human Somatic Cell Into An Enucleated Oocyte, Wherein A Mesenchyme Stem Cell Is Used As A Donor Somatic Cell And A Pig Oocyte Is Used As An Oocyte. The Human Hybrid Stem Cell Produced By Transplanting The Nucleus Of A Human Mesenchyme Stem Cell Into The Enucleated Pig Oocyte Is Also Disclosed. Said Invention Makes It Possible To Develop A Method For Producing Human Hybrid Stem Cells, The Genetic Set Of Which Is Identical To The Set Of A Patient And The Use Of Which In Restorative Therapy Excludes The Probability Of Immune Incompatibility.
ZA200702607	US - 20040933634 - 03/09/2004	SCRIPPS RESEARCH INST		Isolated lineage negative hematopoletic stem cells and methods of treatment therewith

ANEXO I - Códigos dos Países

Código	País	Código	País
AR	Argentina	**IN**	Índia
AT	Áustria	**IS**	Islândia
AU	Austrália	**IT**	Itália
BE	Bélgica	**JP**	Japão
BG	Bulgária	**KR**	República Da Coréia
BR	Brasil	**LU**	Luxemburgo
BS	Bahamas	**LV**	Letônia
CA	Canadá	**MA**	Marrocos
CH	Suíça	**MD**	Republica Moldova
CN	China	**MX**	México
CZ	República Tcheca	**NL**	Holanda
DE	Alemanha	**NO**	Noruega
DK	Dinamarca	**NZ**	Nova Zelândia
DZ	Argélia	**OA**	African Intellectual Property Organization (OAPI)[1]
EA	Organização de Patentes da Eurásia (EAPO)[1]	**PH**	Filipinas
EE	Estônia	**PL**	Polônia
EG	Egito	**PT**	Portugal
EP	Organização Européia de Patentes (EPO)[1]	**RO**	Romênia
ES	Espanha	**RU**	Federação Russa
FI	Finlândia	**SE**	Suécia
FR	França	**SG**	Singapura
GB	Reino Unido	**SI**	Eslovênia
GR	Grécia	**SK**	Eslováquia
HK	Região Administrativa Especial de Hong Kong Da República Popular da China	**TR**	Turquia
HR	Croácia	**TW**	Taiwan
HU	Hungria	**UA**	Ucrânia
ID	Indonésia	**US**	Estados Unidos
IE	Irlanda	**WO**	Organização Mundial de Propriedade Intelectual (WIPO)[2]
IL	Israel	**ZA**	África do Sul

Fonte: http://www.wipo.int/export/sites/www/scit/en/standards/pdf/03-03-01.pdf, acesso: março 2008

[1] A OAPI é um organismo intergovernamental encarregado de emitir títulos de proteção dos direitos de propriedade industrial e de prestar serviços relacionados com a propriedade industrial para cada um dos Estados-membros. Aplica uma legislação uniforme que tem lugar de lei nacional para cada um dos Estados-Membros: o Acordo de Bangui. Estes títulos de proteção têm efeito automático em cada um dos seguintes Estados-membros: Benim, Burquina Faso, Camarões, África Central, Congo, Costa do Marfim, Gabão, Guiné, Guiné Bissau, Guiné Equatorial, Mali, Mauritânia, Nigéria, Senegal, Chade e Togo.

[2] O código "WO" é utilizado para a publicação internacional dos pedidos depositados via Tratado de Cooperação em Matéria de Patentes (PCT) em qualquer um dos países receptores destes pedidos.